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Calmodulin (CaM) is a ubiquitous cytosolic Ca2+-binding protein involved in the binding and 
regulation of more than three-hundred intracellular target proteins.  CaM consists of two globular 
domains joined by a central linker region.  In the archetypical model of CaM binding to a target 
protein, the Ca2+-replete CaM wraps its two domains around a single α-helical target peptide; 
however, other conformations of CaM bound to target peptides and proteins have recently been 
discovered.   Due to its ability to bind and affect many different intracellular processes, there is 
significant interest in a better understanding of the structural and conformational basis of CaM’s 
ability to bind and recognize target proteins.   
The mammalian nitric oxide synthase (NOS) enzymes are bound and activated by CaM.  The 
NOS enzymes catalyze the production of nitric oxide (•NO), a free radical involved in numerous 
intercellular processes such as neurotransmission, vasodilation, and immune defense.  There are three 
different isoforms of nitric oxide synthase (NOS) found in mammals – neuronal NOS (nNOS), 
endothelial NOS (eNOS), and inducible NOS (iNOS).  All three enzymes are homodimeric with each 
monomer consisting of an N-terminal oxygenase domain and a multidomain C-terminal reductase 
domain.   A CaM-binding domain separates the oxygenase and reductase domains.   There is a unique 
opportunity to investigate CaM’s control over •NO production by the NOS enzymes since each 
isoform shows a different mode of activation and control by CaM.  At elevated cellular Ca2+ 
concentrations, CaM is able to bind and activate nNOS and eNOS.  In contrast, the iNOS isozyme is 
transcriptionally regulated and binds to CaM in the absence of Ca2+.  The focus of this thesis is to 
better our present understanding of the conformational and structural basis for CaM’s ability to bind 
and activate the three mammalian NOS isozymes with particular emphasis on the interactions 
between CaM and iNOS. 
iv 
To further investigate the differences in the association of CaM to the Ca2+-dependent and       
Ca2+-independent NOS isoforms, a variety of CaM mutants including CaM-troponin C chimeras, 
CaM EF hand pair proteins, and CaM mutants incapable of binding to Ca2+ were employed.  The 
inherent differences in binding and activation observed using these CaM mutants is described.  
Differences in the binding of the N- and C-terminal domains, as well as the central linker of CaM to 
peptides corresponding to the CaM-binding domain of each NOS enzyme and holo-NOS enzymes 
was investigated.  The conformation of CaM when bound to NOS peptides and holo-NOS enzymes 
was also studied using fluorescence (Förster) resonance energy transfer (FRET).  A preliminary three-
dimensional structural study of Ca2+-replete and Ca2+-deplete CaM in complex with an iNOS CaM-
binding domain peptide is also described.   
Combining the cumulative results in this thesis, a working model for iNOS’s regulation by 
CaM is proposed.  Future suggested experiments are described to further the characterization of CaM 
binding to the NOS enzymes and other CaM-target proteins.  The studies described in this thesis have 
expanded and improved the present understanding of the CaM-dependent binding and activation of 
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Outline of the Thesis 
This thesis consists of eight chapters with a common focus of studying the binding and activation of 
mammalian NOS enzymes by CaM.  A synopsis for each chapter follows: 
 Chapter 1 provides a comprehensive review of CaM and its ability to bind to various CaM-
dependent target peptides and proteins.  CaM binding and activation of NOS and the significance of 
studying this fascinating and physiologically important protein-protein interaction are also discussed.   
 Chapter 2 describes the use of CaM-troponin C chimeric proteins to investigate the effect of 
specific EF hand elements in CaM on the activation of the NOS enzymes using three distinct 
spectrophotometric assays to monitor electron transfer rates at the various redox centers in the 
reductase and oxygenase domains of NOS. 
 Chapter 3 describes the use of CaM EF hand pair proteins to determine the specific domain of 
CaM responsible for the binding and activation of the NOS enzymes.  A particular focus is given to 
the binding and activation of iNOS with a plausible reason for the strong, irreversible association of 
CaM to this Ca2+-independent NOS isozyme. 
 Chapter 4 describes an investigation on the effect of CaM mutant proteins incapable of 
binding to Ca2+ on the association and activation of nNOS and iNOS peptides and enzymes. 
 Chapter 5 describes the use of fluorescently labeled CaM proteins to monitor the differential 
binding of the N-domain, C-domain and central linker of CaM to mammalian NOS peptides and 
enzymes through steady-state fluorescence.  The orientation of CaM when bound to iNOS is also 
determined through the use of FRET.  
  Chapter 6 contains a combination of various studies with the common focus of monitoring 
CaM binding to NOS peptides and enzymes using fluorescence.  The first study in this chapter 
focuses on a selective dual labeling methodology to fluorescently label CaM using single cysteine and 
xxiv 
selenomethionine residues.  The second study involves the monitoring of dynamic conformational 
changes in CaM when associating to NOS peptides and enzymes using FRET. 
 Chapter 7 describes the preliminary NMR structural determination of Ca2+-replete and Ca2+-
deplete CaM when bound to a peptide corresponding to the canonical CaM-binding domain of iNOS.  
A summary of the work performed to date as well as future plans for the completion of this study are 
also included. 
 Chapter 8 presents the overall conclusions of this doctoral study, contributions of this 
research to the scientific community, and recommendations for future studies to further the findings 
presented in this thesis. 





1.1.1 Cellular Calcium 
Ca2+ is an important intracellular secondary messenger that is able to relay information within cells 
to regulate the activity of numerous physiological processes.  An increase of intracellular Ca2+ 
concentration can originate from external sources from outside of the cell or internal Ca2+ stores 
within the cell.  For instance, external Ca2+ from an external source can include an influx of Ca2+ 
through various channels that span the plasma membrane such as voltage-operated Ca2+ channels 
found in excitable cells (such as muscle cells or neurons) or receptor-operated Ca2+ channels (ROCs) 
which respond to the release of neurotransmitters.  Intracellular Ca2+ can also be released into the 
cytosol from internal Ca2+ stores found in the endoplasmic or sarcoplasmic reticulum through 
ryanodine receptor (RyR) Ca2+ release channels in response to intracellular secondary messengers, 
such as inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) generated by phospholipase C (PLC) (Clapham, 
1995; Zalk et al., 2007).   In response to these small molecule stimuli, the influx of Ca2+ into the 
cytosol typically causes a 100 fold increase in free Ca2+ concentrations from approximately 10−7 M 
in a resting cell to 10−5 M in an activated cell (Gifford et al., 2007).  An overall summary of the 
regulation of Ca2+ release within a cell is shown in Figure 1.1. 
Cellular processes regulated by an increase of intracellular Ca2+ concentrations include 
muscle contraction, metabolism, neurotransmission, memory, cell fertilization, cell differentiation, 
cell proliferation, and cell defense.  Cell death can also result if the intracellular concentration of  
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Ca2+ is not properly controlled (Berridge et al., 1998; Berridge et al., 2000).  A brief list of proteins 
that bind to Ca2+ within the cell is given in Table 1.1. 
 
Figure 1.1 – Mechanisms of Ca2+ signaling within the cell. 
Ca2+o, Ca2+c, and Ca2+ER represent Ca2+ originating from outside the cell, cytosolic Ca2+, and Ca2+ 
stored in the endoplasmic reticulum, respectively.  Voltage-operated and receptor-operated Ca2+ 
channels are labeled as VOC and ROC, respectively.  The increased Ca2+ concentrations in the 
cytosol can initiate numerous physiological processes within the cell.  This figure is modified from a 
previous review (Berridge et al., 1998). 
 
Table 1.1 – Examples of mammalian proteins that are activated by Ca2+-binding  
Protein Ca2+-Binding Site Protein Function 
    
Calmodulin EF Hand Ubiquitous modulator of protein kinases and                    other enzymes 
Troponin C EF Hand Modulator of muscle contraction 
Calretinin, retinin, visinin EF Hand Activator of guanylyl cyclase 
Calcineurin B EF Hand Phosphatase 
Calpain EF Hand Protease 
Inositol phospholipid-specific PLC EF Hand Generator of InsP3 and diacylglycerol 
α-Actinin EF Hand Actin-binding protein 
Protein kinase C  Ubiquitous protein kinase 
Ca2+-activated K+ channel  Effector of membrane hyperpolarization 
Ryanodine receptor  Effector of intracellular Ca2+ release 
Na+/Ca2+ exchanger  
Effector of the exchange of Ca2+ for Na+   
           across the plasma membrane 
Ca2+ ATPase  Pumps Ca2+ across membranes 
Caldesmon  Regulator of muscle contraction 
Parvalbumin EF Hand Ca2+ buffer 
Calbindin EF Hand Ca2+ buffer 
Calsequestrin EF Hand Ca2+ buffer 
     
Table is a modified summary from a previously published review (Clapham, 1995). 
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1.1.2 EF Hand Motif 
A common Ca2+-binding motif found in many of the proteins listed in Table 1.1 is the EF hand.  This 
motif consists of a helix-loop-helix structural element with the majority of the ligands used to 
chelate Ca2+ located in the loop of the EF hand (Figure 1.2).   
 
Figure 1.2 – Ca2+ co-ordination in a typical Ca2+-binding EF hand. 
This figure is shown to clarify the helix-loop-helix EF hand motif and how it is able to chelate a Ca2+ 
ion.  (A) The entering and exiting helices are shown in dark grey and light grey, respectively.  The 
co-ordinating amino acid sidechains and backbone and water molecule involved in the chelation of 
Ca2+ are shown in blue and yellow, respectively.  The most common amino acids found at the critical 
positions in the EF hand loop (1, 3, 5, 6, 7, 9, and 12) are shown.  (B) Example of Ca2+ co-ordination 
by the EF hand I of CaM.  The pentagonal bipyramidal co-ordination of the Ca2+ ion and hydrogen 
bonding network used to stabilize the ligand co-ordination of Ca2+ are represented in solid and 
dashed lines, respectively.  The backbone amide groups, side-chain oxygens, Ca2+ ion, and co-
ordinating water are shown in black, red, green and yellow, respectively.  X, Y, and Z represent the 
axial positions of the ligands in the pentagonal bipyramdial coordination when bound to Ca2+.  This 
figure was derived from PDB 1EXR  (Wilson and Brunger, 2000) and modified from a previous EF 
hand review (Gifford et al., 2007).    
 
Aspartate and glutamate residues are the most common ligands in this motif, with Asp being more 
frequent than Glu; this has previously been attributed to a preference in EF hands for less bulky side 
chains (McPhalen et al., 1991).  These amino acid ligands chelate Ca2+ with their negatively charged 
carboxylate groups that can form ionic bonds with the Ca2+ cation (Ca–O bonds).  The ligands bind 
to Ca2+ in a pentagonal bipyramidal coordination involving seven ligands in total (Figure 1.2).  In 
addition, the EF-loop also contains an extensive hydrogen-bonding network between the chelating 
residues and the non-chelating residues that offsets the destabilizing repulsion between the 
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negatively-charged carboxylate sidechains which are in close proximity when coordinated with Ca2+ 
(Gifford et al., 2007).   A summary of the amino acids typically found in EF hand loops is shown in 
Table 1.2. 
Table 1.2 – Frequency of specific amino acid sequences in the EF hand loops. 
Table is modified from a previous EF hand loop review (Gifford et al., 2007). 
a The position in the EF hand loop for the Ca2+ ligands are indicated.  
b The position in the pentagonal bipyramidal coordination where the Y and Z-axes are along the plane of the 
pentagon, while the X-axis is in an axial position that is perpendicular to the Y/Z plane, based upon a previous 
structural study (Strynadka and James, 1989).   
c Codes represent which part of the amino acid at the indicated position is involved in the chelation of the 
metal ion – side chain (sc) or through the backbone (bb).  The asterisk (*) highlights the ligand typically 
hydrogen-bonded to a water molecule via the side chain of the amino acid at position 9.  sc2 denotes the amino 
acid side chain found at position 12 which uses both of its oxygens in its carboxylate group to chelate the Ca2+ 
ion.   
d The most common amino acids at each position are highlighted with their corresponding percentages of 
occurrence in nature.  
e Amino acids that occur with a frequency greater than 5%. 
f
 Amino acids found at the various positions in the four calmodulin EF hand loops.  These were added to show 
the sequence homology of all four EF hand loops in CaM. 
                          
     EF Hand Loop Position a     
                         
                         
 1 2 3 4 5 6 7 8 9 10 11 12 
                          
                          
Coordinating 
ligand b X  Y  Z  -Y  -X   -Z 
  sc c   sc   sc   bb   sc*     sc2 
Most Common 
Amino Acid d Asp Lys Asp Gly Asp Gly Thr Ile Asp Phe Glu Glu 
  100% 29% 76% 56% 52% 96% 23% 68% 32% 23% 29% 92% 
Frequently    Ala Asn Lys Ser   Phe Val Ser Tyr Asp Asp 
Observed   Gln   Arg Asn   Lys Leu Thr Ala Lys   
Amino Acids e   Thr   Asn     Gln   Glu Thr Ala   
    Val         Tyr   Asn Leu Pro   
    Ile         Glu   Gly Glu Asn   
    Ser         Arg   Gln Lys     
    Glu                     
    Arg                     
                          
                          
Calmodulin f  1 2 3 4 5 6 7 8 9 10 11 12  
                          
                          
EF Hand I Asp Lys Asp Gly Asp Gly Thr Ile Thr Thr Lys Glu 
EF Hand II Asp Ala Asp Gly Asn Gly Thr Ile Asp Phe Pro Glu 
EF Hand III Asp Lys Asp Gly Asn Gly Tyr Ile Ser Ala Ala Glu 
EF Hand IV Asp Ile Asp Gly Asp Gly Gln Val Asn Tyr Glu Glu 
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 Typically, EF hand motifs are found in pairs in nature with their Ca2+-binding being 
cooperative (Biekofsky and Feeney, 1998).  Proteins with EF hand pairs include troponin C, S-100 
proteins, and calmodulin. 
1.1.3 Characteristics of Calmodulin 
Calmodulin (CaM) is a ubiquitous Ca2+-binding protein found in all eukaryotic organisms.  Most 
vertebrates contain three genes that code for CaM (CAM I, CAM II, and CAM III) that are 
transcribed into approximately 8 different mRNA molecules.  Although there are 8 mRNA 
transcripts that code for CaM, they all produce identical amino acid sequences when translated 
(Ikura and Ames, 2006).  While CaM is identical in all vertebrates, CaM is also expressed in other 
organisms such as plants, fungi and protozoa (Vetter and Leclerc, 2003).  No CAM gene has been 
found in any of the sequenced bacterial genomes, suggesting that this protein is unique to 
eukaryotes.  CaM acts as a signal transducer for many different physiological processes when 
cellular Ca2+ levels increase within a cell (Yamniuk and Vogel, 2004).   Due to the manifold and 
diverse roles of CaM in intracellular signaling, there is significant interest in a better understanding 
of the structural basis of its recognition of target proteins. 
CaM is a 148-amino-acid (16.7 kDa) protein consisting of two globular domains (N- and C-
terminal domains) joined by a central linker region giving the protein an overall “dumbbell” shape.  
There are four functional Ca2+-binding EF hands located in CaM with an EF hand pair located in 
each of its globular domains.  As mentioned in section 1.1.2, CaM’s Ca2+-binding EF hands are rich 
in aspartate and glutamate residues (Table 1.2) giving CaM a low pI of approximately 4.  CaM’s C-
terminal EF hand pair has a 10 fold higher affinity for Ca2+ than the N-terminal EF hand pair (Martin 
et al., 1985).  This allows for CaM to have various degrees of saturation with Ca2+, which 
correspond to different conformations (Jurado et al., 1999).  Figure 1.3 shows solved nuclear 
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magnetic resonance (NMR) spectroscopy and x-ray crystal structures of CaM in its Ca2+-deplete 
(apo-CaM) and Ca2+-replete (holo-CaM) conformations.   
 
Figure 1.3 – Solved NMR and x-ray crystal structures of CaM in various Ca2+-bound and 
conformational states. 
(A) Apo-CaM (Kuboniwa et al., 1995), (B) Holo-CaM (Chattopadhyaya et al., 1992), (C) trapped 
intermediate of holo-CaM (Grabarek, 2005), and (D) holo-CaM in a compact conformation (Fallon 
and Quiocho, 2003).  The structure for apo-CaM was solved by NMR, while the other three 
structures were solved using x-ray crystallography.  The N- and C-terminal domains of CaM (N-
domain = residues 1-75; C-domain = residues 82-148) are shown in pink and red, respectively.  The 
central linker of CaM (residues 76-81) is shown in grey.  Ca2+ ions are shown in green.  Models were 
derived from PDB 1CFD (apo-CaM), 1CLL (holo-CaM), 1Y6W (trapped intermediate of holo-CaM) 
and 1PRW (compact holo-CaM), respectively, and were visualized using ViewerLite 5.0 (Accelrys). 
 
Apo-CaM has a more compact, less flexible conformation than holo-CaM.  Holo-CaM structures 
have demonstrated that this protein can be in an extended state, a compact form, or in a intermediate 
configuration in between these conformations (Figure 1.3).  This is due to the highly flexible nature 
of CaM’s central linker region (residues 76-81), which can be readily unraveled and bent 
dramatically depending upon the solvent or environment that CaM is exposed to (Slaughter et al., 
2005a) as illustrated in the Figure 1.3B and D.   
The binding of Ca2+ to CaM is cooperative within each lobe of CaM but not between the 
lobes, meaning that Ca2+-binding to the N- and C-domains is exclusive from one another (Linse et 
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al., 1991; Pedigo and Shea, 1995).  The order of Ca2+-binding to CaM has previously been shown to 
be (1) EF hand III, (2) EF hand IV, (3) EF hand I, and finally (4) EF hand II, with the Ca2+ ions 
dissociating in the reverse order (Kilhoffer et al., 1992).  The rate-limiting step for Ca2+ dissociation 
from CaM was also observed to be different between the two domains (EF hands I/II and EF hands 
III/IV) (Kilhoffer et al., 1992).  
CaM contains nine methionines representing 6% of the entire amino acid content of the 
protein, which is significantly higher than the average methionine content of 1% in known 
proteomes (Ikura and Ames, 2006).  The binding of Ca2+ to CaM causes the solvent exposure of 
large hydrophobic patches in the N- and C-terminal domains which are extremely rich in methionine 
residues, with four Met residues exposed in each pocket (Bhattacharya et al., 2004; Ikura and Ames, 
2006) (Figure 1.4).    
 
Figure 1.4 – Structural representation of the exposed hydrophobic patches in the (A) N- and 
(B) C-terminal domains of holo-CaM. 
Methionine and surrounding amino acid residues found in the hydrophobic patches of holo-CaM are 
shown in orange and yellow, respectively.  Models were derived from PDB 1CLL (Chattopadhyaya 
et al., 1992) and were visualized using ViewerLite 5.0 (Accelrys).  This figure is based upon a 
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The exposure of these hydrophobic patches helps to explain CaM’s ability to bind to its various 
target proteins.  Although each domain has hydrophobic patches exposed to solvent, the 
physicochemical properties of the N- and C-terminal domains of CaM are markedly different.  
Comparing the surface binding areas of the N- and C-terminal domains of CaM, the N-terminal 
domain CaM has 49% hydrophobic and 37% acidic character versus the C-terminal domain of CaM 
that is 53% hydrophobic and 41% acidic in area (Bhattacharya et al., 2004).  These marked 
differences in hydrophobicity and acidity of the exposed patches can partially explain the specificity 
for each domain when binding to CaM target proteins.  Furthermore, the amino acid side chains 
(particularly the methionine residues) that interact with target proteins demonstrate innate flexibility 
which allows these domains to accommodate a variety of amino acid side chains (ie. Trp, Phe, Ile, 
Leu, Val, and Lys) in the target peptide (Ikura and Ames, 2006).   Clearly, the flexibility of the 
central linker facilitates the orientation of the N- and C-terminal domains of CaM, in combination 
with the structural plasticity of the methionine amino acids in the CaM hydrophobic patches, allow 
for the promiscuous nature of CaM binding to its numerous target proteins within the cell. 
1.1.4 CaM Binding to Target Peptides and Proteins 
Over the past decade, the number of reported target proteins CaM is able to recognize and bind to 
has risen from approximately 30 to over 300 thanks to the use of protein databases recognizing 
various CaM binding motifs (Crivici and Ikura, 1995; Ikura and Ames, 2006).  CaM’s modular 
characteristic appears to be unique in that the incorporation of a flexible linker between the EF hand 
pairs causes a large increase in the number of associations and/or interactions CaM can achieve 
(Ikura and Ames, 2006).   
Electrostatics has also been suggested to be in involved in the initial attraction of CaM to its 
target proteins (Vetter and Leclerc, 2003).  The numerous negatively charged residues found in CaM 
(Glu and Asp), particularly in the central linker region (residues 73-83) and the C-terminal domain 
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of CaM may form salt bridges with the positively charged residues of the target peptide.  These 
positively charged residues are generally concentrated at either the N- or C-terminus of the CaM-
binding domain of a target protein and are implicated in the determination of CaM’s orientation 
when bound to its target protein (Vetter and Leclerc, 2003) (discussed further in section 1.1.5).  
 Holo-CaM is not the only form of CaM capable of binding to target proteins – apo-CaM is 
also able to associate to some CaM-target proteins.  This contrast between the Ca2+-replete and Ca2+-
deplete association of CaM to target proteins adds another level of complexity in studying CaM.  
The following tables summarize some of the CaM-dependent proteins found in the cell that are 
bound by holo-CaM (Table 1.3) and apo-CaM (Table 1.4). 
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Table 1.3 – Summary of well-characterized holo-CaM Ca2+-dependent proteins. 
      
Group Enzyme or Protein Putative Function of Enzyme/Protein 
      
    
Protein kinases Phosphorylase b kinase Regulate glycogen metabolism 
  Myosin light chain kinase Regulate smooth muscle contraction 
  CaM kinase I Multifunctional 
  CaM kinase II Multifunctional, regulated over 30 enzymes 
    
Phosphoprotein 
phosphatase Calcineurin Metabolic regulation/cell cycle 
    
Second messenger  Type I adenylate cyclase Produce cAMP 
        metabolism cAMP phosphodiesterase Degrade cAMP 
  
Constituitive Nitric oxide 
synthase Produce nitric oxide 
  Ca2+-transport ATPase Decrease cytosolic Ca2+ 
  G protein-coupled receptors Various signaling 
    
Cytoskeletal or muscle Caldesmon Inhibit F-actin binding 
  MARCKS protein Inhibit F-actin binding 
    
Metabolism NAD kinase Convert NAD to NADP 
    
Other Microtubules Inhibit tubulin polymerization 
      
Table is modified from a previously published review (Jurado et al., 1999). 
 
Table 1.4 – Summary of some Apo-CaM binding proteins. 
      
Group Enzyme or Protein Putative Function of Enzyme/Protein or Proposed Role* 
      
    
Enzymes Phosphorylase b kinase Regulate glycogen metabolism 
  Adenylyl cyclase cAMP production 
  
Inducible nitric oxide 
synthase Produce nitric oxide 
  
Glutamate 
decarboxylase Decarboxylation of glutamate to CO2 and γ-aminobutyrate 
  
cGMP-dependent 
protein kinase cGMP- and cAMP-dependent phosphorylation 




trisphosphate receptor Inositol 1,4,5-trisphosphate binding 
         
Sarcoplasmic reticulum 
Ca2+ release channel Release of Ca
2+ from the sarcoplasmic reticulum 
    
Cytoskeletal or 
muscle Neuromodulin 
Reversible CaM storage, regulation of GTP binding to Gα, 
and regulation of phosphatidylinositol metabolism 
  Syntrophin Clustering of Na+ channels * 
    
Actin-binding 
proteins Myr4 ATP-dependent binding to F-actin 
  P190 Actin-activated ATPase 
      
Table is modified from a previously published review (Jurado et al., 1999). 
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CaM interacts with a variety of peptide sequences within its target enzymes.  Typically these 
CaM recognition sequences are approximately 20 amino acids in length and form a basic, 
amphipathic α-helical structure with a periodicity of basic residues on one face of the helix and the 
hydrophobic residues on the opposite side of the helix (Meador et al., 1992; Zhang et al., 1995; 
Venema et al., 1996; Aoyagi et al., 2003).  Although the overall sequences of the peptides that CaM 
recognizes and binds have very little sequence identity, the positions of several bulky hydrophobic 
residues are highly conserved.  There are three typical recognition motifs used in the classification of 
CaM-binding domains known as 1-5-8-14 (which include the 1-8-14 motif), 1-5-10, and IQ motifs.  
The Ca2+-dependent binding of CaM to the 1-5-8-14 motif conforms to the following sequence 
(FILVW)XXX(FAILVW)XX(FAILVW)XXXXX(FILVW) where any of the underlined 
hydrophobic residues can occupy sites 1, 5, 8, and 14 while X can represent any amino acid.  
Examples of CaM-target proteins that have a 1-5-8-14 and 1-8-14 motifs include myosin light chain 
kinase, calcineurin, and the nitric oxide synthases (Rhoads and Friedberg, 1997).  Another Ca2+-
dependent CaM-binding motif is the 1-5-10 motif which has a consensus sequence of 
(FILVW)XXX(FILV)XXXX(FILVW) where any of the underlined hydrophobic residues can 
occupy sites 1, 5, and 10.  Prime examples of CaM-target proteins with 1-5-10 CaM-binding motifs 
include CaM-dependent kinase I, CaM-dependent kinase II and MARCKS protein (Rhoads and 
Friedberg, 1997).  CaM binds to the IQ motif in a Ca2+-independent manner and the sequence 
IQXXXRGXXXR (where X denotes any amino acid) defines this motif; however, this overall motif 
is only loosely adhered to in many cases since the Ile is frequently substituted with a Leu (Jurado et 
al., 1999).  Examples of CaM-target proteins that have IQ motifs are neuromodulin, protein kinase 
C, p68 RNA helicase and voltage-gated Ca2+-channels (Rhoads and Friedberg, 1997).  
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1.1.5 Solved Structures of CaM bound to Peptides and Enzymes 
The structural basis for CaM’s ability to bind to target proteins is of great interest to the research 
community since CaM plays an important role in inter- and intracellular physiological processes.  In 
1992, the original structure of CaM bound to a CaM-target peptide from myosin light chain kinase 
(MLCK) was solved by NMR spectroscopy (Ikura et al., 1992) showing a Ca2+-replete CaM tightly 
wrapped around the peptide.  Soon after this initial structure, an x-ray structure of holo-CaM bound 
to a peptide from CaM-dependent protein kinase II (CaMKII) was released which also demonstrated 
CaM wrapping tightly around a target peptide (Meador et al., 1993).  These two CaM-target peptide 
structures suggested a general mechanism for CaM binding to CaM-dependent proteins and enzymes 
in the cell.  When compared to the structure of holo-CaM (Figure 1.3B), it became apparent that 
CaM’s central linker could readily unwind and allow for the optimal orientation of the N- and C-
terminal domains of CaM to associate to the basic, amphipathic CaM recognition α-helix. 
Since the release of these structures, numerous other CaM-target peptide structures have 
been solved by using x-ray crystallography and NMR spectroscopy, with most of these structures 
being released in recent years.  These structures predominantly show compact conformations of 
CaM having either an anti-parallel or parallel orientation when bound to the target peptide.  When 
CaM binds in an anti-parallel fashion, the N-terminal domain of CaM binds closer to the C-terminus 
of the target peptide, while the C-terminal domain of CaM binds closer to the N-terminus of the 
peptide.  In contrast, when CaM binds to its target protein in a parallel orientation, the N-terminal 
domain of CaM binds closer to the N-terminus of the target peptide, while the C-terminal domain of 
CaM closer to the C-terminus of the peptide.  Figure 1.5 shows all the solved structures of anti-
parallel Ca2+/CaM-target peptide complexes known to date.  These CaM-target peptide complexes 
originate from a wide variety of enzymes including various protein kinases, nitric oxide synthases, 
ion channels, and receptor proteins.  Likewise, Figure 1.6 contains all of the solved structures of 
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holo-CaM bound to its target peptides in a parallel orientation.  These parallel CaM-peptide 
structures include a voltage-gated Ca2+-channel, myristoylated CAP-23/NAP-22 peptide and CaM-
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Figure 1.5 – Solved structures of CaM bound to various target peptides in an anti-parallel 
orientation.  
Structures shown represent CaM when bound to peptides derived from (A) myosin light chain kinase 
(MLCK; (Ikura et al., 1992), (B) CaM-dependent protein kinase II (CaMKII) (Meador et al., 1993), 
(C) endothelial nitric oxide synthase (eNOS) (Aoyagi et al., 2003), (D) neuronal nitric oxide 
synthase (nNOS) (Ng et al. – unpublished, co-ordinates released 2007-12-25), (E) death-associated 
protein kinase I (DAP kinase I) (Kursula et al. - unpublished, co-ordinates released 2006-07-04), (F) 
human death-associated protein kinase II (DAP kinase II) (Kursula et al. - unpublished, co-ordinates 
released 2006-03-21), (G) death-associated related protein kinase I (DRP-1 kinase) (Kursala et al. – 
unpublished, co-ordinates released 2006-11-14), (H) myristoylated alanine-rich C kinase substrate 
(MARCKS) (Yamauchi et al., 2003), (I) CaM-dependent protein kinase I (CaMKI) (Clapperton et 
al., 2002), (J) ryanodine receptor (RyR) (Maximciuc et al., 2006), (K) N-methyl-D-aspartate 
receptor (NMDA receptor) (Ataman et al., 2007), (L) olfactory cyclic-nucleotide gated channel 
(olfactory CNG channel) (Contessa et al., 2005), and (M) alpha II-spectrin (Simonovic et al., 2006).  
The colour scheme used is as previous described in Figure 1.3, with the exception that the CaM-
target peptides are shown in blue.  The N- and C-termini of the target peptides are labeled for clarity 
purposes.  Models were derived from PDB 2BBN (MLCK), 1CDM (CaMKII), 1N1W (eNOS), 
2O60 (nNOS), 1YR5 (DAP kinase I), 1WRZ (DAP kinase II), 1ZUZ (DRP-1 kinase), 1IWQ 
(MARCKS), 1MXE (CaMKI), 1BCX (RyR), 2HQW (NMDA receptor), 1SY9 (olfactory CNG 
channel), and 2FOT (alpha II-spectrin), respectively.  Models were visualized using ViewerLite 5.0 
(Accelrys). 
 




Figure 1.6 – Solved structures of CaM bound to various target peptides in a parallel 
orientation. 
Structures shown represent CaM when bound to peptides derived from (A & B) IQ domain of the 
Ca2+ 1.2 voltage-gated Ca2+ channel (CaV1.2 Ca2+ channel; A – 29 residue peptide solved by x-ray 
crystallography; B – 22 residue peptide solved by x-ray crystallography) (Fallon and Quiocho, 2003; 
Van Petegem et al., 2005), (C) myristoylated CAP-23/NAP-22 peptide (Matsubara et al., 2004), (D 
& E) CaM-dependent kinase kinase (CaMKK; D – 26 residue peptide solved by x-ray 
crystallography (Kurokawa et al., 2001); E – 27 residue peptide solved by NMR spectroscopy, 
(Osawa et al., 1999)).  The colour scheme and labels used are as previous described in Figure 1.5 
with the exception that the myristoyl group in (C) is shown in dark grey.  Models were derived from 
PDB 2BE6 (A) and 2F3Y (B) (CaV1.2 Ca2+ channel), 1L7Z (myristoylated CAP-23/NAP-22), and 
1IQ5 (D) and 1CKK (E) (CaMKK), respectively.  Models were visualized using ViewerLite 5.0 
(Accelrys). 
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 In 1999, the NMR structure of CaM bound to a peptide from the plasma membrane Ca2+-
pump was solved, showing that only the C-terminal domain of CaM associated with the target 
peptide, whereas no association whatsoever occurred with the N-terminal domain of CaM (Elshorst 
et al., 1999)  (Figure 1.7F).  This unique structure changed the classic view that CaM always 
wrapped around its target protein and showed that CaM can take on a variety of other conformations.  
Similarly, the x-ray crystal structure of CaM in complex with small conductance Ca2+-activated K+ 
channel also showed a single domain of CaM associated to the target peptide (Schumacher et al., 
2001).  In this case, only a Ca2+-replete N-terminal domain of CaM is in complex with the peptide, 
while the Ca2+-deplete C-terminal domain of CaM does not interact with the peptide at all (Figure 
1.7A).  Figure 1.7 shows other examples of unique CaM conformations with various target peptides 
and proteins.   
A CaM-target protein structure of particular interest is the unique x-ray crystal structure of 
CaM in complex with the edema factor of adenylyl cyclase from Bacillus anthracis (Figure 1.7E).  
This structure is unique since it is the first intact protein fragment in complex with CaM ever to be 
solved (Drum et al., 2002).  Another point to note regarding this structure is that CaM does not wrap 
around its target protein as it typically does (Figure 1.5 and Figure 1.6); instead, the edema factor 
wraps itself around CaM causing CaM to adopt an extended conformation as well as a decreased 
affinity for Ca2+ in its N-terminal domain, which has since been further corroborated by other x-ray 
crystal structures (Shen et al., 2005).  Another structure of interest is CaM in complex with 
glutamate decarboxylase solved by NMR (Yap et al., 2003) where CaM wraps around two C-
terminal peptides of the enzyme that form a cross-like conformation (Figure 1.7D). 
Clearly, the solved structures of CaM-target peptide/protein complexes (Figure 1.3, 1.5, 1.6, 
and 1.7) demonstrate that CaM’s flexibility enables it to take on a variety of conformations when 
bound to target peptides and proteins ranging from tightly wrapped to extended structures.   
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Figure 1.7 – Solved structures of CaM bound to various target peptides and proteins in unique 
conformations. 
Structures shown represent (A) holo-CaM bound to the gating domain of the small conductance 
Ca2+-activated K+ channel from different perspectives – (i) sideways and (ii) down the barrel of the 
peptide (holo-CaM/SK K+ channel) (Schumacher et al., 2001), (B) apo-CaM bound to the gating 
domain to the small conductance Ca2+-activated K+ channel (apo-CaM/SK K+ channel) (Schumacher 
et al., 2004), (C) fusion protein of CaM with a calcineurin peptide from different perspectives – (i) 
sideways and (ii) on edge (CaM-CaN peptide) (Ye et al., 2006), (D) holo-CaM in complex with 
petunia glutamate decarboxylase from different perspectives – (i) down the barrel of the peptide and 
(ii) sideways (Yap et al., 2003), (E) CaM in complex with the edema factor of adenylyl cyclase of B. 
anthracis (Drum et al., 2002), (F) holo-CaM in complex with the plasma membrane Ca2+-pump 
(Elshorst et al., 1999), and (G) two apo-CaMs bound to an unconventional myosin V IQ domain 
(Houdusse et al., 2006).  Please note that all of these structures were solved with CaM-target 
peptides with the exception of (E), which was solved in the presence of the holo-enzyme.  The 
colour scheme and labels used are as previous described in Figure 1.5.  Models were derived from 
PDB 1G4Y (holo-CaM/SK K+ channel), 1QX7 (apo-CaM/SK K+ channel), 2F2O (CaM-CaN 
peptide), 1NWD (Glutamate decarboxylase), 1K93 (edema factor from B. anthacis), 1CFF (plasma 
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1.1.6 Regulation of CaM binding to target proteins 
An additional feature of CaM that can increase or decrease its affinity of target proteins is 
posttranslational modifications.  Previous studies have demonstrated that CaM can undergo 
acetylation, trimethylation, carboxymethylation, proteolytic cleavage, methionine oxidation and 
phosphorylation in vivo (Watterson et al., 1980; Murtaugh et al., 1983; Murtaugh et al., 1986; Squier 
and Bigelow, 2000; Benaim and Villalobo, 2002).   These chemical modifications of various 
residues in CaM have been suggested as a possible mechanism to modulate its activity as a Ca2+-
sensor protein in the cell; however, the physiological role for these posttranslational modifications of 
CaM and their effect on the binding and activation of CaM target enzymes has yet to be determined 
(Benaim and Villalobo, 2002; Ikura and Ames, 2006). 
 A recent review discussed the possibility of regulating CaM binding to target proteins at the 
transcriptional level by studying the promoter and comparing the stabilities and abundance of 
mRNA transcripts from different CaM genes in rats and humans (ie. CAM I, CAM II, and CAM III) 
(Kortvely and Gulya, 2004); however, this method of studying CaM’s regulation at the 
transcriptional level is relatively new and requires further studies to determine if this will prove to be 
an effective method for controlling CaM expression within the cell. 
The use of small hydrophobic drug molecules is another method that has been studied to 
manipulate CaM’s association to its target proteins.  These drug molecules have been shown to 
directly bind to CaM and interfere with its ability to associate to target proteins that can lead to 
altered intracellular processes (Roufogalis et al., 1983).  The classic CaM antagonist that has been 
studied is trifluoperazine (Figure 1.8A), an anti-psychotic drug that has been shown to markedly 
affect Ca2+/CaM-dependent interactions by binding to the exposed hydrophobic patches in holo-
CaM’s N- and C-terminal domains.  Unfortunately, there is little specificity for this drug in binding 
to CaM since it has also been shown to interact and inhibit other Ca2+-binding proteins and lipid-
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dependent enzymes within the cell (Roufogalis et al., 1983).  It was determined experimentally that 
4 equivalents of trifluoperazine were capable of binding to CaM by HPLC (Massom et al., 1990) and 
this finding was later confirmed by x-ray crystallography (Vandonselaar et al., 1994) (Figure 1.9B).  
Another structure was also solved with trifluoperazine in a 1:1 complex with CaM, demonstrating 
the variability in the number of molecules that can associate to CaM (Cook et al., 1994) (Figure 
1.9A).  In both structures of CaM-trifluoperazine, the binding of the drug stimulates CaM to collapse 
similar to the wrapped conformation of CaM in complex with various target peptides, as previously 
discussed (section 1.1.5). 
 
Figure 1.8 – Chemical structures of CaM antagonist molecules. 
(A) Trifluoperazine (Massom et al., 1990), (B) N-(3,3,-diphenylpropyl)-N'-[1-R-(2,3,4-bis- 
butoxyphenyl)-ethyl]-propylenediamine, (an arylalkylamine-type CaM antagonist, AAA) (Harmat et 
al., 2000), and (C) 3''-(b-chloroethyl)-2'',4''-dioxo-3,5''-spiro-oxazolidino-4-deacetoxy-vinblastine 
(KAR-2) (Orosz et al., 1997). 
  
Recently, other small molecules that bind to CaM have also been studied.  The anti-
pyschotic drug, AAA (Figure 1.8B), was shown to have a similar affect on Ca2+/CaM-dependent 
interactions as trifluorperazine.  The anti-tumor drug KAR-2 (Figure 1.8C) was shown to bind to 
CaM, however, it had very little effect on CaM’s ability to bind target proteins (Orosz et al., 1997).   
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Figure 1.9 – CaM in complex with various small molecules. 
Structures shown represent holo-CaM in complex with (A) 10-[3-(4-methylpiperazin-1-yl)propyl]-2-
(trifluoromethyl)phenothiazine (trifluoperazine, TFP) in a 1:4 complex (Vandonselaar et al., 1994), 
(B) TFP in a 1:1 complex (Cook et al., 1994), (C) N-(3,3,-diphenylpropyl)-N'-[1-R-(2,3,4-bis- 
butoxyphenyl)-ethyl]-propylenediamine (AAA) in a 1:2 complex (Harmat et al., 2000), and (D) 3''-
(b-chloroethyl)-2'',4''-dioxo-3,5''-spiro-oxazolidino-4-deacetoxy-vinblastine (KAR-2) in a 1:1 
complex (Horvath et al., 2005).  The colour scheme and labels used are as previous described in 
Figure 1.5 with the exception that the small molecules in complex with CaM are shown in various 
shades of yellow.  Models were derived from PDB 1XA5 (holo-CaM/KAR-2 1:1 complex), 1QIV 
(holo-CaM/DPD 1:2 complex), 1CTR (holo-CaM/TFP 1:1 complex), and 1LIN (holo-CaM/TFP 1:4 
complex).  Models were visualized using ViewerLite 5.0 (Accelrys). 
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Both of these small hydrophobic drug molecules demonstrate a similar mechanism as trifluoperazine 
on CaM by interacting with the hydrophobic patches in lobes of CaM and causing the protein to 
collapse around the drug molecule (Harmat et al., 2000; Horvath et al., 2005).  Since CaM plays 
such an important role in many cellular processes, it is actually not an ideal drug target.  This method 
of using drugs to regulate CaM binding to target proteins requires further studies to ensure that these 
drugs do not affect other essential physiological processes within the cell. 
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1.2 Nitric Oxide Synthase (NOS) 
As mentioned previously, CaM can bind and/or regulate more than 300 intracellular enzymes and 
proteins.  Among these many and varied target enzymes are the mammalian nitric oxide synthase 
(NOS) isozymes.  This section covers the physiological relevance of nitric oxide, as well as the 
characteristics, mechanism, and regulation of the NOS enzymes.  Particular focus is given to the 
differences in the binding and activation of the NOS enzymes by CaM.    
1.2.1 Nitric Oxide 
 Over the past 15 years, nitric oxide (•NO) has become one of the most studied molecules in 
biochemistry.  The 1998 Nobel Prize in Physiology and Medicine was awarded to Furchgott, 
Ignarro, and Murad for their studies involving •NO as a cardiovascular signal molecule.  A resent 
search on PubMed (www.ncbi.nlm.nih.gov) shows that over the past 15 years, approximately 88,000 
papers have been published on work related to •NO in a wide variety of disciplines. 
 •NO is a highly reactive diatomic free radical that is biologically active due to its ability to 
freely diffuse across cellular membranes and interact with intracellular proteins (Snyder and Bredt, 
1992).  •NO has been found to affect many different processes within mammals including 
neurotransmission, memory, blood-pressure control, blood clotting, and immune defense (Alderton 
et al., 2001; Kroncke et al., 2001), with the list continuing to grow.  The classic example of •NO-
mediated signaling is the activation of soluble guanylyl cyclase in muscle cells surrounding blood 
vessels.  The activation of this enzyme causes an increase of cGMP, an intracellular secondary 
messenger that activates various cGMP-dependent kinases, including protein kinase G (PKG).  PKG 
is able to phosphorylate the IP3 receptor (as described in section 1.1.1) which leads to a decrease in 
intracellular Ca2+ levels (Schmidt et al., 1993).  The lower Ca2+ concentration causes the relaxation 
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of the smooth muscle cells surrounding the blood vessel and results in vasodilation (Schmidt et al., 
1993).   
Although •NO is important in many beneficial physiological processes, it can also 
potentially act as a toxin by reacting with other reactive oxygen species (ROS), such as superoxide 
(•O2-) to form peroxynitritre (OONO-).  Uncontrolled levels of •NO and OONO- can alter cellular 
signaling and cause oxidative damage to lipids, proteins and DNA (Pacher et al., 2007).  Table 1.5 
gives a summary of some of the beneficial and damaging affects •NO can have on various types of 
tissue. 
 
Table 1.5 – •NO-mediated effects in various tissues. 
      
Tissue Messenger/Modulator Toxin 
      
    
Blood vessels Endothelium-derived relaxing factor Septic shock 
  Anti-thrombotic Atherosclerosis 
  Inhibition of smooth muscle              migration and proliferation  
    
Heart Ischemia Septic shock 
  Coronary perfusion  
    
Lung Mucus secretion Immune complex-induced alveolitis 
  Immune defense Acute respiratory distress syndrome?  
  Bronchiociliar motility Asthma? 
    
Central nervous  Memory formation Neurotoxic 
      system Cerebral blood flow and ischemia Migrane 
  Synaptogenesis  
  Synaptic plasticity  
  Olfaction  
    
Pancreas Endocrine/exocrine secretion β-cell destruction 
    
Gastrointestinal Blood flow Mucosal damage 
  Peristalsis Mutagenesis 
  Mucosal protection  
  Exocrine secretion  
    
Immune system Anti-microbial Graft versus host disease 
  Anti-tumour Inflammation 
   Septic shock 
   Tissue damage 
      
Table is modified from a previous •NO review (Schmidt and Walter, 1994). 
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The nitric oxide synthase (NOS, EC 1.14.13.39) enzymes catalyze the production of •NO with L-
citrulline as a byproduct through two successive mono-oxygenation reactions requiring reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) and molecular oxygen (Alderton et al., 
2001) (Figure 1.10).   
 
Figure 1.10 – NOS-catalysed conversion of L-arginine through the intermediate NG-hydroxy-
L-arginine to L-citrulline and •NO.  
Electrons originating from NADPH and molecular O2 are required for each of the mono-oxygenation 
steps.  This figure is modified from a previous review (Feldman et al., 1993). 
 
1.2.2 Structural characteristics of the Mammalian NOS isozymes 
There are three mammalian NOS isoforms - neuronal NOS (nNOS, NOS I), endothelial NOS 
(eNOS, NOS III), and inducible NOS (iNOS, NOS II).  These three distinct NOS isozymes have 
been shown to have 51-57% sequence identity in humans (Alderton et al., 2001) and their respective 
gene locations have been identified.  The human nNOS gene is found on chromosome 12q24.2 and 
extends over 100 kb (Nathan and Xie, 1994).  The human eNOS gene is located on chromosome 
7q35-7q36 and contains 26 exons over a span of 21 kb (Marsden et al., 1993).  The 37 kb gene 
coding for human iNOS is located on chromosome 17cen-q11.2 and contains 26 exons (Marsden et 
al., 1994).   
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The NOS enzymes are homo-dimeric proteins and bind to CaM in a 1:1 ratio when in their 
active form (Alderton et al., 2001).  Each NOS monomer contains an N-terminal oxygenase domain 
and a multidomain C-terminal reductase domain.  The oxygenase domain contains binding sites for 
iron protoporphyrin IX (heme), (6R)-5,6,7,8-tetrahydrobiopterin (H4B), and the substrates L-arginine 
and molecular oxygen (Roman et al., 2002).  The heme iron is penta-coordinated with a cysteine 
residue that provides the single thiolate axial ligand.  This cysteine residue is conserved in all of the 
NOS enzymes and has been determined to be at positions C186 of bovine eNOS (Chen et al., 1994), 
C415 of rat nNOS (Richards et al., 1996), and C200 of human iNOS (Cubberley et al., 1997).  The 
reductase domain binds flavin mononucletide (FMN), flavin adenine dinucleotide (FAD), and 
NADPH (Roman et al., 2002).  A CaM-binding domain separates the oxygenase and reductase 
domains (Figure 1.11).  The chemical structures of the four cofactors found in the reductase and 
oxygenase domains of the mammalian NOS enzymes are shown in Figure 1.12.   
 
Figure 1.11 – Alignment of NOS enzymes. 
The oxygenase and reductase domains are shown in dark grey and light grey, respectively.  A CaM-
binding domain separates the oxygenase and reductase domains.  Numbers represent the amino acid 
residue at the start and end of the oxygenase, FMN, and FAD/NADPH domains.  The myristoylation 
(Myr) modification site as well as the PDZ, protein inhibitor of NOS (PIN), (6R)-5,6,7,8-
tetrahydrobiopterin (H4B), and zinc binding sites are shown.  The A.I. represents the auto-inhibitory 
domains that are exclusive to the nNOS and eNOS enzymes.  This figure is modified from a 
previous review (Alderton et al., 2001). 




Figure 1.12 – Chemical structures of cofactors bound to mammalian NOS enzymes. 
The redox cofactors found in the reductase domain of NOS – (A) Flavin adenine dinucleotide 
(FAD), and (B) Flavin mononucleotide (FMN).  NOS oxygenase cofactors – (C) (6R)-5,6,7,8-
tetrahydrobiopterin (H4B), and (D) Iron protoporphyrin IX (heme). 
 
The nNOS and eNOS enzymes are constitutively expressed, which is why they are 
collectively refered to as the constitutive NOS (cNOS) isoforms.  Both nNOS and eNOS were 
initially found to be produced in neuronal and endothelial tissue respectively, but have since been 
found to be expressed in other tissues throughout the body as well (Ghosh and Salerno, 2003).  The 
molecular weight of rat nNOS and bovine eNOS monomers are 160 kDa and 135 kDa, respectively.  
The molecular weight difference in the cNOS enzymes can be attributed to the size of their N-
termini.  The nNOS enzyme contains a unique PDZ domain that interacts with postsynaptic density 
protein-95 believed to be involved in controlling the localization of nNOS within the cell (Kone, 
2000).  Another N-terminal binding site exists in nNOS for a protein that inhibits the nNOS enzyme 
(protein inhibitor of NOS, PIN) by disrupting the production of •NO and •O2- (Xia et al., 2006).  The 
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eNOS isozyme has a distinctive myristolation (Myr) N-terminal modification site where a fatty acyl 
group is posttranslationally attached to allow the enzyme to be associated to the cellular membrane 
(Figure 1.11).  The cNOS enzymes are Ca2+-dependent since their binding and activation are 
dependent on intracellular Ca2+ and CaM concentrations (Roman et al., 2002).   •NO produced by 
nNOS functions as a neurotransmitter, which allows for signalling between distant and adjacent cells 
(Alderton et al., 2001).  •NO operates as a vasodilator when produced by eNOS in blood vessels, 
allowing for unrestricted blood flow (Snyder and Bredt, 1992). 
In contrast to the cNOS enzymes which are constitutively expressed, iNOS is 
transcriptionally regulated in vivo by cytokines in macrophages and binds to CaM at basal levels of 
Ca2+ (Roman et al., 2002).  Since this enzyme binds to CaM regardless of cellular Ca2+ 
concentrations, this enzyme is classified as Ca2+-independent.  The human iNOS monomer has a 
molecular weight of 125 kDa.  To date, iNOS could not be isolated in its CaM-free form.  
Apparently, the interaction between iNOS and CaM is so strong that CaM is not released once it has 
associated to iNOS.  For this reason, CaM has been classified as a subunit of iNOS (Cho et al., 
1992).  The properties of the NOS enzymes and some of their roles in diseases are summarized in 
Table 1.6. 
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Table 1.6 – Summary of the properties and roles of mammalian NOS isozymes 
       Active homodimers   
Structural and Ca2+-dependent Ca2+-independent 
Enzymatic Parameters nNOS (NOS I) eNOS (NOS III) iNOS (NOS II) 
     
Subunit molecular mass 160 kDa 135 kDa 125 kDa 
     
Inducibility Constituitive Constituitive Inducible 
     
CaM-binding (~ Kd) ~30 x 10-9 M ~30 x 10-9 M 
Subunit-like  
(<< 30 x 10-9 M) 
     
Cofactors H4B, FAD, FMN,  heme, Zn 
H4B, FAD, FMN, 
heme, Zn 
H4B, FAD, FMN,  
heme, Zn 
     
Protein variants α, β, μ, γ tissue-specific isoforms — — 
     
Postranslational modifications Specific phosphorylation  Myristoylation Specific phosphorylation  
             sites present Palmitoylation            site present 
   
Phosphorylation sites 
present  
     
Sources of superoxide formation Heme domain, reductase domain Mainly heme domain Mainly reductase domain 
     
Major physiological function Neurotransmission Vasodilatation Cytotoxicity 
     
Role in disease Stroke Endothelial dysfunction Toxic shock 
  Muscular dystrophy Hypercholesterolemia Inflammation 
  Ischemia-reperfusion injury Hypertension Autoimmune disease 
        
Table modified from a previously published review (Masters, 2000). 
 
Numerous crystal structures of the three NOS oxygenase domains have been published (Fischmann 
et al., 1999; Crane et al., 2000; Matter et al., 2005).  These x-ray crystal structures have shown that 
the interface located between the oxygenase domains and a structural zinc ion coordinated by four 
conserved cysteine residues (two from each monomer) are involved in dimer stability (Figure 1.13).  
To date, there has only been one solved crystal structure of the reductase domain of nNOS released; 
it suggests that the reductase domain can also dimerize (Garcin et al., 2004) (Figure 1.14).   
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Figure 1.13 – X-ray crystal structures of rat nNOS oxygenase with bound L-arginine. 
Each monomer backbone is shown in cyan and green.  Heme, H4B, zinc ion and L-arginine are 
shown in red, blue, black, and yellow, respectively. (A) Solved structure of the rat nNOS oxygenase 
domain (PDB 1ZVL, (Matter et al., 2005), and (B) highlighted region of panel A to clarify cofactor 




Figure 1.14 – X-ray crystal structures of rat nNOS reductase domain. 
Each monomer backbone is shown in cyan and green.  NADP+, FAD and FMN are shown in red, 
orange, and yellow, respectively. (A) Solved structure of the rat nNOS reductase domain (PDB 
1TLL, (Garcin et al., 2004), and (B) highlighted region of panel A to clarify cofactor locations.  
Models were visualized using ViewerLite 5.0 (Accelrys). 
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While there is no doubt that the oxygenase domains of NOS are dimeric, the question of whether the 
reductase domain is also involved in the enzyme’s dimerization is a point of debate.   The dimer 
observed in the nNOS reductase domain crystal structure could be a crystallization artifact or it 
could represent another interface or site for NOS dimerization.  Future structures of the NOS 
reductase domains will hopefully clarify if the reductase domain is in fact a monomer or dimer. 
1.2.3 Electron transfer within NOS 
Electron transfer within the NOS enzymes is dependent on CaM binding.  The mechanism of how 
CaM binding facilitates electron transfer from NADPH to the heme is not fully understood and is not 
equivalent in all three NOS isoforms (Newman et al., 2004; Spratt et al., 2006).  At elevated Ca2+ 
concentrations, CaM binds to the cNOS enzymes and promotes the transfer of electrons originating 
from NADPH through the reductase domain to the catalytic heme of the adjacent NOS monomer’s 
oxygenase domain (Abu-Soud et al., 1994; Chen et al., 1996; Stevens-Truss et al., 1997; Siddhanta 
et al., 1998; Sagami et al., 2001; Ghosh and Salerno, 2003).  In contrast, electron transfer within the 
reductase domain of iNOS has previously been determined to be CaM-independent (Newton et al., 
1998).  Electron transfer from the FMN to the catalytic heme centre in iNOS is generally considered 
to be CaM-dependent  (Siddhanta et al., 1998; Ghosh and Salerno, 2003; Feng et al., 2006).   
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Figure 1.15 – Electron transfer within a NOS dimer. 
The NOS monomers are shown in white and grey, respectively.  CaM is shown in pink.  Electrons 
are transferred through the reductase domain (NADPH to FAD, FAD to FMN) to the heme in the 
oxygenase domain of the opposite NOS monomer.  This model is derived from the solved crystal 
structures of the nNOS oxygenase and reductase domains (as shown in Figure 1.13A and Figure 
1.14A) from a previously published study (Garcin et al., 2004).  
 
Two explanations for the CaM-dependence of electron transfer in NOS have been proposed:  (1) 
CaM may have the ability to change the redox potential difference between the flavins and the heme 
of NOS, or (2) CaM is able to cause a structural change in the NOS enzymes, allowing for more 
efficient electron transfer within the reductase domain and from the reductase to oxygenase domains 
(Daff et al., 2001).  It has been shown that CaM binding to the isolated reductase or oxygenase 
domains of nNOS does not significantly change the redox potentials of the flavins or heme cofactors 
(Noble et al., 1999).  This finding was later confirmed using full length eNOS and nNOS (Gao et al., 
2004).  However, a recent study proved that the binding of CaM and NADP+ to the nNOS reductase 
domain does in fact perturb the redox potential of the flavins (Dunford et al., 2007).  In either case, 
Chapter 1: Literature Review 
 33 
all of these studies agree that CaM binding is pivotal for efficient electron transfer to occur in NOS.  
Protein modelling has suggested that the distances between the FAD and FMN cofactors in the 
reductase domain are too large for efficient electron transfer to take place (Ghosh and Salerno, 
2003).  Furthermore, these models suggest that the distances between the FMN and heme centres are 
greater than 25 Å (Ghosh and Salerno, 2003).  These distances would be too large for electron 
transfer to occur from the flavins to the heme; therefore it is probable that a major structural 
rearrangement is necessary for the NOS enzymes to properly function (Figure 1.16).  This suggests 
that CaM facilitates large conformational changes within NOS by moving the FMN-binding domain, 
a region within the reductase domain that is suggested to be a highly dynamic and flexible due to a 
hinge domain, from an electron-accepting position (FAD FMN) to an electron-donating position 
(FMN heme) (Figure 1.16).   
 
Figure 1.16 – Electron transfer and •NO production controlled by CaM-dependent 
conformational changes between the NOS cofactors. 
(A) Intramolecular electron transfer within the reductase domain, and (B) intermolecular electron 
transfer from the reductase domain to the heme of the oxygenase domain of the adjacent NOS 
enzyme in the dimer.  This model is modified from a previous NOS review (Ghosh and Salerno, 
2003). 
 
Chapter 1: Literature Review 
34 
Another control mechanism for electron transfer in the reductase domain of nNOS is the NADPH 
conformational lock (Craig et al., 2002; Daff, 2003).  Previous studies have suggested that this 
“locked” conformation occurs after NADPH transfers a hydride to FAD to form FADH2 and a 
subsequent NADPH molecule binds and is unable to transfer its hydride to reduced FADH2.  In 
order to unlock the reductase domain, the FAD needs to be regenerated to accept another hydride 
from NADPH and pass electrons through the rest of the NOS enzyme.  The large conformational 
change that CaM induces in the reductase domain of the NOS enzymes (Figure 1.16) allows for the 
FMN domain to interact with both the FAD to accept electrons and pass the electrons on to the heme 
during catalysis.  The electron transfer from FADH2 to FMN regenerates FAD thereby unlocking the 
reductase domain (Craig et al., 2002; Daff, 2003).  Clearly, these conformational changes caused by 
CaM are important in stimulating efficient electron transfer with the NOS enzymes. 
1.2.4 Catalytic mechanism of NOS 
The proposed mechanism for •NO production by NOS involves two successive mono-
oxygenation reactions, similar to the cytochrome P450 mono-oxygenase mechanism (Alderton et al., 
2001).  The first reaction involves the hydroxylation of the guanidino nitrogen of L-arginine to 
produce the intermediate NG-hydroxy-L-arginine (NOHA).  The second reaction oxidizes NOHA to 
•NO and L-citrulline (see Figure 1.10).   
The NOS and cytochrome P450 enzymes share many common traits including a thiolate- 
ligated heme prosthetic group (Gorren and Mayer, 2007).  Since the mechanism of NOS catalysis is 
similar to that of cytochrome P450, the structure of the oxygenase domain of the NOS enzymes was 
originally believed to be similar to other heme containing proteins, such as peroxidases and 
catalases, which have their heme binding pockets lined predominantly with α-helices (Graham and 
Peterson, 1999).  In contrast, the x-ray crystal structure of iNOS’s oxygenase domain demonstrated 
an overall topology similar to a left-handed baseball catcher’s glove with the heme binding-site 
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located in the palm of the mitt and a large cavity above the heme where O2 and L-arginine are able to 
bind (Crane et al., 1997).  Another striking difference between the NOS and cytochrome P450 
enzymes is the presence of H4B in the NOS oxygenase domain which has been implicated in NOS 
dimer stability (Panda et al., 2002). 
 There have been conflicting reports on the role of H4B in the catalytic mechanism of NOS.  
It had previously been postulated that the H4B is a potential electron donor to the heme and is 
regenerated by electrons from the reductase domain (Hurshman and Marletta, 2002).  However, 
crystal structures have shown that H4B is buried within the dimer interface of the enzyme and is 
supposedly inaccessible to electrons from the reductase domain so that it could not be regenerated 
after it is oxidized during the mono-oxygenation reactions (Crane et al., 1998; Stuehr, 1999).   
Although it is generally accepted that the stoichiometry of NADPH oxidation to •NO production is a 
3 to 2 ratio (Griffith and Stuehr, 1995), which is in good agreement with FMN acting as the sole 
electron donor to the heme center, the H4B cofactor still plays an important role in the mechanism of 
the NOS enzymes.  Recent studies have clarified the direct role H4B has in the NOS catalytic 
mechanism.  This updated mechanism is shown in Figure 1.17. 
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Figure 1.17 – Proposed catalytic mechanism of the NOS enzymes through two mono-
oxygenation reactions. 
Arg, NOHA, and Cit represent L-arginine, NG-hydroxy-L-arginine, and L-citruline, respectively.  
The guanidino-group of L-arginine is shown throughout this mechanism to help clarify the 
modifications of L-arginine during the two mono-oxygenation reactions.  FMNH2, FMNH•, and 
•H4B+ represent fully reduced FMN, semi-reduced FMN, and H4B radical formed during catalysis, 
respectively.  This figure is based upon a recent review (Stuehr et al., 2004) and modified from a 
previously published NOS review (Stuehr, 1999). 
 
 
The first mono-oxygenation reaction in the NOS catalytic mechanism involves an electron 
transfer from the reductase domain to the ferric heme (Fe3+) in the oxygenase domain.  This is the 
slowest step of the reaction and allows for the binding of molecular oxygen and the formation of a 
ferric-superoxy species (Fe(III)-O2-; Species I) (Stuehr, 1999; Stuehr et al., 2004).  In order to avoid 
the release of •O2-, the input of a second electron from H4B occurs to generate a ferric-peroxo 
species (Fe(III)-OO2-; Species II).  The formation of a H4B radical has been supported by numerous 
studies and H4B is proposed to be regenerated by another electron from the reductase domain 
(Hurshman and Marletta, 2002; Hurshman et al., 2003; Stuehr et al., 2004; Gorren and Mayer, 
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2007).  The O—O bond in Species II is subsequently cleaved producing an iron-oxo species 
(Fe(IV)=O; Species III) and the release of a water molecule (Mansuy and Renaud, 1995).  Species 
III then hydroxylates L-arginine to produce NOHA (Figure 1.17).   
The second mono-oxygenation reaction involves the generation of species I, as previously 
described for the first reaction.  Originally, Species II was thought to act as an oxidant and abstract 
an electron from NOHA to generate a nucleophilic Fe(III)-OO2- species and an NOHA radical.  This 
reactive species was then predicted to react directly with the NOHA radical, generating a tetrahedral 
intermediate that rearranges to release the products •NO and L-citrulline (Stuehr, 1999).  However, 
recent studies have shown that H4B is also involved in the second mono-oxygenation reaction of 
NOHA by donating an electron and subsequently regenerated later in the reaction (Wei et al., 2003a) 
(Figure 1.17).  The first electron transfer from H4B allows for the formation of Species II, which 
oxidizes NOHA, causing the subsequent release of citrulline (Wei et al., 2003b).  The second 
electron transfer involves the regeneration of H4B and the formation of a ferric-•NO product 
complex (Fe(III) •NO), which then releases •NO, thus completing the NOS catalytic mechanism 
(Wei et al., 2003b).  Another suggested role for H4B is aiding in the release of •NO from NOS by 
preventing the formation of a ferrous-•NO complex (Fe(II) •NO) where •NO would be tightly bound 
(Gorren and Mayer, 2007).    
In summary, the NOS enzymes use two different redox cofactors to donate electrons during 
catalysis – a slow electron transfer from the FMN in the reductase domain and a fast electron 
transfer from H4B to avoid the release of •O2- and aid in the release of •NO during the second mono-
oxygenation reaction (Stuehr et al., 2004). 
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1.2.5 Regulation of NOS 
1.2.5.1 Intrinsic regulation of NOS 
Apart from the CaM-dependence of electron transfer within the NOS enzymes, there are numerous 
other intrinsic structural elements that control •NO production by the NOS enzymes.  These include 
(1) an autoinhibitory domain, (2) a C-terminal tail region, and (3) dimer stability.   
1.2.5.1.1 NOS autoinhibitory domains 
 In general, an autoinhibitory domain is a motif within an enzyme that inhibits the enzyme by 
blocking and/or interfering with the substrate’s ability to bind to the active site (Crivici and Ikura, 
1995).   
 
Figure 1.18 – A generalized model of an autohibitory domain and its displacement by 
Ca2+/CaM. 
As Ca2+/CaM binds to the autoinhibitory domain (light grey), the autohibitory domain is displaced 
allowing the substrate (dark grey) to access and bind to the active site of the enzyme.  This figure is 
modified from a previous CaM review (Crivici and Ikura, 1995).   
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It is of interest that the Ca2+-dependent nNOS and eNOS isozymes each contain an insert of about 40 
amino acids in length in the middle of the FMN-binding subdomains, which is proposed to be an 
autoinhibitory domain (Salerno et al., 1997) (Figure 1.19).   
 
                                               -FMN Ring (re-face) 
CYPOR       AHRYGMRGMS ADPEEYDLAD LSSLPEIDKS LVVFCMATYG EGDPTDNAQD  152 
Human nNOS  FKHAFDAKVM SMEEYDIVHL E------HET LVLVVTSTFG NGDPPENGEK  824 
Human eNOS  FRKAFDPRVL CMDEYDVVSL E------HET LVLVVTSTFG NGDPPENGES  583 
Human iNOS  FTYAFNTKVV CMEQYKANTL E------EEQ LLLVVTSTFG NGDCPSNGQT  601 
 
            -----  ========Location of Regulatory Loop Insert=====    
CYPOR       FYDWLQE--- ---------- ---------- ---------- ----------  159 
Human nNOS  FGCALMEMRH P-NS--VQEE RKSYKVRFNS VSSYSDSQKS SGDGPDLRDN  873 
Human eNOS  FAAALMEMSG PYNSSPRPEQ HKSYKIRFNS ISCSDPLVSS WRRKRKESSN  633 
Human iNOS  LKKSLFMMKE ---------- ---------- ---------- ----------  611 
 
            ==    --------FMN Ring (si-face)-------       
CYPOR       --TDVDLTGV KFAVFGLGNK TYEHRNAMGK YVDQRLEQLG AQRI  201 
Human nNOS  FESAGPLANV RFSVFGLGSR AYPHFCAFGH AVDTLLEELG GERI  917 
Human eNOS  TDSAGALGTL RFCVFGLGSR AYPHFCAFAR AVDTRLEELG GERL  677 
Human iNOS  -----LGHTF RYAVFGLGSS MYPQFCAFAH DIDPKLSHLG ASQL  650 
 
Figure 1.19 – Sequence alignment of the FMN binding region of cytochrome P450 (CYPOR) 
and the NOS enzymes. 
It is important to note that only nNOS and eNOS contain the proposed autoinhibitory inserts in their 
FMN binding regions.  This figure is based upon sequence alignments from two previous studies 
(Salerno et al., 1997; Garcin et al., 2004).  
  
This inhibitory element is absent in the Ca2+-independent iNOS enzyme (Figure 1.19).  Due to its 
position in the reductase domain of nNOS and eNOS, the autohibitory domain is not close to the 
active site in the oxygenase domain.  Therefore, Salerno and co-workers suggested that the 
autoinhibitory domain would act by a different mechanism when regulating the activity of the cNOS 
enzymes than the typical CaM-activated enzymes, as described in Figure 1.18 (Salerno et al., 1997).  
They demonstrated, through the use of peptides corresponding to the proposed autoinhibitory 
domain, that these inserts do in fact impair CaM’s ability to bind to the cNOS enzymes when Ca2+ 
concentrations are low; however, when Ca2+ concentrations increased, Ca2+-replete CaM would be 
able to induce a conformational change in the autohibitory domain causing it to be displaced from 
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the CaM-binding domains of nNOS and eNOS (Salerno et al., 1997).  This Ca2+/CaM-dependent 
displacement allows for efficient electron transfer within the cNOS enzymes.  Furthermore, the 
removal of these cNOS autohibitory domains by mutagenesis have been shown to decrease the Ca2+-
dependent CaM activation and increase the enzyme activities of nNOS and eNOS at lower Ca2+ 
concentrations (Daff et al., 1999; Nishida and Ortiz de Montellano, 1999; Chen and Wu, 2000; 
Montgomery et al., 2000).  These results further illustrate that these inserts in the cNOS enzymes do 
not have the properties of the typical autoinhibitory domains found in CaM-activated enzymes.  A 
model describing how the displacement of the autoihibitory domain by Ca2+/CaM might facilitate 
electron transfer through the reductase domain is shown in Figure 1.20.   
 
Figure 1.20 – A proposed three-step model to explain the mechanism that the autoinhibitory 
insert and CaM use to regulate electron tranfer in the cNOS enzymes. 
The N- and C-terminal domains of CaM are represented as Ca2+-deplete (squares) and Ca2+-replete 
(circles).  Step 1 – CaM-free cNOS is inactive and the autoinhibitory domain is docked.  The 
autoinhibitory domain (AI) is shown to dock with the cNOS oxygenase domain at this step, 
however, the AI may alternatively be docked within the reductase domain.  The AI may prevent 
electron transfer from the FMN to the heme, from FAD to FMN, or a combination of both possible 
electron steps.  Step 2 – As intracellular Ca2+ concentrations increase, the C-terminal domain of CaM 
becomes Ca2+-replete and is able to bind to the cNOS enzyme however the AI continues to keep the 
enzyme inactive.  Step 3 – A further increase Ca2+ concentration results in the N-terminal lobe of 
CaM becoming Ca2+-replete and binding to the enzyme causing the displacement of the AI.  This 
causes the promotion of efficient electron transfer with the cNOS enzyme due to the alignment 
within the reductase domain to allow electron transfer to the oxygenase domain and •NO production.  
This model is based upon a previous study (Lane and Gross, 2000). 
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Another possible role for these autoinhibitory domains in the cNOS enzymes is to protect 
the CaM-binding domains of nNOS and eNOS from proteolysis.  The iNOS enzyme protects itself 
from proteolytic cleavage by calpain (a cysteine protease) by having CaM bound to its CaM-binding 
domain (Walker et al., 2001).  In contrast, the CaM-free cNOS enzymes do not have protection from 
calpain degradation.  nNOS and eNOS have been reported to be susceptible to calpain degradation 
(Barnes and Gomes, 1995; Laine and de Montellano, 1998) and cNOS mutants lacking the 
autoinhibitory domain could only be purified when coexpressed with CaM (Montgomery et al., 
2000)  Therefore, it is conceivable that the autoinhibitory domain not only controls electron transfer 
within NOS, but it may also prevent proteolysis of the cNOS enzymes in the cell. 
1.2.5.1.2 C-terminal tail extension 
An additional CaM-modulated regulatory element found in the each of the NOS enzymes is the C-
terminal tail extension.  This tail extension is not found in cytochrome P450. 
 
 
                           ===============C-terminal tail================          
CYPOR       KLMTKGRYSL DVWS------ ---------- ---------- ---------- ------   678 
Human nNOS  RMRDDNRYHE DIFGVTLRTY EVTNRLRSES IAFIEESKKD TDEVFSS--- ------  1434 
Human eNOS  VLRDQQRYHE DIFGLTLRTQ EVTSRIRTQS FSLQERQLRG AVPWAFDPPG SDTNSP  1202 
Human iNOS  QLKSQKRYHE DIFGAVFSYG VKKGNALEEP KGTRL----- ---------- ------  1147 
 
Figure 1.21 – Comparative sequence alignment of the C-terminal tails of the NOS enzymes and 
cytochrome P450 (CYPOR). 
The extended C-terminal tail element is found in the cNOS enzymes while it is much shorter in the 
iNOS isoform.  The C-terminal tail is absent in cytochrome P450.  This figure is based upon a 




Previous studies have shown that the removal of the C-terminal tail from the cNOS enzymes resulted 
in an enzyme with enhanced electron transfer rates through the reductase domain in the absence of 
CaM; however, the activity of the enzyme was equivalent to wild-type cNOS enzyme in the presence 
of Ca2+/CaM (Roman et al., 2000a).  Similiarly, a truncated C-terminal tail mutant of iNOS 
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demonstrated a 7-10 fold increase in electron transfer rates in its reductase domain when compared 
to wild-type iNOS (Roman et al., 2000b).  These results suggest that the C-terminal tail extension 
found in the NOS enzymes is involved in regulating electron transfer through the NOS enzymes. 
 In a recent study, a mutant of nNOS without its autoinhibitory domain and C-terminal tail 
extension was produced.  It was found that CaM no longer modulates electron transfer through the 
reductase domain of this nNOS mutant; however, CaM was still required to promote electron 
transfer from the FMN domain to the heme for •NO production (Roman and Masters, 2006).  
Clearly, the concerted interactions of the autoinhibitory domain and C-terminal tail extension are 
involved in the binding and regulation of electron transfer within the cNOS enzymes by CaM. 
1.2.5.1.3 •NO-mediated dimer disruption  
Biochemical studies have determined that the NOS oxygenase domains display differences in their 
dimer stability depending on the presence of H4B and of a zinc ion coordinated by four cysteine 
residues at the dimer interface (Alderton et al., 2001) (Figure 1.13).  Furthermore, it has also been 
proposed that CaM has an important role in the dimerization of eNOS monomers (Hellermann and 
Solomonson, 1997).  Recent studies have demonstrated that the exposure of eNOS and iNOS to •NO 
donors or •NO produced by the enzyme itself resulted in the decrease of dimeric NOS enzyme and a 
correlating increase in NOS monomers (Ravi et al., 2004; Mitchell et al., 2005; Li et al., 2006).  The 
NOS enzymes are only active in their dimeric form and inactivated if this dimer is disrupted.  This 
dimer disruption is the result of S-nitrosation of the cysteine residues involved in the co-ordination 
of the structural zinc ion located at the oxygenase dimer interface.  It may act as a mode of feedback 
inhibition for the NOS enzymes – by S-nitrosating its own cysteine residues and causing itself to 
monomerize, the enzyme can attenuate and control its own •NO production levels in vivo (Ravi et 
al., 2004; Mitchell et al., 2005).  
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1.2.5.2 Extrinsic regulation of NOS 
1.2.5.2.1 Posttranslational modifications of NOS 
Posttranslational modifications of the cNOS enzymes, particularly eNOS, have been studied 
extensively.  It has been shown that eNOS can be myristoylated, palmitoylated, acetylated, and 
phosphorylated in its oxygenase domain.  These posttranslational modifications have been 
implicated in the enzyme’s localization in the cell (cytosol, membranes or organelles) but are 
suggested to have no effect on the •NO production levels, with the exception of phosphorylation 
(Liu et al., 1997; Michel and Feron, 1997; Hemmens and Mayer, 1998).    
Phosphorylation of eNOS-Ser(1177) has been shown to be the most important 
posttranslational modification required for eNOS activation (Mount et al., 2007).  Since Ser(1177) is 
located in the C-terminal tail extension of eNOS, which is implicated in attenuating electron transfer 
in the NOS enzymes (see section 1.2.5.1.2), and the phosphorylation of this site allows for an 
increased electron transfer efficiency in eNOS.  Another phosphorylation site has been found in the 
autoinhibitory region of the flavin mononucleotide (FMN) binding domain of eNOS (Mount et al., 
2007).  This site (Ser633) has been shown to increase eNOS activity and appears to be important for 
the maintenance of •NO synthesis rates after initial activation by Ca2+/CaM binding and 
phosphorylation of Ser(1177) (Michell et al., 2002).  A phosphorylation site of interest is eNOS-
Thr(497), which is located in the CaM-binding domain of eNOS.  This modification is performed by 
protein kinase C and has been shown to inhibit •NO production by reducing the affinity of eNOS for 
CaM (Matsubara et al., 2003).   
The nNOS enzyme has also been shown to undergo serine or tyrosine phosphorylation in its 
oxygenase domain, which lowers enzyme activity by two thirds; however, the identity of the 
modified sites and the mechanism of this inhibition remain unclear (Dawson et al., 1993).  
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Phosphorylation of Ser(847) in nNOS, which is located in the FMN domain, leads to marked 
decreases in enzyme activity (Komeima et al., 2000).  Clearly, phosphorylation plays a pivotal role 
in regulating the cNOS enzymes.   
 The iNOS enzyme has also been shown to be posttranslationally modified.  These 
modifications include an N-terminal palmitoyl group, which influences the localization of iNOS in 
the cell (Navarro-Lerida et al., 2004).  iNOS has also been shown to be phosphorylated by tyrosine 
kinases but the effect of this modification on iNOS activity remains unclear (Pan et al., 1996).  
Lastly, iNOS has also been shown to have its rate of turnover in the cell directly regulated by the 
proteosomal degradation pathway (Musial and Eissa, 2001).  In order to control NO synthesis rates 
in the cell, the turnover of iNOS must be tightly regulated to avoid oxidative stress and damage.  
Clearly, posttranslational modifications and protein turnover are involved in the extrinsic regulation 
of iNOS.  
1.2.5.2.2 Protein-protein interactions with the NOS enzymes 
There are numerous proteins that interact with the NOS enzymes in a variety of roles including 
activation, inhibition, and trafficking within the cell.   Due to the detrimental or beneficial effects 
mediated by •NO, the cellular localization of nNOS is tightly regulated.  The function of the PDZ 
domain located in the N-terminus of nNOS is to assemble intracellular proteins into multiprotein 
complexes (Roman et al., 2002).  This PDZ element of nNOS has been shown to bind to a wide 
variety of proteins which is dependent upon the tissue expressing nNOS.  For instance, in the brain 
PSD-95 acts as a “link” protein between nNOS and the NMDA receptor, thereby bringing nNOS in 
close proximity to the NMDA receptor (Christopherson et al., 1999).  Another sequence found in the 
N-terminus of nNOS is recognized by a protein that is termed PIN, since it acts as a “protein-
inhibiting nNOS” by destabilizing the nNOS dimer (Jaffrey and Snyder, 1996).    
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 eNOS has been shown to anchor to caveolae via its N-terminally myristoylate or palmitoyate 
moieties.  Caveolae are characterized as small invaginations found on the surface of epithelial cells 
and signal transduction cells (Kurzchalia and Parton, 1999).   The structural components of caveolae 
are the integral membrane proteins – caveolin-1, caveolin-2, and caveolin-3.  eNOS was shown to be 
inhibited by its interaction with caveolin-1 and caveolin-3 in vitro (Feron et al., 1996).  The binding 
of the molecular chaperone heat shock protein 90 (Hsp90) has been shown to enhance eNOS •NO 
production (Garcia-Cardena et al., 1998).  In these complexes, ATP-dependent conformational 
changes in Hsp90 uncouple electron transfer from •NO production in eNOS, resulting in the 
increased formation of •O2- (Pritchard et al., 2001).  
Similar to eNOS, iNOS also exhibits an interaction with caveolin-1.  A previous study 
demonstrated that caveolin-1 down-regulates iNOS by causing it to colocalize with caveolin-1 in 
detergent insoluble membrane fractions stearing it towards degradation via the proteasome pathway 
(Felley-Bosco et al., 2000).  NOS-associated protein-110 kDa (NAP110) has been shown to interact 
with the N-terminal domain of iNOS between residues 1-70 and decreases iNOS activity by 90% 
(Ratovitski et al., 1999).  Furthermore, NAP110 appears to only interact with iNOS monomers and 
inhibits iNOS homodimerization (Ratovitski et al., 1999).    
Regulation of iNOS also occurs at the transcriptional level.  The induction of iNOS involves 
the cooperative interaction of transcription factors and co-regulatory molecules that bind to the iNOS 
promoter (Zhang et al., 2003).  Nuclear factor kappaB (NF-κB), which has been identified as the 
major trans-activator of the iNOS gene, is able to interact with interferon-γ and histone deacetylase.  
The interaction between interferon-γ and NF-κB has been shown to physically bend the iNOS 
promoter resulting in a dramatic increase of iNOS transcription (Saura et al., 1999).  Likewise, the 
interaction between NF-κB with histone deacetylase has been shown to increase iNOS transcription.  
Hyperacetylation of the iNOS promoter appears to diminish the cytokine induction of iNOS 
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transcription (Zhang et al., 2003).  By recruiting the histone deacetylase enzyme to deacetylate the 
promoter, NF-κB allows itself to efficiently associate to the iNOS gene’s promoter for transcription 
(Yu et al., 2002).  Clearly, the NOS enzymes are extrinsically regulated by a variety of protein-
protein interactions in the cell through direct interactions with the NOS enzymes and/or indirectly 
via transcriptional control.   
 
1.2.6 Previous studies on CaM binding to NOS 
Numerous studies have been performed to better understand CaM’s binding and activation of the 
NOS enzymes.  The majority of the studies published to date have focused on the Ca2+-dependent 
cNOS enzymes, while the Ca2+-independent iNOS isoform has been studied very little prior to 2003.  
The following is a brief summary of previous investigations on the interaction of CaM with the NOS 
enzymes. 
1.2.6.1 CaM binding to NOS CaM-binding domain peptides 
The CaM-binding domains of NOS are categorized under the 1-5-8-14 CaM-binding motif, where 
site 1 is generally an aromatic residue, residues 5 and 8 are hydrophobic, and residue 14 corresponds 
to a large bulky hydrophobic side chain (section 1.1.4).   
 
Figure 1.22 – Sequence alignment of the CaM-binding domains of the NOS enzymes. 
Acidic and basic residues are shown in red and blue, respectively.  Hydrophobic residues found in 
the 1-5-8-14 CaM-binding motif are underlined.  This alignment based upon a previous study 
(Aoyagi et al., 2003). 
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The association of CaM to peptides corresponding to the CaM-binding domains of the NOS enzymes 
has been studied by a variety of biophysical methods including circular dichroism, 1H NMR, and x-
ray crystallography.  Evidence has shown that when CaM binds to these NOS peptides, this induces 
an α-helical conformation in the peptide and forms an amphipathic binding surface that is commonly 
found in CaM-binding sites, as previously described in section 1.1.4 (Zhang et al., 1995; Matsubara 
et al., 1997; Aoyagi et al., 2003).   
 
 
Figure 1.23 – Helical wheel diagrams of the CaM-binding domains of the NOS enzymes. 
Charged or polar residues (blue) and hydrophobic or non-polar residues (black) are highlighted in 
the helical wheel diagrams.  Note that some of the corresponding charged residues in the cNOS 
CaM-binding domains are replaced by hydrophobic residues in iNOS.  This figure is modified from 
a previous study (Aoyagi et al., 2003).  
 
As shown in Figure 1.5C and D, the x-ray crystal structures of CaM-eNOS peptide (Aoyagi et al., 
2003) and CaM-nNOS peptide (Ng et al. –  co-ordinates released 2007-12-25) complexes have been 
solved.   Both of these structures demonstrate that CaM wraps tightly around the target peptide in an 
antiparallel orientation similar to the classic model of MLCK.  Analysis of the CaM-eNOS peptide 
structure demonstrates that CaM binds in an antiparallel orientation, with the majority of the N-
terminal residues of CaM associated with the C-terminal residues of the eNOS peptide and the C-
terminal domain of CaM interacting mainly with the N-terminal residues of the peptide (Table 1.7). 
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Table 1.7 – Residues of CaM shown to be within 4 Å of the eNOS peptide 
              
 
Alignment of NOS CaM-
binding domains CaM sidechains in contact with eNOS peptide  
              








iNOS N-terminal Domain C-terminal Domain 
Central 
Linker 
         
              
  R492 R732 R511 E6, E7*, A10   
  K493 A733 E512  E120*, E123*, E127*  
  K494 I734 I513 E14*   
  T495 G735 P514  M124, E127  
1 F496 F736 L515 L105, M124, E127*, A128, V136, F141, M144   
  K497 K737 K516 E7 E127, M144, A147*  
  E498 K738 V517 E7, A10, E11, E14   
  V499 L739 L518 E14 M109, E114, M124  
5 A500 A740 V519  F92, F141, M144, M145  
  N501 E741 K520 E11* M145  
  A502 A742 A521 E11, E14, A15, L18   
8 V503 V743 V522  V91, F92, L112  
  K504 K744 L523  S81, E84, I85, A88, M145  
  I505 F745 F524 E11, F12, A15, M72  M76 
  S506 S746 A525 A15, L18, F19, L39   
  A507 A747 C526 L39 E87  
  S508 K748 M527 M72, K75 E87 M76 
14 L509 L749 L528 F19, M36, M51, M71, M72, K75   
  M510 M750 M529 L39, Q41, K75* E87*  
              
Residues shown to be involved in hydrogen bonding and ionic interactions are indicated with asterisks.  This 
table is based upon the CaM-eNOS peptide structure (Aoyagi et al., 2003). 
 
Peptides corresponding to the cNOS enzymes have only been shown to bind to Ca2+-replete CaM, 
whereas the iNOS peptide has been shown to bind to apo-CaM and holo-CaM (Matsubara et al., 
1997).  Furthermore, the iNOS peptide also adopts an α-helical conformation when bound to apo-
CaM (Matsubara et al., 1997).   
 An interesting study demonstrated that the Ca2+-dependent nNOS can be mutated to mimic 
the Ca2+-independent iNOS CaM-binding domain.  This study involved the mutation of a single 
glutamate to a lysine residue (E K at position 6; Figure 1.22) allowed the mutated nNOS peptide to 
bind to apo-CaM (Censarek et al., 2002).  Likewise, the conversion of basic residues in the nNOS 
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peptide to the corresponding hydrophobic residues in iNOS (K V, position 3; K L, position 9; 
K M, position 13) resulted in a significant increase in binding affinity for CaM from the 
micromolar to nanomolar range (Censarek et al., 2002), similar to previously reported Kd values for 
CaM’s affinity for iNOS CaM-binding domain peptides (Anagli et al., 1995; Yuan et al., 1998).  
Clearly, the CaM-binding domain peptides can act as a good working model for the Ca2+-dependent 
and Ca2+-independent association of CaM to the NOS enzymes.  
1.2.6.2 CaM binding to NOS enzymes 
A previous study using 125I-labeled CaM suggested that four sequential steps occur when CaM binds 
and activates nNOS (Weissman et al., 2002).  This model is based upon the knowledge that the C-
terminal domain of CaM has a ten fold greater affinity for Ca2+ than the N-terminal domain of CaM 
(Martin et al., 1985).  The first step involves the binding of Ca2+ to the C-terminal domain of CaM, 
followed by the Ca2+-replete C-terminal domain of CaM binding to nNOS.  Upon an increase of 
intracellular Ca2+ concentrations, the N-terminal domain of CaM binds Ca2+.  Finally, the Ca2+-
replete N-terminal domain binds to nNOS (Weissman et al., 2002).  The binding of the N-terminal 
domain of CaM to nNOS causes the activation of nNOS by the displacement of the autoinhibitory 
domain of nNOS.  This model also suggests that the deactivation of nNOS is due to the decrease in 
intracellular Ca2+ and occurs in the reverse order of these four steps (Weissman et al., 2002). 
 Chimeric NOS enzymes have previously been created that combine the CaM-binding 
domain of iNOS with the residual domains from nNOS (Ruan et al., 1996; Lee and Stull, 1998).  
These studies demonstrated that the nNOS containing the iNOS CaM-binding domain could be fully 
activated at lower Ca2+ concentrations than wild-type nNOS, and that the designated CaM-binding 
domain of iNOS is not completely responsible for the Ca2+-independent binding of CaM to iNOS 
(Lee and Stull, 1998).  A subsequent study found that lysine 525 of murine iNOS (position 17), 
which is located in the FMN domain outside the CaM-binding domain, is involved in iNOS’s Ca2+-
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independence but did not increase CaM’s binding affinity at lower Ca2+ levels (Lee et al., 2000).  
Another study demonstrated using truncated iNOS mutants that residues 484-726, corresponding to 
the CaM-binding domain and the FMN binding domain of iNOS are responsible iNOS’s Ca2+-
independence (Ruan et al., 1996).  These studies, in conjunction with the NOS peptide studies 
(section 1.2.6.1), demonstrate the importance of studying the holo-NOS enzymes when determining 
their Ca2+-dependence as there may be flanking regions in the oxygenase and reductase domains 
involved in CaM’s association to the enzyme. 
1.2.6.3 Mutant CaM proteins binding to the cNOS enzymes 
A method commonly used to identify specific elements in CaM essential for CaM-dependent 
enzyme activation is the use of CaM mutant proteins.  These mutant proteins have included a variety 
of single point mutations, the exchange of EF hand motifs within CaM, and truncations of CaM.  To 
date, most of these studies focused solely on the binding and activation of nNOS. 
Dr. Antony Persechini and coworkers have produced numerous CaM mutants in the past that 
were used to study their ability to activate MLCK and nNOS (Persechini et al., 1994; Persechini et 
al., 1996a; b).  These mutants have included single EF hand pairs and duplicated EF hand pairs.  Dr. 
Persechini’s studies demonstrated that the N-terminal domain in conjuction with the central linker of 
CaM is instrumental in the activation of nNOS.  Likewise, Dr. Samuel George and coworkers also 
studied the interaction between nNOS and CaM-troponin C chimeric proteins (i.e. proteins that have 
single EF hands replaced in CaM with its corresponding EF hand from troponin C) to determine 
which specific EF hands are responsible for nNOS activation (George et al., 1990; George et al., 
1993; Su et al., 1995; Gachhui et al., 1998).  These studies demonstrated that helices 2 and 6 of 
CaM, found in EF hands I (N-domain) and III (C-domain) respectively, act as a latch when 
associated to nNOS.  In this model, helices 2 and 6 are in close proximity to one another and are 
suggested to control electron transfer from FMN to the heme by interacting with the reductase and/or 
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the oxygenase domain of nNOS (Su et al., 1995).  Recently, another study using oxidized CaM 
demonstrated that the oxidation of methionine residues in CaM as a result of aging has an inhibitory 
effect on nNOS activity (Montgomery et al., 2003). 
CaM with mutations of glutamate to glutamine residues at position 12 of each EF hand in 
CaM (-Z co-ordination site; Figure 1.2) have been used to study specific Ca2+-binding sites in CaM 
and its association to nNOS (Stevens-Truss et al., 1997).  This study found that CaM EF hand I 
binding to Ca2+ was crucial for nNOS activity.  Other CaM mutants deficient in Ca2+-binding within 
their N- and C-terminal domains have also been produced by mutating conserved aspartate residues 
at position 1 (X co-ordination site; Figure 1.2).  These CaM mutants have been used to study the 
Ca2+-dependent and Ca2+-independent association of CaM to various target proteins such as the 
inositol 1,4,5-trisphosphate receptor (Sienaert et al., 2002; Kasri et al., 2006), small conductance 
Ca2+-activated K+ channels (Lee et al., 2003), and P/Q-type Ca2+ channels (DeMaria et al., 2001); 
however, these mutants have not yet been studied with the NOS enzymes.   
 While eNOS and nNOS demonstrate similarities in their Ca2+-dependence and regulatory 
elements (autoinhibitory domain and C-terminal tail), there has been very little reported on the 
specific elements in CaM that are important for eNOS activation.  Likewise, due to the strong 
association between iNOS and CaM and the necessity of their coexpression to produce active 
enzyme (Cho et al., 1992), little is known about the interaction between iNOS and CaM.   
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1.3 Reasons for studying the interaction of NOS with CaM 
 Over the past seven years, research in our laboratory has been focused on gaining a better 
understanding of the interaction between the NOS enzymes and CaM.  Two facets of the CaM-NOS 
interaction under study are how CaM is able (1) to bind, and (2) to activate the three isoforms of 
NOS.  It is generally accepted that CaM plays a vital role in controlling electron transfer within the 
constitutive NOS isoforms.  There have been several studies demonstrating that different regions and 
elements of CaM play an important role in the binding and activation of the cNOS holoenzymes 
(Persechini et al., 1994; Su et al., 1995; Persechini et al., 1996a; b; Stevens-Truss et al., 1997; 
Gachhui et al., 1998).  The iNOS enzyme can only be purified when coexpressed with CaM, and the 
two proteins remain tightly associated even after the removal of Ca2+.  This has made it difficult to 
dissect the molecular details of the interaction between the iNOS enzyme and CaM.  However, the 
development of coexpression CaM vectors in our laboratory has allowed for a more thorough 
investigation of CaM-iNOS specific interactions.  This coexpression technique has been utilized 
throughout the studies reported in this thesis, using some of the aforementioned mutant CaM 
proteins (section 1.2.6.3) to determine the specific regions of CaM responsible for the Ca2+-
independent association of CaM to iNOS (see Chapters 2, 3, and 4). 
There is a unique opportunity to investigate CaM control over •NO production by the NOS 
enzymes since each NOS isoform shows a different mode of activation and control by CaM; 
however, the underlying mechanism of •NO production remains unclear.  The conformations that 
CaM adopts when bound to the three isoforms of holo-NOS have also not yet been determined.   
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1.4 Research Objectives 
The purpose of this doctoral study was to further elucidate the structure and function of CaM 
when bound to the three different mammalian NOS isozymes.   The overall objectives of this thesis 
were to: 
1. Use CaM mutants to determine the specific elements in CaM responsible for the binding and 
activation of the NOS enzymes. 
2. Determine the conformation of CaM when bound to the NOS CaM-binding domain peptides 
and holo-NOS enzymes. 
3. Determine the three-dimensional structure of CaM in complex with an iNOS CaM-binding 
domain peptide. 
In order to accomplish these objectives, the CaM-NOS interactions were studied using a 
variety of analytical methods including molecular cloning, protein expression and purification, 
kinetic spectrophotometric assays, circular dichroism, steady-state and time-resolved fluorescence, 
fluorescence (Förster) resonance energy transfer (FRET), and nuclear magnetic resonance (NMR) 
spectroscopy.  The results reported in this thesis broaden and clarify our present understanding of the 
CaM-dependent regulation of the mammalian NOS enzymes.   
 
* The results presented in this chapter have been published as part of: 
Newman, E., Spratt, D.E., Mosher, J., Cheyne, B., Montgomery, H.J., Wilson, D.L., Weinberg, J.B., 
Smith, S.M., Salerno, J.C., Ghosh, D.K. and Guillemette, J.G. (2004) Differential activation of nitric-
oxide synthase isozymes by calmodulin-troponin C chimeras. J Biol Chem 279, 33547-33557. 
 




Differential Activation of Mammalian Nitric Oxide Synthase 
Isozymes by Calmodulin-Troponin C Chimeras * 
2.1 Introduction 
Cardiac troponin C (TnC) is a Ca2+-binding protein whose function is to activate the thin filament 
cardiac muscle (da Silva et al., 2002).  The overall structure of TnC is similar to CaM since both 
proteins have two globular domains linked by a central helix with each globular domain composed of 
two EF hands.  In particular, the local structures of EF hands I, III and IV of CaM and TnC are 
closely related.  However, the structure of EF hand II of TnC differs from the corresponding region in 
CaM since helix 4 is redirected significantly when compared to CaM causing a significant difference 
in the global three-dimensional structure of TnC.  Despite their overall structural similarity, TnC has 
only a 70% sequence similarity with CaM (Figure 2.1).  The first EF hand of TnC does not bind Ca2+ 
because of a mutation relative to a CaM-like ancestor so that it can not chelate Ca2+ (Su et al., 1995; 
Gachhui et al., 1998).  In addition, TnC has seven more N-terminal and three more central helix 
residues than CaM.  It is noteworthy that TnC is unable to activate CaM dependent enzymes (George 
et al., 1990; da Silva et al., 2002).  The C-terminal domain of CaM binds Ca2+ with a higher affinity 
(Kd = 10-6 M) than the N-terminal domain (Kd = 10-5 M) (Martin et al., 1985), however, the EF hand 
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IV of TnC binds Ca2+ with 1 order of magnitude greater affinity than EF hand IV of CaM (George et 
al., 1993).  Because of their overall structural similarity, domains of CaM have been exchanged for 
the corresponding domains of TnC to investigate the function of specific regions of the two proteins. 
 
Figure 2.1 – Alignment of CaM and cardiac TnC. 
Residue numbers and locations of the four EF hand domains, subdomain loops and helices are as 
indicated.  Amino acids common to both CaM and TnC are underlined.  Arrows are shown to indicate 
the splice points used to originally construct the CaM-TnC chimeras.  This figure is based upon 
previously published studies (Su et al., 1995; Gachhui et al., 1998). 
 
Previous investigations utilized the exchanging of these domains or EF hand motifs between CaM 
and TnC to find specific regions that affect the activation of CaM-dependent enzymes (George et al., 
1993; Su et al., 1995; George et al., 1996; Gachhui et al., 1998; Wang et al., 1998).  Chimeras of 
CaM including each of the four EF hands from TnC have been constructed (e.g. CaM-1TnC contains 
EF hand I of TnC and EF hands II, III and IV of CaM) (Su et al., 1995; Gachhui et al., 1998).    
There is a significant interest in better understanding the structural basis of CaM’s ability to 
interact with a wide variety of target protein, including the NOS isozymes.  A previous study on 
enzyme binding and activation in our laboratory using both nNOS and eNOS demonstrated important 
differences in the effect that oxidation of CaM methionines has upon the cNOS enzymes 
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(Montgomery et al., 2003).  Moreover, very little was known about the interaction of CaM and 
activation of the iNOS enzyme at the time of this study.  
This study was designed to evaluate the role of the four different CaM EF hands in the 
activation of the eNOS and iNOS enzymes.  Five different CaM-TnC chimeras were used in the 
investigation: CaM- 1TnC, CaM-2TnC, CaM-3TnC, CaM-4TnC, and CaM-3,4TnC (Figure 2.2).   
 
Figure 2.2 – Alignment of CaM and CaM-TnC chimera proteins. 
Ca2+ ions are represented as circles, CaM and TnC proteins (and fragments) are shown in red and 
blue, respectively.  EF hands and central linker are indicated for clarity purposes. 
 
To assess the role of different CaM regions on aspects of NOS enzymatic function, three distinct 
activities associated with NOS were studied: 1) electron transfer from NADPH to the reductase 
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complex (measured by NADPH oxidation); 2) electron transfer from FMN to an acceptor (measured 
by cytochrome c reduction); and 3) electron transfer to the heme (measured by generation of •NO 
using the oxyhemoglobin capture assay).  These biochemical studies with the different CaM-TnC 
chimeras show marked differences in the binding and activation of iNOS and cNOS enzymes by 
CaM.  Although each of the CaM-TnC chimeras are able to bind to iNOS, EF hands II and III of CaM 
show Ca2+-dependent activation of the enzyme.   
This project was originally designed and started by Mrs. Elena Newman (MSc. 2003, U of 
Waterloo) with the initial purification and kinetic analyses performed at the conclusion of her thesis.  
Subsequent to Mrs. Newman’s graduation, the candidate completed this study and performed all of 
the analyses reported in this chapter unless otherwise stated in the experimental procedures section 
(section 2.2). 
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2.2 Experimental Procedures 
2.2.1 Cloning of CaM-TnC Chimera 
The subcloning of CaM-1TnC, CaM-3TnC, CaM-4TnC and CaM-3,4TnC used in this study were 
performed by Mrs. Elena Newman (MSc. 2003, U of Waterloo), a previous graduate student in our 
laboratory.  The vectors pCaM-1TnCAmp, pCaM-3TnCAmp, pCaM-4TnCAmp and pCaM-
3,4TnCAmp were a generous gift from Dr. Dipak Ghosh (Duke University and VA Medical Center, 
Durham, NC, USA).  Their ampicillin resistance necessitated the construction of new vectors for 
coexpression with iNOS (section 2.2.8).  Coding regions for CaM-1TnC, CaM-3TnC, CaM-4TnC and 
CaM-3,4TnC were subcloned into the kanamycin resistant pET28a vector (Novagen) plasmid using 
the unique flanking NcoI and NdeI restriction sites. The resulting vectors, pCaM-1TnCKan, pCaM-
3TnCKan, pCaM-4TnCKan and pCaM-3,4TnCKan, were verified by DNA sequencing. 
 The coding region of CaM-2TnC was cloned into pET28a by Mrs. Elena Newman and the 
candidate.  The vector pCaM-2TnCAmp was a gift from Dr. Ghosh.  The coding region of CaM-
2TnC was PCR amplified from the pCaM-2TnCAmp plasmid introducing unique flanking NcoI and 
NdeI cut sites for subcloning into a vector suitable for coexpression.  Primers used were: 2TnCfor 5’ 
GAATACCATGGCAGATCAGCTGACTGAGAAAC 3’ and  
2TnCrv 5’ GGAATTCAAGCTTCATATGTCACTTCGCTGTCATCATTTG 3’.  The 475 bp PCR 
product was blunt end ligated into the SrfI site of pPCR-SCRIPT Amp SK (+). The pCaM-
2TnCPCRscript vector was subsequently digested with NcoI and NdeI and subcloned into the 
kanamycin resistant pET28a vector (Novagen) cut with the same enzymes.  The resulting pCaM-
2TnCKan vector was verified by sequencing. 
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2.2.2 Expression of Wild-type CaM 
The open reading frame of rat CaM was cloned into the kanamycin resitant pET9d vector (Novagen) 
by Mrs. Elena Newman (MSc. 2003, U of Waterloo) to produce pET9dCaM.  An overnight culture of 
transformed E. coli BL21 (DE3) with pET9dCaM was used to inoculate 2 x 1 L of LB media in 4 L 
flasks supplemented with 30 µg/ml of kanamycin.  These 1 L cultures were grown at 37ºC, 200 rpm 
to an O.D. at 600 nm of 0.6 – 0.8, induced with 500 µM IPTG and harvested after 3 to 4 hours of 
protein expression.  Cells were harvested by centrifugation at 6000 x g at 4oC for 5 minutes, flash 
frozen on dry ice, and subsequently stored at –80ºC.   
2.2.3 Purification of Wild-type CaM 
Cells were thawed on ice, resuspended in 4 volumes of 50 mM MOPS, 100 mM KCl, 1 mM EDTA, 1 
mM DTT, pH 7.5 and lysed by homogenization using an Avestin EmulsiFlex-C5 homogenizer 
(Ottawa, ON).  The lysate was then clarified by centrifugation at 48,000 x g for 30 minutes at 4oC.  A 
CaM purification protocol previously published was followed (Gopalakrishna and Anderson, 1982) 
with a few modifications.  All of the following steps were carried out at 4oC in a fridge or on ice.  To 
the clarified supernatant, CaCl2 was added to a concentration of 5 mM in order to saturate CaM with 
Ca2+ and induce the exposure of hydrophobic patches in the N- and C-domains of CaM to allow CaM 
to interact with the resin.  This Ca2+-saturated supernatant was then loaded onto 20 mL of phenyl 
sepharose 6 fast flow highly-substituted resin (GE Healthcare Bio-Sciences, Baie d’Urfe, PQ) in a 1 
cm x 30 cm Econo-column (Bio-Rad Laboratories, Mississauga, ON) equilibrated with Buffer A (50 
mM Tris-HCl, 1 mM CaCl2, pH 7.5 @ 4oC).  After the Ca2+-saturated solution was loaded, the resin 
was washed with 100 mL of Buffer A (5 column volumes).  The resin was subsequently washed with 
80 mL of Buffer B (4 column volumes of 50 mM Tris-HCl, 500 mM NaCl, 1 mM CaCl2, pH 7.5 @ 
4oC) to remove any non-specific proteins that were interacting with the resin.  The resin was finally 
washed with 50 mL of Buffer A (2.5 column volumes) to remove NaCl from the resin.  Wild-type 
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CaM was then eluted from the phenyl sepharose resin with approximately 30 mL of Buffer  C (10 
mM Tris-HCl, 10 mM EDTA, pH 7.5 @ 4oC) and 2 mL fractions were collected.  Fractions were then 
scanned from 325 to 250 nm on a Varian Cary UV–visible Spectrophotometer (Varian, Mississauga, 
ON).  Fractions displaying the characteristic absorbance peaks of CaM at 277 nm (for tyrosine 
residues) and 269, 265, 259, and 253 nm (for phenylalanine residues) were pooled and dialysed 
overnight against 1 L of Buffer A using 6-8000 MWCO dialysis tubing (VWR International, 
Mississauga, ON).  The normalized absorbance scan of purified wild-type CaM showing peaks at 
277, 269, 265, 259, and 253 nm is shown in Figure 2.3. 
 
Figure 2.3 – UV-absorbance scan of wild-type CaM  
This scan demonstrates the unique absorbance peaks of wild-type CaM found at 277, 269, 265, 259, 
and 253 nm.  Due to the absence of tryptophan residues in CaM, the major peak at 277 nm 
corresponds to the 2 tyrosine residues located in the C-terminal domain of CaM, while the other peaks 
represent the numerous phenylalanine residues found throughout CaM depending upon their 
environment. 
 
Dialysis tubing was prepared by boiling 0.5 L MQH2O with 200 mg of EDTA and 200 mg sodium 
bicarbonate for 10 – 20 minutes, followed by extensive rinsing with MQH2O.  Prior to aliquoting the 
protein for storage, the concentration of CaM was determined using the ε277 of 3029 M-1cm-1 for CaM 
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saturated with Ca2+ (Gao et al., 1998) or using the Lowry method (Lowry et al., 1951) with wild-type 
CaM used as the protein standard.  The purified wild-type CaM was then aliquoted, flash frozen on 
dry ice and stored at –80oC.   
2.2.4 CaM-TnC Expression and Purification 
The CaM-TnC proteins were expressed in E. coli BL21(DE3) transformed with pCaM-1TnCKan, 
pCaM-2TnCKan, pCaM-3TnCKan, pCaM-4TnCKan or pCaM-3,4TnCKan as previously described 
for wild-type CaM (section 2.2.1).  The CaM-TnC proteins were purified using the same procedure 
used to purify wild-type CaM (section 2.2.3).  
2.2.5 Electrospray Ionization-Mass Spectrometry of CaM and CaM Proteins 
Electrospray ionization-mass spectrometry (ESI-MS) using a Quadrupole Time-Of-Flight (QTOF) 
spectrometer (Micromass, Manchester, UK) with an internal standard was then performed on the 
purified CaM protein to ensure that no posttranslational modifications had occurred.  Wild-type CaM 
was prepared for ESI-MS by transferring the protein into water using a Ym10 centrifugal filter device 
(Millipore, Billerica, MA, USA) and then diluted using a 1:1 CH3CN/water solution containing 0.2% 
formic acid to a concentration of approximately 20 μM.  The samples were infused at 10 μl/min.  Raw 
data (m/z) were processed using MaxEnt1 software to yield spectra on a true molecular mass scale. 
2.2.6 eNOS and nNOS Expression 
Bovine eNOS and rat nNOS were expressed in E. coli BL21 (DE3) containing pGroESLChlor co-
transformed with peNOShisAmp and pnNOShisAmp.  The ampicillin resistant vectors, 
peNOShisAmp and pnNOShisAmp, contained the coding regions for bovine eNOS or rat nNOS 
cloned into pCWOri with upstream poly-histidine tags to aid in their purification (section 2.2.7).  The 
original vectors coding for bovine eNOS, rat nNOS, and GroESL were a generous gift from Dr. Betty 
Sue Masters (University of Texas Health Science Center at San Antonio, San Antonio, TX, USA).  
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The chloramphenicol resistant pGroESLChlor vector contained the coding regions for GroESL, a 
molecular chaperone used to help with the proper folding of eNOS and nNOS during protein 
expression.  An overnight culture of transformed E. coli BL21 (DE3) with peNOShisAmp and 
pGroESLChlor or pnNOShisAmp and pGroESLChlor were used to inoculate 3 x 1 L of TB media in 
4 L flasks supplemented with 100 µg/ml of ampicillin and 30 µg/ml of chloramphenicol.  These 1 L 
cultures were grown at 37ºC, 200 rpm to an O.D. at 600 nm of 1 – 1.2 and were induced.  Induction 
of these cultures involved the addition of IPTG (500 µM), δ-aminolevulinic acid (δ-ALA, 400 μM; 
precursor for heme production), ATP (500 µM; for GroESL assembly and activity), ~100 mg of 
riboflavin (precursor for flavin production) and trace metals (9.6 mg/L FeSO4•7H2O, 2.4 mg/L 
MnSO4•H2O, 2.4 mg/L AlCl3•6H2O, 1.0 mg/L CoCl2•6H2O, 0.5 mg/L ZnSO4•7H2O, 2.4 mg/L 
Na2MoO4•2H2O, 0.1 mg/L CuCl2•2H2O, and 0.5 mg/L H3BO3).  The temperature of the shaker was 
then lowered to 25oC, 200 rpm.  After 40 hours of protein expression, the cells were harvested by 
centrifugation at 6000 x g at 4oC for 5 minutes, flash frozen on dry ice, and subsequently stored at –
80ºC.   
2.2.7 eNOS and nNOS Purification 
The overall purification of the NOS enzymes involved the use of ammonium sulfate precipitation, 
followed by metal chelation chromatography, and finally 2’5’ ADP-sepharose chromatography.  Cells 
were thawed on ice, resuspended in 4 volumes of NOS Lysis buffer consisting of 40 mM Tris-HCl, 
pH 7.5 @ 4oC, 10% glycerol, 1 mM L-arginine, 10 μM H4B, 3 mM ascorbic acid, 150 mM NaCl, 1 
mM PMSF, 4 μg/mL leupeptin, 2 μg/mL aprotinin, 3.5 μg/mL E64, and 0.6 μg/mL peptstatin.  The 
numerous protease inhibitors were added to help decrease the proteolysis of the cNOS enzymes 
during their purification, as previously reported (Siddhanta et al., 1998).  The cells were subsequently 
lysed by homogenization using an Avestin EmulsiFlex-C5 homogenizer (Ottawa, ON).  The lysate 
was then clarified by centrifugation at 48,000 x g for 30 minutes at 4oC.  A purification protocol to 
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purify eNOS and nNOS that was previously published was followed (Roman et al., 1995) with a few 
modifications.  All of the following steps were carried out at 4oC in a fridge or on ice.  To the 
clarified supernatant, ammonium sulfate was added to 65% (373 mg/mL), stirred for 1 hour, and 
subsequently centrifuged at 48,000 x g for 30 minutes at 4oC to harvest the precipitated proteins.  The 
ammonium sulfate pellets were then resuspended in a ~100 mL of NOS Pellet buffer (40 mM Tris-
HCl, pH 7.5 @ 4oC, 10% glycerol, 1 mM L-arginine, 250 mM NaCl, and 1 mM PMSF).  Prior to 
loading the protein onto 20 mL of Ni2+-chelating resin (Novagen, La Jolla, CA, USA) in a 1 cm x 30 
cm Econo-column (Bio-Rad Laboratories, Mississauga, ON), the resin was charged by washing the 
column with 3 column volumes of 100 mM NiSO4 and equilibrated with 5 column volumes of NOS 
Pellet buffer.  The resuspended ammonium sulfate pellets were then slowly mixed with charged Ni2+-
chelating resin equilibrated with NOS Pellet buffer for 1 hour with the addition of an EDTA-free 
complete protease inhibitor tablet (Roche, Mississauga, ON).  The NOS loaded Ni2+-chelating resin 
was then poured back into the 1 cm x 30 cm Econo-column.  The column was subsequently washed 
with 10 column volumes of NOS Pellet buffer followed by 5 column volumes of 20 mM imidazole in 
NOS Pellet buffer.  The NOS protein was eluted with 200 mM imidazole in NOS Pellet buffer and the 
most concentrate eluted fraction (~5 mL) was collected. 
Prior to loading the protein onto the 2’5’ ADP-sepharose resin, the resin was regenerated 
using three cycles of alternating washes (2 column volumes each wash) with ADP Regeneration 
Solution 1 (0.1 M Tris-HCl, 0.5 M NaCl, pH 8.5) and ADP Regeneration Solution 2 (0.1 M sodium 
acetate, 0.5 M NaCl, pH 4.5).  Following the regeneration of the column, the 2’5’ ADP-sepharose 
resin was equilibrated with 10 column volumes of ADP Wash buffer (50 mM Tris-HCl, pH 7.5 @ 
4oC, 10% glycerol, 100 μM L-arginine, 100 mM NaCl, 1 mM DTT, and 0.1 mM PMSF).  The eluted 
cNOS protein from the metal chelation chromatography column was then diluted with 2 volumes of 
ADP Wash buffer and loaded onto ~5 mL of 2’5’ ADP-sepharose resin (GE Healthcare Bio-Sciences, 
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Baie d’Urfe, PQ) in a 1 cm x 20 cm Econo-column (Bio-Rad).  The loaded resin was then washed 
with 5 column volumes of ADP Wash buffer, followed by 5 column volumes of ADP Salt Wash 
buffer (50 mM Tris-HCl, pH 7.5 @ 4oC, 10% glycerol, 100 μM L-arginine, 500 mM NaCl, 1 mM 
DTT, and 0.1 mM PMSF).  The saturated 2’ AMP (10 mM) dissolved in ADP Salt Wash buffer 
(which was warmed at 37oC to help solubilize the 2’ AMP) was then used to elute the NOS enzyme 
and collected in 1-2 mL fractions.  Eluted fractions demonstrating the appropriate absorbance peaks 
between 700 and 300 nm were then pooled and dialyzed at 4oC against 1 L of NOS Dialysis buffer 1 
(50 mM Tris-HCl, pH 7.5 @ RT, 10% glycerol, 5 μM L-arginine, 250 mM NaCl, 1 mM DTT, 4 μM 
H4B, 3 mM ascorbic acid, and 0.1 mM PMSF) using 6-8000 MWCO dialysis tubing (VWR 
International, Mississauga, ON).   After 3 hours, the NOS sample was transferred into 1 L of NOS 
Dialysis Buffer 2 (identical to NOS Dialysis Buffer 1 with 100 mM NaCl) and allowed to dialyze 
overnight at 4oC.  Using NOS Dialysis buffer 2 as a baseline, the purified NOS protein was then 
scanned from 700 to 300 nm and the concentration was determined using the ε397 of 72 mM-1 cm-1 
(Stuehr and Ikeda-Saito, 1992).  The normalized absorbance scans of purified nNOS and eNOS 
showing a peak at 397 nm are shown in Figure 2.4. 
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Figure 2.4 – UV-visible absorbance scan of (A) nNOS, (B) eNOS, and (C) iNOS coexpressed 
with wild-type CaM. 
This scan demonstrates the typical absorbance peaks of nNOS, eNOS, and iNOS coexpressed with 
wild-type CaM at 397 (ferric heme), and 450 and 475 nm (flavins).  The absorbance of a pure NOS 
preparation typically demonstrated a 397 nm / 450 nm ratio of 2.5-3. 
 
If the NOS protein was lower than 2 μM, the NOS protein was concentrated using a Vivaspin 15 
ultrafiltration spin column (Sartorius AG Biotechnology, Goettingen, Germany) until the desired 
concentration was obtained.  The purified eNOS and nNOS protein was then aliquoted, flash frozen 
on dry ice, and subsequently stored at –80oC. 
2.2.8 iNOS coexpression with wild-type CaM or CaM-TnC Chimeras 
pΔ70iNOShisAmp, a vector coding for human iNOS carrying a deletion of the first 70 amino acids 
and an N-terminal polyhistidine tail in the ampicillin expression vector pCWOri, was used for the 
expression of iNOS.  This protein will be referred to as iNOS throughout this thesis.  The Δ70iNOS 
was expressed to minimize the proteolysis of iNOS during expression, as well as the numerous rare 
codons (ie. Arg, AGA/AGG and Pro, CCC) found in the 5’ coding region.  In order to coexpress 
iNOS with wild-type CaM and each of the CaM-TnC chimeric proteins, pΔ70iNOShisAmp was co-
transformed with a wild-type CaM vector (pCaMChlor) or a CaM-TnC chimera vector (pCaM-
1TnCKan, pCaM-2TnC, pCaM-3TnCKan, pCaM-4TnCKan and pCaM-3,4TnCKan) into E. coli 
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BL21 (DE3).  For iNOS coexpressed with wild-type CaM, an overnight culture of transformed E. coli 
BL21 (DE3) with pΔ70iNOShisAmp with pCaMChlor was used to inoculate 3 x 1 L of TB media in 
4 L flasks supplemented with 100 µg/ml of ampicillin and 30 µg/ml of chloramphenicol.  For iNOS 
coexpressed with CaM-TnC chimeric proteins, BL21 (DE3) pΔ70iNOShisAmp with each of the 
CaM-TnC chimera vectors were used to inoculate 3 x 1 L of TB media in 4 L flasks supplemented 
with 100 µg/ml of ampicillin and 30 µg/ml of kanamycin.  These 1 L cultures were grown at 37ºC, 
200 rpm to an O.D. at 600 nm of 1 – 1.2 and were induced.  Induction of these cultures involved the 
addition of IPTG (500 µM), δ-ALA (400 μM), ~100 mg of riboflavin, and trace metals (as described 
in section 2.2.6).  The temperature of the shaker was then decreased to 25oC, 200 rpm.  After 40 hours 
of protein expression, the cells were harvested by centrifugation at 6000 x g at 4oC for 5 minutes, 
flash frozen on dry ice, and stored at –80ºC.   
2.2.9 Purification of iNOS coexpressed with wild-type CaM or CaM-TnC 
Chimeric Proteins 
The purification of iNOS coexpressed with wild-type CaM followed the same protocol used for 
eNOS and nNOS (section 2.2.7) with the exception of a 45% ammonium sulfate precipitation (278 
mg/mL). 
The purification of iNOS coexpressed with CaM-TnC chimeric proteins also followed the 
protocol used for eNOS and nNOS (section 2.2.7) with the following modifications.  10 mM CaCl2 
was added to NOS Lysis, ADP Wash, and ADP Salt Wash buffers in order to stabilize the interaction 
between the mutant CaM proteins and iNOS.  Due to numerous attempted purifications of iNOS 
coexpressed with mutant CaM proteins, the metal chelation chromatography step was avoided due to 
the higher susceptibility of NOS being proteolytically cleaved.  Following the lysis of the cells and 
the 45% ammonium sulfate precipitation, the ammonium sulfate pellet was resuspended in ~100 mL 
of ADP Wash buffer, followed by slow mixing with 2’5’ ADP-sepharose resin equilibrated with ADP 
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Wash buffer for 1 hour with the addition of an EDTA-free complete protease inhibitor tablet (Roche).  
The NOS loaded 2’5’ ADP-sepharose resin was then poured into a 1 cm x 20 cm Econo-column (Bio-
Rad).  The column was subsequently washed with ADP Wash and ADP Salt Wash buffers.  The 
iNOS protein was then eluted with 2’ AMP, scanned and dialysed against NOS Dialysis buffers 1 and 
2, as previously described (section 2.2.7).  The normalized absorbance scan of purified iNOS 
coexpressed with wild-type CaM showing a peak at 397 nm is shown in Figure 2.4C. 
 The concentration of iNOS coexpressed with wild-type CaM or iNOS coexpressed CaM-
TnC chimeric proteins were then determined using the ε397 of 72 mM-1 cm-1, aliquoted, flash frozen 
on dry ice, and stored at –80oC as previously described (section 2.2.7).  
 
2.2.10 Spectrophotometic Kinetic Assays 
Four frequently used kinetic assays employed to measure rates of electron transfer in the NOS 
enzymes are the NADPH oxidation, ferricyanide reduction, cytochrome c oxidation, and 
oxyhemoglobin capture assay (Figure 2.5).   These assays are described in the following sections, 
with the exception of the ferricyanide assay, which was used exclusively in Chapter 5 (section 
4.2.4.1). 
Chapter 2: Activation of NOS by CaM-TnC Chimera 
68 
 
Figure 2.5 – Spectrophotometric assays employed to monitor electron transfer within the NOS 
enzymes. 
(1) The NADPH assay measures the oxidation of NADPH to NADP+ + H+ by monitoring decreases in 
absorbance at 340 nm.  (2) The ferricyanide assay measures the hydride transfer to the FAD by 
monitoring the reduction of Fe(III) to Fe(II) with decreases at 420 nm. (3) The cytochrome c assay 
measures electron transfer through the reductase domain to the FMN by monitoring the reduction of 
cytochrome c with increases at 550 nm.  (4) The oxyhemoglobin (HbO4) capture assay measures the 




2.2.10.1 Oxyhemoglobin Capture Assay 
2.2.10.1.1 Oxyhemoglobin Preparation 
A 15 mL falcon tube was filled with approximately 5 mL of loosely packed hemoglobin crystals 
(Sigma) and dissolved in the minimal amount (~2 – 2.5 mL) of 50 mM Tris-HCl, pH 7.5 at room 
temperature.  The total volume of dissolved hemoglobin was approximately 4 – 5 mL and the solution 
was then kept on ice.  Approximately 10 – 20 mg of sodium hydrosulfite was subsequently added to 
the hemoglobin solution and the tube was inverted several times to thoroughly mix the sample.  The 
hemoglobin solution should turn from a brown to a “cherry” red tinge after the addition of sodium 
hydrosulfite.  Four PD10 gel filtration columns (GE Healthcare) were then equilibrated with Tris 
buffer which involved washing each column with 25 mL MQH2O, followed by 25 mL of 50 mM 
Tris-HCl, pH 7.5 @ RT.  One mL of the hemoglobin solution was then loaded onto each PD column.   
The “ruby” red oxyhemoglobin was then collected and the last few drops were not collected to avoid 
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contamination with any excess sodium hydrosulfite.  The collected oxyhemoglobin was subsequently 
aliquoted (200 μL), flash frozen on dry ice and stored at –80oC.  A spectrophotometric scan was taken 
from 700 to 350 nm using a 0.2 cm quartz cuvette before and after reduction by sodium hydrosulfite 
to ensure that the reduction of the hemoglobin was complete.  Using the reduced hemoglobin scan, 
the concentration of oxyhemoglobin in μM was then determined using the following equation: 
 
Equation 2.1 [HbO4] μM = (1.013 x A576 – 0.3269 x A630 – 0.7353 x A560) x 100 x dil. factor x 5 
 
where A576, A630, and A560 represent the absorbance value at 576, 630, and 560 nm respectively.  The 
100 comes from a previous published equation in μM (Hevel and Marletta, 1994), which was based 
upon the previously solved extinction coefficients of oxyhemoglobin by Benesch and coworkers 
(Benesch et al., 1973) whose extinction coefficients were expressed in cm-1M-1 values.  For example, 
ε576 = 1.013 x 10-4 cm-1M-1 by Benesch is equivalent to ε576 = 1.013 * 102 cm-1μM-1 published by 
Hevel.  The multiplication factor of 5 was necessary since a 0.2 cm cuvette was used. 
2.2.10.1.2 Oxyhemoglobin Calibration 
The molar extinction co-efficient for the conversion of oxy- to methemoglobin for the oxyhemoglobin 
capture assay was calculated based upon a previously used method developed by Dr. Heather 
Montgomery (PhD. 2004, U of Waterloo) and Dr. Basil Perdicakis (PhD. 2003, U of Waterloo), 
which was based upon a previously published method (Gross, 1996).  Oxyhemoglobin was oxidized 
to methemoglobin by the addition of potassium ferricyanide (K3Fe(CN)6).  A 12 mM stock solution of 
K3Fe(CN)6 was prepared by dissolving 40 mg of K3Fe(CN)6 in 10 mL of 50 mM Tris-HCl, pH 7.5 @ 
RT, which was subsequently diluted 1 in 10 with 50 mM Tris-HCl to obtain a 1.2 mM K3Fe(CN)6 
working stock solution.  The previously prepared oxyhemoglobin solution was diluted to 40 μM stock 
solution in 50 mM Tris-HCl, pH 7.5 @ RT to produce the oxyhemoglobin working solution.  The 
methemoglobin working solution was prepared by diluting oxyhemoglobin to 40 μM in the presence 
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of 0.12 mM K3Fe(CN)6.  200 μL of the oxyhemoglobin and methemoglobin working solutions were 
added to 3 wells each on a 96 well microtitre plate (ie. oxy- into wells A1-3, and met in wells A4-6).  
100 μL of 50 mM Tris-HCl, pH 7.5 @ RT was then added to rows B-H of columns 1-3, while 50 mM 
Tris-HCl, 0.12 mM K3Fe(CN)6, pH 7.5 @ RT was added to rows B-H of columns 4-6 of the 
microtitre plate in preparation for the serial dilution of oxy- and methemoglobin.  Using a milti-
channel pipettor, serial dilutions were performed by transferring 100 μL of row A to row B, row B to 
row C, etc. to row G, where the final 100 μL was removed.  Row H was used as the blank.  Each 
dilution was performed in triplicate.  Figure 2.6 is shown to help clarify the serial dilution of oxy- and 
methemoglobin in the microtitre plate. 
 
Figure 2.6 – Calibration of oxyhemoglobin in a 96 well microtitre plate using serial dilutions.  
Columns 1-3 and 4-6 contain oxy- and methemoglobin, respectively.  Initially, Row A contained 200 
μL of 40 μM oxy- or methemoglobin.  Using a multi-channel pipettor, serial dilutions of oxy- and 
methemoglobin were performed by sequentially transferring 100 μL from Row A into row B, etc.  
Rows A to G contain 40, 20, 10, 5, 2.5, 1.25 and 0.625 μM oxy- or methemoglobin.  The control 
blanks for the plate are in Row H, as described in section 2.2.10.1.2.   
 
The plate was then read at 401 nm in a SpectraMax 384 Plus 96 well UV-visible spectrophotometer 
using Soft Max Pro software (Molecular Devices, Sunnyvale, CA).  The slopes of OD401 versus 
nanomoles of oxyhemoglobin and OD401 versus nanomoles of oxyhemoglobin were calculated using 
linear regression.  The extinction coefficient (Δε410 nm (met- to oxyhemoglobin)) used in the oxyhemoglobin 
Chapter 2: Activation of NOS by CaM-TnC Chimera 
 71 
assay was determined by taking the difference between the slope of methemoglobin and the slope of 
oxyhemoglobin.  This value ranged from 0.10 to 0.13 OD401 nm per nanomole of hemoglobin, 
depending on the oxyhemoglobin preparation (section 2.2.10.1.1). 
2.2.10.1.3 Oxyhemoglobin Capture Assay 
The spectrophotometric oxyhemoglobin capture assay was used to assess the initial rate of •NO 
synthesis.  This assay was previously developed by Dr. Heather Montgomery and Dr. Basil Perdicakis 
in our laboratory using 96 well microtitre plates (Perdicakis et al., 2004).  This assay involved the use 
of two separate solutions: (1) the enzyme solution and (2) the substrate solution.  The enzyme 
solution consisted of the NOS enzyme in a 50 mM Tris-HCl, pH 7.5 @ RT buffer with 10 μM FAD, 
10 μM FMN, 50 μM H4B, 500 μM NADPH, 100 μM DTT, 50 U/mL catalase, 100 U/mL superoxide 
dismutase (SOD), 0.2 mg/mL bovine serum albumin and 10% glycerol.  NADPH, DTT, and H4B 
were prepared fresh on the day of the assay.  H4B was dissolved in the 20 mM DTT in order to ensure 
that it was in its reduced form (Hevel and Marletta, 1994; Dawson and Knowles, 1999).  The NADPH 
was added to this solution to react with any L-arginine in the enzyme solution from the dialysis buffer 
of the NOS.  SOD and catalase were added to this solution to react with any reactive oxygen species 
caused by uncoupled electron transfer in NOS (Hevel and Marletta, 1994).  The inclusion of 10% 
glycerol and 0.2 mg/mL bovine serum albumin (BSA) were to maintain NOS enzyme stability.  The 
substrate solution contained oxyhemoglobin, L-arginine, Tris-HCl, CaCl2 or EDTA (depending on the 
enzyme being tested), NADPH, BSA, catalase, and SOD. 
 The assay reactions were performed by adding 10 μL of complete enzyme solution (NOS 
enzyme, with or without CaM, and enzyme solution), followed by a 2 minute incubation at 25oC.  
This incubation was included due to the previous finding that the t1/2 of 125I CaM binding to nNOS at 
23oC was less than 2 minutes (Weissman et al., 2002).  Following the incubation, the assay was 
initiated by the addition of 90 μL of substrate solution to each well containing complete enzyme 
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solution, for a total of 100 μL per well.  The final initiated reaction contained oxyhemoglobin (5 μM), 
L-arginine (25 μM), Tris-HCl (50 mM, pH 7.5 @ RT), glycerol (1 %), FMN (1 μM), FAD (1 μM), 
H4B (5 μM), DTT (1 mM), NADPH (450 μM), BSA (0.18 mg/mL), catalase (50 U/mL), and SOD 
(100 U/mL).  eNOS, nNOS, and iNOS coexpressed with CaM or mutant CaM protein were assayed at 
70, 30, and 28.5 nM in 100 μL total well volume in quadruplicate.  CaCl2 (200 μM), EDTA (250 
μM), and CaM (2 μM) or mutant CaM protein were added to the appropriate samples unless 
otherwise stated. 
After initiation, the microtitre plate was read at 25 – 27oC in a SpectraMax 384 Plus 96 well 
UV-visible spectrophotometer using Soft Max Pro software (Molecular Devices, Sunnyvale, CA).  
The reactions were read at 401 nm over 5 minutes at 7 second intervals.  Equation 2.2 was used to 
calculate the activity of the enzyme based upon the rate of absorbance change at 401 nm. 
 
Equation 2.2 Activity = v x 60 s • min-1 / Δε410 nm (met- to oxyhemoglobin) / (well volume x  
    [NOS enzyme] in nM x NOS molecular weight in g/mol x 1000 mg/g)  
 
where v represents the slope of the change of absorbance over time in seconds.  Activity is expressed 
as nanomoles of •NO produced per minute per milligram of enzyme (nmol •NO min-1 mg-1). 
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2.2.10.2 Cytochrome c Reduction Assay 
2.2.10.2.1 Cytochrome c Preparation 
A 15 mL falcon tube was filled with approximately 5 mL of loosely packed horse heart cytochrome c 
crystals (Sigma) and dissolved in the minimal amount (~ 2 – 2.5 mL) of 50 mM Tris-HCl, pH 7.5 at 
room temperature.  The total volume of the dissolved cytochrome c was approximately 4 – 5 mL and 
the solution was then kept on ice.  Approximately 10 – 20 mg of bis(dipicolinato)cobaltate (III) was 
added to the cytochrome c solution and the tube was inverted several times to thoroughly mix the 
sample.  The solution should turn from a brown to a redish tinge after the addition of 
bis(dipicolinato)cobaltate (III).  Four PD10 gel filtration columns (GE Healthcare) were then 
equilibrated with Tris buffer which involved washing each column with 25 mL MQH2O, followed by 
25 mL of 50 mM Tris-HCl, pH 7.5 @ RT.  One mL of the cytochrome c solution was then loaded 
onto each PD column.  The oxidized cytochrome c was then collected.  The final few drops were not 
collected to avoid unwanted contamination with any excess bis(dipicolinato)cobaltate (III).  The 
collected oxidized cytochrome c was then aliquoted (200 μL), flash frozen on dry ice and stored at     
–80oC.  A spectrophotometric scan was taken from 700 to 350 nm using a 0.2 cm quartz cuvette 
before and after oxidation by bis(dipicolinato)cobaltate (III) to ensure that the oxidation of the 
cytochrome c was complete.  Using the oxidized cytochrome c scan, the concentration of cytochrome 
c in μM was then determined using the ε410 of 106.1 mM-1cm-1 (Margoliash and Frohwirt, 1959) and 
the following equation: 
Equation 2.3  [Cytochrome c] μM = (A410/ε410) x dilution factor x 5 x 1000 
 
where A410 represents the absorbance value at 410 nm.  The multiplication factor of 5 was necessary 
since a 0.2 cm cuvette was used.  The 1000 converts the solved concentration of cytochrome c from 
mM to μM. 
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2.2.10.2.2 Cytochrome c Calibration 
The calibration of cytochrome c was performed in a similar manner to the calibration of 
oxyhemoglobin (section 2.2.10.1.2) with the exception that 500 μM DTT was used to reduce 
cytochrome c instead of K3Fe(CN)6.  The dilutions of cytochrome c were performed in a 96 well 
microtitre plate, similar to that shown in Figure 2.6, over a concentration range of 20, 40, 60, 80, 100, 
120 and 140 μM in the presence (red. cytochrome c) or absence (ox. cytochrome c) of DTT. 
The plate was then read at 550 nm in a SpectraMax 384 Plus 96 well UV-visible 
spectrophotometer using Soft Max Pro software (Molecular Devices, Sunnyvale, CA).  The slopes of 
OD550 versus nanomoles of reduced cytochrome c and OD550 versus nanomoles of oxidized 
cytochrome c were then calculated using linear regression.  The extinction coefficient (Δε550 nm (reduced 
cyt c- to oxidized cyt c)) used in the cytochrome c assay was determined by taking the difference between the 
slope of reduced cytochrome c and oxidized cytochrome c.  Depending on the cytochrome c 
preparation, the extinction coefficient value ranged from 0.047 to 0.050 OD550 nm per nanomole of 
cytochrome c (section 2.2.10.2.1). 
2.2.10.2.3 Cytochrome c Assay 
The spectrophotometric NADPH-dependent cytochrome c assay was used to assess the initial rate of 
electron transfer in the NOS reductase domain to the FMN domain.  This assay was previously 
standarized by Dr. Heather Montgomery in our laboratory using 96 well microtitre plates.  This assay 
was performed in a similar manner to the oxyhemoglobin capture assay (section 2.2.10.1.3) with the 
exception that no DTT or H4B added.  In order to observe the reduction of cytochrome c exclusively 
caused by NOS, DTT and H4B were not included in this assay because of their ability to reduce 
cytochrome c.  This assay involved the use of three separate solutions: (1) the enzyme solution, (2) 
the cytochrome c solution, and (3) the NADPH solution.  The enzyme solution consisted of the NOS 
enzyme in a 50 mM Tris-HCl, pH 7.5 @ RT buffer with 10 μM FAD, 10 μM FMN, 200 μM NADPH, 
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10 U/mL catalase, 10 U/mL SOD, 0.1 mg/mL BSA and 10% glycerol.  NADPH was prepared fresh 
on the day of the assay.  The NADPH was added to this solution to react with any L-arginine in the 
enzyme solution from the dialysis buffer of the NOS.  The cytochrome c solution contained 
cytochrome c, Tris-HCl, CaCl2 or EDTA (depending on the enzyme being tested), BSA, catalase, and 
SOD.  The NADPH solution contained only the NADPH used to initiate the assay.  
 The assay reactions were performed by adding 10 μL of complete enzyme solution (NOS 
enzyme, with or without CaM, and enzyme solution), followed by a 2 minute incubation at 25oC.  
Following the incubation, 50 μL of cytochrome c solution was added to each well containing the 
complete enzyme solution, followed by a 30 second incubation.  After this brief incubation, the assay 
was initiated by the addition of 40 μL of NADPH solution to each well, for a total of 100 μL per well.  
The final initiated reaction contained cytochrome c (100 μM), Tris-HCl (50 mM, pH 7.5 @ RT), 
glycerol (1%), FMN (1 μM), FAD (1 μM), NADPH (200 μM), BSA (0.1 mg/mL), catalase (10 
U/mL), and SOD (10 U/mL).  eNOS, nNOS, and iNOS coexpressed with CaM or mutant CaM 
protein were assayed at 50, 5.5, and 5.5 nM in 100 μL total well volume in quadruplicate.  CaCl2 (200 
μM), EDTA (250 μM), and CaM (2 μM) or mutant CaM protein were added to the appropriate 
samples unless otherwise stated. 
After initiation, the microtitre plate was read at 25 – 27oC in a SpectraMax 384 Plus 96 well 
UV-visible spectrophotometer using Soft Max Pro software (Molecular Devices, Sunnyvale, CA).  
The reactions were read at 550 nm over 5 minutes at 7 second intervals.  Equation 2.4 was used to 
calculate the activity of the enzyme based upon the rate of absorbance change at 550 nm. 
 
Equation 2.4   Activity = v * 60 s • min-1 / Δε550 nm (reduced cyt c- to oxidized cyt c)  / (well volume x 
     [NOS enzyme] in nM x NOS molecular weight in g/mol x 1000 mg/g)  
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where v represents the slope of the change of absorbance over time in seconds.  Activity is expressed 
as nanomoles of cytochrome c reduced per minute per milligram of enzyme (nmol red. cyt c min-1  
mg-1). 
2.2.10.3 NADPH Oxidation Assay 
The UV-spectrophotometric NADPH assay was used to monitor the initial rate of NADPH oxidation 
to NADP+ by the reductase domain of the NOS enzymes.  This assay, which was previously 
developed by Dr. Heather Montgomery, utilizes the difference in absorbance at 340 nm of NADPH 
(absorbant) and NADP+ (non-absorbant) to monitor the rate of NADPH consumption by NOS.  This 
assay was performed in an almost identical manner to the oxyhemoglobin capture assay (section 
2.2.10.1.3).  This assay involved the use of two separate solutions: (1) the enzyme solution and (2) the 
NADPH solution.  The enzyme solution consisted of the NOS enzyme in a 50 mM Tris-HCl, pH 7.5 
@ RT buffer with 10 μM FAD, 10 μM FMN, 50 μM H4B, 3 mM DTT, 50 U/mL catalase, 100 U/mL 
SOD, 0.2 mg/mL BSA and 10% glycerol.  NADPH, DTT, and H4B were prepared fresh on the day of 
the assay, with H4B was dissolved in the 20 mM DTT, as previously described (section 2.2.10.1.3).  
The NADPH was added to this solution to react with any L-arginine in the enzyme solution from the 
dialysis buffer of the NOS.  SOD and catalase were added to this solution to react with any reactive 
oxygen species caused by uncoupled electron transfer in NOS.  The NADPH solution contained 
NADPH, L-arginine, Tris-HCl, CaCl2 or EDTA (depending on the enzyme tested), BSA, catalase, 
and SOD. 
The assay reactions were performed by adding 10 μL of complete enzyme solution (NOS 
enzyme, with or without CaM, and enzyme solution), followed by a 2 minute incubation at 25oC.  
Following the incubation, the assay was initiated by the addition of 90 μL of NADPH solution to each 
well containing complete enzyme solution, for a total of 100 μL per well.  The final initiated reaction 
contained NADPH (500 μM), L-arginine (5 mM), Tris-HCl (50 mM, pH 7.5 @ RT), glycerol (1%), 
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H4B (5 μM), DTT (300 μM), BSA (0.2 mg/mL), catalase (50 U/mL), and SOD (100 U/mL).  eNOS, 
nNOS, and iNOS coexpressed with CaM or mutant CaM protein were assayed at 100, 70, and 49 nM 
in 100 μL total well volume in quadruplicate.  CaCl2 (200 μM), EDTA (250 μM), and CaM (2 μM) or 
mutant CaM protein were added to the appropriate samples unless otherwise stated. 
After initiation, the microtitre plate was read at 25 – 27oC in a SpectraMax 384 Plus 96 well 
UV-visible spectrophotometer using Soft Max Pro software (Molecular Devices, Sunnyvale, CA).  
The reactions were read at 340 nm over 5 minutes at 7 second intervals.  Equation 2.5 was used to 
calculate the NADPH oxidase activity based upon the rate of absorbance change at 340 nm. 
 
Equation 2.5 Activity = v x 60 s • min-1 / Δε340 nm NADPH to NADP+) / (well volume x 
    [NOS enzyme] in nM x NOS molecular weight in g/mol x 1000 mg/g)  
 
where v represents the slope of the change of absorbance over time in seconds.  The extinction 
coefficient Δε340 nm NADPH to NADP+ of -0.0152 OD340 per nanomole was used.  Activity is expressed as 
nanomoles of NADPH oxidized per minute per milligram of enzyme (nmol NADPH ox. min-1 mg-1). 
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2.3 Results 
2.3.1 Protein Expression and Purification 
Each of the expressed and purified CaM-TnC chimeric proteins yielded a high amount of protein 
ranging from 50 to 80 mg of protein/L of media, depending upon the CaM mutant.  Purified CaM-
TnC chimeras were then analyzed by SDS-PAGE and were judged to be over 95% homogeneous.  
 
Figure 2.7 – SDS-PAGE of CaM-TnC chimeras. 
The purified chimeras were run on a 15% SDS-polyacrylamide gel. Ten μg of each chimeric protein 
was loaded using buffer containing 5 mM EDTA. Lane 1, low molecular mass protein standard (Bio-
Rad); lane 2, wild-type CaM; lane 3, CaM-1TnC; lane 4, CaM-2TnC; lane 5, CaM-3TnC; lane 6, 
CaM-4TnC; lane 7, CaM-3,4TnC. 
 
These CaM-TnC proteins were analyzed in buffers containing EDTA because the chimeras undergo 
typical shifts toward lower apparent molecular weights when run in a Ca2+-containing loading buffer 
(results not shown). Electrospray ionization-mass spectrometry was used to further assess the 
homogeneity of the CaM samples and rule out any modification (Table 2.1).  
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Table 2.1 – Masses of CaM-TnC Chimera proteins a 
      
 Mass (Da) b 
     
     
  Observed Theoretical 
 CaM proteins     
   
Wild-type CaM 16706.0 16706 c 
CaM-1TnC 17795.6 17796 
CaM-2TnC 17272.5 17273 
CaM-3TnC 16732.3 16732 
CaM-4TnC 16893.7 16895 
CaM-3,4TnC 16948.3 16941 
   
a ESI-MS results from Elena Newman, MSc. – University of Waterloo Thesis (2003) 
b Masses of deconvoluted ESI-MS spectra were determined with an accuracy of ± 5 Da. 
c Calculated masses based upon amino acid sequence. 
 
In order to study the effect of the exchanged EF hand motifs in the CaM-TnC chimeric 
proteins, the iNOS enzyme was coexpressed with wild-type CaM and each of the individual CaM-
TnC chimeras.  The yield of protein varied depending upon the chimeric protein.  iNOS coexpressed 
with wild-type CaM produced the highest yields of purified iNOS enzyme (5 mg/L media).  The 
yields of iNOS obtained when the enzyme was coexpressed with either CaM-1TnC or CaM-2TnC 
(1.4 mg/L media) were more than double of the amount of iNOS obtained when coexpressed with 
CaM-3TnC, CaM-4TnC, or CaM-3,4TnC (0.3 to 0.7 mg/L).  When comparing the amounts of iNOS 
produced when coexpressed with each of the CaM-TnC chimeras, a pattern emerged indicating that 
the chimeras expressing the C-terminal half of CaM better stabilized the iNOS enzyme.  The visible 
spectra of the iNOS enzymes coexpressed with each of the CaM-TnC chimeras were very similar to 
wild-type CaM indicating that these enzymes contained proportionate heme and flavins cofactors 
(results not shown). All of the enzymes were capable of producing •NO based upon the 
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oxyhemoglobin assay indicating that stable, active enzyme was expressed with each of the mutant 
chimeric proteins. 
2.3.2 cNOS Activation by CaM-TnC Chimeras 
After performing the oxyhemoglobin capture, cytochrome c reduction, and NADPH oxidation assays, 
it was apparent that specific residues in EF hands I, III, and IV of CaM are important for nNOS 
activation.  CaM-TnC chimeras containing TnC elements corresponding to any of these EF hands 
were only capable of activating •NO production from nNOS less than 20% when compared to wild-
type CaM (Figure 2.8).  
 
Figure 2.8 – Ability of CaM-TnC chimeras to activate nNOS. 
The oxyhemoglobin capture assay, the cytochrome c assay, and the NADPH oxidation assay were 
performed in the presence of either wild-type CaM (2 μM) or CaM-TnC chimeric protein (2 μM) in 
the presence of either CaCl2 (200 μM) or EDTA (250 μM), as indicated.  The activities obtained with 
nNOS (30 nM) bound to wild-type CaM at 25 °C in the presence of 200 μM CaCl2 were set to 100%. 
Under these conditions, the activities for nNOS bound to wild-type CaM were 148 min-1 for NADPH 
oxidation, 1163 min-1 for cytochrome c reduction, and 40 min-1 for •NO synthesis. The bar values 
represent the means ± standard deviation. Each assay was performed in quadruplicate and repeated 
three or more times. 
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In contrast, CaM-2TnC, the chimera containing TnC EF hand II, was able to fully activate •NO 
production by nNOS.  Ranking the order the rates of •NO production by nNOS activated by the CaM-
TnC chimeras was wild-type CaM ≈ CaM-2TnC >> CaM-3TnC ≈ CaM-4TnC > CaM-1TnC > CaM 
3,4 TnC.  All of the chimeras were unable to activate •NO production by nNOS in the presence of 
EDTA.  These results are consistent with previous investigations of nNOS activation by CaM-TnC 
chimeras measured by the L-citrulline formation end point assay (Su et al., 1995) and the 
oxyhemoglobin capture assay (Gachhui et al., 1998).   
 This study was the first report on the activation of eNOS by CaM-TnC chimera.  Ranking the 
initial rates of •NO production by eNOS activated by wild-type CaM and CaM-TnC chimera were as 
follows: wild-type CaM >> CaM-2TnC > CaM-4TnC > CaM-3TnC > CaM-1TnC > CaM-3,4TnC 
(Figure 2.9).   
 
Figure 2.9 – Ability of CaM-TnC chimeras to activate eNOS. 
The •NO synthesis, cytochrome c reduction, and NADPH oxidation rates were measured as 
previously described in Figure 2.8.  The activities for eNOS (70 nM) bound to wild-type CaM (set to 
100%) were 31 min-1 for NADPH oxidation, 70 min-1 for cytochrome c reduction, and 10 min-1 for 
•NO synthesis.   
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Although the order of activation for the eNOS was similar to that observed for nNOS, it is notable 
that CaM-2TnC was not able to fully activate the eNOS enzyme.  With the exception of CaM-2TnC, 
all of the chimeras were able to activate •NO production by eNOS to a significantly greater extent 
than nNOS (Figure 2.9). 
 The activation of nNOS and eNOS by wild-type CaM resulted in an NADPH consumption to 
•NO production ratio of more than three instead of the theoretical ratio of 1.5.  Similar results for 
eNOS were previously reported where the researchers reported that the higher relative NADPH 
consumption was associated with the redox cycling of exogenous unbound flavins added to the 
reaction buffer of the assay (Vasquez-Vivar et al., 1998).  The rate of NADPH oxidation by nNOS 
activated by either wild-type CaM or the CaM-TnC chimeric proteins showed the same ranking order 
observed for •NO production, indicating that the observed electron uncoupling from •NO synthesis 
may be related to the redox cycling of free flavins in the cNOS reductase domain.  The observed ratio 
of NADPH oxidation to •NO synthesis was identical for nNOS activated by both wild-type CaM and 
CaM-2TnC.  These studies demonstrate that wild-type CaM and the CaM-TnC chimeras are able to 
stimulate nNOS to pass electrons from the flavins in the reductase domain to the heme in the 
oxygenase domain.  Slightly higher ratios of NADPH oxidation to •NO synthesis for the CaM-3TnC 
and CaM-4TnC chimeras suggest that there is a partial uncoupling of electron transfer from •NO 
synthesis when using these mutants.  NADPH oxidation by eNOS activated by either wild-type CaM 
or the CaM-TnC chimeric proteins did not show the same ranking order as observed for the 
production of •NO (Figure 2.9).  In each case, eNOS activated by CaM-TnC chimeras showed higher 
ratios of NADPH consumption to •NO production.  This result suggests that eNOS may be more 
susceptible to electron uncoupling of NADPH oxidation from the production of •NO than nNOS 
when activated by mutant CaM proteins. 
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The cytochrome c reduction studies demonstrated that each of the chimeras, with the 
exception of CaM-1TnC, were capable of promoting electron transfer in the reductase domain of 
nNOS.  The reduction rates of cytochrome c were markedly higher than the corresponding rates of 
•NO synthesis for the cNOS enzymes activated by the CaM-3TnC and CaM-4TnC chimeras.  The 
rate of cytochrome c reduction by nNOS activated by CaM-2TnC was identical to the rate observed 
when activated by wild-type CaM.  These results demonstrate that EF hands II, III, and IV of TnC are 
sufficient for the activation of electron transfer within the reductase domain of nNOS.  In contrast, 
specific residues in EF hand I of wild-type CaM appear to be important in order to promote electron 
transfer through the reductase domain of nNOS since its replacement by its corresponding TnC EF 
hand results in minimal electron transfer to cytochrome c.  In contrast, a different trend was observed 
when investigating the role of the four CaM EF hand domains in the activation of electron transfer 
within the reductase domain of eNOS.  The replacement of either domain 3 or 4 in CaM only slightly 
diminished the rate of reduction of cytochrome c.  Furthermore, unlike the result observed with 
nNOS, the CaM-1TnC chimera still allowed production of about 60% maximal cytochrome c 
reduction by eNOS.  In addition, the CaM-2TnC chimera allowed only about 30% maximal 
cytochrome c reduction rate for eNOS, completely different than that observed for nNOS.  The lower 
rate of production of •NO by eNOS bound to CaM-2TnC in comparison with nNOS can possibly be 
explained by differences in the interactions between CaM and the reductase domain.  This inference 
can be supported by the observed diminished rate of cytochrome c reduction by eNOS activated by 
CaM-2TnC.  
2.3.3 iNOS Activation by CaM-TnC Chimeras 
Previous investigations on the CaM-dependent activation of iNOS have been limited and problematic 
due to the strong binding between the enzyme and CaM.  In addition, the sensitivity of iNOS to 
proteolysis during purification has effectively prevented the isolation of an intact CaM-free iNOS.  In 
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order to circumvent this problem, each of the five CaM-TnC chimeras used in this study were 
coexpressed separately with the human iNOS enzyme.  As previously reported, the coexpression of 
iNOS with wild-type CaM results in a highly stable complex that shows only a small decrease in 
activity when treated with EDTA (Venema et al., 1996).  The coexpression of iNOS with the different 
CaM-TnC chimeras provided a unique opportunity to determine the effect of specific regions of CaM 
that are important for the activation and tight binding of CaM to iNOS. 
 
Figure 2.10 – Ability of coexpressed CaM-TnC chimeras to activate iNOS. 
The human iNOS enzyme was coexpressed separately with each of the CaM-TnC chimeric proteins.  
The •NO synthesis, cytochrome c reduction, and NADPH oxidation rates were measured as 
previously described in Figure 2.8 with the exception that no exogenous CaM protein was added to 
the assays.  Each assay was performed in the presence of either CaCl2 (200 μM) or EDTA (250 μM) 
as indicated.  The activities obtained for iNOS coexpressed with wild-type CaM and assayed in the 
presence of CaCl2 (200 μM) at 25°C were all set to 100%.  The rates observed for each assay were 77 
min-1 (NADPH oxidation, 1395 min-1 (cytochrome c reduction), and 47 min-1 (•NO synthesis).  The 
bar values represent the mean values ± standard deviation.  Each assay was performed in 
quadruplicate and repeated three or more times. 
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The replacement of CaM EF hands I, III, or IV with their corresponding EF hands in TnC resulted in 
higher reproducible rates of •NO production ranging from 110 to 123% (Figure 2.10).  In contrast, the 
replacement of EF hand II of CaM (CaM-2TnC) activated iNOS to about 60% maximal velocity.  
Likewise, the CaM-3,4TnC chimera activated iNOS to about 70% maximal activity.  The addition of 
excess wild-type CaM to each iNOS enzyme coexpressed with CaM-TnC chimeric proteins did not 
result in any significant change in the activity of the enzyme, indicating that the CaM-binding domain 
of iNOS were saturated with the mutant CaM-TnC proteins (results not shown).   
The addition of 250 μM EDTA to chelate Ca2+ resulted in a significant decrease in •NO 
production by all of the chimeras (Figure 2.10).  This Ca2+-dependence was very marked for the iNOS 
enzyme coexpressed with CaM-2TnC, CaM-3TnC, and CaM-3,4TnC.  However, the subsequent 
addition of excess Ca2+ completely reversed the effect of EDTA.  These results show that EF hands II 
and III of CaM contain important elements or residues required for the tight binding of CaM to the 
iNOS enzyme.  In contrast, the addition of EDTA to the iNOS enzymes coexpressed with CaM-1TnC 
and CaM-4TnC resulted in only a small decrease in enzyme activity that was comparable to that 
observed for iNOS coexpressed with wild-type CaM.  The absence of a Ca2+-dependent activation of 
iNOS by these two chimeras, CaM-1TnC and CaM-4TnC is consistent with two aspects: (1) the first 
EF hand of TnC is known not to bind Ca2+ and (2) the fourth EF hand of TnC binds Ca2+ an order of 
magnitude stronger than EF hand IV of CaM (George et al., 1993).  The addition of excess CaM in 
the presence of EDTA resulted in over 90% maximal activity for all of the enzymes coexpressed with 
the CaM-TnC chimeras with the exception of CaM-3,4TnC which only showed 50% activation 
(results not shown).  The mutant CaM-TnC chimeras appear to possibly be displaced by wild-type 
CaM when incubated in a buffer containing EDTA (discussed in further detail in Chapter 3).  These 
results demonstrate for the first time that there are specific elements in CaM necessary for the tight 
binding of CaM to iNOS.   
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A comparison of the CaM-TnC chimeric proteins’ ability to activate NADPH oxidation 
showed similar trends to their activation of •NO synthesis by iNOS (Figure 2.10).  The coexpression 
of wild-type CaM, CaM-1TnC, or CaM-4TnC with iNOS resulted in a stoichiometry of about 1.5 
NADPH oxidized per •NO synthesized, even in the presence of excess EDTA.  These results indicate 
that the the iNOS mechanism is more tightly coupled than that found in the cNOS enzymes when 
using the oxyhemoglobin and NADPH assays.  Since the increased levels of NADPH consumption 
have been associated with the possible redox cycling of exogenous unbound flavins added to the 
assay buffers (Vasquez-Vivar et al., 1998), the observed difference in electron coupling to •NO 
production between iNOS and cNOS enzymes may be due to a higher affinity for the FMN in the 
iNOS enzymes or, alternatively, both having a similar affinity for FMN but iNOS having a much 
higher rate of •NO production.  The iNOS coexpressed with CaM-2TnC, CaM-3TnC, or CaM-
3,4TnC also resulted in the proper stoichiometry of 1.5 NADPH molecules consumed per •NO 
produced, but the addition of EDTA led to a greater than 2-fold increase in the relative rate of 
NADPH oxidation. EF hands II and III of CaM appear to contain elements necessary to maintain the 
Ca2+/CaM-dependent coupling of electrons in the iNOS enzyme.   
The cytochrome c assays were used to monitor electron transfer from the FMN domain in the 
reductase of iNOS to an exogenous electron acceptor.  The iNOS enzymes coexpressed with each of 
the CaM-TnC chimeric proteins all showed 100% or more greater maximal activity in the presence of 
both high and low levels of Ca2+ (Figure 2.10).  These results are consistent with our previous study 
showing electron transfer from the reductase domain of iNOS enzymes to an artificial electron 
acceptor is CaM independent (Newton et al., 1998).  Most notably, the rates of cytochrome c 
reduction relative to wild-type CaM are over 100% for iNOS enzymes coexpressed with CaM-1TnC, 
CaM-2TnC, and CaM-3TnC.  These increased rates may be due to the replacement of residues in 
CaM that are not necessary for electron transfer but may normally attenuate the rates of electron 
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transfer in the reductase domain of iNOS by altering specific interactions between the FAD and FMN 
or possibly other regions of the enzyme. 
2.4 Discussion 
The present investigation of CaM interactions with all three NOS isoforms was undertaken to further 
our understanding of the activation of these enzymes.  The binding of CaM to the cNOS enzymes has 
been shown to affect electron transfer within the reductase domain, whereas the effect of CaM on 
electron transfer in iNOS is less well understood.  In order to study the specific regions of CaM 
responsible for the activation of the cNOS and iNOS enzymes, CaM-TnC chimeric proteins that have 
each CaM EF hand  replaced with their corresponding EF hands from TnC were employed. 
As demonstrated in the results section (section 2.3), the CaM-TnC chimeric proteins showed 
marked effects on the rates of •NO production and NADPH oxidation of nNOS (Figure 2.8).  In 
contrast, when EF hands III and IV of CaM were exchanged with TnC a small effect on electron 
transfer rates from NADPH into the reductase domain of nNOS were observed.  This is indicative that 
the lower •NO production rates observed with CaM-3TnC and CaM-4TnC is associated with the 
reduction of heme by FMN and not within the reductase domain of nNOS.  Surprisingly, CaM-2TnC, 
which contains the replacement of both EF hand II and the central linker of CaM with the 
corresponding domain in TnC and the largest change of primary sequence of all the CaM-TnC 
mutants, was able to fully activate nNOS.  This interesting result suggests that residues in the C-
domain of CaM-3TnC and CaM-4TnC, as well as CaM 1TnC may make important contacts with 
sequence regions outside the canonical CaM-binding region that may affect electron transfer within 
nNOS.   
Although eNOS displayed a similar activation profile to nNOS with the CaM-TnC chimeras, 
the activation of eNOS was not equivalent with all the chimeric proteins (Figure 2.9). For instance, 
the transfer of electrons within the reductase domain of eNOS monitored by the cytochrome c assay 
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was less susceptible to the mutations of CaM than nNOS.  Furthermore, although CaM-2TnC was the 
most potent activator of the five CaM mutants tested, it was only able to activate eNOS to 50% of the 
maximal activity when compared to wild-type CaM.  Likewise, the activation of eNOS by CaM-
3TnC and CaM-4TnC was markedly greater when compared to wild-type CaM than what was 
observed for nNOS.  Additionally, CaM-3TnC, CaM-4TnC, and CaM-3,4TnC all promoted electron 
transfer to cytochrome c in eNOS to a greater extent than they activated •NO production.  This 
observation is similar to what was previously observed for nNOS indicating that the less effective 
activation of •NO production by these chimeric proteins results specifically from a lower rate of FMN 
to heme electron transfer and not a lower rate of electron transfer within the reductase domain of 
eNOS.  In contrast, CaM-2TnC is less effective in promoting cytochrome c reduction in eNOS than in 
the activation of •NO production suggesting that CaM-2TnC’s inability to fully activate •NO 
production in eNOS may be related to a slower electron transfer rate to the FMN.   
The following is the first report on CaM specific interactions in the binding and activation of 
iNOS.  Prior to this study, CaM had to be coexpressed with iNOS to produce a stable and active 
enzyme.  The investigation of the role of different regions of CaM on the activation of iNOS required 
the development of separate coexpression systems for each of the CaM-TnC chimera proteins.  Using 
these mutant CaM proteins copurified with iNOS, significant differences in the role of CaM in 
activating iNOS were observed when compared to the cNOS enzymes (Figure 2.10).  Coexpression 
with each of the five CaM-TnC chimeras in the presence or absence of Ca2+ showed little or no effect 
on electron transfer rates into the reductase domain as monitored using the cytochrome c assay. These 
results are consistent with our previous studies using only the reductase domains of both human and 
mouse iNOS (Newton et al., 1998).  In contrast to the result observed for nNOS, CaM-2TnC 
activated •NO production by iNOS was over 40% less than that observed for iNOS coexpressed with 
wild-type CaM under Ca2+ replete conditions. Although CaM-2TnC activates •NO production to the 
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same percentage in iNOS and eNOS when compared to the maximal activity with wild-type CaM, it 
is important to note that CaM-2TnC is the most potently activating chimeric protein of the cNOS 
enzymes, while it is the least effective in activating iNOS.  In contrast, CaM-1TnC is significantly 
more effective than wild-type CaM in activating •NO production by iNOS, while CaM-3TnC and 
CaM-4TnC are only slightly more effective; CaM-3,4TnC is more effective than CaM-2TnC but less 
effective than wild-type CaM (Figure 2.10).  Clearly, the results observed for CaM-4TnC indicate that 
the C-terminal domain of CaM is less important for activating iNOS than in eNOS and nNOS, which 
is further supported in Chapter 3.  Overall, the activation of iNOS indicates that iNOS’s requirement 
for CaM is less stringent than the CaM requirement of eNOS and nNOS and that different regions of 
CaM that affect the activation of iNOS have a completely different effect on cNOS activation. 
The exchange of EF hands II and III, as well as the central linker of CaM with the 
corresponding TnC motifs, also demonstrated a Ca2+-dependence for CaM-iNOS interactions.  The 
addition of excess EDTA resulted in a significant decrease in •NO production by iNOS coexpressed 
with CaM-2TnC, CaM-3TnC, or CaM-3,4TnC.  This Ca2+-dependent decrease in •NO production was 
also observed using the NADPH oxidation rates, while no effect was observed for cytochrome c 
reduction rates.  This can be explained by the rate-limiting electron transfer occurring between the 
FMN and heme, since both the NADPH and oxyhemoglobin assays are dependent on electrons being 
transferred to the heme, while the cytochrome c assay only required electrons being transferred 
through the reductase domain to the FMN.  Furthermore, in the presence of EDTA, CaM-2TnC, 
CaM-3TnC, and CaM-3,4TnC all demonstrated that NADPH was consumed to a greater extent than 
•NO production indicative that at low Ca2+ concentrations, the binding of these chimeras to iNOS 
caused an increase in electron uncoupling to •NO synthesis.  Since CaM-1TnC contains TnC EF hand 
I which is incapable of binding Ca2+ (Su et al., 1995), it was expected that this mutant would be 
unable to stabilize the strong interactions between CaM and iNOS to the extent of the replaced EF 
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hand I of CaM.  Unexpectedly, CaM-1TnC actually stabilized the interaction and had no adverse 
effect on enzyme stability and activity.  A Ca2+-deplete EF hand I is surprising since the cNOS 
enzymes and numerous other CaM-dependent proteins require the N-domain of CaM to be Ca2+-
replete to bind and activate their target proteins.  This Ca2+-independence of EF hand I is further 
discussed in later chapters (Chapter 3, 5, and 6).  On the other hand, the CaM-2TnC and CaM-3TnC 
results demonstrate that these regions are related to the Ca2+-independent activity of iNOS.  All of the 
single domain replacement chimeras were at least as effective as wild-type CaM in activating electron 
transfer to cytochrome c; CaM-1TnC, CaM-2TnC, and CaM-3TnC were significantly more effective 
at promoting electron transfer through the iNOS reductase domain than wild-type CaM.  Overall, the 
results observed for iNOS, eNOS, and nNOS indicate that the requirements for the activation of 
cytochrome c reduction are less stringent than the requirements for the activation of •NO production.   
Specific NOS isoform requirements with CaM-1TnC showed that this mutant was completely 
ineffective in activating cytochrome c reduction by nNOS, while CaM-2TnC was less effective than 
the other chimeras at activating cytochrome c reduction in eNOS.   These results for both nNOS and 
eNOS support the previous published studies that demonstrated that CaM can activate reductase 
domain catalysis by a mechanism other than stimulating electron transfer into the oxygenase domain 
(Gachhui et al., 1998).  Furthermore, these results also show a similar activation profile for eNOS 
when compared to nNOS, however, the effects of the chimeric proteins on all the electron transfer 
rates in eNOS are not equivalent.  There are still notable differences in the CaM-dependent activation 
of nNOS and eNOS.  Additionally, a marked difference between CaM and TnC is the elongation of 
the central helix by three additional amino acids (91KGK93, Figure 2.2) in TnC, which is found 
exclusively in CaM-2TnC and not in wild-type CaM.  Previous researchers have proposed that the 
flexibility of CaM’s linker region allows the protein to adjust the orientation of the two globular 
domains with respect to each other and to the target peptide (Roth et al., 1991; Meador et al., 1993; 
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Vogel and Zhang, 1995; Ishida and Vogel, 2006).  These three additional residues in the linker region 
of the CaM-2TnC chimera elongate the central helix by about 4.5 Å.  However, it is apparent that this 
elongated helix in CaM-2TnC has no adverse effect on the activation of the cNOS enzymes, meaning 
that the chimeric protein is capable of making slight adjustments to ensure a proper binding 
orientation when associated to the cNOS enzymes.  In contrast, the effect of CaM-2TnC on the 
Ca2+/CaM dependence of •NO production by iNOS could be due to a change in the interaction of the 
linker region of CaM with the enzyme or a subtle conformational change in the relative positions of 
the globular domains of CaM when bound to iNOS.   
2.5 Conclusions 
Overall, it is clear that interactions between CaM and the canonical CaM-binding site found between 
the reductase and oxygenase domains alone are insufficient to account for the activation profiles 
observed in this study, as previously suggested by other researchers (Ruan et al., 1996; Venema et al., 
1996; Ishida and Vogel, 2006).  In the cNOS enzymes, regions outside of the CaM-binding domain 
such as the FMN domain and hinge subdomain, which are involved in positioning the FMN- and 
FAD-binding domains, are in contact or close proximity with the outside of bound CaM.  These 
regions contain cNOS specific insertions that are associated with CaM control and are thought to be 
well positioned to interact directly with the exterior of CaM (Salerno et al., 1997).  Similarly, regions 
flanking the canonical CaM-binding domain of iNOS have also been implicated in the Ca2+-
independent binding of CaM (Ruan et al., 1996; Venema et al., 1996). 
In summary, the results presented in this study show that EF hand I is vital for the CaM-
dependent activation of nNOS, which is in agreement with previously published reports (Stevens-
Truss et al., 1997; Gachhui et al., 1998).  Furthermore, eNOS demonstrated a similar activation 
profile using CaM-TnC chimeric proteins as nNOS; however, the activation of eNOS was not 
equivalent, demonstrating that nNOS and eNOS have subtle differences in their regulation by CaM.  
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In contrast to the results observed for the cNOS enzymes, EF hands II and III were found to be 
directly related to the Ca2+-dependence of iNOS.  This finding was later supported by another group 
through the use of Drosophila CaM that had Ca2+-deficient mutations (Glu Gln) to study the Ca2+-
independence of CaM binding to iNOS (Gribovskaja et al., 2005).  Clearly, there are marked 
differences in the Ca2+-dependent/independent regulation of NOS by CaM that can be correlated to 
the various interactions that can occur between the NOS enzymes and each of CaM’s four EF hands. 
 
* The results presented in this chapter have been published: 
Spratt, D.E., Newman, E., Mosher, J., Ghosh, D.K., Salerno, J.C., and Guillemette, J.G. (2006) 
Binding and Activation of Nitric Oxide Synthase Isozymes by Calmodulin EF Hand Pairs. FEBS 
Journal 273, 1759-1771. 
 




Binding and Activation of Nitric Oxide Synthase Isozymes 
by Calmodulin EF Hand Pairs * 
3.1 Introduction 
CaM is a 148 amino acid protein consisting of two globular domains joined by a central linker region.  
Each domain of CaM contains an EF hand pair.  The C-terminal EF hand pair has an affinity for Ca2+ 
(Kd = 10-6 M) ten fold greater than the N-terminal EF hand pair (Kd = 10-5 M) (Martin et al., 1985).  
Previous studies involving the exchange of EF hand pairs within CaM have been performed to study 
specific interactions of CaM domains during their binding and activation with various target proteins, 
such as the smooth and skeletal myosin light chain kinases, as well as nNOS (Persechini et al., 1996a; 
b).  The present investigation was designed to further assess the role of the two CaM EF hand pairs in 
the binding and activation of NOS enzymes.  To accomplish this study, four different mutant CaM 
proteins were employed - nCaM, cCaM, CaMNN, and CaMCC.  The truncated nCaM construct 
includes only the N-terminal EF hand pair without the central linker region (residues 1-75), and the 
complementary cCaM construct includes only the C-terminal EF hand pair including the central 
linker region (residues 76-148).  In addition, CaMNN contains two repeats of the N-terminal EF hand 
pair (residues 1-81, 9-75), and CaMCC contains two repeats of the C-terminal EF hand pair (residues 
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1-8, 82-148, 76-148).  CaMNN and CaMCC EF hand pairs are both connected via the central linker 
region (residues 76-81). Figure 3.1 shows a schematic representation of the EF hand CaM mutant 
proteins used in this study.  
 
Figure 3.1 – Alignment of CaM and EF Hand mutant CaM proteins.   
Ca2+ is represented as circles, while the N-terminal and C-terminal domains of CaM are shown in red 
and blue, respectively.  The central linker region of CaM is shown in black. 
 
To date, CaM-iNOS interactions have not been well studied because iNOS could originally only be 
purified when coexpressed with wild-type CaM (Cho et al., 1992).  We previously overcame this 
problem by coexpressing iNOS with mutant CaM proteins and successfully produced active enzyme 
(Newman et al., 2004).  During our previous study (Chapter 2), CaM-troponin C (CaM-TnC) 
chimeric proteins were used to probe specific NOS-CaM interactions and we demonstrated that the 
requirements for iNOS activation were far less stringent than the requirements for cNOS activation 
(Newman et al., 2004).  The primary requirements for iNOS activation were associated with EF 
hands II and III while the requirements for the cNOS enzymes were associated with EF hand I.  The 
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present study reports on the CaM-dependent activation of mammalian NOS isozymes with a greater 
focus on CaM-iNOS interactions. 
3.2 Experimental Procedures 
3.2.1 CaM Protein Subcloning and Mutagenesis 
The subcloning and mutagenesis used to produce the CaM EF hand pair mutants used in this study 
were performed by Mrs. Elena Newman (MSc. 2003, U of Waterloo) and Miss Bo Cheyne (BSc. U of 
Waterloo, Summer Student), former members in our laboratory.  The following subsections (3.2.1.1-
3) are summaries on the construction and molecular manipulations employed to produce these CaM 
mutants. 
3.2.1.1 pnCaMChlor 
The chloramphenicol resistant CaM expression vector pCaMChlor used in this study was a generous 
gift from Dr. A. Persechini (University of Missouri-Kansas City, Kansas City, MO, USA).  
Introduction of a stop codon at residue 76 and a reporter XbaI cut site by PCR mutagenesis produced 
pnCaMChlor, encoding for the N-terminal residues 1-75.  The forward and reverse primers were:  
pC76STF  5’ ATGGCGAGGAAGATGTAATCTAGAGACACGGACAGCGAAG 3’ and pC76STR  
5’ CTTCGCTGTCCGTGTCTCTAGATTACATCTTCCTCGCCAT 3’.  The construction of 
pnCaMChlor was verified by sequencing and used for coexpression with iNOS. 
3.2.1.2 pcCaMKan 
pcCaMKan, coding for residues 76-148, was used for coexpression with iNOS.  The coding region 
was PCR amplified from the kanamycin resistant pET9dCaM plasmid, consisting of the pET9d vector 
(Novagen) carrying rat CaM, introducing unique flanking NcoI and EcoRI sites for subcloning into a 
vector suitable for coexpression.  Primers used were: 
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cCaMNcoI53 5’ CGATGATGGCGAGGACCATGGAGGACACGGACAGCG 3’ and 
cCaMEcoRI35 5’ TGCATGATAAAGAAGGAATTCTCACTTAGCCGTCATC 3’.  The PCR 
product was blunt end ligated into the SrfI site of pPCR-SCRIPT Amp SK (+). The pcCaMPCRscript 
vector was subsequently digested with NcoI and EcoRI and subcloned into the kanamycin resistant 
pET28a vector (Novagen) cut with the same enzymes and the resulting pcCaMKan vector was 
verified by sequencing. 
3.2.1.3 pCaMNNKan and pCaMCCKan 
The vectors pCaMNNAmp and pCaMCCAmp, coding  for CaMNN (residues 1-81, followed by 9-
75) and CaMCC  (residues 1-8, 82-148, 76-81, followed by 82-148), were a generous gift from Dr. 
Anthony Persechini (Persechini et al., 1996a).  Their ampicillin resistance necessitated the 
construction of new vectors for coexpression with iNOS.  Coding regions for CaMNN and CaMCC 
were subcloned into the kanamycin resistant pET9dCaM plasmid using the unique flanking NcoI and 
PstI restriction sites.  The products, pCaMNNKan and pCaMCCKan, were verified by sequencing. 
3.2.2 Expression and Purification of CaM EF Hand Pair Proteins 
The CaM EF hand pair proteins were expressed and purified by Mrs. Elena Newman and Miss 
Jennifer Mosher (BSc. U of Waterloo, Summer Student).  Overnight cultures of transformed E. coli 
BL21 (DE3) were used to inoculate 1 L of LB media in 4 L flasks supplemented with 30 µg/ml of 
appropriate antibiotics, kanamycin or chloramphenicol, depending on the CaM mutant (section 3.2.1). 
1 L cultures were grown at 37ºC to an O.D. at 600 nm of 0.8 to 1.2, induced with 500 µM IPTG and 
harvested after 3 hours of expression. Cells were harvested, frozen, and stored at –80ºC.  CaM was 
purified using phenyl sepharose chromatography as previously described (section 2.2.3), frozen in 
aliquots on dry ice, and stored at –80oC.  ESI-MS was performed on purified proteins using with an 
internal standard as previously described in section 2.2.5. 
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3.2.3 Expression and Purification of NOS Enzymes 
Rat neuronal and bovine endothelial NOS were expressed in E. coli BL21 (DE3) and purified as 
previously described in sections 2.2.6-7.  Human iNOS carrying a deletion of the first 70 amino acids 
and an N-terminal polyhistidine tail was coexpressed with CaM or a CaM mutant in E. coli BL21 
(DE3) as previously described (section 2.2.8-9).  This protein was coexpressed and purified using 
ammonium sulfate precipitation, metal chelation chromatography, and 2’5’-ADP affinity 
chromatography as previously described in section 2.2.9 (Montgomery et al., 2000; Newman et al., 
2004).  Mrs. Elena Newman and Miss Jennifer Mosher expressed and purified iNOS coexpressed 
with CaMNN and CaMCC, while the other NOS enzymes used in this study were expressed and 
purified by the candidate. 
3.2.4 Enzyme Kinetics 
The initial rate of •NO synthesis was measured using the spectrophotometric oxyhemoglobin assay at 
401 nm as previously described in section 2.2.10.1.3.  NADPH oxidation by NOS was monitored at 
340 nm as previously described in section 2.2.10.3.  The NADPH-dependent reduction of cytochrome 
c was monitored at 550 nm as described in section 2.2.10.2.3. 
3.2.5 Gel Filtration Studies 
The dimerization of iNOS coexpressed with native CaM and nCaM was evaluated by gel filtration on 
a Superdex 200 HR 10/30 column (Amersham Biosciences), equilibrated with TGND buffer (50 mM 
Tris-HCl, pH 7.5, 10% glycerol, 0.1 M NaCl, and 1 mM DTT) when observing the effect of basal 
Ca2+ levels, and equilibrated with TGND buffer plus 250 µM EDTA to chelate endogenous Ca2+.  The 
flow rate was maintained at 0.5 mL/min with an AKTApurifier System for Chromatography 
(Amersham Biosciences) and the temperature was kept constant at 7oC with an electronic wine cooler 
(Sylvania).  Eluted protein and heme were detected at 280 and 398 nm, respectively, using with a 
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UV-Vis flow-through detector. A gel filtration standard kit (Sigma) containing multiple molecular 
weight markers was used to calibrate the column. 
3.2.6 Native PAGE Studies 
Native PAGE was performed as reported by Sigma (Technical Bulletin No. MKR-137, 1986), which 
is based upon previous experiments by (Hedrick and Smith, 1968) with some modifications.  Briefly, 
the 5% separating gel was prepared as described in the technical bulletin with 5 minutes of deaeration 
and poured between two glass plates.  The stacking gel was prepared by substituting 2 mL of water 
for the riboflavin solution to the described recipe, as well as the addition of 80 μL 10% APS and 24 
μL of TEMED to increase polymerization efficiency, and poured on top of the separating gel using a 
10 well comb to prepare the loading wells.  The enzyme was incubated in appropriate EDTA 
concentrations for 5 minutes prior to loading.  Sample protein was loaded at 0.25 mg/mL with 
carbonic anhydrase used as a standard at a concentration of 1 mg/mL.  The gel was stained using Co-
massie Brilliant Blue R-250 and destained in a 40% methanol, 7% acetic acid solution. 
3.2.7 Aggregation Reversibility for iNOS coexpressed with nCaM 
Using the spectrophotometric oxyhemoglobin assay, the initial rate of •NO synthesis was measured as 
previously described (section 2.2.10.1.3) with some slight modifications.  iNOS coexpressed with 
nCaM were assayed at 28.5 nM in a 100 μl total well volume.  The enzyme was initially incubated in 
the presence of EDTA for 15 minutes with all other assay constituents present at concentrations 
previously reported (Montgomery et al., 2003; Newman et al., 2004).  The reaction was initiated by 
adding oxyhemoglobin and NADPH to the final concentrations of 5 and 450 μM, respectively.  5 mM 
EDTA, 10 mM CaCl2 and 2 μM wild-type CaM were added to the appropriate samples before 
incubation or at 0, 2, or 5 minutes after the incubation in EDTA and prior to the initiation of the 
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assay.  iNOS coexpressed with nCaM not incubated in EDTA and initiated without excess Ca2+ 
present was used as the control set at 100%. 
3.2.8 CaM Mobility Shift Assay with Synthetic NOS peptides 
The NOS CaM-binding domain peptides for bovine eNOS, TRKKT FKEVA NAVKI SASLM 
(residues 493-512), rat nNOS, KRRAI GFKKL AEAVK FSAKL MGQ (residues 725-747) and 
human iNOS, RPKRR EIPLK VLVKA VLFAC MLMRK (residues 507-531) were synthesized by 
SynPeP (SynPeP Corporation, Dublin, CA USA).  The ability of CaM and CaM mutant proteins to 
bind the synthetic NOS peptides was determined from the relative mobility shift of CaM in the 
presence of each peptide (Erickson-Viitanen and DeGrado, 1987).   In a total volume of 15 μL, CaM, 
CaMNN, and CaMCC (20 μM) were incubated with increasing molar ratios of peptide to CaM 
protein (0, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, and 8) in binding buffer (100 mM Tris-HCl, pH 7.5, with 
either 0.2 mM CaCl2 or 1 mM EDTA) at room temperature for 1 hour.  nCaM and cCaM (60 μM) 
were incubated with increasing molar ratios of peptide to CaM protein (0, 0.125, 0.25, 0.375, 0.5, 
0.75, 1, 2, 4, and 8) using the same conditions as CaM.  After 1 hour, volumes of the samples were 
halved by the sample loading buffer consisting of 50% glycerol with bromophenol blue as a tracer.  
The mixtures were then electrophoresed on 15% non-denaturing polyacrylamide gels containing 
0.375 M Tris-HCl, pH 8.8, 4 M urea, and either 0.2 mM CaCl2 or 1 mM EDTA.  Gels were run at a 
constant voltage of 100 V in electrode running buffer, which consisted of 25 mM Tris-HCl, pH 8.3, 
192 mM glycine, 4 M urea, and either 0.2 mM CaCl2 or 1 mM EDTA.  The gels were then stained 
and visualized using Coomassie Brilliant Blue R-250. 
Chapter 3: Binding and Activation of NOS by CaM EF Hand Pairs 
100 
3.3 Results 
3.3.1 Protein Expression and Purification 
The mutant CaM constructs previously described in section 3.2 expressed well yielding independent 
expression ranging from 8 to 26 mg protein/L of media depending on the CaM mutant.  Purified CaM 
constructs appeared over 95% homogeneous on 15% SDS-PAGE (Figure 3.2).  ESI-MS QTOF 




Figure 3.2 – 15% SDS-PAGE of purified EF Hand Pair CaM proteins.   
5 µg of each purified CaM protein was loaded in a buffer containing 5 mM EDTA.  Lane 1, low 
molecular mass protein standard (GE Healthcare Bio-sciences); Lane 2, wild-type CaM; Lane 3, 
nCaM; Lane 4, cCaM; Lane 5, CaMNN; Lane 6, CaMCC. 
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Table 3.1 – Masses of CaM EF Hand Pair proteins a 
      
 Mass (Da) b 
     
     
  Observed Theoretical 
 CaM proteins     
   
Wild-type CaM 16706.0 16706 c 
nCaM 8315.9 8317 
cCaM 8408.2 8408 
CaMNN 16379.0 16379 
CaMCC 17034.0 17034 
   
a ESI-MS results from Elena Newman, MSc. – University of Waterloo Thesis 
b Masses of deconvoluted ESI-MS spectra were determined with an accuracy of  ± 5 Da. 
c Calculated masses based upon amino acid sequence. 
 
  The iNOS enzyme was coexpressed with CaM or a mutant CaM construct.  Coexpression 
with wild-type CaM produced the highest yields of purified iNOS (3.2 mg/L of media).  
Coexpression of iNOS with CaMNN yields were 2 mg/L while coexpression with nCaM gave 0.6 
mg/L.  Expression of iNOS with cCaM and CaMCC gave the lowest yields of 0.2 mg/L.  CaM 
constructs containing the N-terminal EF hand pair produced higher yields of iNOS, indicating better 
protection of the CaM binding region than provided by the C-terminal EF pair.  Visible spectra of 
iNOS coexpressed with CaM constructs were indistinguishable from those of iNOS coexpressed with 
wild-type CaM, indicating proportionate heme and flavin content.  All of the CaM constructs showed 
production of active iNOS by the oxyhemoglobin capture assay, however, the activity of iNOS 
coexpressed with cCaM was very low.   
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3.3.2 cNOS Activation by CaM EF Hand Pair Proteins 
The nNOS and eNOS enzymes displayed similar but not fully equivalent activation profiles when 
associated with different CaM mutants.  The only CaM construct able to activate •NO production by 
nNOS was CaMNN; nCaM, cCaM and CaMCC produced little or no activity (Table 1).   
 
Table 3.2 – CaM EF Hand Pair Protein Dependent Activation of cNOS Enzymes a 
 Neuronal NOS  Endothelial NOS  
CaM protein NADPH Cyt c ●NO NADPH Cyt c ●NO 
 oxidation Reduction Production oxidation Reduction Production 
  % % % % % % 
       
CaM 100 ± 2 100 ± 6 100 ± 5 100 ± 4 100 ± 2 100 ± 2 
nCaM 6 ± 2 37 ± 3 NAAb 5 ± 3 17 ± 1 5 ± 1 
cCaM 4 ± 3 NAA NAA NAA NAA NAA 
CaMNN 93 ± 4 90 ± 5 81 ± 3 115 ± 4 111 ± 3 98 ± 4 
CaMCC 5 ± 2 NAA NAA 4 ± 3 43 ± 1 17 ± 3 
CaM (EDTA) 6 ± 3 NAA NAA NAA NAA NAA 
               
a The oxyhemoglobin capture assay used to measure the rate of CaM-activated •NO production, the cytochrome c assay and 
the NADPH oxidation assay were performed in the presence of either 2 µΜ wild-type or mutant CaM protein and either 200 
µM CaCl2 or 250 µM EDTA, as indicated.  The activities obtained with the respective enzyme bound to wild-type CaM at 
25oC in the presence of 200 µM CaCl2 were all set to 100%.  The activities for nNOS bound to CaM were 45.5 min-1 (•NO 
synthesis), 142 min-1 (NADPH oxidation) and 917.5 min-1 (cytochrome c reduction).  The activities for eNOS bound to CaM 
were 11 min-1 (•NO synthesis), 30 min-1 (NADPH oxidation) and 50.7 min-1 (cytochrome c reduction). 
b NAA – No apparent activity 
 
These results correlate well with previous reports (Persechini et al., 1994; Persechini et al., 1996a).  
None of the CaM constructs activated •NO production by nNOS in the presence of 250 µM EDTA, 
consistent with our previous study of NOS activation by CaM-TnC chimeras (Newman et al., 2004). 
CaMNN was also the only CaM construct that produced appreciable •NO production from 
eNOS.  CaMCC activated eNOS to a much smaller extent (20%), while nCaM and cCaM produced 
little or no activity (Table 3.2).  Although the order of activation for eNOS was similar to that of the 
nNOS enzyme, CaMNN fully activated eNOS but only activated nNOS to about 80% when compared 
Chapter 3: Binding and Activation of NOS by CaM EF Hand Pairs 
 103 
to wild-type CaM.  None of the CaM proteins activated •NO synthesis by eNOS in the presence of 
EDTA. 
The activation of nNOS and eNOS by wild-type CaM resulted in an NADPH consumption to 
•NO production ratio of more than 3 instead of the theoretical ratio of 1.5.  High NADPH 
consumption rates with eNOS were previously attributed to redox cycling of exogenous unbound 
flavins added to the reaction buffer of the assay (Vasquez-Vivar et al., 1998).  The rate of NADPH 
oxidation by nNOS activated by wild-type CaM or mutant CaM proteins shows the same degree of 
enhancement as •NO production.  This indicates that any redox cycling requires the reduction of free 
flavins by the NOS reductase domain.  The ratio of NADPH oxidation to •NO synthesis were 
indistinguishable for nNOS activated by CaM and CaMNN.  NADPH oxidation by eNOS activated 
by either CaM or the mutant CaM proteins did not show the same order as observed for the 
production of •NO (Table 3.2).  The eNOS enzyme showed greater electron uncoupling than nNOS 
for wild-type CaM and CaMNN.  This suggests that eNOS may be more susceptible than nNOS to the 
uncoupling of electrons from NADPH oxidation to •NO production when activated by mutant CaM 
proteins, similar to our findings in a previous study (Newman et al., 2004).   
Only CaM constructs containing the N-terminal domain of CaM, nCaM and CaMNN, 
activated cytochrome c reduction by nNOS.  Constructs lacking the N-terminal domain of CaM, 
cCaM and CaMCC, produced little or no activation of electron transfer to cytochrome c.  Specific 
residues in the N-terminal domain of CaM appear to be required for activation of electron transfer in 
nNOS.   
The activation of electron transfer within the reductase domains of eNOS showed a similar 
trend to the results obtained for nNOS cytochrome c reduction.  The details of activation by CaM 
constructs are not identical; with eNOS, CaMNN is a slightly more potent activator of cytochrome c 
reduction than wild-type CaM, while nCaM produces markedly lower rates of cytochrome c 
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reduction.  Notably, CaMCC promoted electron transfer in the reductase domains of eNOS but not 
nNOS.  It appears that specific residues in the N-terminal domain are important for electron transfer 
in the reductase domains of the cNOS enzymes, and that the central linker region may also play a 
pivotal role. 
3.3.3 iNOS coexpressed with CaM EF Hand Pair Proteins EDTA Titration 
Studies 
In order to determine the concentration of EDTA where •NO production by iNOS coexpressed with 
CaM and the CaM proteins diminished, the oxyhemoglobin assay was employed to monitor •NO 
synthesis rates at an enzyme concentration of 28.5 nM with logarithmic increases in EDTA 
concentrations (Figure 3.3, see Table 3.3 for assay conditions).  It is apparent from Figure 3.3A that 
as EDTA concentrations increase from 0 to 5 mM, activity decreases for iNOS coexpressed with 
CaM to approximately 50%, however, with the addition of excess CaM under the same conditions, 
the activity declines but at a much slower rate. 
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Figure 3.3 – EDTA titration of iNOS coexpressed with CaM EF Hand Pair Proteins.   
The oxyhemoglobin capture assay was used to measure the rate of CaM-activated •NO production at 
an enzyme concentration of 28.5 nM in the presence of EDTA (──) or EDTA with 2 µΜ CaM (─ ─), 
respectively.  iNOS coexpressed with wtCaM set at 100% at endogenous Ca2+ concentrations.  A) 
iNOS coexpressed with wtCaM, B) iNOS coexpressed with nCaM, C) iNOS coexpressed with cCaM, 
D) iNOS coexpressed with CaMNN, E) iNOS coexpressed with CaMCC.   The bar values represent 
the mean ± standard deviation. 
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Conversely, in Figure 3.3B-E, iNOS coexpressed with the CaM mutant proteins titrated with 
increasing concentrations of EDTA alone showed substantial decreases in activity between 5 and 50 
μM.  The most noteworthy result was observed for iNOS coexpressed with nCaM which showed 70% 
maximal activity with basal levels of Ca2+ while having no apparent activity in the presence of EDTA 
above 50 μM (see Figure 3.3B).  With the addition of excess CaM to the assay conditions, activity 
was restored to iNOS coexpressed with nCaM to approximately 70% at EDTA concentrations of 50 
μM and above.  This result indicates that wild-type CaM is capable of binding to iNOS coexpressed 
with nCaM in a Ca2+ depleted environment.  iNOS coexpressed with cCaM displayed a similar trend 
to the enzyme coexpressed with nCaM, but with a more delayed decrease in activity (see Figure 
3.3C).  This may be due to the cCaM protein binding more tightly to its Ca2+ ions since the C-
terminal domain has an order of affinity greater for Ca2+ than the N-terminal domain of CaM (Martin 
et al., 1985).  It appears that the cCaM protein is not displaced from the CaM-binding domain of 
iNOS and the enzyme may be denatured during purification or Ca2+ chelation since it cannot be 
reactivated through the addition of excess CaM.   
In Figure 3.3D and E, iNOS coexpressed with CaMNN and CaMCC showed similar trends.  
They both display a decrease in •NO production rates with increasing concentrations of EDTA to 
20% and 10%, respectively, and display marked increases in activity when excess CaM is added to 
the Ca2+ replete environment.  They both display enhanced •NO production rates in the presence of 
higher EDTA concentrations with excess CaM when compared to their respective activities at basal 
Ca2+ levels.   
 The EDTA concentration of 250 μM was chosen for subsequent assay conditions for iNOS 
coexpressed with CaM proteins.  This is due to there being the greatest difference between the 
absence and presence of excess CaM for all the iNOS enzymes coexpressed with the CaM proteins. 
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3.3.4 iNOS Activation by CaM EF Hand Pair Proteins 
The coexpression of iNOS with CaM constructs containing the N-terminal domain of CaM, nCaM 
and CaMNN, resulted in reproducible •NO production rates of approximately 70% in the presence of 
Ca2+ (Table 3.3).   
 
Table 3.3 – CaM EF Hand Pair Protein Activation of iNOS a 
      NADPH Oxidation        Cyt c Reduction  ●NO Production  
               
CaM Protein  250 µM  250 µM  250 µM 500 µM EDTA 
  EDTA  EDTA  EDTA with 2 µM CaM 
  % % % % % % % 
        
CaM 100 ± 4 96 ± 6 100 ± 2 94 ± 1 100 ± 2 66 ± 2 81 ± 3 
nCaM 80 ± 7 28 ± 3 109 ± 3 115 ± 2 71 ± 2 NAAb 59 ± 2 
cCaM 44 ± 3 20 ± 3 62 ± 1 77 ± 2 12 ± 1 NAA 31 ± 2 
CaMNN 48 ± 3 58 ± 3 133 ± 4 133 ± 1 74 ± 7 23 ± 1 94 ± 1 
CaMCC 75 ± 1 38 ± 3 69 ± 2 82 ± 3 54 ± 1 7 ± 1 80 ± 2 
          
a •NO synthesis, cytochrome c reduction and NADPH oxidation rates were measured as described in Table 1 except that no 
exogenous CaM was added to the assay.  Each assay was performed in the presence of either 200 µM CaCl2 or 250 µM 
EDTA as indicated.  The activities obtained for iNOS coexpressed with CaM and assayed in the presence of 200 µM CaCl2 
at 25oC were all set to 100% and were 47 min-1 (•NO synthesis), 101 min-1 (NADPH oxidation) and 1397 min-1 (cytochrome 
c reduction).  
b NAA – No apparent activity 
 
In contrast, CaM proteins consisting of only the C-terminal domains of CaM resulted in reproducible 
•NO production rates of less than 50%.  The addition of excess wild-type CaM to iNOS coexpressed 
with each of the CaM constructs did not result in any significant change in the activity of the enzyme, 
indicating that the CaM-binding sites were saturated with mutant CaM proteins and do not exchange 
rapidly with CaM in solution (results not shown).   
The addition of 250 µM EDTA to chelate Ca2+ resulted in a significant decrease in the 
stimulation of •NO production by all of the CaM proteins with the most noteworthy being iNOS 
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coexpressed with nCaM, which decreased from 70% to no apparent activity (Table 3.3).  The iNOS 
enzyme coexpressed with CaMNN experienced a similar trend, but still retained 25% activity in the 
presence of EDTA.  Little or no activity was observed for iNOS coexpressed with cCaM and CaMCC 
in the presence of EDTA.  These results show that the N-terminal EF hand pair of CaM contains 
important elements required for the activation of iNOS.  Since iNOS coexpressed with CaMNN 
maintains some activity in the presence of EDTA, in contrast to iNOS coexpressed with only nCaM, 
the central linker region of CaM may play an important role in the Ca2+-independent binding and 
activation of iNOS.  
Significant levels of •NO synthesis were restored when excess wild-type CaM was added to 
iNOS coexpressed with any of the four mutant CaM proteins in the presence of EDTA (Table 3.3). 
These results indicate that a Ca2+-dependent reorganization of the bound mutant can allow for the 
binding and activation of iNOS by the addition of excess native CaM. 
Comparing the stimulation of NADPH oxidation by the CaM constructs showed a pattern 
comparable to the activation of •NO synthesis by iNOS (Table 3.3).  Coexpression of CaM, nCaM, 
CaMNN and CaMCC with iNOS resulted in a stoichiometry of about 1.5 NADPH oxidized per •NO 
formed in the presence of Ca2+, while cCaM showed a higher ratio, probably due to electron 
uncoupling from •NO production.  A previous study has reported the production of •O2- from the 
flavin-binding sites of iNOS’s reductase domain of iNOS (Xia et al., 1998) which could be a 
plausible explanation for this observed electron uncoupling from •NO synthesis.  In the presence of a 
large excess of EDTA, only iNOS coexpressed with wild-type CaM maintained tightly coupled 
electron transfer, whereas iNOS coexpressed with the any of the CaM constructs oxidized more 
NADPH per •NO produced.  These results indicate that •NO production by iNOS coexpressed with 
CaM and mutant CaM proteins is more tightly coupled than •NO production by cNOS enzymes.  This 
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tendency is especially marked in the presence of Ca+2, but is also evident when Ca2+ has been 
removed with EDTA.  
Using the cytochrome c assay to monitor electron transfer from the flavins to an exogenous 
electron acceptor, the iNOS enzymes coexpressed with the CaM proteins, nCaM and CaMNN, 
reproducibly displayed over 100% of the maximal activity obtained with wild-type CaM in the 
presence of Ca2+ and EDTA.  These results are consistent with a previous study in our laboratory 
showing that electron transfer from the reductase domain of iNOS enzymes to an artificial electron 
acceptor is CaM independent (Newton et al., 1998). 
3.3.5 Enzyme Quaternary Structure 
3.3.5.1 Gel Filtration Studies on iNOS coexpressed with CaM and nCaM 
Gel filtration studies were performed to investigate the effects of metal ion chelation by EDTA on 
iNOS dimerization.  Using blue dextran (MW 600 kDa), the calibrated column had a void volume of 
8.35 mL.  The iNOS enzymes were incubated for 5 minutes in the presence of 5 mM EDTA prior to 
loading the sample onto the gel filtration column equilibrated with buffer containing 250 µM EDTA.  
The iNOS enzyme coexpressed with wild-type CaM was mainly in the form of a dimer and was not 
sensitive to Ca2+ depletion or the addition of excess CaM (Figure 3.4A-C).  The iNOS dimer eluted at 
a volume of 11.22 mL, corresponding to a molecular weight of ~290 kDa, whereas excess native 
CaM eluted at 16.0 mL, which represents a protein of less than 30 kDa.  As previously reported by 
many researchers, all of the elution profiles obtained for iNOS coexpressed with CaM contain a 
contaminating peak apparently representing a proteolytic cleavage fragment (Siddhanta et al., 1998). 
Chapter 3: Binding and Activation of NOS by CaM EF Hand Pairs 
110 
 
Figure 3.4 – Gel filration elution profiles of iNOS coexpressed with CaM proteins.   
Absorbance at 280 and 398 nm are shown as ( ) and ( ), respectively.  D, M, and CaM 
represent NOS dimer, monomer, and excess CaM, respectively.  (A) 80 µg of purified iNOS 
coexpressed with CaM was loaded on a Superdex 200 HR 10/30 column equilibrated with 50 mM 
Tris-HCl, pH 7.5, containing 10% glycerol, 0.1 M NaCl, and 1 mM DTT (TGND Buffer).  (B)  
profile of iNOS coexpressed with wild-type CaM incubated with 5 mM EDTA for 5 minutes before 
loading on the column equilibrated with TGND buffer in the presence of 250 µM EDTA, and (C) 
profile of iNOS coexpressed with wild-type CaM under the same conditions as in panel B, with 10 
fold excess wild-type CaM added to the 5 minute incubation mixture.   (D) 25 µg of purified iNOS 
coexpressed with nCaM in the same conditions as in panel A, (E) profile of iNOS coexpressed with 
nCaM under the same conditions as in panel B, and (F) profile of iNOS coexpressed with nCaM 
under the same conditions as in panel C.  Results shown are representative of three similar 
experiments.  
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The iNOS enzyme coexpressed with nCaM was used in these experiments because it showed 
the greatest Ca2+ sensitivity of all the iNOS enzymes coexpressed with CaM EF hand pair proteins.  
In the presence of Ca2+, the elution profile showed the enzyme sample consisted of a mixture of iNOS 
monomers and dimers (Figure 3.4D).  The iNOS monomer eluted at 12.45 mL, corresponding to ~160 
kDa.  The chelation of Ca2+ resulted in the disappearance of the dimer, a substantially decreased 
enzyme peak and a significant increase in aggregated protein that eluted in the void volume (Figure 
3.4E).  The increased aggregated protein consists of iNOS since the void volume shows a strong 
heme absorbance at 398nm.  The apparent aggregation of iNOS coexpressed with nCaM in the 
presence of EDTA accounts for the lost enzyme activity (Table 3.3).  Figure 3.4F shows the elution 
profile for iNOS coexpressed with nCaM treated with EDTA in the presence of excess wild-type 
CaM.  The addition of the excess native CaM appears to prevent the apparent aggregation of the 
protein.  This is likely to occur due to a change in the interaction of nCaM with the enzyme that may 
expose regions of the protein that are prone to aggregation.  These results are fully consistent with the 
activation properties of the enzyme when excess CaM is added in the absence of Ca2+ (Table 3.3). 
3.3.5.2 Native-PAGE of iNOS coexpressed with nCaM 
Non-denaturing gel electrophoresis of iNOS coexpressed with nCaM indicates that the aggregation of 
iNOS occurs when pre-incubated with higher concentrations of EDTA (Figure 3.5A).  Consistent 
with the previous result observed with gel filtration, EDTA induced aggregation is diminished when 
the enzyme is simultaneous incubated with excess wild-type CaM (Figure 3.5B). 
Chapter 3: Binding and Activation of NOS by CaM EF Hand Pairs 
112 
 
Figure 3.5 – 5% Native PAGE studies for iNOS coexpressed with nCaM.   
(A) 0.25 mg/mL in the presence of EDTA alone, (B) 0.25 mg/mL in the presence of EDTA and 10 
fold excess wild-type CaM.  Lane 1 – [EDTA] = 0 nM; Lane 2 – [EDTA] = 50 nM; Lane 3 – [EDTA] 
= 500 nM; Lane 4 – [EDTA] = 5 µM; Lane 5 – [EDTA] = 50 µM; Lane 6 – [EDTA] = 500 µM; Lane 
7 – [EDTA] = 5 mM.  wt and CA represent 0.25 mg/mL iNOS coexpressed with wild-type CaM and 
1 mg/mL carbonic anyhydrase, each used as a standard, respectively.  Arrows indicate the iNOS 
coexpressed with wild-type CaM and nCaM. 
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3.3.5.3 Spectropolarimetry of nCaM with Synthetic NOS Peptides 
 The structures of synthetic peptides of minimal length derived from the CaM-binding regions 
of the three mammalian NOS enzymes were studied by circular dichroism (CD) spectroscopy (Note: 
these results were published with the study described in Chapter 5 – please refer to Figure 5.6 for 
reference).  The iNOS and eNOS peptides alone in solution had predominantly random coil 
conformations.  In the presence of Ca2+, the addition of an equimolar ratio of CaM to either of the 
peptides resulted in a significant increase in α-helical content.  The addition of equal amounts of 
either iNOS or eNOS peptide to nCaM also resulted in an increase in the α-helical content of both the 
iNOS and eNOS peptides.  As expected, the addition of excess EDTA to eNOS resulted in a mainly 
random coil structure.  Notably, under similar conditions, the iNOS peptide retained some α-helical 
structure suggesting that the nCaM protein is able to bind to the iNOS peptide in the presence of 
excess EDTA.  Our results show for the first time that while the N-terminal EF hand pair of CaM 
alone can accommodate the Ca2+-independent binding of wild-type CaM for iNOS, apo-nCaM is not 
able to activate the enzyme. 
3.3.5.4 Gel Mobility Shift Assays of CaM EF Hand Pair Proteins with NOS Peptides 
Gel mobility shift assays were performed to investigate the binding of the three NOS peptides 
to the different CaM constructs.  Complex formation between the peptide and CaM construct is 
monitored by the shift in the mobility of the CaM protein with increasing peptide concentration 
(Figure 3.6).  The mobility of the complexes formed reflects a change in conformation of the protein 
upon binding to the target peptide in addition to a change in the molecular weight and charge of the 
complex.   
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Figure 3.6 – Gel Mobility Shift Assay with Synthetic NOS peptides binding to CaM proteins.  
CaM, CaMNN, and CaMCC (20 μM) incubated with increasing molar ratios of peptide to CaM of 0, 
0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, and 8 in the presence 0.2 mM CaCl2. The nCaM and cCaM mutants (60 
μM) were incubated with molar ratios of 0, 0.125, 0.25, 0.375, 0.5, 0.75, 1, 2, 4, and 8 using the same 
conditions as described for CaM.   The samples were then analyzed by PAGE (15% acrylamide) 
containing 0.375 M Tris, pH 8.8, 4 M urea, and 0.2 mM CaCl2 and visualized with Coomassie Blue 
R-250. 
 
Stoichiometric binding in a 1:1 ratio was observed for CaM with all three NOS peptides in the 
presence of Ca2+.  In contrast, nCaM, CaMNN and CaMCC showed strong binding to the iNOS 
peptide but in a 2:1 protein to peptide ratio.  The 2:1 ratio observed for the three CaM constructs 
indicates that the iNOS peptide can accommodate more than one protein.  In contrast, the cCaM 
protein appears to bind very weakly to the iNOS peptide. 
The cCaM and CaMCC constructs seem to only weakly interact with the cNOS peptides 
resulting in a streaked protein migration (Figure 3.6) while the nCaM protein does not interact at all. 
Only CaMNN shows binding using this assay but it never goes to completion.  These results are 
consistent with activity assays previous discussed (Table 3.2). 
An investigation of complex formation was performed using the apo forms of the CaM 
constructs incubated with each of the NOS peptides by incubating the samples in the presence of 1 
mM EDTA.   No mobility shifts were observed for any of the apo-CaM constructs under these 
conditions (results not shown).  The observation of Ca2+-dependent complex formation by CaM 
incubated with iNOS CaM-binding peptides has been previously reported using this assay (Matsubara 
Chapter 3: Binding and Activation of NOS by CaM EF Hand Pairs 
 115 
et al., 1997).   The shorter iNOS peptides used in these two studies do not bind strongly enough to 
show complex formation using this assay; however, we did observe proof of binding based on CD 
analysis, consistent with previously reported studies (Matsubara et al., 1997; Yuan et al., 1998). 
3.3.6 Aggregation Reversibility of iNOS coexpressed with nCaM 
To determine if the observed aggregation of iNOS coexpressed with nCaM was permanent or 
reversible, a modified oxyhemoglobin capture assay was employed involving the incubation of the 
enzyme in EDTA followed by the addition of excess Ca2+ prior to the initiation of the assay.  When 
compared to the positive control of iNOS coexpressed with nCaM not incubated in EDTA and 
initiated without excess Ca2+ present, the enzyme when incubated in EDTA alone showed some 
activity (~20%) while the addition of excess Ca2+ to the assay showed an increase in enzyme •NO 
production rate to approximately 40% (See Figure 3.8) indicative that the aggregation observed is 
partially reversible.  The addition of wild-type CaM to the incubation mixture showed an increase in 
enzyme activity of approximately 100%. 
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Figure 3.7 – Aggregation reversibility for iNOS coexpressed with nCaM.   
After the enzyme was incubated for 15 minutes EDTA, wild-type CaM was added and incubated for 
at 0 (white), 2 (striped), and 5 minutes (black), respectively.  The activities obtained for iNOS 
coexpressed with nCaM and assayed at 25oC without the addition of EDTA, no excess wild-type 
CaM or excess Ca2+ (xsCa) added after the 15 minute incubation were all set to 100%.  The bar values 
represent the mean ± standard deviation.  See Table 3.3 for assay conditions. 
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3.4 Discussion 
The structure of CaM interacting with target peptides derived from sources including myosin light 
chain kinase, CaM-dependent kinase, and eNOS has been shown to consist of two EF hand pairs 
linked by a short connector wrapped around a helical target. This model has provided a general 
mechanism for how CaM binds and activates target proteins (Ikura et al., 1992; Meador et al., 1992; 
1993; Aoyagi et al., 2003).  However, recent studies have also shown that CaM is able to take on 
many different conformations when bound to divergent target proteins (Elshorst et al., 1999; Osawa 
et al., 1999; Schumacher et al., 2001; Drum et al., 2002). 
Our previous kinetic study involving all three isoforms of NOS with CaM-TnC chimeras 
demonstrated that the roles of the four EF hands in the binding and activation of the cNOS and iNOS 
enzymes are distinct (Chapter 2) (Newman et al., 2004).  Replacement of any CaM EF hand by its 
TnC cognate resulted in significantly decreased •NO synthesis by cNOS; in contrast to the iNOS 
results, EF hand II was the least sensitive even though it diverges furthest in TnC.  These results 
could be interpreted in terms of the tethered shuttle model where the FMN binding domain is a 
mobile region of the enzyme and connects the oxygenase domain with the reductase complex (Ghosh 
and Salerno, 2003).  In cNOS, cytochrome c reduction required only that the FMN binding domain be 
released from the reductase complex, but •NO production also required that CaM mediate the 
interaction of the FMN binding domain with the oxygenase domain.  
If CaM is assumed to bind to the NOS enzymes in the closed configuration like MLCK, the 
N-terminal EF hands bind to the C-terminal end of the target peptide with EF hand II in closest 
contact with the reductase domain in an antiparallel fashion with the C-terminal EF hands are 
associated with the N-terminal end of the target peptide.  Several possible interactions between CaM 
EF hand pair proteins and the CaM-binding domains of NOS can occur based upon this classic CaM 
bound structure.  The nCaM protein can be assumed to bind to the N-type recognition site for N-
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terminal EF hands, but a minority population of alternative bound species could also exist where a 
secondary nCaM can bind to the C-type site where the C-domain of CaM usually associates.  
Likewise, cCaM would also be expected to bind preferentially to recognition sites for the C-terminal 
EF hand, but a secondary cCaM could also bind to the N-type recognition site.  
 CaMNN and CaMCC could be bound with either of the two EF hand pairs in position to 
recognize their preferred targets and with the other pair unassociated with the binding site.  However, 
it is likely that the other EF hand pair often fills the position occupied by the opposite EF hand pair in 
wild-type CaM.  For example, CaMNN would bind with the N-terminal N-type pair associated with 
the N-type recognition site at the C-terminal end of the target.  Meanwhile, the C-terminal N-type pair 
would weakly associate with the C-domain recognition site at the N-terminal end of the NOS target 
peptide.  Single molecules of CaMNN and CaMCC can in principle occupy the entire CaM-binding 
site; however, the duplicated CaM EF hand proteins would have a much lower affinity than wild-type 
CaM. 
CaMNN was the only CaM protein that showed appreciable •NO production rates with nNOS 
and eNOS (Table 3.2), which correlates well with strong binding to the NOS CaM binding domains 
(Figure 3.6).  All other mutant CaM proteins failed to either activate or bind the cNOS enzymes.  
These results indicate that the N-terminal domain in conjunction with at least the central linker region 
is required for binding and •NO production by cNOS enzymes.  In addition, it is possible that the C-
terminal EF hands of CaMNN occupies part of the binding domain usually filled by the C-terminal 
EF hand pair.  The nNOS enzyme is not completely activated when bound to CaMNN, but CaMNN 
fully activates •NO synthesis by eNOS and reproducibly activates eNOS NADPH oxidation and 
cytochrome c reduction more efficiently than wild-type CaM.  CaMCC also slightly activates •NO 
production (~15%), indicating that eNOS is not as selective for specific elements in the N-terminal 
CaM domain as nNOS.  Our findings correlate well with previous reports of significant differences 
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between cNOS enzyme activity and electron transfer using mutant CaM proteins and the oxidation of 
CaM methionine residues (Gachhui et al., 1998; Montgomery et al., 2003; Newman et al., 2004).    
Electron transfer through the reductase domains of nNOS to cytochrome c was stimulated by 
constructs that contained the N-terminal EF hand pair of CaM, although CaMNN, with four EF hands 
and the CaM central linker region, was much more effective than nCaM (Table 3.2).  This suggests 
that interactions between the N-terminal domain of CaM and the reductase domains of nNOS 
promote the release of the FMN domain from its shielded position in the reductase complex, allowing 
for efficient electron transfer to an exogenous acceptor.  However, in the case of nCaM, electron 
transfer is partially uncoupled from •NO production, suggesting that the presence of the central linker 
region of CaM (and perhaps of any C-terminal EF hands) is important in promoting the association of 
the FMN domain with the oxygenase domain. 
 Conversely, electron transfer through the reductase domain of eNOS to cytochrome c was 
stimulated by constructs with two EF hand pairs joined by the central linker region, although 
CaMNN, which contains the N-terminal EF hand pair of CaM, was the most effective.  The nCaM 
protein slightly stimulated cytochrome c reduction. Since both CaMNN and CaMCC are capable of 
promoting electron transfer to cytochrome c, it appears that CaM requirements for the promotion of 
FMN domain release in eNOS are not as stringent as in nNOS (Newman et al., 2004).  Although the 
patterns of cNOS activation by the mutant CaM constructs are similar, differences in the relative 
importance of the elements of CaM reveal underlying differences between nNOS and eNOS. 
 Due to the high susceptibility of iNOS to proteolysis during purification, coupled with the 
enzyme’s strong binding to wild-type CaM, studies on the mechanism of CaM’s ability to promote 
electron transfer within the iNOS homodimer have been limited.  As in our previous work (Newman 
et al., 2004), studies on the role of different EF hand pairs of CaM in iNOS activation necessitated the 
development of separate coexpression systems for each of the mutant CaM proteins.  Our results 
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using the enzymes bound to the CaM proteins showed significant differences in the role of CaM 
activating iNOS when contrasted with the cNOS enzymes (compare Table 3.2 and Table 3.3).  
Similar results were recently reported using a coexpression method consisting of iNOS and different 
Drosophila CaM proteins with mutations in each of the Ca2+-binding sites of CaM (Gribovskaja et 
al., 2005).  Their results further support our earlier findings that EF hands II and III are important for 
iNOS-CaM activation.  Coexpression with each of the CaM proteins did not significantly affect 
electron transfer through the reductase domains to the cytochrome c.  These results are consistent 
with our previous study demonstrating that electron transfer within the reductase domain of iNOS is 
CaM-independent using only the reductase domains of both human and mouse iNOS (Newton et al., 
1998). 
In contrast to the results obtained for nNOS and eNOS, we found that nCaM is just as 
effective in promoting •NO production as CaMNN when bound to iNOS.  This result was surprising 
since nCaM only consists of the N-terminal EF hand pair with no central linker region.  The 
requirement of the N-terminal EF hand pair of CaM for the activation of •NO production by iNOS 
suggests that this structure is vital in promoting FMN/oxygenase domain interactions (Table 3.3).  
This result is consistent with our earlier study showing the importance of EF hand II of CaM in 
binding and activating the iNOS enzyme in the presence and absence of Ca2+ (Newman et al., 2004).  
It is noteworthy that iNOS coexpressed with CaMCC produces •NO at 50% of the rate of iNOS 
coexpressed with CaM.  This may be caused by a tethering effect, in which the central linker region 
orients the N-terminal domains of CaMCC into a conformation capable of promoting a reduced level 
of •NO production (Persechini et al., 1996b; a).  The addition of excess EDTA to the assays resulted 
in significant decreases in •NO production rates by iNOS coexpressed with all of the mutant CaM 
proteins but not with wild-type CaM.   
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 The iNOS enzyme coexpressed with wild-type CaM showed no notable difference in 
NADPH oxidation rates in the presence of higher and lower concentrations of Ca2+, which was 
expected since the iNOS enzyme’s affinity for CaM is very strong even in the presence of 10 mM 
EGTA (Venema et al., 1996).  Although NADPH oxidation rates for iNOS coexpressed with nCaM, 
cCaM and CaMCC in the presence of Ca2+ and EDTA do not correlate well with the corresponding 
•NO production rates, the addition of EDTA significantly decreased both NADPH consumption and 
•NO production stimulated by these constructs (Table 3.3).  The very low rates of electron transfer 
from the FMN to the heme at lower Ca2+ concentrations suggest that these CaM constructs are better 
at promoting FMN domain release than FMN domain/oxygenase association.  This trend does not 
extend to iNOS coexpressed with CaMNN, since there was no significant decrease in NADPH 
oxidative activity at high or low Ca2+ concentrations.  This indicates that two EF hand pairs joined by 
the central linker region in combination with the N-terminal EF hand pair of CaM is sufficient to 
maintain NADPH oxidation activity in the presence or absence of Ca2+.  
iNOS coexpressed with nCaM and CaMNN both displayed reproducibly higher rates of 
cytochrome c reduction in the presence and absence of Ca2+ when compared to wild-type CaM (Table 
3.3).  The increased rates observed with nCaM and CaMNN may indicate that these constructs 
produce a higher yield of enzyme in which the FMN domain is exposed to cytochrome c rather than 
shielded by interactions with the rest of the reductase complex or the oxygenase domain, suggesting 
that they are better at promoting the release of the FMN domain towards the oxygenase domain than 
its reassociation to the reductase domain.  
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The iNOS enzyme coexpressed with wild-type CaM is a highly stable complex; removal of 
free Ca2+ from the system has little effect on enzyme stability.  However, Ca2+ chelation does affect 
•NO production by iNOS through a conformational change within the N-terminal domain of CaM.  In 
contrast, iNOS coexpressed with each of the CaM mutants is less stable than iNOS coexpressed with 
wild-type CaM.  This is apparent from the gel filtration (Figure 3.4) and gel shift assays (Figure 3.6) 
when comparing iNOS coexpressed with wild-type CaM versus the mutant CaM proteins.  In the 
presence of EDTA, the enzyme coexpressed with mutant CaM protein loses all detectable activity and 
appears to aggregate.  The addition of exogenous CaM to these samples in the presence of EDTA 
appears to protect the enzyme based on enzyme activity assays (Table 3.3) and apparently maintains 
the dimeric structure of the enzyme (Figure 3.4F). 
The kinetic, gel filtration, and Native PAGE results obtained for iNOS coexpressed with 
nCaM when incubated in the presence of EDTA indicate that the nCaM has either (1) become 
displaced by wild-type CaM or (2) iNOS has formed a complex involving both nCaM and wild-type 
CaM competing for the CaM-binding domain.  To test these possibilities, a modified oxyhemoglobin 
capture assay was performed which involved the prolonged incubation of iNOS coexpressed with 
nCaM in the presence of EDTA, followed by the subsequent addition of excess Ca2+.  This assay was 
performed to determine if (1) nCaM is still bound or if it is released from the CaM-binding domain 
and (2) if the aggregation observed by gel filtration and Native PAGE is reversible or irreversible in 
the presence of Ca2+.  The results in Figure 3.7 show that nCaM is still bound to the CaM-binding 
domain of iNOS and aggregation is partially reversible with the addition of excess Ca2+.   CD spectra 
of nCaM and wild-type CaM bound to synthetic peptide in the presence of EDTA and the subsequent 
addition of excess Ca2+ demonstrated that this partial reversibility of aggregation is also observable 
for the iNOS CaM-binding domain peptide (results not shown).  Both the modified oxyhemoglobin 
capture assay and CD analysis indicate that the effects of EDTA incubation are partially reversible by 
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Ca2+ addition, suggesting that nCaM rebinds and may not even be fully dissociated.   By these 
criteria, wild-type CaM is more efficient at reversing the EDTA-induced aggregation of iNOS at 
higher Ca2+ concentrations.  However, it is important to note that this observed aggregation effect may 
be concentration dependent.  The gel filtration, Native-PAGE and spectropolarimetry studies are 
performed at micromolar concentrations versus nanomolar concentrations used during kinetics; it is 
conceivable that the 1000 fold lower concentration of iNOS under the assay conditions used may 
produce significant differences in aggregation behavior. 
The statistical mechanics algorithm TANGO predicts the propensity of peptides and proteins 
to aggregate (Fernandez-Escamilla et al., 2004).  Under the conditions used in our experiments, the 
iNOS CaM-binding peptide has a very high propensity for aggregation (AGG value = 338.19) 
compared to eNOS (AGG value = 1.00) and nNOS (AGG value = 0).  The TANGO results also 
suggest that the iNOS CaM-binding sequence ‘AVLFACML’ is particularly susceptible to 
aggregation (Figure 3.8).  
 
 
Figure 3.8 – Alignment of CaM-binding domain sequences of the three NOS isoforms.   
The amino acids in red and blue represent acidic and basic residues, respectively.  The amino acid 
residues underlined are described in the discussion section (section 3.4). 
 
Based upon the CaM-eNOS peptide structure (Aoyagi et al., 2003), the N-terminal domain residues 
of CaM would be expected to predominantly interact with this region of the iNOS CaM-binding 
peptide (Table 3.4).   
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Table 3.4 – Comparison of eNOS and iNOS CaM-binding domains predicted to aggregate by 
TANGO with CaM residues that interact with the peptide residues 
CaM-Binding 
Domain                                 CaM amino acids in contact with eNOS peptidea,b 
eNOS iNOS N-terminal domain C-terminal domain 
Central 
Helix 
A502 A521 Glu11, Glu14, Ala15, Leu18   
V503 V522  Val91, Phe91, Leu112  
K504 L523  Ser81, Glu84, Ile85, Ala88, Met145  
I505 F524 Glu11, Phe12, Ala15, Met72  Met76 
S506 A525 Ala15, Leu18, Phe19, Leu39   
A507 C526 Leu39 Glu87  
S508 M527 Met72, Lys75 Glu84 Met76 
L509 L528 Phe19, Met36, Met51, Met71, Met72, Lys75  
a Amino acid residues in CaM shown to be within 4 Å of the eNOS CaM-binding peptide reported in (Aoyagi et al., 2003). 
b Amino acids in bold represent conserved residues in the respective eNOS and iNOS CaM-binding domains. 
 
Using the published co-ordinates for the structure of an eNOS peptide bound to CaM (Aoyagi 
et al., 2003), a model shown in Figure 3.9 was created consisting of the eNOS peptide bound to only 
the first 75 residues of CaM to represent the nCaM construct.   
 
 
Figure 3.9 – Structures of nCaM bound to eNOS peptide. 
(A) Structure from the perspective of looking down the eNOS peptide barrel, and (B) a perpendicular 
representation of panel A.  Structures are derived from the PDB 1NIW (Aoyagi et al., 2003). CaM 
residues 4 to 75 peptide backbone, Ca2+ ions, and eNOS peptide backbone are shown in red, yellow, 
and blue, respectively.  Peptide residues V503, K504, and A507 are shown in grey.  Structures were 
visualized using ViewerLite 5.0 (Accelrys). 
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Our CD results indicate that the peptide forms a helical structure when bound to nCaM (please refer 
to Figure 5.6).  As shown in Figure 3.9, most of the helical target site including the predicted binding 
site of the N-terminal EF hand pair of CaM is shielded from solvent.  Complete or partial dissociation 
of nCaM in the presence of EDTA should expose hydrophobic residues in this region.  The CaM-
binding domain of iNOS has greater hydrophobic character than the cNOS enzymes, which may in 
part account for the increased affinity of iNOS peptides for CaM in the presence of EDTA. 
The model in Figure 3.9 shows that eNOS residue K504 is solvent exposed.  The alignment 
of the CaM-binding sequences in the three NOS isoforms shown in Figure 3.8 indicate that the lysine 
residue found at this position in both cNOS enzymes is a hydrophobic leucine residue in iNOS.  The 
exposure of a hydrophobic region upon helix formation of the iNOS peptide could account for the 
tendency of this peptide to aggregation, which can possibly be translated to the observed aggregation 
of the holo-iNOS enzyme (Figure 3.4 and Figure 3.5).  Our gel shift assays indicate that two nCaM 
molecules bind to each iNOS peptide (Figure 3.6).  In the presence of excess peptide, the nCaM 
protein does not enter the gel and appears to aggregate.  At low peptide to CaM ratios, the first nCaM 
protein must bind to the normal site on the peptide while the second nCaM likely interacts weakly at 
another site on the peptide further shielding it from the solvent.  Upon the addition of excess peptide, 
the weakly bound nCaM is displaced to bind the freshly added peptide.  This displacement exposes 
the hydrophobic regions of the iNOS peptide including the aforementioned leucine residue resulting 
in a process that may lead to aggregation. 
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3.5 Conclusions 
Tryptic digestions of CaM have previously been performed to determine which domains of CaM are 
necessary for target enzyme activation.  It has been determined that residues 1-77 and 78-148, each 
very similar to our constructs for nCaM and cCaM, were unable to activate cAMP phosphodiesterase 
or calcineurin (Newton et al., 1984), while residues 78-148 were able to fully activate phosphorylase 
kinase although having a lower affinity than wild-type CaM (Kuznicki et al., 1981).   
In a similar study using residues 1-75 of CaM, which is identical to nCaM used in this study, 
and residues 78-148 of CaM, it was observed that nCaM and the C-terminal domain of CaM are able 
to activate skeletal myosin light chain kinase (skMLCK) to 20 and 65%, respectively, whereas with 
gizzard smooth muscle MLCK (gMLCK), the protein was only activated to approximately 10% for 
each CaM fragment (Persechini et al., 1994).  However, when the trypic digests were combined in the 
assay at higher concentrations (~1000 times more concentrated), skMLCK and gMLCK activity was 
restored to 85 and 80%, respectively, signifying that the tethering effect of CaM’s central helix is not 
necessary for maximal activity (Persechini et al., 1994).  Subsequently, it has also been shown that 
nNOS is able to be activated in the presence of 5 x 106 fold excess nCaM to 50% whereas the C-
terminal domain shows no apparent activity.  When nNOS was assayed in the presence of nCaM and 
cCaM, 50% maximal activity was observed, indicating that an intact central helix is required for the 
full activation of the enzyme (Persechini et al., 1994; Persechini et al., 1996a).  Our findings are in 
good correlation with previously reported literature, where the N-terminal domain in conjunction with 
the central linker region is required for nNOS activation (Persechini et al., 1996a).   
A more recent study tested the possibility that the C-terminal domain of CaM alone is 
sufficient for the activation of the edema factor of adenylyl cyclase from Bacillus anthracis (Drum et 
al., 2000).  They observed no enzyme activity of the exotoxin by the C-terminal domain of CaM, 
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which indicated that both the N- and C-terminal domains of CaM contributed to activation of the 
exotoxin.   
Our results are novel since the N-terminal domain of CaM alone is sufficient to activate the 
iNOS isozyme to 70% maximal activity in the presence of Ca2+.  Although this is not the first time 
that a single domain of CaM has been reported to activate its target protein, it is unique in that iNOS 
is 70% active at stoichiometric concentrations of nCaM. 
In addition, our results provide further insight into the requirement of CaM for iNOS 
expression.  Cleavage of iNOS at the CaM-binding site by calpain I in the absence of CaM to protect 
the enzyme has been reported previously (Walker et al., 2001); however, the aggregation phenomena 
observed here in vitro suggests that in the absence of coexpressed CaM, the iNOS enzyme can 
aggregate forming inclusion bodies and greatly reducing protein yield.  A recent paper reported that 
mammalian cells may regulate iNOS by removing misfolded and aggregated proteins by a pathway 
that leads to the formation of aggresomes (Kolodziejska et al., 2005).  This may provide a rapid 
means of clearing the cells of iNOS that would be detrimental to the cell due to its prolonged 
production of large amounts of •NO.  Our finding that displacement of CaM from iNOS leads to 
aggregation provides a possible mechanism for the regulation of the enzyme. The total intracellular 
concentration of CaM in the cell appears to be significantly lower than the total concentration of its 
targets, making it a limiting factor in their regulation (Persechini and Stemmer, 2002).  In the 
dynamic environment of the cell, the network of CaM-dependent signaling pathways may play a role 
in the cellular regulation of protein processing.  Excess production of iNOS in the absence of 
sufficient quantities of CaM may lead to the aggregation of the enzyme and ultimately its disposal. 
 
 
* The results presented in this chapter have been published: 
Spratt, D.E., Taiakina, V., and Guillemette, J.G. (2007) Calcium-deficient Calmodulin Binding and 
Activation of Neuronal and Inducible Nitric Oxide Synthases. Biochim Biophys Acta 1774, 1351-
1358. 
 




Calcium-deficient Calmodulin Binding and Activation of 
Neuronal and Inducible Nitric Oxide Synthases * 
4.1 Introduction 
CaM consists of two globular lobes containing an EF hand pair joined by a central linker 
region.  The C-terminal EF hand pair has a ten fold greater affinity for Ca2+ than the N-terminal EF 
hand pair (Martin et al., 1985).  The binding of Ca2+ to CaM induces conformational changes in both 
lobes, leading to a binding state with increased exposure of hydrophobic amino acids that allows for 
CaM to associate with several target proteins including the NOS isozymes.  At elevated Ca2+ 
concentrations, CaM binds to the cNOS enzymes, nNOS and eNOS, making them the Ca2+-dependent 
NOS enzymes.  In contrast, iNOS is transcriptionally regulated in vivo by cytokines and binds to CaM 
at basal levels of Ca2+.  Although iNOS is commonly referred to as being Ca2+-independent, we and 
others have shown that •NO production decreased by about 30% when Ca2+ is chelated in vitro 
(Venema et al., 1996; Newman et al., 2004; Spratt et al., 2006). 
The question of whether the apo-form of CaM binds to iNOS cannot be simply tested by 
chelating Ca2+ due to the possibility of chelating other divalent metal ions present in the iNOS 
enzyme or CaM that are potentially essential for enzyme function, such as Fe2+, Zn2+, and Cu2+ 
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(Demura et al., 1998; Perry and Marletta, 1998; Crane et al., 1999).  Additionally, previous studies 
have demonstrated the effect of various divalent cations on the activation or inhibition of nNOS 
(Nishimura et al., 1999; Weaver et al., 2002; 2004), which may or may not have an effect on iNOS.  
Furthermore, the interaction of CaM with its target protein facilitates the tighter binding of Ca2+ to 
CaM (Olwin and Storm, 1985), although exceptions have been reported.  For example, the association 
of CaM with the SK channel results in the locking of the C-terminal lobe of CaM in a Ca2+-free semi-
open state (Schumacher et al., 2001).  Furthermore, the binding of the edema factor from B. anthracis 
to CaM locks the N-terminal lobe of CaM in a closed conformation regardless of its Ca2+ loading 
state, causing a significant reduction of the N-terminal lobe of CaM’s affinity for Ca2+ (Shen et al., 
2005). 
We decided to further investigate the Ca2+-dependent/independent properties of both the 
binding and activation of iNOS by CaM.  To accomplish this, we employed a series of CaM mutants 
that are defective in Ca2+ binding in either the N-terminal lobe (CaM12; CaM D21A and D56A 
mutations), the C-terminal lobe (CaM34; CaM D93A and D131A), or all four of its Ca2+-binding EF 
hands (CaM1234; mutations at D21A, D56A, D93A and D131A inclusive).  Figure 4.1 shows a 
schematic representation of these Ca2+-deficient CaM mutants.  A previous investigation using single 
EF hand Ca2+-deficient CaM mutant proteins only studied their effect on the activation of iNOS 
(Gribovskaja et al., 2005).  In order to unequivocally determine whether the binding and activation of 
iNOS by CaM is Ca2+-independent, we used CaM1234 to emulate Ca2+-free CaM.  However, as 
previous studies have demonstrated that the N- and C-terminal lobes of CaM can also be devoid of 
Ca2+ when associated with its target proteins (Schumacher et al., 2001; Shen et al., 2005), we have 
also used CaM12 and CaM34 to determine if the Ca2+-independent association of CaM to iNOS is 
related solely to the Ca2+-free N- or C-terminal lobe of CaM. 
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Figure 4.1 – Schematic representation of CaM12, CaM34, and CaM1234. 
Mutations at the highly conserved aspartate residues at position 1 in each CaM EF hand (shown in 
yellow) make the Ca2+-binding motif incapable of binding Ca2+.  CaM12, which is unable to bind Ca2+ 
in EF hands I and II (N-domain, mutations D21A and D56A) is labeled in blue.  CaM34, which is 
unable to bind Ca2+ in EF hands III and IV (C-domain, mutations D93A and D131A), is labeled in 
red.  CaM1234, which is incapable of binding Ca2+ in all four EF hands (both the N- and C-domains, 
mutations D21A, D56A, D93A, and D131A inclusive), contains all four mutations shown in blue and 
red.  This schematic representation is based upon a previous study (Kilhoffer et al., 1992) and was 
derived from PDB 1CLL (Chattopadhyaya et al., 1992). 
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4.2 Experimental Procedures 
4.2.1 Molecular Cloning of CaM12, CaM34, and CaM1234 
Plasmids coding for CaM12, CaM34 and CaM1234 were a generous gift from Dr. John Adelman 
(Oregon Health & Sciences University, Portland, OR, USA) (Lee et al., 2003).  The ampicillin 
resistance of these plasmids necessitated the construction of new vectors for coexpression with iNOS.  
The cloning of these CaM constructs was performed by the candidate and assisted by Miss Valentina 
Taiakina (UW Co-op student). The coding regions of each CaM protein were PCR amplified 
introducing unique flanking NcoI and SacI restriction sites for subcloning into a vector suitable for 
coexpression.  The primers used were:  
ApoCaMfr 5’ ATTCTAGACCATGGCTGACCAACTGACTGAAGAGCAGATCG 3’ and 
ApoCaMrv 5’ ATGTCGACGAGCTCTTATCACTTCGCTGTCATCATTTGTAC 3’.  The PCR 
products were subcloned into the kanamycin resistant vector pET28a (Novagen) using the unique 
NcoI and SacI sites.  The resulting vectors, pCaM1234Kan, pCaM12Kan, and pCaM34Kan, were 
verified by DNA sequencing to ensure that no spontaneous mutations had occurred. 
4.2.2 Ca2+-deficient CaM protein Expression and Purification 
Wild-type CaM was expressed and purified as previously described (sections 2.2.2 and 2.2.3). 
Overnight cultures of E. coli BL21 (DE3) transformed with pCaM1234Kan, pCaM12Kan, and 
pCaM34Kan were used to inoculate 2 x 1 L of Luria-Bertani media in 4 L flasks supplemented with 30 
µg/ml of kanamycin.  Cultures were grown at 37ºC, 200 rpm to an OD600 of 0.6 to 0.8, induced with 
500 µM IPTG and were subsequently harvested after 4 hours of expression, flash frozen on dry ice, 
and stored at –80ºC.  Cells were lysed by five rapid cycles of freeze-thawing between liquid nitrogen 
and 37°C in a buffer containing 50 mM MOPS, pH 7.5, 100 mM KCl, 1 mM EDTA, 5 mM DTT and 
1 mM PMSF.  The lysate was clarified by centrifugation at 48,000 g for 30 minutes at 4oC.  In order 
Chapter 4: Binding and Activation of NOS by Ca2+-deficient CaMs 
132 
to remove excess contaminating RNA, the supernatant was treated with NaOH (0.285 M final) heated 
at 65oC for 15 minutes to allow the RNA complete its self-cleavage.  To every 7.5 mL of supernatant, 
5 mL of 0.5 M EDTA, 4.5 mL of H2O, and 0.5 mL of 10 M NaOH was added.  This reaction was 
neutralized with the addition of an equal volume of 1 M HEPES, pH 7.4, which lowered the pH to 
8.0.  The sample was subsequently heated at 85oC for 10 minutes to precipitate the E. coli proteins, as 
previously described (Salas et al., 2005) and immediately cooled on ice.  The sample was then 
clarified by centrifugation at 48,000 g for 30 minutes at 4oC.  Since the larger molecular weight 
proteins were precipitated by heating, the sample was concentrated with an Amicon YM-10 
membrane until the total volume was less than 10 mL, similar to the method previously described to 
purify CaM1234 (Sienaert et al., 2002).  The CaM proteins were then exhaustively dialysed against 50 
mM Tris, pH 7.5, 1 mM CaCl2, and 1 mM DTT.   The purity of the CaM proteins was verified by 
SDS-PAGE and the final protein concentrations were determined using the DC Bio-Rad Protein 
Assay (Bio-Rad Laboratories, Mississauga, ON) based upon the Lowry method (Lowry et al., 1951).  
Finally, the CaM proteins were aliquoted, flash frozen on dry ice, and stored at –80oC.  Electrospray 
ionization-mass spectrometry (ESI-MS) was performed on the purified CaM proteins using a 
Micromass Q-Tof Ultima GLOBAL mass spectrometer (Manchester, U.K.) with an internal standard 
as previously described in section 2.2.5 (Spratt et al., 2006). 
4.2.3 NOS Enzyme Expression and Purification 
Rat nNOS was expressed and purified as previously described (Roman et al., 1995) with the 
exception that the enzyme had an N-terminal polyhistidine tail cloned upstream from its respective 
start codon.  Human iNOS carrying a deletion of the first 70 amino acids and an N-terminal 
polyhistidine tail was coexpressed with wild-type CaM or CaM mutant protein in E. coli BL21 
(DE3), as previously described in section 2.2.8.  The coexpression and purification of iNOS 
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coexpressed with these CaM mutant proteins was performed by the candidate and assisted by Miss 
Valentina Taiakina (UW Co-op student). 
Purification of iNOS coexpressed with CaM proteins involved a 45% ammonium sulfate 
precipitation followed by metal chelation chromatography (section 2.2.9).  After elution of the protein 
with 200 mM imidazole, the samples were dialysed as previously described in section 2.2.9 followed 
by the use of a Vivaspin 15 ultrafiltration spin column (Sartorius AG Biotechnology, Goettingen, 
Germany) to concentrate the sample to approximately 2 mL in order to prepare the protein sample for 
gel filtration.  Using a HiLoad 16/60 Superdex 200 prep grade column (GE Healthcare Bio-Sciences, 
Baie d’Urfe, PQ) equilibrated with 50 mM Tris-HCl, pH 7.5, 10% glycerol, 0.1 M NaCl, and 1 mM 
DTT, the sample was loaded and 1 mL fractions were collected.  The flow rate was maintained at 0.6 
mL/min using an AKTApurifier System for Chromatography (GE Healthcare Bio-Sciences) and 
eluted protein, heme and flavins were monitored at 280 nm, 398 nm, and 450 nm respectively.  A gel 
filtration standard kit (Sigma, Oakville, ON) containing multiple molecular mass markers was used to 
calibrate the column.  Fractions that eluted around 56.6 mL, which corresponds to the dimer of iNOS 
with CaM bound, were collected and pooled.  An example elution profile for iNOS coexpressed with 
CaM12 is shown in Figure 4.2. 
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Figure 4.2 – Gel filration elution profile of iNOS coexpressed with CaM12. 
Absorbance at 280 (protein; ▬), 398 (heme; ▬), and 450 nm (flavins; ▬) were monitored to track 
the elution of iNOS coexpressed CaM12 the from HiLoad 16/60 Superdex 200 prep grade column.  
Two milliliters of iNOS coexpressed with CaM12 was loaded on to the gel filtration column 
equilibrated with 50 mM Tris-HCl, pH 7.5, containing 10% glycerol, 0.1 M NaCl, and 1 mM 
dithiothreitol.  Results shown are representative of two similar experiments. 
 
No iNOS monomer was observed using this methodology.  The purified iNOS enzymes were 
subsequently aliquoted, flash frozen on dry ice and stored at -80oC.  Flavin content was determined as 
previously described (Faeder and Siegel, 1973). 
4.2.4 NOS Enzyme Kinetics 
The NADPH oxidation (section 2.2.10.3), ferricyanide (FeCN) reduction (described in section 
4.2.4.1), cytochrome c reduction (section 2.2.10.2), and the oxyhemoglobin capture (section 2.2.10.1) 
assays were performed to monitor electron transfer rates at each redox center of each NOS enzyme, as 
previously described in Figure 2.5.  All of the assays were performed in 96 well microtitre plates in 
total well volumes of 100 µl at 25oC in a SpectraMax 384 Plus 96 well UV-visible spectrophotometer 
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using Soft Max Pro software (Molecular Devices, Sunnyvale, CA).  200 µM CaCl2 or 250 µM EDTA, 
as well as 2 µM wild-type CaM or mutant CaM proteins were added to the appropriate samples. 
4.2.4.1 Ferricyanide Reduction Assay 
The spectrophotometric NADPH-dependent ferricyanide assay was used to assess the initial rate of 
electron transfer in the NOS reductase domain to the FAD domain.  This assay was performed in a 
similar manner to the cytochrome c reduction assay (section 2.2.10.2) with the exception that no DTT 
or H4B was added.  Since we want to observe the reduction of ferricyanide exclusively by NOS, DTT 
and H4B were not included in this assay because of their ability to reduce ferricyanide.  This assay 
involved the use of three separate solutions: (1) the enzyme solution, (2) the ferricyanide solution, and 
(3) the NADPH solution.  The enzyme solution consisted of the NOS enzyme in a 50 mM Tris-HCl, 
pH 7.5 @ RT buffer with 10 μM FAD, 10 μM FMN, 200 μM NADPH, 10 U/mL catalase, 10 U/mL 
SOD, 0.1 mg/mL BSA and 10% glycerol.  NADPH was prepared fresh on the day of the assay.  The 
NADPH was added to this solution to react with any L-arginine in the enzyme solution from the 
dialysis buffer of the NOS.  The ferricyanide solution contained ferricyanide (ε420 = 1.2 mM-1 cm-1), 
Tris-HCl, CaCl2 or EDTA (depending on the enzyme being tested), BSA, catalase, and SOD.  The 
NADPH solution contained only NADPH used to initiate the assay.  
 The assay reactions were performed adding 10 μL of complete enzyme solution (NOS 
enzyme, with or without CaM, and enzyme solution), followed by a 2 minute incubation at 25oC.  
Following the incubation, 50 μL of ferricyanide solution was added to each well containing the 
complete enzyme solution, followed by a 30 second incubation.  After this brief incubation, the assay 
was initiated by the addition of 40 μL of NADPH solution to each well, for a total of 100 μL per well.  
The final initiated reaction contained ferricyanide (1 mM), Tris-HCl (50 mM, pH 7.5 at 25°C), 
glycerol (1%), FMN (1 μM), FAD (1 μM), NADPH (200 μM), BSA (0.1 mg/mL), catalase (10 
U/mL), and SOD (10 U/mL).  eNOS, nNOS, and iNOS coexpressed with CaM or mutant CaM 
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protein were assayed at 50, 5.5, and 5.5 nM in 100 μL total well volume in quadruplicate.  CaCl2 (200 
μM), EDTA (250 μM), and CaM (2 μM) or mutant CaM protein were added to the appropriate 
samples unless otherwise stated. 
After initiation, the microtitre plate was read at 25 – 27oC in a SpectraMax 384 Plus 96 well 
UV-visible spectrophotometer using Soft Max Pro software (Molecular Devices, Sunnyvale, CA).  
The reactions were read at 420 nm over 5 minutes at 7 second intervals.  Equation 4.1 was used to 
calculate the activity of the enzyme based upon the rate of absorbance change at 420 nm. 
 
Equation 4.1   Activity = v x 60 s • min-1 / Δε420 nm (ox FeCN to red FeCN)  / (well volume x  
    [NOS enzyme] in nM x NOS molecular weight in g/mol x 1000 mg/g) 
 
where v represents the slope of the change of absorbance over time in seconds.  The extinction 
coefficient Δε420 nm ox FeCN to red FeCN of -0.04882 OD340 per nanomole was used.  Activity is expressed as 
nanomoles of ferricyanide reduced per minute per milligram of enzyme (nmol red FeCN min-1 mgP-1). 
4.2.5 CaM Proteins Fluorescent Labeling with Dansyl Chloride 
The CaM proteins were transferred into labeling buffer (0.1 M sodium bicarbonate, pH 7.5 containing 
1 mM EDTA) by gel filtration using a Sephadex G-25 PD-10 column (Amersham Biosciences), as  
described in section 6.2.2.5 (Lang et al., 2005).  The concentrations of the CaM proteins were at least 
5 mg/mL and the labeling conditions and duration using dansyl chloride (Figure 4.3) were performed 
as suggested by the manufacturer (Molecular Probes, Eugene, OR, USA).  
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Figure 4.3 – Chemical structure of dansyl chloride used to N-terminally label wild-type CaM, 
CaM12, CaM34, and CaM1234. 
Dansyl chloride (5-dimethylaminonapthalene-1-sulfonyl chloride) was purchased from Molecular 
Probes. 
 
Excess dansyl chloride was removed by exhaustive dialysis against 50 mM HEPES, 1 mM EDTA, 
150 mM NaCl, pH 7.5 to ensure that all non-covalently linked dye was removed from the labeled 
CaM proteins, as described in section 5.2.3 and other labeling studies (Ottl et al., 1998; Waxham et 
al., 1998; Spratt et al., 2007b).  Labeling yields were determined from absorbance spectra using the 
ε372 of 3,900 M-1cm-1 (Molecular Probes) and were compared to actual protein concentrations 
determined using the Lowry method (Lowry et al., 1951) with wild-type CaM used as the protein 
standard.  Dansyl-labeling versus protein concentration showed that 0.6-0.8 mol of dansyl chloride 
was incorporated for each mol of CaM protein.  ESI-MS (section 2.2.5) was used to confirm 
successful dansyl-labeling of each CaM protein. 
4.2.6 Steady-state Fluorescence Measurements 
Fluorescence emission spectra were obtained using a PTI QuantaMaster spectrofluorimeter (London, 
ON).  In an initial volume of 1 mL, a scan of each dansyl-CaM protein (2 μM) was taken in a buffer 
consisting of 50 mM HEPES, 1 mM EDTA, 150 mM NaCl, pH 7.5.  The excitation wavelength for 
all of the dansyl-labeled CaMs was set at 340 nm and emission was monitored between 400 and 600 
nm.  Slit widths were set at 2 nm for excitation and 1 nm for emission.  The free [Ca2+] was calculated 
to be <1 nM according to the online algorithm WEBMAXC (Patton et al., 2004).  After the first scan, 
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CaCl2 (0.5 mM final) was added to the cuvette (calculated free [Ca2+] of 0.500 mM), the sample was 
mixed thoroughly, allowed to incubate for three minutes to reach equilibrium, and scanned.  Synthetic 
rat nNOS or human iNOS CaM-binding domain peptide (10 μM) was subsequently added to the 
cuvette, the sample was mixed, allowed to incubate, and finally scanned.  The NOS CaM-binding 
domain peptides for rat nNOS (KRRAI GFKKL AEAVK FSAKL MGQ; residues 725–747) and 
human iNOS (RPKRR EIPLK VLVKA VLFAC MLMRK; residues 507–531) were synthesized by 
Sigma-Genosys (Oakville, ON).  A large blue-shifted emission spectra represents a change in the 
environment of the dansyl fluorophore due to the CaM protein binding to the NOS peptide.  Finally, 
excess EDTA (5 mM final) was added (calculated free [Ca2+] of 5.8 nM), incubated for three minutes, 
and a final scan was taken. 
4.2.7 Circular Dichroism of Ca2+-deficient CaM Proteins Bound to Synthetic 
NOS Peptides 
CD was performed using a Jasco J-715 CD spectropolarimeter and analyzed using J-715 software 
(Jasco Inc., Easton, MD, USA) as previously described (Fernando et al., 2002) with some 
modifications.  Samples were measured in a 1 mm quartz cuvette (Hellma, Concord, ON) and kept at 
25°C using a Peltier type constant-temperature cell holder (model PFD 3505, Jasco, Easton, MD).  
Samples consisted of 10 µM wild-type CaM or Ca2+-deficient CaM proteins alone or with equimolar 
concentrations of synthetic nNOS or iNOS CaM-binding domain peptide.  Samples were mixed in 10 
mM Tris-HCl buffer (pH 7.5), 150 mM NaCl, containing 200 µM CaCl2 followed by 1 mM EDTA. 
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4.3 Results and Discussion 
Numerous studies have used Ca2+ chelators such as EGTA and EDTA to study the Ca2+-dependence 
of CaM and CaM mutants binding to various CaM-dependent target proteins, including the NOS 
isozymes (Persechini et al., 1996a; b; Venema et al., 1996; Stevens-Truss et al., 1997; Gachhui et al., 
1998; Montgomery et al., 2003; Newman et al., 2004; Gribovskaja et al., 2005; Spratt et al., 2006).  
Since the interaction of CaM with its target protein myosin light chain kinase (MLCK) facilitates the 
tighter binding of Ca2+ to CaM (Olwin and Storm, 1985), the use of chelators cannot always be used 
to infer apo-CaM’s association to a target protein.  Although CaM does bind to the nNOS and iNOS 
in an antiparallel orientation (Zhang et al., 1995; Spratt et al., 2007b), similar to CaM in complex 
with MLCK, the tighter binding of Ca2+ to the CaM-NOS complex has yet to be proven.  In order to 
determine unequivocally that apo-CaM binds to a Ca2+-independent CaM-target protein, biophysical 
studies must demonstrate that the protein’s association occurs with apo-CaM and not with a CaM 
variant bound to 1, 2, 3 or 4 Ca2+ ions (Jurado et al., 1999).  In order to overcome the need of Ca2+ 
chelators, we have coexpressed iNOS with CaM12, CaM34, and CaM1234 to investigate Ca2+-free forms 
of each lobe and the entire CaM protein’s abilities to bind and activate iNOS in vitro.  Furthermore, 
other divalent cations have previously been shown to have a direct effect on the activity of the NOS 
enzymes.  Perry and Marletta have reported that NOS has the ability to bind to transition metals in a 
stoichiometric fashion, and have demonstrated that the rate of •NO catalysis is also enhanced by a 
non-heme iron (Perry and Marletta, 1998).  Similarly, Crane and coworkers reported a correlation 
between the three-dimensional swapping of the N-terminal hook and zinc metal ion release with 
disulfide formation where they proposed that these may have an impact on iNOS’s stability and 
regulation in vivo (Crane et al., 1999).  Another study reported that divalent copper ions are capable 
of activating eNOS activity in crude cell extracts and intact endothelial cells (Demura et al., 1998).  
Previous studies using nNOS have also demonstrated that the addition of metals such as Ni2+, Ba2+, 
Chapter 4: Binding and Activation of NOS by Ca2+-deficient CaMs 
140 
Mn2+, Pb2+, Sr2+, Cd2+, and Rb2+ are able to activate nNOS, whereas Cd2+ and combinations of Ca2+ 
with Ni2+, Cd2+, or Mn2+ can potently inhibit the enzyme (Nishimura et al., 1999; Weaver et al., 2002; 
2004).  Our investigation was performed to remove any possible effect that divalent metal chelation 
has on enzyme activity.  The mutant CaM proteins used allowed for the specific investigation of Ca2+-
dependent/independent activation and binding of CaM to iNOS. 
4.3.1 Protein Expression and Purification 
The CaM1234, CaM12, and CaM34 constructs previously described (section 4.1) produced good 
independent expression ranging from 75.3 to 105.8 mg protein/L media, depending on the CaM 
mutant.  Purified CaM constructs appeared over 95% homogeneous on 15% SDS-PAGE and ESI-MS 
QTOF ruled out posttranslational modification and confirmed homogeneity (Figure 4.4; Table 4.1) 
 
Figure 4.4 – 15% SDS-PAGE of the purified Ca2+-deficient CaM proteins. 
A 10 μg sample of each purified CaM protein was loaded onto a standard SDS-PAGE loading buffer 
containing either 10 mM CaCl2 or EDTA. Lane 1 – low molecular weight SDS protein marker (GE 
Healthcare Bio-sciences), Lanes 2 and 3 – wild-type CaM in the presence of Ca2+ and EDTA, 
respectively, Lanes 4 and 5 – CaM1234 in Ca2+ and EDTA, Lanes 6 and 7 – CaM12 in Ca2+ and EDTA, 
Lanes 8 and 9 – CaM34 in Ca2+ and EDTA. 
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Table 4.1 – Masses of CaM proteins and fluorescently labeled CaM proteins 
      
 Mass (Da) a 
     
     
  Observed Theoretical 
 CaM proteins     
   
Wild-type CaM 16706.0 16706 b 
CaM1234 16530.0 16530 
CaM12 16617.5 16618 
CaM34 16617.5 16618 
   
Fluorescent CaM proteins   
   
Dansyl-wild-type CaM 16936.6 16940 c 
Dansyl-CaM1234 16762.6 16764 
Dansyl-CaM12 16852.0 16853 
Dansyl-CaM34 16851.2 16853 
   
a Masses of deconvoluted ESI-MS spectra were determined with an accuracy of ± 4 Da. 
b Calculated masses based upon amino acid sequence. 
c Expected mass difference with covalently attached dansyl group is 234.3 (Molecular Probes).  The manufacturer’s MW of 
the dye is 269.8 Da, which includes a chloride ion that is released upon reaction with the N-terminal amino group. 
 
The iNOS enzyme was coexpressed with CaM or a mutant CaM construct.  Coexpression 
with wild-type CaM produced the highest yields of purified iNOS (4.8 mg/L).  Coexpression of iNOS 
with CaM12 yielded 0.4 mg/L while coexpression with CaM34 gave 0.5 mg/L.  Expression of iNOS 
with CaM1234 gave the lowest yields of 0.2 mg/L.  Heme and flavin content of the purified iNOS 
enzymes coexpressed with CaM12 and CaM34 constructs were the same as that of iNOS coexpressed 
with wild-type CaM.  In contrast, coexpression of iNOS with CaM1234 demonstrated a lower content 
of flavin to heme (25% when compared to iNOS coexpressed with wild-type CaM), indicative of 
protein instability during expression or purification.  From the relative yields of iNOS enzyme 
isolated with each of the CaM mutants, it is apparent that some form of Ca2+-dependent change in 
CaM’s structure is required to produce stable and active iNOS enzyme. 
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4.3.2 nNOS Activation by Ca2+-deficient CaM Proteins 
Wild-type CaM was the only CaM protein capable of activating nNOS to produce •NO and reduce 
cytochrome c.  CaM12, CaM34, and CaM1234 showed little or no activity (Figure 2A).  Furthermore, 
wild-type CaM was unable to bind and activate nNOS in the presence of 250 µM EDTA.  These 
results are consistent with previous reports that Ca2+-replete CaM is required to bind and fully 
activate nNOS (Stevens-Truss et al., 1997; Newman et al., 2004; Spratt et al., 2006). 
4.3.3 iNOS Activation by Ca2+-deficient CaM Proteins 
The coexpression of iNOS with CaM12 and CaM34 constructs resulted in reproducible •NO production 
rates of approximately 75% and 115%, respectively, in the presence of Ca2+ (Figure 4.5A).  In 
contrast, iNOS coexpressed with CaM1234 resulted in lower •NO production rates of less than 25% 
which can be correlated to the lower FMN content of the enzyme.  The addition of excess wild-type 
CaM and mutant CaM proteins to iNOS coexpressed with each of the CaM constructs did not result 
in any significant change in enzyme activity, indicative that the CaM-binding sites were saturated 
with mutant CaM proteins and did not exchange rapidly with CaM in solution, identical to our 
previous studies (Newman et al., 2004; Spratt et al., 2006). 
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Figure 4.5 – Ability of wild-type CaM and Ca2+-deficient mutant CaM proteins to activate NOS 
enzymes. 
(A) Activation of nNOS by mutant CaM proteins.  The oxyhemoglobin capture and cytochrome c 
reduction assays were performed in the presence of either 2 µΜ wild-type or mutant CaM protein and 
either 200 µM CaCl2 or 250 µM EDTA, as indicated.  The activities obtained with nNOS bound to 
wild-type CaM at 25oC in the presence of 200 µM CaCl2 were all set to 100%. Under these 
conditions, the activities for nNOS bound to CaM were 54.5 min-1 (•NO synthesis) and 848.5 min-1 
(cytochrome c reduction).  (B) Activation of iNOS by mutant CaM proteins.  The iNOS enzyme was 
coexpressed separately with each of the CaM proteins and then purified. •NO synthesis, cytochrome c 
reduction, ferricyanide reduction, and NADPH oxidation rates were measured as described in (A) 
except that no exogenous CaM was added to the assay.  Each assay was performed in the presence of 
either 200 µM CaCl2 or 250 µM EDTA as indicated.  The activities obtained for iNOS coexpressed 
with CaM and assayed in the presence of 200 µM CaCl2 at 25oC were all set to 100% and were 61.7 
min-1 (•NO synthesis), 978 min-1 (cytochrome c reduction), 32688 min-1 (ferricyanide reduction) and 
88.5 min-1 (NADPH oxidation).  The bar values represent the mean ± standard deviation.  Each 
experiment was performed in quadruplicate and repeated three or more times. 
Chapter 4: Binding and Activation of NOS by Ca2+-deficient CaMs 
144 
The addition of 250 µM EDTA to chelate Ca2+ resulted in a significant decrease in the 
stimulation of •NO production by wild-type CaM and CaM34.  The iNOS enzyme coexpressed with 
wild-type CaM decreased to 75%, which was consistent with previous studies that demonstrated there 
is some Ca2+-dependence in iNOS •NO synthesis (Venema et al., 1996; Newman et al., 2004; Spratt 
et al., 2006).  Similarly, iNOS coexpressed with CaM34 decreased to 50% in the absence of Ca2+ 
(Figure 4.5B).  In contrast, iNOS coexpressed with CaM1234 and CaM12 showed no Ca2+-dependence 
in •NO synthesis rates.  These results show that a Ca2+-dependent rearrangement of the N-terminal 
lobe of CaM may be responsible for the partial Ca2+-dependence of iNOS.  Furthermore, the 
observation that the maximal activity of iNOS coexpressed with CaM12 is identical in the presence 
and absence of Ca2+ at 75% further supports this result.  Consistent with our previous studies, the C-
terminal lobe of CaM is responsible for the binding and stability of iNOS, while the N-terminal 
domain contains the important elements requiring Ca2+-replete conditions for the activation of iNOS 
(Spratt et al., 2006).   
Comparing the stimulation of NADPH oxidation by the CaM constructs showed a pattern 
comparable to the activation of •NO synthesis by iNOS (Figure 4.5B). Coexpression of wild-type 
CaM, CaM1234, CaM12 and CaM34 with iNOS resulted in a stoichiometry of about 1.5 NADPH 
oxidized per •NO formed in the presence of Ca2+.  Likewise, in the presence of a large excess of 
EDTA, all of the iNOS enzymes maintained tightly coupled electron transfer, with only iNOS 
coexpressed with wild-type CaM and CaM34 showing a slight increase in uncoupling with an NADPH 
to •NO produced ratio of 2 to 1.  The greater uncoupling under Ca2+-depleted conditions of iNOS 
coexpressed with wild-type CaM and CaM34 may again be due to a decreased efficiency of electron 
transfer due to the aforementioned Ca2+-dependent rearrangement of the N-terminal lobe of CaM.  
The uncoupled reaction could be the result of the production of •O2-.  Xia and coworkers reported that 
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iNOS generates •O2- mainly at the flavin-binding sites of the reductase domain when the enzyme is 
treated with heme blockers or L-arginine analogue NOS inhibitors (Xia et al., 1998).  
The ferricyanide and cytochrome c assays were used to monitor electron transfer from the 
FAD and FMN, respectively, to an exogenous electron acceptor (Figure 2.5).  The coexpressed CaM12 
with iNOS reproducibly displayed over 140% (FeCN and cyt. c) of the maximal activity obtained 
with wild-type CaM in the presence or absence of Ca2+ (Figure 4.5B).  Similar to iNOS coexpressed 
with wild-type CaM, CaM34 had approximately 100% activity with little or no variance due to Ca2+ 
concentrations.  These findings are consistent with the iNOS reductase domain being CaM-
independent (Newton et al., 1998).  The iNOS enzymes coexpressed with CaM1234 showed slightly 
higher FeCN reduction rates but much lower rates of reduction for cytochrome c.  The diminished 
rate of cytochrome c reduction can be attributed to low FMN content of this enzyme when 
coexpressed with CaM1234.  
4.3.4 Ca2+-deficient CaM-NOS Peptide Binding Studies 
4.3.4.1 Steady-state Fluorescence of Dansyl-labeled CaM Proteins  
The binding of N-terminally labeled wild-type and Ca2+-deficient CaM proteins to synthetic NOS 
CaM-binding domain peptides was observed using steady-state fluorescence.  The addition of Ca2+ to 
the dansyl-labeled wild-type CaM proteins all demonstrated a blue-shifted emission and increased 
intensity, indicating that wild-type CaM is Ca2+-replete and a structural rearrangement had occurred 
(Figure 4.6).  
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Figure 4.6 – Fluorescence emission spectra of dansyl-CaM proteins in the presence of nNOS 
and iNOS peptides. 
In an initial volume of 1 mL, either dansyl-wild-type CaM, dansyl-CaM1234, dansyl-CaM12, or dansyl-
CaM34 (2 μM final) was added to 50 mM HEPES, 150 mM NaCl, 1 mM EDTA, pH 7.5 with the 
emission of each sample observed between 400 and 600 nm (▬).  The excitation wavelength was set 
to 340 nm and the excitation and emission slit widths were set at 2 and 1 nm, respectively.  CaCl2 (0.5 
mM final) was subsequently added and another scan was obtained (▬).  Wild-type CaM, CaM12, and 
CaM34 showed slight changes in fluorescence while CaM1234 showed no effect, representing this 
protein’s inability to bind Ca2+.  Synthetic NOS peptide (10 μM) was added, mixed thoroughly, 
allowed to incubate for 3 minutes to reach equilibrium, and another scan was taken (▬).  Lastly, 
EDTA was added to a final concentration of 5 mM, the sample was mixed, and a final scan was taken 
(▬).  
 
As expected, the addition of Ca2+ to dansyl-CaM1234 resulted in no change in fluorescence since 
CaM1234 is incapable of binding to Ca2+.  The addition of the nNOS peptide to dansyl-wild-type CaM 
caused a large increase in emission intensity and blue-shift, indicative of wild-type CaM’s association 
to the nNOS peptide.  Furthermore, the fluorescence increase observed caused by the CaM-nNOS 
peptide complex was completely reversible with the addition of EDTA, causing the release of the 
nNOS peptide. Conversely, there was no observed fluorescence change for CaM1234, CaM12, and 
CaM34 when nNOS peptide was added, representing no interaction between the mutant CaM proteins 
and the nNOS peptide (Figure 4.6).  These results are consistent with our kinetic results that        
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Ca2+-replete CaM is required for its binding to nNOS.  In contrast, wild-type CaM as well as each of 
the declawed CaM proteins are capable of binding to the iNOS CaM-binding domain peptide in a 
Ca2+-independent manner (Figure 4.6).  The addition of excess EDTA had no effect on the association 
of CaM to the iNOS peptide, showing that unlike nNOS, this process appears to be irreversible.  This 
result, especially with CaM1234, confirms definitively that apo-CaM does in fact associate with iNOS. 
4.3.4.2  Circular Dichroism of Ca2+-deficient CaM Proteins  
CD was employed to further investigate the Ca2+-deficient CaM proteins ability to bind Ca2+ as well 
as their interaction with the nNOS and iNOS CaM-binding domains peptides.  As expected, CaM1234 
showed no evidence of binding to Ca2+ by spectropolarimetry (Figure 4.7), which is in good 
agreement with our fluorescence result (Figure 4.6).  In contrast, CaM12 and CaM34 showed slight 
increases in α-helical content; however, the increase in secondary structure was smaller than the Ca2+-
dependent changes in wild-type CaM.  This result was expected since Ca2+ binding to the N- and C-
lobes is cooperative, where Ca2+-binding to the C-terminal lobe of CaM effects the N-terminal’s 
affinity for Ca2+ by inducing increased α-helicity in the central linker of CaM (Jurado et al., 1999).   
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Figure 4.7 – CD spectra for (A) wild-type CaM, (B) CaM1234, (C) CaM12, and (D) CaM34 in the 
presence and absence of Ca2+. 
Concentrations of CaM and CaM proteins were 10 μM in 10 mM Tris-HCl, pH 7.5, containing 150 
mM NaCl and 200 μM CaCl2 or 1 mM EDTA.  CaM protein in the presence of Ca2+ or EDTA are 
shown as ( ) and ( ), respectively. 
 
Previous investigations have shown that spectropolarimetry is a useful method to monitor the 
secondary structure of peptides bound to CaM (Matsubara et al., 1997; Yuan et al., 1998; Spratt et al., 
2007b).  In the absence of CaM proteins, both the nNOS and iNOS peptides showed no secondary 
structure and were predominantly random coil.  The binding of Ca2+-replete wild-type CaM to both 
the nNOS and iNOS peptide resulted in a large increase in α-helical content for each peptide (Figure 
4.8).   
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Figure 4.8 – Difference CD spectra for iNOS and nNOS CaM-binding domain peptides in the 
presence of (A) wild-type CaM, (B) CaM1234, (C) CaM12, and (D) CaM34. 
The spectra were calculated by subtracting the spectra for 10 μM CaM alone from the spectra for 10 
μM CaM in the presence of 10 μM NOS peptide.  Spectra for iNOS peptide in the presence of Ca2+ 
and EDTA are shown as ( ) and ( ), respectively.  Spectra for nNOS peptide in the presence 
of Ca2+ ( ) and EDTA ( ) are shown to demonstrate the difference between the Ca2+-
dependent nNOS and Ca2+-independent iNOS enzymes.  Data is expressed as the mean residue 
ellipticity (θ) in degree cm2 dmol–1. 
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The subsequent addition of EDTA caused no change in secondary structure for the wild-type CaM-
iNOS peptide complex while the nNOS peptide’s secondary structure returned to random coil.  These 
results are consistent with CaM-binding to iNOS being Ca2+-independent and binding to nNOS being 
Ca2+-dependent.   
There was no evidence of association between CaM1234 and CaM34 with the nNOS peptide as 
there was no increase in α-helicity.  In contrast, all three CaM mutants did show tight Ca2+-
independent binding to the iNOS peptide (Figure 4.8), which correlated well to the fluorescent 
dansyl-CaM results (Figure 4.6).  In contrast to CaM1234 and CaM34, CaM12 did show some Ca2+-
dependent association to the nNOS peptide (Figure 4.8).  Although this result does not correlate with 
the dansyl-CaM12 binding results (Figure 4.6), it is important to note that the C-terminal lobe is likely 
the binding domain, while the N-terminal lobe may not be associated to the peptide at all.  In a 
previous model describing sequential CaM binding to nNOS, it was proposed that the C-terminal lobe 
associates to the CaM-binding domain, followed by the N-terminal lobe (Weissman et al., 2002).  
Since the C-terminal lobe of CaM12 is capable of binding to Ca2+, as evidenced by fluorescence 
(Figure 4.6) and spectropolarimetry (Figure 4.7), it is conceivable that CaM12 would be able to 
associate to nNOS, however, it would not be able to wrap around the CaM-binding element as it 
normally would when activating the enzyme.  
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4.4 Conclusions 
Our present results with CaM1234, CaM12, and CaM34 demonstrate that our earlier studies using 
chelators are representative of apo-CaM binding and activation of iNOS (Newman et al., 2004; Spratt 
et al., 2006) and that using these chelators is a suitable method to observe Ca2+-
dependent/independent interactions between CaM and the NOS enzymes.  We have shown that apo-
CaM is capable of binding and partially activating iNOS in a Ca2+-independent manner, however, 
Ca2+-replete conditions are required for the full activation of the enzyme.  The Ca2+-independence of 
CaM binding has previously been attributed to favorable van der Waals contacts between the peptide 
and CaM as well as conformational changes that minimize the exposure of hydrophobic regions of the 
peptide to solution (Aoyagi et al., 2003).  However, other studies have also demonstrated that regions 
flanking the CaM-binding domain are also responsible for the apparent Ca2+-independent binding of 
CaM (Ruan et al., 1996; Lee and Stull, 1998; Nishida and Ortiz de Montellano, 1998; Lee et al., 
2001).  Clearly, a better mechanistic understanding of exactly how CaM both binds and activates the 
iNOS enzyme continues to be of great interest because of the multiple physiological roles performed 
by •NO. 
 
* The results presented in this chapter have been published: 
Spratt, D.E., Taiakina, V., Palmer, M., and Guillemette, J.G. (2007) Differential Binding of 
Calmodulin Domains to Constitutive and Inducible Nitric Oxide Synthases. Biochemistry 46, 8288-
8300. 
 




Differential Binding of Calmodulin Domains to Constitutive 
and Inducible Nitric Oxide Synthase Enzymes * 
5.1 Introduction 
Interactions between CaM and various CaM target peptides and proteins have previously 
been measured by fluorescence using single or double cysteine CaM mutants labeled with an 
appropriate fluorophore.  Fortunately, wild-type CaM is devoid of any cysteine residues making a 
single cysteine substitution a facile method for thiol-specific labeling of CaM for steady-state 
fluorescence binding studies.  For example, previous investigations on CaM-target peptide 
interactions have involved the fluorescently labeled central linker of CaM to determine CaM’s 
association and dissociation rates from myosin light chain kinase, calcineurin, and CaM kinase II 
(Torok and Trentham, 1994; Waxham et al., 1998; Quintana et al., 2005).  Other examples include 
single or double cysteine mutations in the N- and C-domains of CaM for fluorescence resonance 
energy transfer studies (FRET) measurements when binding to a ryanodine receptor peptide and the 
edema factor of adenylyl cyclase from Bacillus anthracis (Drum et al., 2000; Maximciuc et al., 
2006).  In the archetypical model of CaM binding to a target protein, the Ca2+-replete CaM wraps its 
two domains around a single α-helical target peptide (Ikura et al., 1992; Meador et al., 1992);  
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however, other conformations of CaM when bound to target proteins have been discovered 
(Schumacher et al., 2001; Drum et al., 2002; Yap et al., 2003; Ishida and Vogel, 2006; Ye et al., 
2006).   
The x-ray structure of CaM bound to the CaM-binding domain of eNOS shows that CaM 
binds in an anti-parallel fashion with the N-terminal domain of CaM binding to the N-type site closer 
to the C-terminus, which corresponds to the reductase domain, while the C-terminal domain of CaM 
binds to the C-type site closer to the N-terminus, corresponding to the oxygenase domain (Aoyagi et 
al., 2003).  In contrast to the cNOS enzymes, iNOS is transcriptionally regulated in vivo by cytokines 
and binds to CaM at basal levels of Ca2+.  The Ca2+-independent activity of iNOS appears to result 
from the concerted interactions of CaM with both the oxygenase and reductase domains in addition to 
the canonical CaM-binding region (Lee and Stull, 1998).  The orientation of CaM when bound to 
iNOS has previously been proposed to bind in a parallel fashion based on kinetic analysis 
(Gribovskaja et al., 2005), however, this model has yet to be proven. 
There have been several studies demonstrating that the different regions of CaM are 
important for the binding and activation of the cNOS holoenzymes (Su et al., 1995; Persechini et al., 
1996a; b; Stevens-Truss et al., 1997; Gachhui et al., 1998); however, very little has been reported on 
the binding and activation of the iNOS enzyme by CaM (Newman et al., 2004; Gribovskaja et al., 
2005; Spratt et al., 2006).  In the present study, we employed three different mutant CaM proteins 
with single cysteine substitutions found in each region of CaM: CaM-T34C (N-domain), CaM-K75C 
(central linker), and CaM-T110C (C-domain).  These cysteine CaM mutants were fluorescently 
labeled with acrylodan and Alexa Fluor 546 C5-maleimide in order to monitor their binding to 
synthetic NOS CaM-binding domain peptides and the holo-NOS enzymes, respectively.  The CaM-
binding peptides and holoenzymes of all three mammalian NOS isoforms were utilized since studies 
involving uncommon CaM-target binding modes require the use of target elements that extend well 
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outside of the typical CaM binding region of the protein (Ishida and Vogel, 2006).  This study was 
designed to use steady-state fluorescence and CD in the investigation of select regions of CaM when 
binding to the CaM-binding domain peptides and holo-enzymes of the three mammalian NOS 
isozymes and to determine the orientation of CaM when bound to iNOS through the use of FRET. 
5.2 Experimental Procedures 
5.2.1 Site-directed Mutagenesis of CaM 
The QuikChange site-directed mutagenesis procedure (Wang and Malcolm, 1999) was used to 
convert the threonine codons at positions 34 and 110 to cysteines into the kanamycin resistant 
pET9dCaM plasmid consisting of the pET9d vector (Novagen) carrying rat calmodulin (Spratt et al., 
2006).  The construction of pCaM-T34C and pCaM-T110C was performed by the candidate and 
assisted by Miss Valentina Taiakina (UW Co-op student).  The forward and reverse primers for the 
T34C mutation incorporated a unique SacI reporter cut site: wt-T34Cfr 5’ 
CAATAACAACCAAGGAGCTCGGGTGTGTGATGCGGTCTC 3’ and wt-T34Crv 5’ 
GAGACCGCATCACACACCCGAGCTCCTTGGTTGTTATTG 3’.  The forward and reverse 
primers for the T110C mutation involved the removal of a PmlI cut site:  wt-T110Cfr 5’ 
GCAGAGCTTCGCCACGTTATGTGTAACCTTGGAGAGAAG 3’ and wt-T110Crv 5’ 
CTTCTCTCCAAGGTTACACATAACGTGGCGAAGCTCTGC 3’.  The resulting pCaM-T34C and 
pCaM-T110C vectors were confirmed by DNA sequencing.  The pCaM-K75C in the ampicillin 
resistant pET23d vector (Novagen) was a generous gift from Dr. Neal Waxham (University of Texas 
Medical School at Houston, TX, USA) (Waxham et al., 1998). 
5.2.2 CaM Protein Expression and Purification 
The expression and purification of CaM-T34C, CaM-K75C, and CaM-T110C was performed by Miss 
Valentina Taiakina (UW Co-op student).  Overnight cultures of E. coli BL21 (DE3) transformed with 
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pCaM-T34C and pCaM-T110C were used to inoculate 2 x 1 L of Luria-Bertani (LB) media in 4 L 
flasks supplemented with 30 µg/ml of kanamycin.  E. coli BL21 (DE3) pLysS transformed with 
pCaM-K75C grown to saturation overnight was used to inoculate 2 x 1 L of LB media supplemented 
100 µg/ml of ampicillin and 30 µg/ml chloramphenicol.  Cultures were grown at 37ºC, 200 rpm to an 
OD600 of 0.6 to 0.8, induced with 500 µM IPTG and harvested after 4 hours of expression.  Cells were 
harvested by centrifugation, flash frozen on dry ice, and stored at –80ºC.  Cells were thawed on ice, 
resuspended in 4 volumes of 50 mM MOPS, pH 7.5, 100 mM KCl, 1 mM EDTA, 1 mM DTT, and 
homogenized using an Avestin EmulsiFlex-C5 homogenizer (Ottawa, ON).  The CaM proteins were 
purified using phenyl-sepharose chromatography as previously described in section 2.2.3 with the 
exception that the dialysis buffer contained 1 mM DTT.  The CaM protein concentrations were 
determined using the ε277 of 3029 M-1cm-1 (Gao et al., 1998) and were subsequently frozen in aliquots 
on dry ice and stored at –80oC.  Electrospray ionization-mass spectrometry (ESI-MS) was performed 
on the purified CaM proteins using a Micromass Q-Tof Ultima GLOBAL mass spectrometer 
(Manchester, U.K.) with an internal standard (Newman et al., 2004; Spratt et al., 2006).  The CaM 
samples were analysed by ESI-MS, as previously described in section 2.2.5. 
5.2.3 CaM Protein Labeling with Acrylodan and Alexa Fluor 546 C5-maleimide 
The CaM proteins were transferred into labeling buffer (50 mM Tris-HCl, pH 7.2 containing either 1 
mM EDTA or 1 mM CaCl2) by gel filtration using a Sephadex G-25 PD-10 column (Amersham 
Biosciences) in order to remove the excess reducing agent in the CaM sample, as previously 
described (Lang et al., 2005).  Prior to labeling, the CaM proteins were tested with 5,5'-dithio-bis(2-
nitrobenzoic acid) (DTNB; Sigma, Oakville, ON) to ensure that the reactivity of the cysteine 
sulfhydryl side chains were completely reduced and sufficiently reactive for labeling with acrylodan 
and Alexa Fluor 546 C5 maleimide (Figure 5.1; Molecular Probes, Eugene, OR, USA).   
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Figure 5.1 – Chemical structures of (A) Acrylodan, (B) Alexa Fluor 546 C5 maleimide, and (C) 
Dabsyl chloride. 
Acrylodan (6-acryloyl-2-dimethylaminonapthalene) and Alexa Fluor 546 C5 maleimide were used to 
thiol specifically label CaM-Cys proteins to monitor the binding of the CaM-Cys proteins to the NOS 
peptides and holo-enzymes in this study.  Dabsyl chloride (4-dimethylaminoazobenzene-4’-sulfonyl 
chloride) was exclusively used to label the N-terminal primary amine of iNOS peptide to determine 
the orientation of CaM when bound to iNOS. 
 
Using TNB’s ε412 of 13,600 M-1cm-1, the cysteine residues were determined to be completely reactive 
in the presence of Ca2+ and EDTA.  Acrylodan and Alexa Fluor 546 C5-maleimide were dissolved in 
N,N’-dimethylformamide and 50 mM Tris, pH 7.5, respectively, to a concentration of 20 mM.  Either 
100 μL of acrylodan or Alexa Fluor 546 solution was added to 1 mL of 100 μM CaM protein (1.67 
mg/mL).  For acrylodan, the mixture was allowed to react overnight at 10oC with slow mixing, 
whereas with Alexa Fluor 546, the mixture was mixed slowly and allowed to react for 2 hours at 
room temperature.  The labeling reactions were quenched with the addition of either excess β-
mercaptoethanol or dithiothreitol.  Excess dye was removed by gel filtration using a PD-10 column 
pre-equilibrated with 50 mM HEPES, 1 mM EDTA, 150 mM NaCl, pH 7.5.  Exhaustive dialysis 
against 50 mM HEPES, 1 mM EDTA, 150 mM NaCl, pH 7.5 was performed to ensure that all non-
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covalently linked dye was removed from the labeled CaM proteins, as previously described in other 
labeling studies (Ottl et al., 1998; Waxham et al., 1998).  Labeling yields were determined from 
absorbance spectra on a Varian Cary UV–visible Spectrophotometer (Varian, Mississauga, ON).  The 
amount of covalently bound acrylodan was determined using ε391 of 20,000 M-1cm-1 (Molecular 
Probes).  Covalently linked Alexa Fluor 546 was determined with the ε554 of 93,000 M-1cm-1 
(Molecular Probes).  To determine the extent of labeling, the CaM proteins labeled with acrylodan or 
Alexa Fluor 546 were subjected to ESI-MS to ensure only sulfhydryl-specific labeling. 
5.2.4 iNOS Peptide Labeling with Dabsyl Chloride 
Two milligrams of lyophilized human iNOS CaM-binding domain peptide, RPKRR EIPLK VLVKA 
VLFAC MLMRK (residues 507-531 prepared by Sigma Genosys) was dissolved in 1 mL of dabsyl 
chloride labeling buffer consisting of 0.1 M NaHCO3, pH 7.1.  A labeling buffer with a more neutral 
pH was used to ensure selective labeling of the N-terminus of the peptide as opposed to other primary 
amines found in the peptide, such as the numerous lysine residues.  Dabsyl chloride (Figure 5.1C; 
Supelco, Bellefonte, PA, USA) was dissolved in N,N’-dimethylformamide to a concentration of 25 
mM.  100 μL of dabsyl chloride solution was added to 1 mL of iNOS peptide (2 mg/mL) and the 
mixture was allowed to react for 1.5 hours at 4oC with slow mixing.  The reaction mixture was then 
centrifuged for 5 minutes at 14,000 x g to remove particulate from the sample.  Due to the large size 
of the pellet, the pellet was solubilized in 95% (v/v) H2O, 5% (v/v) CH3CN, and 0.1% (v/v) TFA, 
incubated for 10 minutes at room temperature, and subsequently centrifuged to remove insoluble 
particles.  The presence of peptide in the resolubilized supernatant was confirmed using the DC 
Protein assay (Bio-Rad), based upon the Lowry method (Lowry et al., 1951).   
The dabsyl-labeled iNOS peptide was then purified by reverse-phase chromatography on an 
AKTApurifier System for Chromatography (Amersham Biosciences, Baie d’Urfe, PQ) using a Delta-
PakTM C18 HPLC column (2 x 150 mm, 300 Å pore size, 5 μm particle size).   The aqueous mobile 
Chapter 5: Differential Binding of CaM Domains to NOS 
158 
phase consisted of 95% (v/v) H2O, 5% (v/v) CH3CN, and 0.1% (v/v) TFA while the organic mobile 
phase containing 95% (v/v) CH3CN, 5% (v/v) H2O, and 0.1% (v/v) TFA.  After a 2 column volume 
wash of the column with the aqueous phase, a linear gradient of the organic mobile phase (1.5% / 
min) was used to elute the labeled peptide from the column.  Eluted peptide was detected at 215 and 
254 nm while dabsyl chloride was monitored at 466 nm.  Unlabeled peptide was eluted at 63% 
organic mobile phase while the labeled peptide was eluted at 72% organic mobile phase.  Isolation of 
dabsyl-labeled iNOS peptide was confirmed by ESI-MS with only a singly-labeled species observed.  
The concentration of dabsyl-iNOS peptide was determined using the ε466 of 33,000 M-1 cm-1.  
5.2.5 NOS Enzyme Expression and Purification 
Rat neuronal and bovine endothelial NOS were expressed and purified as previously described in 
sections 2.2.6 and 2.2.7.  Human iNOS carrying a deletion of the first 70 amino acids and an N-
terminal polyhistidine tail was coexpressed with CaM or nCaM mutant protein in E. coli BL21 
(DE3), as previously described in sections 2.2.8.  Each NOS enzyme was purified using ammonium 
sulfate precipitation, metal chelation chromatography, and 2’5’-ADP affinity chromatography. 
5.2.6 Enzyme Kinetics 
The initial rate of •NO synthesis was measured using the spectrophotometric oxyhemoglobin assay as 
previously described in section 2.2.10.1.3.  Assays were performed at 25oC in a SpectraMax 384 Plus 
96 well UV-visible spectrophotometer using Soft Max Pro software (Molecular Devices, Sunnyvale, 
CA).  eNOS, nNOS and iNOS coexpressed with CaM or nCaM were assayed at concentrations of 70, 
30 and 28.5 nM, respectively in 100 µl total well volumes.  200 µM CaCl2 or 250 µM EDTA as well 
as 2 µM wild-type CaM, mutant CaM protein, and labeled CaM proteins were added to the 
appropriate samples. 
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5.2.7 Steady-State Fluorescence 
Fluorescence emission spectra were obtained using a PTI QuantaMaster spectrofluorimeter (London, 
ON).  100 nM of CaM-T34C-acr, CaM-K75C-acr, or CaM-T110C-acr were used as the fluorescent 
reporter in the quartz cuvette, similar to a previous study involving calcineurin (Quintana et al., 
2005).  The excitation wavelength for all of the acrylodan labeled CaMs was set at 375 nm.  Slit 
widths were set at 2 nm for excitation and 2 nm for emission.  In a volume of 1 mL, an initial scan 
was taken with each CaM-Cys-acr protein in a buffer consisting of 50 mM HEPES, 1 mM EDTA, 
150 mM NaCl, pH 7.5.  After the first scan, synthetic NOS CaM-binding domain peptide (500 nM) 
was added to the cuvette, the sample was mixed thoroughly, incubated for three minutes to allow the 
sample to reach equilibrium, and scanned.  The calculated free [Ca2+] in this system is <1 nM based 
on calculations using the online algorithm WEBMAXC (Patton et al., 2004).  The NOS CaM-binding 
domain peptides for human iNOS, RPKRR EIPLK VLVKA VLFAC MLMRK (residues 507-531) 
was prepared by Sigma Genosys, while bovine eNOS, TRKKT FKEVA NAVKI SASLM (residues 
493-512) and rat nNOS, KRRAI GFKKL AEAVK FSAKL MGQ (residues 725-747) were 
synthesized by SynPeP (SynPeP Corporation, Dublin, CA USA).  The sample was then brought to a 
final free Ca2+ concentration calculated to be 0.500 mM, mixed, allowed to incubate for three 
minutes, and scanned.  Finally, excess EDTA (5 mM final) was added (calculated free [Ca2+] of 5.8 
nM), incubated for three minutes, and a final scan was taken.  
 Steady-state fluorescence measurements of CaM-Cys-Alexa Fluor 546 proteins (50 nM) 
binding to holo-NOS proteins (250 nM) were performed as previously described (see above) with the 
exception that the excitation wavelength was set at 540 nm with emission monitored between 550 and 
700 nm.  Fluorescence emission maximum of Alexa labeled CaM was observed at 567 nm, regardless 
of Ca2+ or EDTA presence in the buffer. 
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5.2.8 Determination of Binding Affinities of CaM-Cys-acr proteins to NOS CaM-
binding Domain Peptides 
In a starting volume of 1 mL containing CaM-Cys-acr proteins at various concentrations (50, 75, 100, 
125, and 150 nM) in a buffer of 50 mM HEPES, 1 mM CaCl2, 150 mM NaCl, pH 7.5, scans were 
taken between increasing molar ratios of peptide to CaM protein (0, 0.25, 0.5, 0.75, 1, 1.5, 2, and 4).  
The sample was mixed, incubated for three minutes to reach equilibrium, and scanned between each 
successive peptide addition.  In order to determine the KCaM values for each acrylodan labeled CaM 
protein when binding to the CaM-binding domain peptides of each NOS isoform, we used a method 
similar to that previously developed and employed by Dr. Basil Perdicakis (PhD 2003, U of 
Waterloo) and Dr. Heather Montgomery (PhD 2004, U of Waterloo), former graduate students in our 
laboratory  (Montgomery et al., 2003), with the exception that steady-state fluorescence was used 
instead of spectrophotometric kinetic analysis.  Using the assumption that there is a rapid 
establishment of equilibrium among all species in the sample, the NOS peptide concentration that 
results in half-maximal fluorescence of the CaM-NOS peptide complex with depletion of free 
acrylodan-labeled CaM due to binding with NOS peptide can be described by the following formula 
(Equation 5.1): 
 
Equation 5.1              AC50 = 0.5CaMo + KCaM 
 
where AC50 is the NOS peptide concentration that results in half-maximal fluorescence signal at a 
given CaM concentration (nanomolar), CaMo is the total CaM concentration in the sample 
(nanomolar), and KCaM is the binding constant in nM, which is determined using the following 
formula (Equation 5.2): 
 
Equation 5.2        KCaM = [NOS peptide][CaM] 
                [NOS peptide • CaM] 
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The estimated KCaM for the CaM-Cys-acr proteins binding to the NOS peptides was calculated from 
the ordinal intercept of the plot of AC50 versus NOS peptide concentration, as previously described 
(Montgomery et al., 2003). 
5.2.9 FRET Measurements of Alexa-labeled CaM Proteins with Dabsyl-labeled 
iNOS Peptide 
FRET measurements between dabsyl-labeled iNOS peptide and CaM-T34C-Alexa and CaM-T110C-
Alexa were determined in a buffer consisting of 50 mM HEPES, 1 mM CaCl2, 150 mM NaCl, pH 7.5.  
Using the identical fluorimeter setup as described for steady-state measurements with Alexa-labeled 
CaMs (see section 5.2.7), an initial scan of 50 nM CaM-T34C-Alexa or CaM-T110C-Alexa alone in a 
volume of 1 mL was taken.  This was followed by the addition of dabsyl-iNOS peptide, the sample 
was mixed well and incubated for 3 minutes, and a subsequent measurement was taken. 
5.2.10 Circular Dichroism of nCaM and cCaM bound to synthetic NOS peptides 
CD was performed in a Jasco J-715 CD spectropolarimeter using J-715 analysis software as 
previously described (section 4.2.7) with some modifications.  Samples were measured in a 1 mm 
quartz cuvette (Hellma, Concord, ON) kept at 25°C using a Peltier type constant-temperature cell 
holder.  Samples consisted of 25 µM nCaM or cCaM alone or equimolar concentrations of CaM 
protein with synthetic iNOS CaM-binding domain peptide.  Samples were mixed in 10 mM Tris-HCl 
buffer (pH 7.5) containing 150 mM NaCl and 200 µM CaCl2, followed by 1 mM EDTA.  Spectra 
were recorded over a 190-250 nm range with a 1.0 nm band width, 0.2 nm resolution, 100 mdeg 
sensitivity at a 0.125 s response and a rate of 100 nm/min with a total of 25 accumulations.  Data is 
expressed as the mean residue ellipticity (θ) in degree cm2 dmol–1. 
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5.3 Results 
5.3.1 Protein Expression and Purification 
The CaM constructs used in this study have previously been employed in FRET and fluorescence 
binding studies with CaM target proteins due to their optimal positions in the N- and C-terminal 
domains (Drum et al., 2000; Allen et al., 2004), as well as the central linker of CaM (Waxham et al., 
1998; Quintana et al., 2005) with all three CaM mutants showing no significant effect on enzyme 
activity.  Figure 1 shows the positions of the mutant residues in the reported protein structures of 
holo-CaM (PDB 1CLL; (Chattopadhyaya et al., 1992), apo-CaM (PDB 1CFD; (Kuboniwa et al., 
1995), and CaM in complex with eNOS peptide (PDB 1NIW; (Aoyagi et al., 2003).  
 
 
Figure 5.2 – X-ray and NMR structures showing the positions of T34, K75 and T110 in A) Holo-
CaM, B) Apo-CaM, and C) CaM when bound to eNOS peptide. 
CaM, eNOS peptide, and Ca2+ ions are shown in red, blue, and black, respectively.  T34, K75, and 
T110 are shown in yellow, purple, and pink, respectively.  Models are derived from PDB 1CLL 
(Chattopadhyaya et al., 1992), 1CFD (Kuboniwa et al., 1995), and 1NIW (Aoyagi et al., 2003). 
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When comparing the three structures in Figure 5.2, these residues exhibit varying solvent exposure 
depending upon the target protein CaM binds to, making these sites optimal for fluorescence binding 
studies with fluorophores that are highly sensitive to their environment, such as acrylodan (Figure 
5.1). 
The cysteine CaM proteins were successfully overexpressed in E. coli.  After purification, we 
obtained 37.7, 31.0, and 39.3 mg protein/L media of CaM-T34C, CaM-K75C, and CaM-T110C, 
respectively.  ESI-MS QTOF confirmed homogeneity and ruled out any posttranslational 
modification (Table 5.1). 
Table 5.1 – Masses of CaM and fluorescently labeled CaM-Cys proteins 
      
 Mass (Da) a 
     
     
CaM proteins  Observed Theoretical b 
      
   
wtCaM 16706.0 16706 
CaM T34C 16709.0 16708 
CaM K75C 16680.5 16681 
CaM T110C 16709.0 16708 
CaM T34C-acr (EDTA) 16932.5 d 16934 d 
CaM T34C-Alexa Fluor 546 (EDTA) 17717.5 e 17720 e 
CaM K75C-acr (EDTA) 16905.5 16907 
CaM K75C-Alexa Fluor 546 (EDTA) 17690.5 17693 
CaM T110C-acr (EDTA) 16932.5 16934 
CaM T110C-Alexa Fluor 546 (Ca2+) 17717.5 17720 
      
a Masses of deconvoluted ESI-MS spectra were determined with an accuracy of ± 3 Da. 
b Calculated masses pre- and post-labeling with acrylodan. 
c Condition used to label CaM-Cys protein for 100% single labeling (see section 5.2.3)  
d Expected mass difference after labeling CaM-Cys proteins with acrylodan is 225.3 Da (Molecular Probes). 
e Expected mass difference after labeling CaM-Cys proteins with Alexa Fluor 546 C5 maleimide is 1011.4  Da (Molecular 
Probes).  The manufacturer’s MW of the dye is 1034.3, which includes a single counter sodium ion. 
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5.3.2 Characterization of Fluorescently Labeled CaM-Cys Proteins 
The CaM-Cys proteins were tested with DTNB to ensure that the cysteine sulfhydryl side chains were 
completely reduced and sufficiently reactive for labeling with acrylodan.  All of the sulfhydryls in the 
CaM-Cys proteins were determined to be 100% reactive in the presence of Ca2+ and EDTA.  This 
result was confirmed using ESI-MS (Table 5.1). 
 Previous fluorescent labeling of CaM in our laboratory showed that the cysteine residue in a 
T110C-CaM mutant exhibited less reactivity in the presence of EDTA (~10%), however, this cysteine 
residue was 100% reactive in the presence of Ca2+ (Lang et al., 2005).  This result indicates that Ca2+-
binding dictates the solvent exposure of this residue in the C-terminal domain of CaM.   In order to 
determine if the presence of Ca2+ would affect the labeling yield of the CaM-Cys mutants that were 
used in this study, parallel labeling reactions were performed in the presence of 1 mM CaCl2 and 1 
mM EDTA.  In the reactions containing 1 mM EDTA, only a single-labeled species was obtained 
with little or no unlabeled CaM-Cys protein observed.  Conversely, in the reactions containing 1 mM 
CaCl2, the majority of the CaM species were singly-labeled with a marked amount of double-labeled 
CaM (results not shown).  This non-specific double labeling of CaM result has also been previously 
observed using proteins with single selenomethionine residues (Lang et al., 2006).  The possible 
second labeling of CaM has been previously postulated to be the result of non-specific interactions 
between the dye and the protein (Allen et al., 2004), or possibly due to the exposure of another 
residue that may display some reactivity towards acrylodan.  We exclusively used CaM-Cys-acr 
labeled in the presence of EDTA because the labeling reactions in the presence of Ca2+ showed some 
undesired double-labeling.  Since only single-labeled species were observed by ESI-MS (Table 5.1), 
the concentrations of CaM-T34C-acr, CaM-K75C-acr, and CaM-T110C-acr were determined 
spectrophotometrically using the ε391 of 20,000 M-1cm-1 (Molecular Probes). 
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Knowing that CaM-T34C and CaM-K75C showed specific labeling in the presence of EDTA 
with acrylodan, the same labeling conditions were used when labeling these CaM-Cys mutants with 
Alexa Fluor 546 C5-maleimide.  Inefficient labeling was previously observed with CaM-T110C in the 
presence of EDTA, whereas 100% labeling was obtained in the presence of Ca2+ when labeling with 
another maleimide dye, N-[4-(dimethylamino)-3,5-dinitrophenyl]-maleimide (DDPM) (Lang et al., 
2005).  Therefore, CaM-T110C was labeled with Alexa Fluor 546 in the presence of Ca2+.  Complete 
and specific labeling was obtained with all of the CaM-Cys proteins and no apparent secondary 
labeling was confirmed by ESI-MS (Table 5.1).  The concentrations of CaM-T34C-Alexa, CaM-
K75C-Alexa and CaM-T110C-Alexa were determined using the ε554 of 93,000 M-1cm-1 (Molecular 
Probes). 
Acrylodan fluorescence was measured exclusively in the presence of the NOS CaM-binding 
domain peptides.  Alexa Fluor 546 C5-maleimide (Figure 5.1B; Molecular Probes) was used during 
FRET binding studies using the N-terminally dabsyl-labeled iNOS peptide as well as steady-state 
fluorescence binding studies with the holo-NOS enzymes due to its far red-shifted excitation and 
emission spectra.  This dye is advantageous due to its ability to be specifically excited in the presence 
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5.3.3 NOS Activation by CaM-Cys and Fluorescently-Labeled CaM Proteins 
The oxyhemoglobin capture assay was employed to determine if the CaM-Cys and the fluorescently 
labeled CaM-Cys proteins were capable of binding and activating the holo-NOS enzymes.  The eNOS 
and nNOS enzymes all exhibited approximately 100% activity in the presence of CaM-T34C, CaM-
K75C, and CaM-T110C when compared to wild-type CaM (Table 5.2).  
Table 5.2 – CaM-Cys and fluorescently labeled CaM Dependent Activation of cNOS enzymes a 
CaM protein Neuronal NOS Endothelial NOS 
  % % 
   
CaM 100 ± 6 100 ± 1 
CaM-T34C 114 ± 7 106 ± 5 
CaM-T34C-acrylodan 238 ± 6b 87 ± 1 
CaM-T34C-Alexa Fluor 546 156 ± 7c 104 ± 5 
CaM-K75C 113 ± 3 116 ± 2 
CaM-K75C-acrylodan 260 ± 7b 102 ± 2 
CaM-K75C-Alexa Fluor 546 64 ± 4c 97 ± 5 
CaM-T110C 89 ± 6 97 ± 2 
CaM-T110C-acrylodan 157 ± 9b  116 ± 1 
CaM-T110C-Alexa Fluor 546 185 ± 6c 93 ± 6 
CaM (EDTA) NAAd NAA 
      
a The oxyhemoglobin capture assay used to measure the rate of CaM-activated •NO production was performed in the 
presence of either 2 µΜ wild-type or mutant CaM protein and either 200 µM CaCl2 or 250 µM EDTA, as indicated.  The 
activities obtained with the respective enzyme bound to wild-type CaM at 25oC in the presence of 200 µM CaCl2 were all 
set to 100%.  The activities for nNOS and eNOS bound to CaM were 35.4 and 9.5 min-1, respectively. 
b Each assay that contained acrylodan labeled-CaM showed markedly greater activity than the equivalent CaM-Cys protein 
not labeled with acrylodan.  
c Alexa-CaMs showed increased activity when the N- and C-domains were labeled, but displayed decreased activity when 
the central linker was labeled. 
d NAA – No apparent activity 
 
The activation of eNOS by the acrylodan and Alexa Fluor 546 labeled CaM proteins was the same as 
observed for the unlabeled CaM-Cys proteins (Table 5.2)   In contrast, when nNOS was assayed in 
the presence of the acrylodan-labeled CaM proteins, the •NO production rates were enhanced from 
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160 (for CaM-T110C-acr) up to 260% (for CaM-T34C-acr) of the rate obtained for wild-type CaM.  
This observation may be due to acrylodan’s highly hydrophobic properties causing a non-specific 
hydrophobic interaction between the CaM-Cys-acr proteins and nNOS.  Similarly, when nNOS was 
assayed with CaM-T34C-Alexa and CaM-T110C-Alexa, •NO synthesis rates were also enhanced.  
The nNOS activity in the presence of CaM-K75C-Alexa was decreased to approximately 60%, which 
may be due to the large Alexa dye disrupting the CaM central linker interaction with nNOS.  It is 
noteworthy that all of the CaM-Cys and labeled CaM-Cys proteins required the presence of Ca2+ to 
activate the cNOS enzymes.  Clearly, all of the fluorescently labeled CaM-Cys mutants are able to 
bind and activate the cNOS enzymes, with nNOS showing marked increases in •NO production rates. 
In order to monitor if the labeled and unlabeled CaM-Cys proteins were capable of activating 
iNOS, we used iNOS coexpressed with nCaM (CaM residues 1-75).  In our previous study, we 
showed that iNOS coexpressed with nCaM displayed no apparent activity in the presence of EDTA; 
however, with the addition of 2 µM wild-type CaM with EDTA present, activity was maintained 
(Spratt et al., 2006).  This result indicated that a Ca2+-dependent reorganization of the bound 
truncated nCaM mutant could facilitate its displacement and allow for the binding and activation of 
iNOS when excess native CaM is added.  Significant levels of •NO synthesis were observed when 
excess CaM-Cys and CaM-Cys-acr mutants were added to iNOS coexpressed with nCaM in the 
presence of EDTA (Table 5.3).   
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Table 5.3 – CaM-Cys and fluorescently labeled CaM Activation of iNOS a 
CaM protein CaM protein 
Inducible 
NOS 
  added % 
   
iNOSwtCaM (Ca2+) No 100 ± 2 
iNOSnCaM (Ca2+)  No 64 ± 2 
iNOSnCaM (EDTA) No NAA b 
" CaM 61 ± 4 
" CaM-T34C 60 ± 5 
" CaM-T34C-acrylodan 63 ± 6 
" CaM-T34C-Alexa Fluor 546 21 ± 1 
" CaM-K75C 54 ± 2 
" CaM-K75C-acrylodan 56 ± 2 
" CaM-K75C-Alexa Fluor 546 26 ± 1 
" CaM-T110C 56 ± 4 
" CaM-T110C-acrylodan 85 ± 3 
" CaM-T110C-Alexa Fluor 546 21 ± 2 
      
a •NO synthesis rates were measured as described in Table 1 with 2 µM exogenous CaM protein added only to the assays 
indicated.   Each assay was performed in the presence of either 200 µM CaCl2 or 250 µM EDTA as shown.  The activity 
obtained for iNOS coexpressed with CaM and assayed in the presence of 200 µM CaCl2 at 25oC was 50.5 min-1 and was set 
to 100%.  
b NAA – No apparent activity 
 
All of the mutant CaM proteins displayed identical activation profiles to that of iNOS 
coexpressed with nCaM with excess wild-type CaM (~60% maximal activation).  The only exception 
was CaM-T110C-acr, which activated the enzyme to 85% maximal activity when compared to iNOS 
coexpressed with wild-type CaM (Table 5.3).  This marked difference between CaM-T110C and its 
acrylodan-labeled equivalent may be due to a stronger hydrophobic interaction with iNOS, similar to 
the results previously observed with nNOS (Table 5.2).  The Alexa Fluor 546-labeled CaM proteins 
showed low activation of iNOS (~20%), likely due to steric hindrance by the fluorophore (Table 5.3).  
Clearly, all of the acrylodan- and Alexa-labeled CaM proteins are capable of activating, and hence, 
binding to the iNOS enzyme in the absence of Ca2+.  The fact that the fluorescently labeled CaM 
proteins bind and activate the NOS isozymes indicates that the fluorescent binding studies we present 
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in this study are relevant in describing CaM’s association with the various NOS CaM-binding 
domains. 
5.3.4 CaM-NOS Peptide Binding Studies 
5.3.4.1 FRET studies using Alexa-labeled CaM proteins with Dabsyl-labeled iNOS 
peptide 
It has previously been shown that CaM binds to the CaM-binding domain of eNOS in an anti-parallel 
fashion, where the N-terminal domain of CaM binds closer to the C-terminus of the target peptide, 
classified as the N-type binding site, while the C-terminal domain of CaM binds closer to the N-
terminus, corresponding to the C-type binding site (Aoyagi et al., 2003).  It has also previously been 
determined that CaM binds to nNOS in an anti-parallel orientation through NMR (Zhang et al., 
1995).  Although it has previously been proposed that CaM binds to iNOS in a parallel orientation 
based upon kinetic data (Gribovskaja et al., 2005), this model has yet to be proven.  In order to 
determine the orientation of CaM when bound to the CaM-binding domain of iNOS we employed 
FRET to determine relative distances between the N- and C-domains from the N-terminus of an iNOS 
target peptide.  CaM-T34C and CaM-T110C labeled with Alexa Fluor 546 was used as the FRET 
donor while a synthetic iNOS peptide N-terminally labeled with dabsyl chloride, which is a potent 
quencher, was used as the FRET acceptor.  In essence, the greater the amount of quenching observed 
represents the Alexa-labeled site on CaM being closer to the N-terminus of the iNOS peptide.  Should 
CaM-T34C-Alexa be quenched to a greater extent than CaM-T110C-Alexa, this would indicate that 
CaM binds in a parallel manner, however, if the reverse result is observed, this would indicate that 
CaM binds to iNOS in an anti-parallel fashion.   
Our results shown in Figure 5.3 indicate that the fluorescence signal of CaM-T110C-Alexa is 
quenched to a greater extent than CaM-T34C-Alexa in the presence of dabsyl-iNOS peptide 
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signifying that when CaM is bound to the iNOS peptide, the C-domain of CaM is closer to the N-
terminus of the peptide than the N-domain of CaM.   
 
Figure 5.3 – FRET analysis of (A) CaM-T34C-Alexa and (B) CaM-T110C-Alexa binding to 
iNOS peptide N-terminally labeled with dabsyl chloride. 
Alexa-labeled CaMs alone in the presence of Ca2+ and in the presence of dabsyl-iNOS peptide are 
shown as (▬) and (▬), respectively.  The fluorescence signal of CaM-T110C-Alexa is quenched to a 
greater extent than CaM-T34C-Alexa in the presence of dabsyl-iNOS peptide signifying that when 
CaM is bound to the iNOS peptide, the C-domain of CaM is closer to the N-terminus of the peptide 
than the N-domain of CaM.  This result suggests that CaM binds to the iNOS CaM-binding domain in 
an anti-parallel orientation, similar to that already determined for the cNOS enzymes. 
 
These results demonstrate that CaM does in fact bind to the iNOS CaM-binding domain in an anti-
parallel orientation, similar to that previously determined for the cNOS enzymes (Zhang et al., 1995; 
Aoyagi et al., 2003).  These FRET results we observed correlate well with the distances between T34 
and T110 with the N-terminus of the peptide in the CaM-eNOS structure.  This FRET donor-acceptor 
pair of Alexa Fluor 546 and dabsyl chloride has a theoretical Förster distance value (RO) of 29 Å 
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(Molecular Probes), which is optimal for measurements within this CaM-NOS peptide complex, 
based upon the solved CaM-eNOS structure (Figure 5.2C).  The distance between the hydroxyl 
moiety of T34 in CaM to the N-terminus of the eNOS peptide is 26.3 Å, while the distance between 
the hydroxyl of T110 to the N-terminus of the eNOS peptide is 19.2 Å.  The fluorescence intensity of 
CaM-T34C-Alexa is approximately 50% when compared to its initial intensity without the dabsyl-
iNOS peptide present representing that the fluorescence measurement is approximately equal to the 
R0 value of 29 Å.   This value is comparable to the measured distance between T34C and the N-
terminus of the peptide in the CaM-eNOS structure further supporting our finding that CaM binds to 
iNOS in an anti-parallel fashion.   
5.3.4.2 Ca2+-Dependent Association of Different Regions of CaM to NOS peptides 
The binding of acrylodan-labeled CaM proteins to synthetic NOS CaM-binding domain peptides was 
observed using steady-state fluorescence.  The addition of Ca2+ to the acrylodan-labeled CaM proteins 
alone all demonstrated marked changes in fluorescence intensity (Figure 5.4).  Emission maxima 
showed marked blue-shifts in the presence of Ca2+ for CaM-T34C-acr and CaM-K75C-acr.  CaM-
T34C-acr showed fluorescence peaks that shifted from 512 nm (EDTA) to 476 nm (Ca2+).  The 
fluorescence maxima for CaM-K75C-acr were 496 and 484 nm in the presence of EDTA and Ca2+, 
respectively, and were identical to values previously reported (Waxham et al., 1998; Quintana et al., 
2005).  In contrast, the emission peak for CaM-T110C-acr at 474 nm in the presence of EDTA moved 
to 484 nm when Ca2+ was added, indicating that acrylodan becomes more solvent exposed when this 
CaM protein is Ca2+-replete. 
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Figure 5.4 – Steady-state Fluorescence of CaM-Cys-acr proteins binding to synthetic NOS CaM 
binding domain peptides. 
(A) In an initial volume of 1 mL, either CaM-T34C-acr, CaM-K75C-acr, and CaM-T110C-acr (100 
nM final) was added to 50 mM HEPES, 150 mM NaCl, 1 mM EDTA, pH 7.5 and emission of each 
sample was observed between 400 and 600 nm ( ).  Excitation wavelength was set to 375 nm and 
the excitation and emission slit widths were set at 2 nm.  Synthetic NOS peptide (500 nM) was added, 
mixed thoroughly, and another scan was taken ( ).  1.5 mM CaCl2 (0.5 mM final) was then added 
and another scan was obtained ( ).   In all cases, the addition of Ca2+ to the cuvette showed 
changes in fluorescence emission signal and maxima.  Lastly, EDTA was added to a final 
concentration of 5 mM and an additional scan was taken ( ).   In between each addition, the 
sample was allowed to incubate for 3 minutes to reach equilibrium.  (B) Conditions used were 
identical as in (A) with the exception that CaCl2 (0.5 mM) was added to the cuvette before the 
addition of any iNOS peptide.  The order of addition to the cuvette was as follows: (1) 100 nM CaM-
Cys-acr in 1 mM EDTA ( ), (2) CaCl2 (0.5 mM final, ), (3) 500 nM iNOS peptide ( ), 
and finally (4) EDTA (5 mM final, ).  Samples were incubated for three minutes between each 
measurement.  These measurements were taken to ensure that the fluorescence spectra obtained in (A) 
for iNOS with each of the CaM-Cys-acr mutants were reproducible regardless of the order of Ca2+ or 
NOS peptide addition. 
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The addition of the eNOS and nNOS peptides caused little or no change in fluorescence 
emission of the CaM-T110C-acr protein in the presence of EDTA, signifying minimal or no 
interaction between the acrylodan labeled CaMs and the cNOS peptides.  In contrast, there was ~20% 
quenching when the iNOS peptide was added, indicative of an association between the peptide and 
CaM-T110C-acr (Figure 5.4A).  The addition of Ca2+ resulted in a marked red-shift and a 
fluorescence intensity decrease of CaM-T110C-acr in the presence of all three NOS peptides, 
indicating that the fluorophore becomes more solvent exposed upon CaM binding to the NOS 
peptides (Figure 5.4A).  These large Ca2+-dependent changes in acrylodan fluorescence with Ca2+ 
added are indicative of CaM binding to the cNOS peptides, while it represents a large Ca2+-dependent 
conformational change in the C-domain of CaM when bound to the iNOS peptide.  Finally, after the 
addition of excess EDTA, the acrylodan fluorescence signals closely returned to their original peaks 
prior to Ca2+ addition, signifying the release of the cNOS peptides from the acrylodan-labeled CaM 
proteins (Figure 5.4A).  These results are consistent with the interaction of CaM with eNOS and 
nNOS being Ca2+-dependent.  While these results demonstrate that the C-domain of CaM does 
interact with the iNOS CaM-binding domain in a Ca2+-independent manner, it is notable that this 
domain also experiences a large Ca2+-dependent conformational change when it is associated with 
iNOS. 
 CaM-T34C-acr showed no change in fluorescence in the presence of EDTA indicating no 
apparent interaction with the eNOS and nNOS peptides (Figure 5.4A).  A marked blue-shift in 
fluorescence emission was observed with the addition of Ca2+, signifying that CaM-T34C-acr is 
associating with the cNOS peptides; however, the subsequent addition of EDTA caused the 
fluorescence signal to return to its original intensity, representing the release of CaM-T34C-acr from 
the cNOS peptides (Figure 5.4A).  These observations further demonstrate that the association of the 
N-domain of CaM is Ca2+-dependent when binding to the eNOS and nNOS peptides.  In contrast, 
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CaM-T34C-acr showed a blue-shift upon addition of the iNOS peptide in the presence of EDTA 
(Figure 5.4A) indicating Ca2+-independent binding.  The subsequent addition of Ca2+ to the CaM-
T34C-acr protein showed a slight red-shift in emission, while the final addition of excess EDTA 
showed small changes in fluorescence intensity, but the spectra never returned to its original peak 
prior to the addition of iNOS peptide or Ca2+ (Figure 5.4A).  These changes in fluorescence are 
indicative of small structural rearrangements in the N-domain of CaM when associated with the iNOS 
peptide depending on the Ca2+ concentration rather than the release of the peptide.  This is further 
exemplified as shown in Figure 5.4B where Ca2+ addition to CaM-T34C-acr alone, results in a 5 fold 
increase in fluorescence with a large blue-shift, indicative of the fluorophore moving to a more 
hydrophobic environment in a Ca2+-dependent manner.  With the subsequent addition of the iNOS 
peptide, fluorescence is markedly attenuated, which could only result from CaM-T34C-acr’s 
association to the iNOS peptide (Figure 5.4B).  Furthermore, the fluorescence spectra after the 
addition of the iNOS peptide were identical for all of the acrylodan-labeled CaMs binding to the 
iNOS peptide in the presence of Ca2+ (Figure 5.4B) as was observed in Figure 5.4A, where the 
peptide was added to the cuvette before Ca2+.  Taken together, the fluorescence spectra obtained for 
acrylodan-labeled CaM in the presence of iNOS is reproducible regardless of the order of addition of 
either Ca2+ or the iNOS peptide (Figure 5.4).  CaM binding to the iNOS peptide in the absence of 
Ca2+ was observable with CaM-T34C-acr, which is indicative that the Ca2+-independent association 
previously observed with peptides derived from the CaM-binding domain of iNOS (Anagli et al., 
1995; Zoche et al., 1996; Matsubara et al., 1997; Yuan et al., 1998) may be predominantly due to the 
binding of the Ca2+-depleted N-terminal lobe of CaM. 
Fluorescence measurements of CaM’s central linker with CaM-K75C-acr showed Ca2+-
dependence when binding to the cNOS peptides (Figure 5.4A).  This can be related to its position in 
the central linker of CaM between the two CaM domains that demonstrated a Ca2+-dependent 
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association to the eNOS and nNOS peptides (Figure 5.4A).  In contrast, CaM-K75C-acr showed 
moderate Ca2+-dependent changes in fluorescence likely due to some structural rearrangement in the 
presence of the iNOS peptide and EDTA (Figure 5.4).  These fluorescent changes are most likely due 
to the C-terminal Ca2+-dependent conformational changes when associated with the iNOS peptide.  In 
summary, these steady-state fluorescence studies indicate that the N- and C-terminal domains of CaM 
bind to the iNOS peptide in a Ca2+-independent manner.  The N-domain of CaM demonstrated a 
lower susceptibility to Ca2+ concentrations as shown by minimal changes in its conformation, while 
the C-terminal domain of CaM shows evidence of a Ca2+-dependent rearrangement when associated 
with the iNOS peptide. 
Our steady-state results for acrylodan-labeled CaM proteins binding to cNOS CaM-binding 
domain peptides are in agreement with the degree of solvent exposure of these residues in the holo- 
and apo-CaM structures represented in Figure 5.2.  For T34, the residue is highly solvent exposed in 
the apo-CaM structure, almost completely exposed in holo-CaM but more protected from solvent in 
the CaM-eNOS structure.  K75 is relatively solvent exposed in the apo- and holo-CaM structures, 
whereas, when CaM is bound to eNOS, this residue is more buried.  Finally, T110 is relatively buried 
in the apo- and holo-CaM structures; conversely, T110 is more solvent exposed in the CaM-eNOS 
crystal structure. 
5.3.4.3  Binding Affinities of CaM-Cys-acr proteins to NOS CaM-binding Domain 
Peptides 
The large change in fluorescence intensity upon peptide binding to Ca2+-replete acrylodan-
labeled CaM proteins provided a means of determining their binding affinities to each of the NOS 
CaM-binding domain peptides.  Scans were taken between increasing molar ratios of NOS peptide to 
CaM and repeated for various concentrations for each of CaM-Cys protein labeled with acrylodan.  
Figure 5.2 shows an example of a titration for CaM-T110C-acr binding to the eNOS peptide.  The 
binding affinities determined for each CaM-Cys-acr protein are shown in Table 5.4. 
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Figure 5.5 – Determination of KCaM binding constant for CaM-T110C-acr binding to the eNOS 
CaM-binding domain peptide using steady-state fluorescence. 
(A) AC50 curves of eNOS peptide at CaM-T110C-acr concentrations of 50 nM ( , 36 nM), 75 nM (●, 
47 nM), 100 nM (▲, 54 nM), 125 nM (■, 58 nM), and 150 nM ( , 70 nM) were determined.  The 
determined AC50 values for each curve are shown in parentheses.  (B) AC50 versus CaM-T110C-acr 
concentration.  The activation constant for CaM binding to nNOS was calculated from the ordinal 
intercept of panel B as determined by linear regression of the data (R2 = 0.98) and was equal to 21 ± 5 
nM, as previously described (Montgomery et al., 2003). All measurements were taken in the presence 
of 1 mM CaCl2 essentially as described in section 5.2.9 with the exception that incremental increases 
of NOS peptide were added to saturating concentrations (Molar ratios of 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 
and 4).  Error bars in panel B denote the 95% confidence interval for each point and is representative 
of collected fluorescence data. 
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Table 5.4 – Calculated KCaM affinity constants for acrylodan labeled-CaMs binding to NOS 
peptides  
    
  Affinity (KCaM)a  
    
CaM proteins nNOS peptide eNOS peptide iNOS peptide 
 (nM) (nM) (nM) 
    
T34C-acr 4 ± 1 16 ± 4 18 ± 4 
K75C-acr 7 ± 2 32 ± 7 4 ± 1 
T110C-acr 6 ± 1 21 ± 5 5 ± 1 
        
a KCaM values were calculated from the ordinal intercept of AC50 versus enzyme concentration as determined by 
linear regression (Figure 5.5B).  The number of data points used in the linear regression for each CaM mutant 
ranged from four to five.  R2 values were ≥ 0.96.  The ± symbol denotes the standard error of the regressed KCaM 
value. 
 
The affinities of the CaM-Cys-acr proteins for the nNOS peptide are equivalent to previously 
reported binding studies using the nNOS enzyme and peptide (Vorherr et al., 1993; Zoche et al., 
1996; Montgomery et al., 2003).  Although the previous reported values were determined using 
various methods such as kinetic assays, surface plasmon resonance and steady-state fluorescence, our 
KCaM values are virtually identical.  Similarly, the binding affinities obtained for each of the CaM-
Cys-acr proteins for the eNOS peptide are comparable to previously reported KCaM values of wild-
type CaM for the eNOS enzyme and peptide (Venema et al., 1996; Matsubara et al., 1997; 
Montgomery et al., 2003).  Although our KCaM values are slightly higher than previously reported 
binding constants, this observation can be accounted for by the addition of a covalently linked non-
polar fluorophore which may affect CaM’s physicochemical properties slightly when associating with 
the peptide.  However, it is important to note that each of the CaM-Cys-acr proteins are capable of 
fully activating the eNOS enzyme (Table 5.2) demonstrating that there are no adverse effects to these 
fluorescent CaM proteins’ ability to bind and activate the eNOS isoform.   
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There have been many varying values reported for CaM’s affinity for the iNOS CaM-binding 
domain peptide; however, all of the KCaM values were in the lower nanomolar concentrations, ranging 
from <0.1 nM to 4 nM (Anagli et al., 1995; Zoche et al., 1996; Matsubara et al., 1997; Yuan et al., 
1998).  The affinity constants we determined for the mutant CaM-Cys proteins acrylodan-labeled in 
the central linker (CaM-K75C-acr) and C-terminal domain (CaM-T110C-acr) are in a similar 
concentration range as reported in the literature.  In contrast, the N-terminal domain mutant of CaM 
(CaM-T34C-acr) showed a lower affinity than the other regions of CaM (Table 5.4).  This 
observation may be related to the disruption of the stronger interactions between the N-domain of 
CaM and the N-type site of the iNOS CaM-binding domain, which is discussed in greater detail in the 
discussion section (section 5.4).     
5.3.4.4 Effect of nCaM and cCaM on the Secondary Structure of the iNOS peptide 
Using circular dichroism (CD), the interaction between the N- and C-lobes of CaM and the iNOS 
CaM-binding domain was further investigated.  Two previous studies have shown that 
spectropolarimetry can be used to monitor the secondary structure of peptides that are bound to CaM 
(Matsubara et al., 1997; Yuan et al., 1998).  In order to obtain a CD spectrum for nCaM and cCaM 
when bound to the iNOS peptide, measurements were taken at 25 µM concentration (Figure 5.6).  
Chapter 5: Differential Binding of CaM Domains to NOS 
 179 
 
Figure 5.6 – Effect of Ca2+ and EDTA on the secondary structure of (A) nCaM and (B) cCaM 
bound to synthetic iNOS CaM-binding domain peptide. 
Spectropolarimetry was performed on 25 µM nCaM (CaM residues 1-75) or cCaM (CaM residues 76-
148) with and without 25 µM iNOS peptide.  nCaM and cCaM proteins alone in the presence of 200 
µM CaCl2 or 1 mM EDTA are shown as ( ) and ( ).  nCaM or cCaM with iNOS peptide 
in the presence of  200 µM CaCl2 or 1 mM EDTA are shown as ( ) and ( ).  The inset 
figure shows the difference CD spectrum of the CaM proteins with iNOS peptide minus the CaM 
proteins alone in the presence of 200 µM Ca2+ ( ) and 1 mM EDTA ( ) as well as iNOS 
peptide alone ( ) for comparison purposes.  The difference CD spectra show that the iNOS 
peptide retains partial α-helical structure when bound to both nCaM and cCaM in the absence of Ca2+. 
 
In the absence of nCaM or cCaM, the iNOS peptide showed no secondary structure and was 
predominantly random coil (Figure 5.6 – inset).  The binding of either Ca2+-replete nCaM or cCaM to 
the iNOS peptide resulted in a large increase in α-helical content.  Ca2+ chelation by EDTA resulted in 
a decrease in α-helical content of the complex (Figure 5.6).  Further analysis of the difference spectra 
in these experiments shows that the peptide retains some α-helical content when the iNOS peptide is 
in the presence of either apo-nCaM or apo-cCaM (Figure 5.6 – inset).  These results are consistent 
with published investigations of the binding of holo and apo-CaM to the iNOS CaM-binding peptide 
(Matsubara et al., 1997; Yuan et al., 1998).  It is notable that both lobes can remain bound and induce 
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α-helical structure upon the peptide under Ca2+-depleted conditions.   These results also further 
support our steady-state fluorescence observations that the interaction of the N- and C-domains of 
CaM associate to the iNOS peptide in a Ca2+-independent fashion. 
5.3.5 CaM-Holo-NOS Enzyme Binding Studies 
CaM-binding domain peptides provide a good model for CaM binding to a target protein; however, in 
order to obtain a true representation of the CaM’s interaction with the target protein in vitro and in 
vivo, measurements with the target holo-enzyme are required.  This is due to other regions outside of 
the CaM binding element which may or may not affect CaM’s association to the target protein (Ishida 
and Vogel, 2006). 
5.3.5.1 Alexa-CaM Binding to Holo-NOS Enzymes using Steady-State Fluorescence 
Prior to measuring CaM proteins associating with holo-NOS enzymes, control fluorescence 
measurements with Alexa-labeled CaM proteins with the NOS peptides were performed.  No marked 
differences in fluorescence were observed, regardless of Ca2+ or EDTA presence, indicating that no 
quenching of the fluorophore emission occurs when bound to the NOS peptides (results not shown).  
The CaM-Cys-Alexa proteins, which all emit at 567 nm, all showed a Ca2+-dependent 
association to the eNOS and nNOS enzymes, as shown by quenching (Figure 5.7), as well as kinetic 
analysis (Table 5.2).  This is apparent from the marked quenching of the fluorophore upon the 
addition of Ca2+ to the cuvette, possibly due to the dye being in close proximity to the heme cofactor 
since the heme shows broad absorbance over the entire visible spectrum, whereas FMN and FAD 
absorb very poorly in the 550-700 nm range (Munro and Noble, 1999). 
We have previously used gel shift mobility assays to show that peptides coding for the CaM-
binding domain of iNOS were capable of binding to two nCaM proteins, which consist of only the N-
terminal EF hand pair of CaM (Spratt et al., 2006).  This indicated that nCaM was capable of binding 
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to both the N-type and C-type binding regions of the iNOS CaM-binding peptide.  The activity of 
iNOS coexpressed with nCaM was also shown to be Ca2+-sensitive and the addition of excess wild-
type CaM was able to activate the enzyme under Ca2+-depleted conditions (Table 5.1; Chapter 3).  
This was likely due to the replacement of nCaM from the C-type binding site by the C-terminal 
domain of wild-type CaM.  Since the Alexa-labeled CaM proteins were also capable of activating the 
iNOS coexpressed with nCaM in the presence of excess EDTA (Table 5.3), we concluded that the 
labeled-CaMs were binding to the iNOS enzyme in a Ca2+-independent manner.  After the addition of 
iNOS coexpressed with nCaM to the Alexa-labeled CaMs, the samples were incubated for five 
minutes to allow the mixture to reach equilibrium.  In each case, quenching of the fluorophore was 
observed, indicating CaM associating to iNOS (Figure 5.7).  CaM-T110C-Alexa showed the largest 
quenching effect, which can be attributed to the labeled residue binding directly to the C-type site 
being closest to the heme containing oxygenase domain.  This is in agreement with our FRET studies 
that show CaM binding to iNOS in an anti-parallel fashion.  The CaM-T34C-Alexa and CaM-K75C-
Alexa showed smaller but similar trends in quenching (Figure 5.7). 
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Figure 5.7 – Steady-state Fluorescence of Alexa Fluor 546 labeled CaM-Cys proteins binding to 
holo-NOS enzymes. 
In an initial volume of 1 mL, CaM-T34C-Alexa, CaM-K75C-Alexa, or CaM-T110C-Alexa (50 nM 
final) was added to 50 mM HEPES, 150 mM NaCl, pH 7.5.  The initial scans of eNOS and nNOS 
contained 1 mM EDTA while scans with iNOS coexpressed with nCaM contained 1 mM CaCl2.  The 
excitation and emission slit widths were set at 2 nm.  The excitation wavelength was set to 540 nm 
and emission of each sample was monitored between 550 and 600 nm (▬).  Holo-eNOS, nNOS, or 
iNOS coexpressed with nCaM (250 nM) was then added (▬ ▬), followed by 1.5 mM CaCl2 (0.5 
mM final) (▬ ─ ▬), and finally 5.5 mM EDTA (5 mM final) (─ ─ ─ ─).  In between each 
successive addition, individual scans were taken.  Extra Ca2+ was not added to the samples containing 
iNOS coexpressed with nCaM because its initial scan already contained 1 mM CaCl2. 
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Upon the addition of EDTA to the cuvette, a greater quenching effect was observed for the CaM 
proteins labeled at residues 75 and 110, likely due to a Ca2+-dependent conformational change in the 
C-terminus of the CaM protein that affects its interactions with iNOS (Figure 5.7).  In contrast, CaM-
T34C-Alexa showed almost no quenching upon the addition of EDTA (Figure 5.7) possibly a result 
of the N-domain of the labeled CaM failing to displace the coexpressed nCaM that is tightly bound to 
the N-type binding site of iNOS. 
 In contrast, we found that Alexa-CaM can displace nCaM from a dabsyl chloride labeled 
iNOS peptide.  Unlike the result we observed with holo-iNOS coexpressed with nCaM where nCaM 
remains bound to the N-type site of iNOS, both nCaMs that were bound to both the C- and N-type 
binding sites of the iNOS peptide are able to be completely displaced by CaM-T34C-Alexa and CaM-
T110C-Alexa since their FRET measurements were identical to the data presented in Figure 5.3.  
These results using the iNOS peptide further demonstrate why it is important to use holo-enzymes 
when monitoring CaM binding to its target proteins because regions outside of the CaM-binding 
domain affect CaM’s association.  This is in agreement with a previous study that suggests both the 
CaM-binding domain and FMN domain of iNOS are required for the iNOS enzyme’s Ca2+-
independent activity (Ruan et al., 1996).   
5.3.5.2 Displacement of Alexa-CaM from iNOS by the Addition of Excess CaM Proteins 
Since CaM-T110C-Alexa showed Ca2+-dependent binding and the highest amount of fluorescence 
quenching when bound to iNOS, we tested if this binding of the C-terminal domain of CaM-T110C-
Alexa was permanent or a transient species by the addition of excess CaM proteins under Ca2+-
depleted conditions.  If the fluorescence signal increases, this would indicate that CaM-T110C-Alexa 
is released from the iNOS enzyme.  Interestingly, fluorescence did increase upon the addition of 100 
fold excess (when compared to Alexa-CaM concentration) of wild-type CaM, cCaM, consisting of the 
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central linker and C-terminal domain of CaM (residues 76-148), and nCaM, consisting of only the N-
terminal domain of CaM with no central linker (residues 1-75) (Figure 5.8). 
 
 
Figure 5.8 – Dissociation of CaM-T110C-Alexa from iNOS coexpressed with nCaM after the 
addition of excess CaM proteins. 
An initial scan of CaM-T110C-Alexa in the presence of 1 mM CaCl2 (▬) was taken, followed by the 
addition of iNOS coexpressed with nCaM (250 nM) and EDTA to a final concentration of 5 mM    
(▬ ─ ▬).  Once the sample reached equilibrium, a scan was taken showing the quenched 
fluorescence due to the Alexa-labeled CaM binding to the iNOS enzyme.  100 fold excess of 
unlabeled CaM protein was subsequently added and scans were taken every minute until no further 
fluorescence increase was observed (─ ─ ─ ─).  Wild-type CaM, cCaM, and nCaM each took 
approximately 5 minutes, 15 minutes, and 2 hours, respectively, to reach equilibrium. 
 
This result indicated that the observed apo-CaM-T110C-Alexa association to the C-type binding site 
of iNOS is a transient species and can be replaced by another CaM protein.  Although all of the 
excess CaM proteins were capable of out-competing CaM-T110C-Alexa, it is notable that the 
dissociation rates of the Alexa-labeled CaM were not equivalent.  Wild-type CaM showed the 
quickest dissociation in approximately 5 minutes, followed by cCaM in 15 minutes (Figure 5.8).  
These proteins contain the CaM C-terminal domain that normally interacts with the C-type binding 
site in the iNOS CaM-binding domain.  In contrast, CaM-T110C-Alexa was displaced very slowly by 
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excess nCaM, taking approximately 2 hours to reach equilibrium (Figure 5.8).  This result shows that 
the N-terminal lobe of CaM is capable of displacing CaM-T110C-Alexa from the C-type site; 
however, this dissociation is much slower which can be attributed to apo-nCaM having a weak 
interaction with the C-type binding site.  It is also important to note that this transient displacement of 
CaM-T110C-Alexa was only observed when excess CaM proteins were added to the sample. 
Chelation of Ca2+ alone was not sufficient to displace CaM-T110C-Alexa when bound to holo-iNOS. 
5.4 Discussion 
The strong Ca2+-independent binding of CaM to iNOS target sequence is quite remarkable but this 
strong association has also made it difficult to investigate.  The solved structures of CaM in complex 
with peptides representing some of its target sequences have shown that CaM’s association is 
predominantly in an anti-parallel orientation, such as smooth muscle myosin light chain kinase (Ikura 
et al., 1992; Meador et al., 1992), calcineurin (Ye et al., 2006), alphaII-spectrin (Simonovic et al., 
2006), ryanodine receptor (Maximciuc et al., 2006), olfactory cyclic-nucleotide gated channel 
(Contessa et al., 2005), CaM-dependent protein kinase I (Clapperton et al., 2002), and eNOS (Aoyagi 
et al., 2003). The exception to these solved anti-parallel CaM target peptide-complexes are the CaM-
IQ motifs complexes, which bind in a parallel fashion, such as the  voltage-gated 1.2 Ca2+ channel 
(Fallon et al., 2005; Van Petegem et al., 2005).   Recently reported structures of CaM bound to larger 
proteins that encompass its target sequences show the existence of additional novel modes of CaM-
binding.  Examples of these novel binding modes are CaM in complex with the edema factor of 
adenylyl cyclase from B. antracis (Drum et al., 2002), the Ca2+-activated K+ channel (Schumacher et 
al., 2001), plant glutamate decarboxylase (Yap et al., 2003), CaMKK (Kurokawa et al., 2001), CAP-
23/NAP-22 (Matsubara et al., 2004), MARCKS (Yamauchi et al., 2003), the plasma membrane Ca2+ 
pump (Elshorst et al., 1999), and a cross-linked calcineurin consisting of two CaMs and two peptides 
(Ye et al., 2006).  The ability of CaM to associate with these many and varied target proteins is not 
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surprising due to CaM’s highly flexible central linker which allows for the N- and C-lobes of CaM to 
obtain the most favorable conformation in order to bind with its target proteins.  Both of the Ca2+-
dependent cNOS isoforms have been shown to bind in an anti-parallel fashion (Zhang et al., 1995; 
Aoyagi et al., 2003).  Surprisingly, a recent investigation has proposed that iNOS binds to CaM in a 
parallel orientation (Gribovskaja et al., 2005).  This model would suggest that CaM may bind in a 
similar process to other Ca2+-independent IQ motifs, such as neuromodulin, however, the CaM 
binding domain of iNOS does not have any apparent homology to the IQ motifs.   If this proposed 
model were true, it would have important implications for the interactions between CaM and iNOS.  
For this reason, we designed an experiment to determine the orientation of CaM binding to the iNOS 
peptide.  We have found that CaM binds in an anti-parallel fashion to iNOS, similar to that previously 
observed for the cNOS enzymes.  Since the CaM-binding domains of the NOS enzymes show 
significant homology (Spratt et al., 2006), our finding that CaM binds to iNOS in an anti-parallel 
orientation was not surprising.   
The use of short synthetic target peptides alone will not provide a full understanding of CaM 
binding and activation of target proteins (Ishida and Vogel, 2006).  Previous observations have 
indicated there are additional regions outside of the canonical CaM-binding domain that are important 
for the Ca2+-independent binding of CaM to iNOS (Anagli et al., 1995; Ruan et al., 1996; Venema et 
al., 1996): To address this situation, we decided to use both an iNOS target peptide as well as the 
iNOS holoenzyme in our investigation of CaM binding and activation.  The Ca2+-independence of 
CaM for the iNOS has previously been attributed to favourable van der Waals contacts between the 
peptide and CaM and conformational changes to minimize unfavourable solvent exposure of the 
hydrophobic regions of the peptide (Aoyagi et al., 2003).  The exposure of hydrophobic regions of the 
iNOS CaM-target peptide upon complex formation has led to problems in aggregation (Matsubara et 
al., 1997) necessitating our use of a shorter iNOS CaM-target peptide and modified experimental 
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procedures.  A thorough investigation also necessitated the use of holoenzymes in our investigation: 
This required the purification of iNOS holoenzymes coexpressed in E. coli with either CaM of nCaM.  
We previously demonstrated that iNOS can be coexpressed with the N-terminal domain of CaM alone 
to produce a stable and active enzyme (Spratt et al., 2006).  We further confirmed our previous study 
by demonstrating that the association of nCaM to the N-type binding site of the iNOS CaM-binding 
domain is very stable and does not appear to dissociate from holo-iNOS.  This finding is supported by 
our steady-state fluorescence using holo-iNOS enzyme and Alexa-labeled CaMs, as well as our CD 
data monitoring the association between the iNOS CaM-binding peptide and the N- and C-lobes of 
CaM.  
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5.5 Conclusions 
A sequential binding model consisting of the ordered binding of the C-terminal lobe to a C-type site 
followed by the binding of the N-terminal to the N-type site has been proposed for various target 
proteins including nNOS (Persechini et al., 1994).  This mode of CaM association is consistent with 
the ten-fold higher affinity for Ca2+ in the C-lobe than the N-lobe of CaM (Martin et al., 1985) as well 
as the increased Ca2+-affinity when CaM is bound to its target sequence (Olwin and Storm, 1985).  At 
low basal levels of Ca2+, the C-lobe of CaM is Ca2+-replete and bound to the target sequence.  As the 
cellular concentration increases due to some signaling event, the N-lobe binds to Ca2+ allowing for its 
association with its target sequence leading to activation of the Ca2+/CaM-dependent protein.  We 
investigated the roles of different regions of CaM by using CaM proteins selectively labeled at three 
different residues.  Notably, we showed that both CaM lobes are able to bind to iNOS in a Ca2+-
independent process.  We were surprised to discover that the C-lobe, and not the N-lobe of CaM, 
showed the greatest Ca2+-dependent changes in conformation when associated with either the iNOS 
peptide or the holoenzyme.  Our results indicate that the aforementioned sequential model for nNOS 
(Persechini et al., 1994) does not necessarily apply to the Ca2+-independent iNOS enzyme.  This may 
be the case with iNOS where it has been shown that CaM’s association and activation of iNOS is 
affected by the CaM-binding domain as well as other flanking regions of the enzyme (Anagli et al., 
1995; Ruan et al., 1996; Venema et al., 1996).  
Our results help to explain how iNOS remains active even under basal levels of Ca2+ in the 
cell.  Unlike the cNOS enzymes, the N-terminal lobe of apo-CaM binds to the iNOS enzyme and 
retains activity, consistent with our previous study (Spratt et al., 2006).  In the cell where the number 
of CaM binding proteins exceeds the amount of CaM present (Persechini and Stemmer, 2002; Tran et 
al., 2005), the ability of iNOS to rapidly bind to CaM in a Ca2+-independent manner is required to 
prevent aggregation of the enzyme (Kolodziejska et al., 2005).  Although the structural basis for how 
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these enzymes are bound and activated by CaM is not fully understood, our results further 
demonstrate that there are marked differences between the Ca2+-dependent and -independent NOS 




FRET Conformational Studies of Calmodulin Bound to 
Nitric Oxide Synthase Enzymes * 
6.1 Introduction 
The ability of CaM to associate with its various target proteins is due in large part to the inherent 
flexibility of the central linker separating the N- and C-domains of CaM (Ishida and Vogel, 2006).  
This flexibility allows CaM to undergo dynamic conformational changes in order to make itself 
amenable to binding to the various target proteins that CaM can activate, which include the NOS 
enzymes.  Fluorescence (Förster) Resonance Energy Transfer (FRET) has been widely used for 
studying protein conformation over the past two decades (Heyduk, 2002).  FRET is a very versatile 
method with applications ranging from global conformational studies on native proteins in vivo to a 
single protein molecule.  It is a useful tool for the determination of the distance between two different 
fluorescently labeled residues that are ~10 Å to ~100 Å apart (Heyduk, 2002).  Since most biological 
molecules fall within this distance criterion, it is not surprising that FRET has been used on a variety 
of proteins, including CaM.  CaM has been utilized in numerous FRET studies to determine CaM’s 
conformation when bound to various target proteins due to the ability of CaM to bend its central 
linker bringing the N- and C-domains of CaM into close proximity of each other.   These previous 
studies involved the use of double cysteine mutations in the N- and C-domains of CaM, specifically at 
sites T34 and T110C (located in helices 2 and 6 of CaM, respectively), which were fluorescently 
labeled for FRET measurements when binding to these target proteins.  Figure 6.1 shows the 
positions of T34 and T110 in CaM and demonstrates why these sites in the protein are optimal for 
FRET measurements. 
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Figure 6.1 – X-ray crystal structures showing the positions of T34 and T110 in (A) Holo-CaM 
compared to CaM when bound to (B & C) the eNOS and (D & E) the nNOS CaM-binding 
domain peptides. 
CaM, NOS peptide, and Ca2+ ions are shown in red, blue, and green, respectively.  T34 and T110 
residues are shown in yellow and purple, respectively.  Models are derived from PDB 1CLL 
(Chattopadhyaya et al., 1992), 1NIW (Aoyagi et al., 2003), and 2O60 (Ng et al. – unpublished, co-
ordinates released 2007-12-25).  The distances measured between the hydroxyl groups of T34 and 
T110 are shown to demonstrate that the dynamic conformational change CaM undergoes when bound 
to the eNOS and nNOS peptides are amenable to FRET measurements. 
There are numerous examples in the literature of CaM T34C/T110C being utilized to monitor CaM’s 
conformation, such as CaM bound to a ryanodine receptor peptide, Ca2+/CaM-dependent protein 
kinase II, human cardiac L-type Ca2+-voltage gated channel (CaV1.2), and the edema factor of 
adenylyl cyclase from Bacillus anthracis (Drum et al., 2000; Torok et al., 2001; Xiong et al., 2005; 
Maximciuc et al., 2006) or monitoring CaM’s conformation when exposed to various organic, 
viscous, and denaturing solvents (Slaughter et al., 2005a; Slaughter et al., 2005b).  Another recent 
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study employed synthesized p-aminophenylalanine derivatives linked with BODIPY fluorophores at 
the p-amino group and introduced these non-natural amino acids into CaM at various sites using the 
four-base codons GGGU and CGGG in an E. coli cell-free translation system (Kajihara et al., 2006). 
There is considerable interest in understanding the structural basis of CaM’s target protein 
interactions and diverse regulatory functions.  It is well established that CaM is able to interact with 
its target enzymes in many different conformations, varying from being tightly wrapped when bound 
to myosin light chain kinase (Ikura et al., 1992), and eNOS (Aoyagi et al., 2003), as determined by 
NMR and x-ray crystallography, to having an extended structure when bound to the edema factor of 
adenylyl cyclase from Bacillus anthacis, as determined by FRET (Drum et al., 2000) and x-ray 
crystallography (Drum et al., 2002).  The fact that the FRET results of CaM bound to the edema 
factor were later confirmed by x-ray crystallography validates that the conformation of CaM 
determined by FRET is representative of a protein’s true conformation in vitro. 
The structure of CaM bound to a peptide corresponding to the CaM-binding domain of eNOS 
(Aoyagi et al., 2003) and nNOS (PDB 2O60, released 12-25-2007) have been solved and it is known 
that CaM binds to the NOS enzymes in an anti-parallel orientation (Zhang et al., 1995; Aoyagi et al., 
2003; Spratt et al., 2007b).  Although the structures and orientation of CaM bound to cNOS peptides 
have been determined, the conformation of CaM when bound to the holo-NOS enzymes has not been 
determined.  This is due in large part to the size of the NOS enzymes (~124-160 kDa), which would 
not make it amenable to determine using NMR, as well as the dynamic structural rearrangements that 
occur within the reductase domain and CaM-binding domains of the NOS enzymes, which would 
make it difficult to obtain the protein crystals required to perform x-ray crystallography.  There are 
numerous solved crystal structures of the oxygenase domains for each of the NOS isozymes, as well 
as a solved crystal structure of the nNOS reductase domain without the autoinhibitory domain and 
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Figure 6.2 – X-ray crystal structures of rat nNOS oxygenase and reductase domains. 
Oxygenase domain, heme, and H4B are shown in red, green, and pink, respectively.  FMN and 
FAD/NADPH binding domains of the nNOS reductase domain are shown in orange and blue.  FMN, 
FAD and NADP+ cofactors are shown in yellow, cyan, and dark green, respectively.  The structure 
and conformation of CaM when bound to the holo-NOS enzymes is unknown.  Models are derived 
from PDB 1ZVI (oxygenase) (Matter et al., 2005) and 1TLL (reductase) (Garcin et al., 2004).  
 
Furthermore, determining CaM’s conformation when bound to the NOS enzymes may also be 
affected by flanking regions outside of the putative CaM-binding domain of each NOS isozyme.  For 
instance, regions in the FMN domain of iNOS have been implicated in the Ca2+-independent 
association of CaM to this enzyme (Ruan et al., 1996).  Likewise, the autoinhibitory domain and C-
terminal tail in the reductase domains of cNOS enzymes have been shown to be involved in the Ca2+-
dependent association of CaM to these enzymes (Roman and Masters, 2006). 
The present study was designed to determine the conformation of CaM when bound to all 
three NOS isoforms.  Previous studies in our laboratory have demonstrated differences in CaM 
binding and activation of the NOS enzymes using CaM-troponin C chimeras, CaM EF hand pair and 
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Ca2+-deficient mutant CaM proteins (Newman et al., 2004; Spratt et al., 2006; Spratt et al., 2007a).  
Furthermore, our most recent study demonstrated differences in the Ca2+-dependence of the N- and C-
domain when bound to iNOS when compared to the cNOS enzymes using steady-state fluorescence 
(Spratt et al., 2007b).  We anticipate that marked differences will be observed when comparing 
CaM’s conformation bound to the cNOS and iNOS enzymes.  These studies will further our 
understanding of the enzymatic mechanism of the NOS isozymes when bound and activated by CaM. 
6.1.1 Chapter Overview 
This chapter is in two sections.  The first section (section 6.2) discusses work performed in 
collaboration with Dr. Shenhui Lang (PhD, U of Waterloo) and Dr. Michael Palmer (Associate 
Professor, U of Waterloo) involving the development of a methodology of dual targeted specific 
labeling of single cysteine and selenomethionine residues in proteins.  The second section (section 
6.3) focuses on an alternative method employed to double label CaM with fluorescent dyes and the 
subsequent FRET analysis of the dual labeled CaM T34C/T110C when bound to NOS peptides and 
holo-enzymes. 
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6.2 Dual-targeted labeling of proteins using cysteine and 
selenomethionine residues 
6.2.1 Introduction 
The site-selective labeling of CaM has been used extensively to study CaM’s ability to interact with 
target peptides and proteins.  Frequently, these studies involved the introduction of a cysteine into the 
N- or C-domain since CaM does not contain any cysteine residues making this a facile method to site-
specifically label CaM with a fluorescent dye.  Although there are numerous other residues that can 
be modified in CaM, such as the numerous lysine residues, it is much more difficult to ensure that  
site-specific labeling of these residues occur without any unwanted secondary labeling which would 
make fluorescent binding studies more tedious and difficult to analyze.   
Another amino acid residue that has low to moderate frequency in proteins is methionine.  
Although CaM is methionine rich, containing nine residues out of a total of 148, previous studies in 
our laboratory have demonstrated that replacement of all nine methionines to leucine has little or no 
effect on the ability of CaM to bind and activate the cNOS enzymes (Montgomery et al., 2003), as 
well as making the mutant inert to chemical modification.  Previous studies have demonstrated that 
methionine can be labeled with a varieity of alkylating agents, such as iodoacetate (Gundlach et al., 
1959), iodoacetamide derivatives (Zukin et al., 1977; Chung and Lewis, 1986), benzyl bromide 
(Rogers et al., 1976) or dansylaziridine (Grabarek et al., 1983), which all result in the formation of 
sulfonium salts (Figure 6.3A). 
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Figure 6.3 – Reaction schemes involving (A) selenomethionine with iodoacetamide to form 
selenonium or sulfonium salts, and (B) the cleavage of the selenonium by free thiols. 
 
Unfortunately, these alkylation reactions with methionine are relatively inefficient which can account 
for why their use to modify methionine has not been frequently used as a strategy to site-selective 
label proteins by the research community. 
An alternative to the inefficient labeling of methionine is the use of selenomethionine, an 
analogue of methionine with selenium substituted for the sulphur in its side chain.  Selenomethionine 
has been used extensively in x-ray crystallography by metabolically incorporating selenomethionine 
in place of methionine residues to avoid the need for heavy-atom screening, such as mercury or lead; 
however, previous reports have demonstrated that selenomethionine is capable of being chemically 
modified (Shepherd and Huber, 1969; Smith and Thompson, 1998).  Since selenium is more 
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nucleophilic than sulfur, Dr. Shenhui Lang (PhD 2003, U of Waterloo) and Dr. Michael Palmer 
(Associate Professor, U of Waterloo) reasoned that selenomethionine could possibly be a better target 
for modification with iodoacetamide reagents than methionine.  Their preliminary studies confirmed 
that iodoacetamides react more efficiently with free selenomethionine than methionine.  They tested 
and proved that the site-specific labeling of a single selenomethionine expressed in streptococcal 
protein CAMP factor could occur.  
In collaboration with Dr. Lang and Dr. Palmer, a methodology was developed to site-
specifically label selenomethionine residues in proteins for fluorescent studies.  In order to further 
support their studies, the candidate was asked to demonstrate that their technique could also be 
amenable to fluorescently label other proteins using CaM as a model.  This methodology was also 
expanded upon to include a technique that allows for the dual-labeling of a target protein with single 
cysteine and selenomethionine residues making the protein amenable for dynamic conformational 
studies through the use of FRET.  Using these approaches to single- and dual-label proteins, we found 
that metabolically incorporated selenomethionine in proteins provides a facile, highly specific and 
completely reversible procedure to fluorescently label proteins in vitro.   
6.2.2 Experimental Procedures 
6.2.2.1 Mutagenesis of CaM-L9 
The pCaM-L9 vector, consisting of the pET15b ampicillin resistant vector (Novagen) containing a 
CaM construct with of all nine methionines found in CaM converted to leucines, was a generous gift 
from Dr. Thomas C. Squier (Pacific Northwest National Laboratory, Richland, WA).  The 
QuikChange site-directed mutagenesis procedure (Wang and Malcolm, 1999) was used to convert a 
threonine codon at position 34 to a methionine in the methionine-free template pCaM-L9 
(Montgomery et al., 2003) to yield the plasmid pT34MCaM-L9.  Forward and reverse primers 
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removed a SacI cut site: T34MLfr2 5' CTACAAAGGAGCTGGGGATGGTGCTGAGATCAC 3' and 
T34MLrv2 5' GTGATCTCAGCACCATCCCCAGCTCCTTTGTAG 3'.  Into the resulting pT34M-
CaM-L9 vector, a single cysteine codon was introduced by replacing a threonine codon at position 
110, yielding plasmid pT34M-T110C-L9.  The forward and reverse primers incorporated a PmlI 
reporter cut site: 
T110CLfr 5' GCAGAACTTCGTCACGTGCTGTGCAATCTTGGGGAGAAGCTAAC 3' and 
T110CLrv 5' GTTAGCTTCTCCCCAAGATTGCACAGCACGTGACGAAGTTCTGC 3'.   The 
successful construction of the pT34MCaM-L9 and pT34M-T110CCaM-L9 vectors was confirmed by 
DNA sequencing. 
6.2.2.2 CaM Expression and Selenomethionine Incorporation 
CaM-L9, T34M CaM-L9, T110C CaM-L9, and T34M/T110C CaM-L9 were expressed as previously 
described (section 2.2.2) with the exception that they were grown in the presence of 100 mg/L 
ampicillin.  Initial attempts to metabolically incorporate selenomethionine into CaM-T34M and CaM-
T34M-T110C was performed as previously described (Guerrero et al., 2001) with slight 
modifications.  E. coli BL21 (DE3) cells containing either pT34MCaM-L9 and pT34M-T110CCaM-
L9 plasmids were grown in 500 mL of LB medium with 100 μg/mL of ampicillin at 200 rpm, 37 °C 
overnight.  Minimal medium was prepared from NH4Cl (1 g), KH2PO4 (3 g), and Na2HPO4·7H2O (6 
g), dissolved in 0.9 L of deionized water and autoclaved.  20 g glucose, 0.3 g MgSO4, 10 mg FeCl3, 
and 10 mg thiamine were then dissolved in 100 mL water, the pH was adjusted to 7.4, filter-sterilized, 
and added to the above solution.  L-selenomethionine was added to the minimal medium to a final 
concentration of 25 mg/L immediately prior to induction.  The cells were recovered by centrifugation, 
washed twice by resuspension and centrifugation with sterilized distilled deionized water, and 
resuspended in 1 L of selenomethionine minimal medium, yielding an OD600 of 0.8 to 1.  Protein 
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expression was induced with 1 mM IPTG for an additional 5 hours at 30°C, 200 rpm.  The cells were 
then harvested by centrifugation and stored at –80°C overnight.   
Using this method with E. coli BL21 (DE3) (Guerrero et al., 2001) was found to be 
inefficient at incorporating selenomethionine into CaM (~50%).  To ensure that selenomethionine 
was efficiently incorporated, the methionine-auxotrophic strain E. coli strain B834 (DE3) (Novagen) 
was employed  and a modifed version of a previously published protocol was used (Duewel et al., 
1997).  M9 salts were prepared from Na2HPO4·7H2O (12.8 g/L), KH2PO4 (3.0 g/L), NaCl (0.5 g/L), 
and NH4Cl (1.0 g/L).  After adjusting the pH to 7.4 and autoclaving, the 1 L of M9 salts were used to 
prepare M9 minimal medium by adding filter-sterilized solutions of MgSO4 to 2 mM, CaCl2 to 100 
μM, glucose to 4 g/L, and ampicillin to 100 μg/mL.  
The B834 (DE3) cells were transfected with pT34MCaM- L9 or pT34M-T110CCaM-L9 and 
then grown in 20 mL LB medium with 100 mg/mL of ampicillin at 225 rpm, 37°C overnight; 10 mL 
of the overnight culture was used to inoculate 1 L of M9 minimal medium with 50 mg L-methionine 
added.  The cells were then grown to an OD600 of 0.6 to 0.8 at 200 rpm at 37°C, harvested by 
centrifugation, washed in M9 salts, and finally resuspended in a second liter of M9 minimal medium. 
The cells were allowed to grow for an additional 30 minutes to exhaust any remaining methionine in 
the medium. After 30 minutes, 50 mg of L-selenomethionine was added, protein expression was 
induced with the addition of IPTG (500 μM final concentration), and incubation continued for 5 hours 
with shaking at 200 rpm, 37 °C.  The cells were then harvested by centrifugation, flash frozen on dry 
ice, and stored at –80 °C.  This expression protocol resulted in virtually complete replacement of 
methionine in CaM-T34M and CaM-T34M/T110C by selenomethionine as judged by mass 
spectrometry (see Table 6.1).  These CaM proteins with selenomethionine incorporated will be 
referred to as T34SeM CaM-L9 and T34SeM/T110C CaM-L9 throughout this chapter. 
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6.2.2.3 T34SeM CaM-L9 and T34SeM/T110C CaM-L9 Protein Purification 
The CaM mutants were purified as previously described by hydrophobic interaction chromatography 
on phenyl–Sepharose CL-4B (section 2.2.3).  All of the CaM mutants were dialyzed overnight into 50 
mM Tris-HCl, 1 mM CaCl2, pH 7.5 with 0.5 mM dithiothreitol. 
6.2.2.4 cNOS Enzyme Kinetics 
The initial rate of •NO synthesis was measured using the oxyhemoglobin capture assay as previously 
described (section 2.2.10.1.3).  Assays were performed at 25oC in a SpectraMax 384 Plus 96 well 
UV-visible spectrophotometer using Soft Max Pro software (Molecular Devices, Sunnyvale, CA).  
eNOS and nNOS were assayed at concentrations of 70 and 30 nM, respectively in 100 µl total well 
volumes.  200 µM CaCl2 or 250 µM EDTA as well as 2 µM wild-type CaM and mutant CaM protein 
were added to the appropriate samples. 
6.2.2.5 Chemical labeling of selenomethionine residues with IAEDANS 
T34SeM CaM-L9 and T34SeM/T110C CaM-L9 was transferred into a labeling buffer consisting of 
100 mM sodium acetate, 150 mM NaCl, 1 mM EDTA, pH 5.0 by gel filtration using a Sephadex G-
25 PD-10 column (Amersham Biosciences, Baie d’Urfe, PQ) immediately prior to labeling.  5-((((2-
iodoacetyl)amino)ethyl)amino)naphthalene-1-sulfonic acid (IAEDANS; Figure 6.4A), purchased 
from Sigma Aldrich (Oakville, ON), was dissolved in 0.5 M MES buffer, pH 6.0, to a concentration 
of 100 mM.  
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Figure 6.4 – Fluorescent dyes used to selectively label selenomethionine and cysteine residues of 
T34SeM/T110C CaM-L9. 
(A) 1,5-IAEDANS, 5-((((2-iodoacetyl)amino)ethyl)amino) naphthalene-1-sulfonic acid – ε336 = 6100 
M-1cm-1, em.max at 490 nm, FW = 434.25; (B) DDPM, N-(4-Dimethylamino-3,5-
dinitrophenyl)maleimide – ε443 = 2930 M-1cm-1, no emission, FW = 306.23; (C) BODIPY 507/545 IA, 
N-(4,4-difluoro-1,3,5,7- tetramethyl-4-bora-3a,4a-diaza-s- indacene-2-yl)iodoacetamide – ε508 = 
69,000 M-1cm-1, em.max at 543 nm, FW = 431.03;  (D) 5-TMRIA *single isomer*, 
tetramethylrhodamine-5-iodoacetamide dihydroiodide – ε543 = 89,000 M-1cm-1, em.max at 567 nm, FW 
= 825.22; (E) QSY 9 C5 maleimide – ε562 = 90,000 M-1cm-1, no emission, FW = 1083.30; (F) QSY 35 
C5 iodoacetate – ε475 = 24,000 M-1cm-1, no emission, FW = 453.20; (G) Alexa Fluor 546 C5 
maleimide – ε554 = 93,000 M-1cm-1, em.max at 570 nm, FW = 1034.37; (H) DABIA, N-(4-(4-
dimethylaminophenylazo)phenyl)iodoacetamide – ε436 = 29,000 M-1cm-1, no emission, FW = 408.24. 
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IAEDANS was added to a final concentration of 10 mM and the labeling reaction was incubated at 
25°C for 16 hours.  The concentration of T34SeM CaM-L9 used in the labeling reaction was 
approximately 0.83 mg/mL (49 μM).  The labeling reaction was ended and excess dye was removed 
by gel filtration using another PD-10 column equilibrated with 20 mM HEPES, 150 mM NaCl, 1 mM 
EDTA, pH 7.0.  Labeling yields were determined from absorbance spectra on a Varian Cary UV–
visible Spectrophotometer (Varian, Mississauga).  For unlabeled CaM saturated with Ca2+, ε277 was 
taken to be 3029 M-1cm-1 (Gao et al., 1998).  ε280 and ε336 of IAEDANS were 1060 and 6100 M-1cm-1, 
respectively (Hudson and Weber, 1973).  ESI-MS was used to confirm chemical modification of the 
selenomethionine residue with IAEDANS in T34SeM CaM-L9, as previous described (section 2.2.5). 
6.2.2.6 Cysteine labeling of T34SeM/T110C CaM-L9 
Cysteine residue of T34SeM/T110C CaM-L9 was labeled with N-(4-Dimethylamino-3,5-
dinitrophenyl) maleimide (DDPM; Figure 6.4B; Sigma Aldrich) as previously described (section 
5.2.3) in a labeling buffer consisting of 50 mM Tris-HCl, 1 mM CaCl2, pH 7.2 by gel filtration using 
a Sephadex G-25 PD-10 column (Amersham Biosciences).  DDPM was dissolved in dimethyl 
sulfoxide to a working stock concentration of 0.5 mM; the DDPM was added to a final concentration 
of 30 mM and incubated at 25oC for 2 hours.  The reaction was terminated with the addition of excess 
dithiothreitol followed by the removal of excess label by gel filtration, as previously described 
(section 6.2.2.5).  ε280, ε336, and ε443 of DDPM were 9100, 1636, and 2930 M-1cm-1 respectively.  ESI-
MS was used to confirm thiol specific modification of the cysteine residue with DDPM in 
T34SeM/T110C CaM-L9, as previous described (section 2.2.5). 
6.2.2.7 Targeted dual labeling of T34SeM/T110C CaM-L9 with maleimide and 
iodoacetamide derivatives 
The thiol-labeled T34SeM/T110C-DDPM CaM-L9 was subsequently incubated with IAEDANS to 
derivatize the selenomethionine.  The same methodology as previously described to label 
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selenomethionine residues (section 6.2.2.5) was utilized.  A schematic demonstrating the step by step 
labeling of the cysteine residue followed by the selenomethionine of T34SeM/T110C CaM-L9 is 
shown in Figure 6.5.  ESI-MS was used to verify that dual labeling of T34SeM/T110C CaM-L9 with 
IAEDANS and DDPM, as previous described (section 2.2.5).   
 
Figure 6.5 – Selective dual labeling of cysteine and selenomethionine residues in 
T34SeM/T110C CaM-L9. 
Ca2+, N- and C-terminal domains of CaM shown in green, red, and blue, respectively.  Maleimide and 
iodoacetamide derivatized fluorophores are shown in pink and yellow.  Cysteine labeling occurred in 
the presence of 1 mM CaCl2, while selenomethionine labeling was exclusively in the presence of 1 
mM EDTA.  Methodology was used as described in sections 6.2.2.5 and 6.2.2.6. 
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This methodology was also employed with a variety of red-shifted dyes with the goal of performing 
FRET measurements with the holo-NOS enzymes.  Donor-acceptor pairs that were attempted to be 
utilized for FRET studies using single selenomethionine (which was reacted exclusively with 
iodoacetamide derivatives) and cysteine (which was reacted with maleimide or iodoacetamide 
derivatives) were as follows in sequential order: (1) BODIPY 507/545 IA (Figure 6.4C, donor labeled 
on T110C – Molecular Probes,) and 5-TMRIA (Figure 6.4D, acceptor labeled on T34SeM – 
Molecular Probes,); (2) 5-TMRIA (donor labeled on T34SeM) with QSY 35 maleimide (Figure 6.4E, 
acceptor labeled on T110C – Molecular Probes,); (3) Alexa Fluor 546 C5 maleimide (Figure 6.4G, 
donor labeled on T110C – Molecular Probes,) with QSY 9 C5 maleimide (Acceptor labeled on 
T110C); (4) Alexa Fluor 546 C5 maleimide (Donor labeled on T110C) with QSY 35 iodoacetamide 
(Figure 6.4F, acceptor labeled on T34SeM – Molecular Probes,); and (5) Alexa Fluor 546 C5 
maleimide (donor labeled on T110C) with DABIA (Figure 6.4H, Acceptor on T34SeM – GenoLite 
Biotek, Portland, OR, USA,). 
6.2.2.8 Steady-state fluorescence of single and dual labeled CaM-L9 
Fluorescence emission spectra were performed using a PTI QuantaMaster spectrofluorimeter.  
Fluorescence measurements were performed on IAEDANS labeled T34SeM CaM-L9 and 
T34SeM/T110C CaM-L9 (2 μM) as previously described (section 4.2.6) with some slight 
modifications.  Excitation was at 336 nm, and emission was measured from 400 to 550 nm. 
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6.2.3 Results and Discussion 
6.2.3.1 CaM-L9 Mutant Protein Expression and Purification 
The CaM-L9 proteins were successfully overexpressed in E. coli and purified as previously described 
(sections 2.2.2 and 2.2.3).  The yields of each CaM-L9 protein per liter are summarized in Table 6.1.  
ESI-MS QTOF confirmed homogeneity and ruled out any unwanted posttranslational modification 
(Table 6.1). 
 
Table 6.1 – Masses and Purification Yield of CaM-L9 mutant proteins 
       
 Mass (Da) a Protein Yield 
     (mgP/L media) 
CaM proteins  Observed Theoretical b  
       
    
CaM-L9 16544.0 16544 39.6 
T34M CaM-L9 16574.5 16574 43.6 
T34SeM CaM-L9 16619.0    16621 c 23.2 
T110C CaM-L9 16546.0 16546 46.0 
T34M/T110C CaM-L9 16576.0 16576 48.3 
T34SeM/T110C CaM-L9 16620.5    16623 c 24.3 
       
a Masses of deconvoluted ESI-MS spectra were determined with an accuracy of ± 3 Da. 
b Calculated masses based upon amino acid sequence of the protein. 
c Expected mass difference from substituting methionine with selenomethionine is 46.9 Da 
 
6.2.3.2 cNOS Activation by CaM-L9 Mutant Proteins 
Prior to the fluorescent labeling of the mutant CaM-L9 proteins, the ability of these proteins to bind 
and activate the cNOS enzymes was tested using the oxyhemoglobin capture assay.  These 
measurements were taken to ensure that the mutations introduced in the CaM-L9 protein would not 
impair their ability to bind to the NOS enzymes.  All of the proteins demonstrated Ca2+-dependent 
activation of eNOS and nNOS (Table 6.2) similar to the results previously described in section 5.3.3.  
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Table 6.2 – CaM-L9 Mutant Proteins Dependent Activation of cNOS enzymes a 
CaM protein Neuronal NOS Endothelial NOS 
  % % 
   
CaM  100 ± 3 100 ± 3 
CaM-L9 77 ± 1 78 ± 3 
T34M CaM-L9 68 ± 4 71 ± 5 
T34SeM CaM-L9 54 ± 2 59 ± 4 
T110C CaM-L9 51 ± 3 59 ± 2 
T34M/T110C CaM-L9 84 ± 1 56 ± 5 
T34SeM/T110C CaM-L9 58 ± 2 67 ± 3 
CaM (EDTA) NAA b NAA b 
      
a The oxyhemoglobin capture assay used to measure the rate of CaM-activated •NO production was performed in the 
presence of either 2 µΜ wild-type or mutant CaM protein and either 200 µM CaCl2 or 250 µM EDTA, as indicated.  The 
activities obtained with the respective enzyme bound to wild-type CaM at 25oC in the presence of 200 µM CaCl2 were all 
set to 100%.   
b NAA – No apparent activity 
 
These results demonstrate that all of the mutant CaM-L9 proteins are capable of binding to the cNOS 
enzymes.  These results are in good correlation with previous studies in our laboratory using CaM-L9 
and other methionine to leucine mutant CaM proteins (Montgomery et al., 2003). 
 
6.2.3.3 Single and Dual Labeling of CaM-L9 Proteins 
As previously described (section 5.3.1), the positions of T34 and T110 in CaM have been used 
repeatedly by many researchers to monitor the binding of CaM to various target peptides and 
proteins.  While calmodulin contains nine methionine residues, it has been shown that all of these 
residues can be replaced with leucine without any detrimental effect on its ability to bind and activate 
its target proteins, such as the cNOS enzymes (Montgomery et al., 2003).  A single mutant 
methionine codon at position 34 was put into the methionine-free CaM mutant, CaM-L9.  In contrast 
to the findings with streptococcal protein CAMP factor and another previous study (Guerrero et al., 
2001), quantitative replacement of methionine by selenomethionine required the use of a methionine-
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auxotrophic E. coli strain B834 (DE3) for expression.  Labeling yields of T34SeM CaM-L9 with 
IAEDANS were similar to those observed for the single selenomethionine mutant of CAMP factor, at 
approximately 95-100%.  These results were confirmed by absorbance and ESI-MS (Figure 6.6). 
 
 
Figure 6.6 – Mass spectrometry of (A) IAEDANS labeled T34SeM CaM-L9 and (B) 
IAEDANS/DDPM labeled T34SeM/T110C CaM-L9 proteins. 
(A) The T34SeM CaM-L9 protein, which contains one residue of selenomethionine but no cysteine, 
was labeled with IAEDANS (10 mM) for 16 hours. The highest peak at 16,927.0 Da corresponds to 
the expected singly labeled species.  Peaks at higher molecular weight are likely due to phosphate 
ions associated with the protein.  (B) The T34SeM/T110C CaM-L9 protein, which contains one 
residue of selenomethionine and one cysteine, was labeled with DDPM (30mM) for 2 hours, followed 
by IAEDANS (10 mM) for 16 hours.  The 17,234.0 Da peak corresponds to the IAEDANS–DDPM 
dually-labeled protein.  The 17,252.0-Da peak probably corresponds to labeled protein with an 
ammonium ion adduct.  The peak at 17,540.5 Da corresponds to the protein labeled with two 
AEDANS moieties, with ammonium adduct peaks at 17,558.5 and 17,577 Da. 
 
The use of the red-shifted dyes shown in Figure 6.4 also resulted in the successful dual labeling of 
T34SeM/T110C CaM-L9.  These collective results further support Dr. Lang and Dr. Palmer’s finding 
that selenomethionine residues incorporated into a protein can be specifically and efficiently labeled 
with iodoacetamide derivatized fluorophores. 
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6.2.3.4 Complications with Steady-State Fluorescence using IAEDANS-labeled 
Selenomethionine containing CaM Proteins 
Initial steady-state fluorescence measurements with AEDANS-T34SeM CaM-L9 showed some 
unexpected and complicated results.  Successive measurements on the sample showed increasing 
blue-shifted fluorescence emission spectra (Figure 6.7A).  
 
Figure 6.7 – Steady-state fluorescence complications with IAEDANS-labeled T34SeM CaM-L9. 
(A) Time-dependent change in AEDANS-T34SeM CaM-L9 fluorescence.    (B) Effect of exposure of 
AEDANS-T34SeM CaM-L9 to direct sunlight.  (C) Fluorescence of AEDANS-T34SeM CaM-L9 in 
the presence of 4 M guanidine hydrochloride.  Measurements for all of these samples were taken 
every two minutes until the signal displayed no further change. 
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This large blue-shift in fluorescence is representative of a significant change in the AEDANS 
fluorophore’s environment, moving from a hydrophilic to a hydrophobic environment.  In order to 
determine if the excitation or light exposure was the cause of this fluorescence change, AEDANS-
T34SeM CaM-L9 was treated with (1) direct exposure to sunlight for 30 minutes prior to 
fluorescence, and (2) treatment with guanidine hydrochloride to unfold the fluorescently labeled 
protein.   
The exposure of AEDANS-T34SeM CaM-L9 to direct sunlight resulted in a five fold 
increase in fluorescence (Figure 6.7B), correlating well with the fluorophore moving into a 
hydrophobic environment upon the exposure to light.  The control for this sunlight exposure 
experiment involved incubating the sample for 30 minutes prior to fluorescence measurements in the 
absence of sunlight.  This control demonstrated a similar trend to what was previously observed in 
Figure 6.7A, with a time-dependent blue-shift in fluorescence.   
The treatment of AEDANS-T34SeM CaM-L9 with guanidine hydrochloride was intended to 
unfold the protein and cause the hydrophilic exposure of the fluorophore to solvent.  This control 
should have remained red-shifted since the fluorophore would be in a hydrophilic environment; 
however, the repeated measurements of this sample also displayed a blue-shift over time, as 
previously demonstrated in Figure 6.7A.  Dr. Art Szabo (Dean of Science, Wilfrid Laurier 
University), a fluorescence expert, suggested that these blue-shifted emission spectra were possibly 
due to the photolysis of selenonium salt (Figure 6.3A) and the subsequent covalent re-attachment or 
non-covalent interaction of the AEDANS fluorophore at a hydrophobic pocket of CaM. 
Another complication with using the selenomethionine labeling method that arose is the thiol-
specific cleavage of the selenonium salt (Figure 6.3B).  FRET measurements with the dually-labeled 
T34SeM/T110C CaM-L9 protein were planned to be performed on the holo-NOS enzymes, which are 
purified in the presence of dithiothreitol, a reducing agent that helps to maintain the stability of the 
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enzyme.  Since the use of free thiols, in combination with the photolysis of the selenonium salt by 
light, both of which would result in the unwanted release of the fluorophore from the CaM protein 
and complicated fluorescence analysis, it was decided that an alternative method to dual-label CaM 
using a double cysteine CaM mutant would be more appropriate (section 6.3). 
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6.3 FRET Conformational Analysis of Calmodulin Bound to Nitric 
Oxide Synthase Peptides and Enzymes 
6.3.1 Introduction 
As previously mentioned (section 6.1), numerous studies have dually-labeled CaM at sites 34 and 110 
to determine the conformation of CaM when bound to various target proteins and in different solvents 
using FRET (Drum et al., 2000; Torok et al., 2001; Slaughter et al., 2005a; Slaughter et al., 2005b; 
Xiong et al., 2005; Maximciuc et al., 2006).  Due to the unforeseen difficulties with the 
selenomethionine labeling methodology (section 6.2), it was decided that the conventional method of 
dual-labeling CaM would be adopted.  Using thiol-specific dyes to label CaM results in stable 
covalent linkages between the fluorophores and CaM, allowing for the inclusion of reducing agents, 
such as dithiothreitol to maintain and stabilize the holo-NOS enzymes during steady-state and time-
resolved fluorescence measurements.  The present study describes the dual labeling of T34C/T110C 
CaM mutant protein and its subsequent usage to determine the conformation of CaM when bound to 
NOS peptides and enzymes using FRET. 
6.3.2 Experimental Procedures 
6.3.2.1 Mutagenesis of CaM to produce T34C/T110C 
The QuikChange site-directed mutagenesis procedure (Wang and Malcolm, 1999) was used to 
convert the threonine codon at position 34 to a cysteine into the kanamycin resistant pCaM-T110C 
plasmid consisting of the pET9d vector (Novagen) carrying rat calmodulin with a T110C mutation 
(section 5.2.1).  The construction of pCaM-T34C/T110C was performed by the candidate and assisted 
by Miss Valentina Taiakina (UW Co-op student).  The forward and reverse primers for the T34C 
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mutation were wt-T34Cfr and wt-T34Crv, as previously described (section 5.2.1).  The resulting 
pCaM-T34C/T110C vector was confirmed by DNA sequencing. 
6.3.2.2 CaM T34C/T110C Expression, Purification and Fluorescent Labeling 
CaM T34C/T110C was expressed and purified by Miss Valentina Taiakina (UW Co-op student) as 
previously described (sections 2.2.2 and 2.2.3), with the exception that the dialysis buffer contained 1 
mM DTT.  The CaM protein concentrations were determined using the ε277 of 3029 M-1cm-1 for CaM 
saturated with Ca2+ (Gao et al., 1998) and were subsequently frozen in aliquots on dry ice and stored 
at –80oC.   
 Labeling of CaM T34C/T110C was performed as previously described (section 5.2.3).  The 
CaM T34C/T110C was transferred into labeling buffer (50 mM Tris-HCl, 1 mM EDTA, pH 7.2) by 
gel filtration using a Sephadex G-25 PD-10 column (Amersham Biosciences) in order to remove the 
excess reducing agent in the CaM sample (Lang et al., 2005).  Alexa Fluor 546 C5-maleimide and 4-
dimethylaminophenylazophenyl-4’-maleimide (DABMI) were dissolved in 50 mM Tris, pH 7.5 and 
N,N’-dimethylformamide, respectively, to a concentration of 10 mM. 
 
 
Figure 6.8 – Chemical structures of (A) Alexa Fluor 546 C5 maleimide and (B) DABMI used to 
dual label CaM T34C/T110C. 
Alexa Fluor 546 (Molecular Probes) and DABMI (4-dimethylaminophenylazophenyl-4’-maleimide; 
Molecular Probes) were used to thiol specifically label the cysteine residues in CaM T34C/T110C for 
FRET analysis. 
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50 μL of Alexa Fluor 546 and DABMI solutions (500 μM final concentration) were added to 1 mL of 
100 μM CaM T34C/T110C (1.67 mg/mL).  The reaction was mixed slowly and allowed to proceed 
for 2.5 hours at room temperature.  The labeling reaction was subsequently quenched with the 
addition 10 mM dithiothreitol.  Excess dye and dithiothreitol was removed by gel filtration using a 
PD-10 column pre-equilibrated with 50 mM HEPES, 1 mM EDTA, 150 mM NaCl, pH 7.5.  Dialysis 
against 50 mM HEPES, 1 mM EDTA, 150 mM NaCl, pH 7.5 with two changes of buffer were 
performed to help remove any remaining non-covalently linked dye from the labeled CaM proteins. 
The dually-labeled CaM T34C/T110C was then purified by reverse-phase chromatography on 
an AKTApurifier System for Chromatography (Amersham Biosciences, Baie d’Urfe, PQ) using a 
Vydac 214TP C4 HPLC column (250 x 4.6 mm, 300 Å pore size, 5 μm particle size).   The aqueous 
mobile phase consisted of 95% (v/v) H2O, 5% (v/v) CH3CN, and 0.1% (v/v) TFA while the organic 
mobile phase containing 95% (v/v) CH3CN, 5% (v/v) H2O, and 0.1% (v/v) TFA.  The column was 
washed with two column volumes of the aqueous phase followed by a linear gradient of the organic 
mobile phase (2.5% / min, up to 30%).  The dually-labeled CaM proteins (double DABMI, followed 
by Alexa 546/DABMI, and finally double Alexa 546) were eluted using a linear gradient of the 
organic mobile phase (0.4 % / min, 30 to 50%).  The column was subsequently cleaned with a linear 
gradient of organic mobile phase (4.2% / min, 50 to 100%).  Eluted protein was detected at 278 nm, 
while DABMI and Alexa Fluor 546 were monitored 467 and 556 nm, respectively.  Double-labeled 
DABMI CaM T34C/T110C eluted at 39.8% organic mobile phase, followed by dually-labeled 
DABMI/Alexa Fluor 546 CaM at 41.2%, and finally double-labeled Alexa Fluor 546 CaM at 42.3%.  
Labeling yields were determined from absorbance spectra on a Varian Cary UV–visible 
Spectrophotometer (Varian, Mississauga, ON).  The concentrations of DABMI and Alexa Fluor 546 
were determined using the ε419 = 34,000 M-1 cm-1 and the ε554 of 93,000 M-1cm-1 (both from Molecular 
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Probes).  Isolation of each double- and dually-labeled CaM species was confirmed by ESI-MS 
(section 2.2.5).   
6.3.2.3 Site-directed Mutagenesis of eNOS, nNOS and iNOS 
In order to create NOS enzymes incapable of binding to the catalytic heme, the QuikChange site-
directed mutagenesis procedure (Wang and Malcolm, 1999) was used to convert the conserved 
proximal cysteine that acts as a thiolate ligand to the heme to alanines at positions C186 of bovine 
eNOS (Chen et al., 1994), C415 of rat nNOS (Richards et al., 1996), and C200 of human iNOS 
(Cubberley et al., 1997), as previously described.  The construction of pCWOri-eNOSC186A, 
pCWOri-nNOSC415A, and pCWOri-iNOSC200A was performed by the candidate and assisted by 
Miss Valentina Taiakina (UW Co-op student).  The ampicillin pCWOri vectors with an N-terminal 
poly-histidine tag containing the coding regions for bovine eNOS, rat nNOS, and human iNOS 
carrying a deletion of the first 70 amino acids were used as the templates for mutagenesis.  The 
forward and reverse primers for the C186A mutation of eNOS involved the incorporation of a unique 
XhoI reporter cut site: eNOSC186Afr 5’ GGCGCAATGCACCTCGAGCCGTGGGCCGCATCCAG 
3’ and eNOSC186Arv CTGGATGCGGCCCACGGCTCGAGGTGCATTGCGCC 3’.  The primers 
used to produce the C415A mutation in nNOS incorporated a XhoI site and removed a BamHI site: 
nNOSC415Afr 5’ GGAACGCCTCTCGAGCCGTGGGCAGAATCCAGTGGTCCAAGC 3’ and 
nNOSC415Arv 5’ GCTTGGACCACTGGATTCTGCCCACGGCTCGAGAGGCGTTCC 3’.  
Likewise, the iNOS enzyme C200A mutation involved the use of primers adding a unique XhoI site 
and the removal of a BamHI site:   
iNOSC200Afr 5’ CGCAATGCCCCTCGAGCCATTGGGAGAATCCAGTGGTCCAAC 3’ and 
iNOSC200Arv 5’ GTTGGACCACTGGATTCTCCCAATGGCTCGAGGGGCATTGCG 3’.  The 
resulting plasmids (pCWOri-eNOSC186A, pCWOri-nNOSC415A, and pCWOri-iNOSC200A) were 
confirmed by DNA sequencing (see Appendix A for primer and vector sequences). 
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6.3.2.4 Expression and Purification of Heme-free NOS Enzymes 
Bovine eNOS C186A and rat nNOS C415A were expressed as previously described (section 2.2.6).  
Human iNOS C200A was coexpressed with wild-type CaM and nCaM as previously described 
(section 2.2.8). 
 The purification of the heme-free eNOS and nNOS enzymes involved precipitation with 45% 
ammonium sulfate followed by metal chelation chromatography as previously described (section 
2.2.7).  After elution of the protein with 200 mM imidazole, the samples were dialysed as previously 
described (section 2.2.7) followed by the use of a Vivaspin 15 ultrafiltration spin column (Sartorius 
AG Biotechnology, Goettingen, Germany) to concentrate the eNOS and nNOS samples to 
approximately 2 mL in order to prepare the protein sample for gel filtration.  The sample was the 
loaded on a HiLoad 16/60 Superdex 200 prep grade column (GE Healthcare Bio-Sciences, Baie 
d’Urfe, PQ) equilibrated with 50 mM Tris-HCl, pH 7.5, 10% glycerol, 0.1 M NaCl, and 1 mM DTT, 
and 1 mL fractions were collected.  The flow rate was maintained at 0.6 mL/min using an 
AKTApurifier System for Chromatography (GE Healthcare Bio-Sciences) and eluted protein was 
monitored at 280 nm, while the flavins were monitored at 450 and 480 nm.  The nNOS C415A 
protein that eluted around 54.8 mL, which corresponds to the dimer of nNOS, were collected and 
pooled.  The eNOS C186A protein eluted around 55.6 mL, corresponding to dimeric eNOS, was 
collected and pooled.  The purified heme-free cNOS enzymes were subsequently concentrated using a 
Vivaspin 15 ultrafiltration spin column and scanned on Varian Cary UV–visible Spectrophotometer.  
The concentration of the cNOS proteins was determined using ε455 of 15,400 M-1cm-1 (Newton et al., 
1998).  Figure 6.9 gives a representative absorbance scan of a heme-free NOS enzyme using eNOS 
C186A as an example.  The proteins were subsequently aliquoted, flash frozen on dry ice and stored 
at -80oC. 
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Figure 6.9 – UV-visible absorbance scan of holo-eNOS and eNOS C186A. 
These scans demonstrate the spectal differences between the holo-NOS enzymes and heme-free NOS 
enzymes, using holo-eNOS (▬) and heme-free eNOS (▬) as an example. 
 
 In contrast, iNOS C200A coexpressed with wild-type CaM and nCaM was purified as 
previously described for iNOS coexpressed with nCaM using ammonium sulfate precipitation, 
followed by 2’5’ ADP Agarose affinity chromatography (sections 2.2.9 and 3.3.3).  The concentration 
of the heme-free iNOS protein was determined using the ε455 of 21,000 M-1cm-1 (Newton et al., 1998). 
6.3.2.5 Steady-State Fluorescence Measurements of Alexa-labeled CaM Proteins with 
NOS Peptides and Enzymes 
Fluorescence emission spectra were obtained using a PTI QuantaMaster spectrofluorimeter.  50 nM 
CaM-T34C-Alexa Fluor 546 (section 5.2.3) or Alexa Fluor 546/DABMI T34C/T110C CaM were 
used as the fluorescent reporter in the quartz cuvette.  The excitation wavelength for Alexa Fluor 546 
labeled CaM was set at 540 nm and emission was monitored between 550 and 700 nm.  Slit widths 
were set at 2 nm for excitation and 1 nm for emission.  In an initial volume of 1 mL, a scan was taken 
with each of CaM protein in a buffer consisting of 50 mM HEPES, 1 mM EDTA, 150 mM NaCl, pH 
7.5.  After the initial scan, synthetic NOS CaM-binding domain peptide or heme-free cNOS enzyme 
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(250 nM) was added to the cuvette, the sample was mixed thoroughly, incubated for three minutes to 
allow the sample to reach equilibrium, and scanned.  The NOS CaM-binding domain peptides for 
human iNOS, RPKRR EIPLK VLVKA VLFAC MLMRK (residues 507-531), bovine eNOS, 
TRKKT FKEVA NAVKI SASLM (residues 493-512) and rat nNOS, KRRAI GFKKL AEAVK 
FSAKL MGQ (residues 725-747) were synthesized by Sigma Genosys (Sigma Aldrich, Mississauga, 
ON).  The sample was then brought to a final free Ca2+ concentration calculated to be 0.500 mM, 
mixed, allowed to incubate for three minutes, and scanned.  Finally, excess EDTA (5 mM final) was 
added, incubated for an additional three minutes, and a final scan was taken.  The fluorescence 
emission maximum of CaM-T34C-Alexa and Alexa/DABMI T34C/T110C CaM was observed at 567 
nm, regardless of the presence of Ca2+ in the buffer. 
6.3.2.6 Quin-2 Free Ca2+ Concentration Calibration 
Quin-2, a fluorescent Ca2+ indicator dye developed for the determination of free Ca2+ concentrations 
in solution and cells (Tsien and Pozzan, 1989), was purchased from Molecular Probes (Figure 6.10).   
 
Figure 6.10 – Structure of the fluorescent Ca2+ indicator dye Quin-2. 
This dye was utilized to determine the free Ca2+ concentration in solution during steady-state and 
time-resolved fluorescence measurements.  Quin-2, N-(2-((8-(bis(carboxymethyl)amino)-6- methoxy-
2-quinolinyl)methoxy)-4- methylphenyl)-N-(carboxymethyl)-glycine, ε353 = 4000 M-1cm-1, emmax at 
495 nm, FW = 541.51. 
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Since physiological concentrations of Ca2+ in the cell are low, a calibrated Ca2+ buffer kit was also 
purchased from Molecular Probes with two solutions containing 30 mM MOPS, pH 7.2, 100 mM KCl 
with a 10 mM K2EGTA buffered solution ("zero" free Ca2+) and a 10 mM Ca/EGTA buffered 
solution (39 µM free Ca2+) prepared using a previously published method (Tsien and Pozzan, 1989).  
Steady-state fluorescence measurements were taken in the presence of Quin-2 using the known free 
Ca2+ concentrations of Ca2+ at 20oC.  For increasing free Ca2+ concentrations, these buffers were 
mixed with increasing ratios of Ca/EGTA to K2EGTA (ie. 1 mM Ca/EGTA, 2 mM Ca/EGTA, etc.). 
 The excitation wavelength for Quin-2 was set at 330 nm and emission was monitored 
between 400 and 600 nm.  Excitation and emission slit widths were set at 1 nm and the sample was 
measured at 20oC.  Samples consisted of 1 mL of the mixed Ca/EGTA buffers (ie. 0, 1, 2…9, 10 mM 
Ca/EGTA) containing 2 μM Quin-2 in a 1 cm quartz cuvette.  Once collected, the steady-state 
fluorescence data was plotted as the log of the [Ca2+]free (x-axis) versus the log((F - Fmin)/(Fmax - F)) 
(y-axis).  Using this double log plot, the x-intercept was used to determine the Kd for Quin-2 (M), as 
previously described in a detailed protocol for the Ca2+ calibration buffer kit (C-3008, Molecular 
Probes). 
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Figure 6.11 – Determination of the Kd of Quin-2 using Ca/EGTA buffers. 
(A) Steady-state fluorescence and (B) double log plot for the calibration of Quin-2 in 0–10 mM 
Ca/EGTA buffers.  Using the data from A, plot B was derived and the Kd of Quin-2 was determined 
from the x-intercept (experimental Kd = 66 nM).   
 
The experimentally determined Kd for Quin-2 (66 nM) was in good agreement to the previously 
published Kd for Quin-2 of 60 nM (Tsien and Pozzan, 1989).  Using this curve and Kd, the free Ca2+ 
concentrations were determined for subsequent time-resolved fluorescence measurements. 
6.3.2.7 Time-Resolved Fluorescence Measurements of Alexa-labeled CaM Proteins 
with NOS Peptides and Enzymes 
Time-resolved fluorescence was measured using a PicoQuant FluoTime 100 Compact Fluorescence 
Lifetime Spectrometer (PicoQuant GmbH, Berlin, Germany) using an LED with maximal emission at 
500 nm.  Settings used on the FluoTime 100 were 50-100% transmittance, intensity 90, and 520 nm 
bandpass cut-off filter.  Samples containing 100 nM CaM-T34C-Alexa (Donor alone) and 
Alexa/DABMI T34C/T110C CaM (Donor/acceptor) were measured under Ca2+-deplete and -replete 
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conditions using buffers consisting of 50 mM HEPES, 150 mM NaCl, pH 7.5 with 1 mM EDTA or 
CaCl2.  Using the Ca/EGTA buffer kit (as described in section 6.3.2.6), intermediate Ca2+ 
concentrations were measured over the range of physiological free Ca2+ concentrations.  These 
measurements were taken with labeled CaM alone, as well as in the presence of synthetic NOS 
peptides or heme-free NOS enzymes (500 nM each).  Fluorescence decay curves were fit with one or 
more lifetime components using PicoQuant FluoFit software with the lowest χ2 value used to 
determine the best fit of the fluorophore’s lifetime. 
6.3.2.8 Determination of the Förster Distance (RO) for Alexa Fluor 546 and DABMI 
labeled proteins 
To determine the Förster distance (RO), which is defined as the distance where energy transfer 
between the donor (Alexa Fluor 546) and acceptor (DABMI) is 50%, steady-state fluorescence of 
singly labeled CaM-Alexa proteins and absorbance of CaM-DAB proteins were measured in the 
presence of EDTA and Ca2+.  Steady-state fluorescence of CaM-T34C-Alexa and CaM-T110C-Alexa 
was measured on PTI QuantaMaster spectrofluorimeter with excitation set at 475 nm and emission 
monitored from 350-700 nm.  The absorbance of CaM-T34C-DAB and CaM-T110C-DAB was 
measured from 300-700 nm on an Ultrospec 2100 pro UV/Vis Spectrophotometer (Biochrom Ltd., 
Cambridge, UK).  The RO value was determined using a macro programmed for Microsoft Excel by 
Dr. Michael Palmer (Associate Professor, U of Waterloo) entitled “SpectraAnalysis” which allows 
the user to analyse fluorescence or absorbance spectra in a variety of ways including determining the 
overlap integral, J(λ), an important constant involved in the determination of the RO value for FRET.  
Figure 6.12 demonstrates the spectral overlap of Alexa Fluor 546 and DABMI-labeled proteins. 
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Figure 6.12 – Emission of Alexa Fluor 546 and absorbance of DABMI-labeled CaM proteins for 
the determination of spectral overlap interval J(λ). 
The normalized fluorescence emission of CaM-T34C-Alexa and absorbance of CaM-T110C-DAB  in 
the presence of EDTA are shown as ( ) and ( ), respectively.  The overlap interval is 
highlighted in red. 
 
The overlap integral J(λ) is calculated using the following formula: 
              ∞ 
Equation 6.1          J(λ) = ∫ FD(λ)εA(λ) λ4 dλ 
             0 
 
where FD(λ)  represents the corrected fluorescence intensity of the donor in the wavelength range λ to 
λ + Δ λ with the area under the curve normalized, εA(λ) represents the extinction coefficient of the 
acceptor at λ, and λ represents the wavelength in nm (Lakowicz, 2006).  The overlap integral J(λ) is 
expressed in units of M-1 cm-1 (nm)4 (Lakowicz, 2006). 
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The RO value (in Å) can then be determined using J(λ) in the following formula: 
 
Equation 6.2             RO = 0.211[κ2n-4QDJ(λ)]1/6 
 
 
where κ2 represents the dipole-dipole coupling orientation factor which is normally assumed to be ⅔; 
n represents the refractive index of the medium and is normally assumed to be 1.4 for proteins in 
aqueous solution (Lakowicz, 2006); QD represents the quantum yield of the donor and was assumed 
to be 0.79 for Alexa Fluor 546 (Molecular Probes), which can also be determined as previously 
described (Van der Meer et al., 1994; Lakowicz, 2006). 
6.3.2.9 FRET distance determination for Alexa Fluor 546/DABMI T34C/T110C CaM with 
NOS peptides and enzymes 
Using the fluorescence lifetimes determined using the methodology in section 6.3.2.7, the energy 
transfer efficiency (E) was determined using the following formula: 
Equation 6.3          E = 1 – τDA/τD 
 
where τDA and τD represent the fluorescent lifetimes for donor-acceptor labeled CaM (Alexa Fluor 
546/DABMI T34C/T110C CaM) and donor-labeled CaM (CaM-T34C-Alexa), respectively.  
 Using the energy transfer efficiency (E) values and the RO value determined in section 6.3.2.8, 
the FRET distances (R) were finally calculated using the following formula (expressed in Å):  
 
Equation 6.4      R = RO[(1 – E)/E]1/6 
 
 
It is important to note that because energy transfer efficiency (E) is strongly dependent on the 
distance between the donor and acceptor, FRET distance measurements are only reliable when R is 
within a factor of 2 of RO (Lakowicz, 2006).  For instance, when R = 2RO, the energy transfer 
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efficiency would equal 1.54%, where as when R = 0.5RO, then E would equal 98.5%.  This 
phenomenon is demonstrated in Figure 6.13. 
 
 
Figure 6.13 – Dependence of energy transfer efficiency (E) on the distance (R) between the 
donor and acceptor dyes. 
RO represents the Förster distance, the distance between the donor and acceptor where energy transfer 
efficiency is 50%. 
Chapter 6:FRET Studies of CaM Bound to NOS 
224 
6.3.3 Results 
6.3.3.1 Characterization of Fluorescently Labeled CaM-Cys Proteins 
As previously mentioned in Chapter 5, the double cysteine mutants utilized in this study have been 
used extensively in FRET studies focusing on CaM’s conformation alone and in complex with CaM 
target proteins and peptides (Drum et al., 2000; Torok et al., 2001; Allen et al., 2004; Maximciuc et 
al., 2006).  Their position in helices 2 (T34C) and 6 (T110C) of CaM are in close proximity to each 
other in the classic wrapped conformation, as seen in the CaM-MLCK complex (Ikura et al., 1992).  
In contrast, these residues are markedly separated when CaM is in an extended conformation, as seen 
in holo-CaM (Chattopadhyaya et al., 1992), apo-CaM (Kuboniwa et al., 1995), and CaM in complex 
with the edema factor from B. anthracis (Drum et al., 2002).    
The cysteine CaM mutants were successfully overexpressed in E. coli.  ESI-MS QTOF 
confirmed homogeneity and ruled out any posttranslational modification (Table 5.1). 
Table 6.3 – Masses of Alexa 546 and DABMI labeled CaM-Cys proteins 
      
 Mass (Da) a 
     
     
CaM proteins  Observed Theoretical b 
      
   
wtCaM 16706.0 16706 
CaM T34C 16709.0 16708 
CaM T110C 16709.0 16708 
CaM T34C-Alexa Fluor 546 17717.5 b 17720 b 
CaM T110C-Alexa Fluor 546 17717.5 17720 
CaM T34C-DABMI 17027.0 c 17029 c 
CaM T110C-DABMI 17027.0 17029 
CaM T34C/T110C-Alexa/DABMI 18040.5 d 18040 d 
      
a Masses of deconvoluted ESI-MS spectra were determined with an accuracy of ± 3 Da.. 
b Expected mass difference after labeling CaM-Cys proteins with Alexa Fluor 546 C5-maleimide is 1011.4 Da (Molecular 
Probes).  The manufacturer’s MW of the dye is 1034.3, which includes a single counter sodium ion. 
c Expected mass difference after labeling CaM-Cys proteins with DABMI is 320.35 Da (Molecular Probes).   
d Expected mass difference after dual labeling CaM T34C/T110C with Alexa Fluor 546 C5-maleimide and DABMI is 
1331.75 Da (Molecular Probes).   
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The CaM T34C and T110C proteins were singly labeled with Alexa Fluor 546 and DABMI as 
previously described in section 5.2.3.  Labeling was determined to be complete and was confirmed by 
ESI-MS (Table 6.3).  Protein concentrations were determined using the ε419 = 34,000 M-1 cm-1 and the 
ε554 of 93,000 M-1cm-1 for DABMI and Alexa Fluor 546, respectively. 
 Using the formulas outlined in section 6.3.2.8, the RO distance was determined to be 31.07 Å 
in the presence of EDTA and 30.99 Å in the presence of Ca2+.  Since both of these values are in good 
agreement, the assumed RO used throughout this chapter is 31 Å.  This experimentally determined RO 
distance correlates well with the theoretical RO for Alexa Fluor 546 and DABMI of 29 Å (Molecular 
Probes).  
6.3.3.2 Steady-State Fluorescence of Alexa-labeled CaM Proteins with NOS Peptides 
and Enzymes 
Steady-state fluorescence was used to observe if quenching of the Alexa Fluor 546 by DABMI was 
occurring in the presence of the NOS CaM-binding domain peptides.  Quenching of the Alexa Fluor 
dye represents the dyes being in close proximity to each other, while a lack of quenching would 
represent the dyes being separated.  From the previously published CaM-eNOS (Aoyagi et al., 2003) 
and CaM-nNOS complexes (Ng et al. – unpublished, co-ordinates released 2007-12-25), it is apparent 
that CaM adopts a tightly wrapped conformation when associated to these peptides and that the T34 
and T110 residues are in close proximity to one another.  Therefore, it is expected that we should see 
a marked amount of quenching when the dually-labeled CaM is associated to the cNOS peptides.  To 
date, very little has been reported on the conformation and structure of CaM when associated to 
iNOS; however, due to the sequence similarity between the cNOS and iNOS CaM-binding domains 
(Figure 6.14A) and evidence of the iNOS CaM-binding domain becoming α-helical when bound to 
CaM (Matsubara et al., 1997; Yuan et al., 1998; Spratt et al., 2007a), it is anticipated that CaM will 
also have a wrapped conformation when bound to the iNOS peptide.   
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As mentioned previously in section 5.3.5.1, singly-labeled CaM-T34C-Alexa showed no 
fluorescence changes upon the addition of the NOS peptides regardless of Ca2+ or EDTA presence, 
indicating that no quenching of the fluorophore emission occurs when bound to the NOS peptides.  In 
contrast to the singly-labeled CaM measurements, marked fluorescence changes were observed for 
dually-labeled Alexa/DABMI CaM in the presence of the NOS peptides, which depended upon the 
presence of Ca2+ (Figure 6.14). 
 
Figure 6.14 – Steady-state FRET measurements using Alexa/DABMI labeled CaM T34C/T110C 
with synthetic NOS CaM-binding domain peptides. 
(A) Alignment of CaM-binding domain peptides for human eNOS, nNOS and iNOS used in this 
study. (B) Steady-state FRET measurements using double labeled CaM T34C/T110C Alexa Fluor 
546/DABMI with NOS CaM-binding domain peptides.  Measurements shown were in the presence of 
EDTA (▬), Ca2+ with NOS peptide (▬), and EDTA with NOS peptide (▬).  Excitation was set at 
540 nm and emission was monitored between 550-600 nm. 
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CaM alone in the presence of EDTA showed little or no quenching, indicating that CaM is in an 
extended conformation under these conditions.  The subsequent addition of Ca2+ and NOS peptide 
resulted in a dramatic fluorescence decrease, indicating that the dyes now are in close proximity to 
one another, and therefore that CaM wraps around the peptide.  The final addition of EDTA to the 
eNOS and nNOS peptide samples resulted in the return of the fluorescence to its originating intensity.  
This signifies that CaM releases itself from the peptide and returns to its original extended 
conformation that also prevails in the absence of NOS peptide.  This is in good agreement with 
previous studies indicating that the interaction between CaM and cNOS peptides is Ca2+-dependent.  
In contrast, upon addition of EDTA to the CaM-iNOS peptide sample, fluorescence increased slightly 
but did not return to its original intensity for CaM alone.  This shows that CaM is still associated to 
the iNOS peptide; however, a Ca2+-dependent change in conformation appears to occur as a result of 
the EDTA addition.   
Previous studies have shown that the heme in NOS is a potent quencher of Alexa Fluor 546 
and would interfere with FRET measurements (Chapter 5).  To avoid this undesired quenching from 
the heme in the NOS enzymes, the conserved cysteine residue that is axially coordinated to the heme 
was mutated to an alanine.  These cysteine to alanine mutations (nNOS C415A, eNOS C186A, and 
iNOS 200A) have previously been shown to produce heme-free NOS enzymes (Chen et al., 1994; 
Richards et al., 1996; Cubberley et al., 1997; Spratt et al., 2006).  Furthermore, the oxidized FMN 
and FAD cofactors in the reductase domain of NOS absorb poorly in the 550-700 nm range (Munro 
and Noble, 1999). 
Similar to the steady-state measurements taken with the NOS peptides, singly labeled CaM-
T34C-Alexa and dually-labeled CaM T34C/T110C Alexa/DABMI were measured in the presence of 
EDTA.  This was followed by the addition of Ca2+ and heme-free cNOS enzyme, and finally excess 
EDTA.  The singly labeled CaM-T34C-Alexa demonstrated a slight quenching in the presence of 
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Ca2+ and heme-free NOS enzymes (Figure 6.15); however, this quenching was less than what was 
previously observed with holo-cNOS enzymes in our previous study (Chapter 5) (Spratt et al., 
2007b).  Although the removal of the heme does not completely stop the quenching of Alexa Fluor 
546 fluorescence, it does demonstrate that the removal of the heme can decrease the amount of 
quenching and minimize its effect in subsequent FRET measurements.   
 
Figure 6.15 – Steady-state FRET measurements using singly labeled CaM-T34C-Alexa (CaM-
D) and dual labeled CaM T34C/T110C Alexa/DABMI (CaM-DA) with heme-free cNOS 
enzymes. 
Measurements for CaM-D were in the presence of EDTA alone (▬), EDTA with heme-free cNOS 
(▬), and Ca2+ with heme-free cNOS (▬).  Measurements for CaM-DA were in the presence of 
EDTA alone, EDTA with heme-free cNOS (▬), and Ca2+ with heme-free cNOS (▬).  Excitation was 
set at 540 nm and emission was monitored between 550-600 nm. 
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Similar to the previous results with the cNOS peptides, there was marked quenching of Alexa Fluor 
546 emission in the presence of Ca2+ and the heme-free cNOS enzymes.  This shows that the dually-
labeled CaM also wraps around the cNOS enzymes, similar to that previously observed with the 
cNOS peptides.  The subsequent addition of EDTA also caused the release of CaM from the enzymes 
further demonstrating the Ca2+-dependent association between the cNOS enzymes and CaM. 
Since iNOS cannot be purified without CaM or CaM mutant coexpression and we cannot 
coexpress dually-labeled fluorescent CaM protein with iNOS, we performed FRET measurements 
with iNOS coexpressed with the Ca2+-sensitive CaM mutant, nCaM (Chapter 3).  This CaM mutant 
was previously shown to bind to iNOS in a 2:1 ratio (Spratt et al., 2006) and could be displaced from 
the C-type binding site of the CaM-binding domain by another CaM protein in the presence of EDTA 
(Spratt et al., 2007b).  Although this is a surrogate system and not a true representation of CaM 
binding to the enzyme, it is the only available method to date that has been shown to have some flux 
in CaM’s association to the iNOS CaM-binding domain.  Furthermore, we have also previously 
shown that nCaM bound to the N-type site of the CaM-binding domain is permanent and cannot be 
displaced.  This is due to the tightly bound nCaM blocking the association of the N-terminal domain 
of the fluorescently labeled CaM from binding to the N-type site of iNOS’s CaM-binding domain 
(Spratt et al., 2007b).  Due to these reasons, performing FRET experiments with the dually-labeled 
CaM T34C/T110C Alexa/DABMI on iNOS would be difficult to measure and analyse.   Therefore, 
iNOS C200A coexpressed with nCaM is exclusively used as a control for heme-Alexa FRET 
measurements used later in this chapter (see section 6.3.3.3.5). 
6.3.3.3 Time-resolved measurements for the determination of FRET distances 
Steady-state fluorescence provides an average of the fluorescent species in a sample.  In contrast, 
time-resolved fluorescence allows for the determination of different conformational species within a 
sample that can be used to determine FRET distances.  Singly-labeled CaM-T34C-Alexa was used as 
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a control by using the lifetime of the donor alone without the acceptor being present as a reference set 
at 100%.  Any lifetime shorter than the donor alone’s lifetime would represent FRET between the 
donor and the acceptor dyes and could be used to determine the FRET distance between T34 and 
T110 of CaM in solution.   
Fluorescence measurements were taken using dually-labeled CaM T34C/T110C 
Alexa/DABMI over a range of physiological free Ca2+ concentrations (0 to 2 μM) for (1) CaM alone, 
(2) CaM with NOS CaM-binding domain peptides, and (3) CaM with the heme-free cNOS enzymes.  
As an example, the time-resolved fluorescence exponential decays determined for CaM-T34C-Alexa 
and CaM T34C/T110C Alexa/DABMI with nNOS peptide are shown in Figure 6.16. 
 
Figure 6.16 – Time-resolved fluorescence of (A) Alexa 546-T34C CaM and (B) Alexa 
546/DABMI-T34C-T110C CaM. 
Measurements were taken of CaM alone in the presence of EDTA (▬) and Ca2+ (▬), as well as in the 
presence of Ca2+ with nNOS peptide (▬).  Lifetimes and FRET distances were determined from these 
fluorescence decay curves by fitting them to multiple exponentials using PicoQuant FluoFit software.  
The fitting results from the data shown in this figure are summarized in Table 6.6. 
 
6.3.3.3.1 FRET distance determination: Dually-labeled CaM alone 
A summary of determined fluorescent lifetimes and FRET distances for dually-labeled CaM 
T34C/T110C Alexa/DABMI with increasing free Ca2+ concentrations is shown in Table 6.4.   
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Table 6.4 – Determined FRET distances for Alexa 546/DAB-T34C-T110C CaM alone with 
increasing free Ca2+ concentrations. 
[Ca2+]free RO
a τDb τ1(DA)     
distance 
(da1)e τ2(DA)     
distance 
(da2) 
(μM) (Å) (ns) [χ2] (ns) [χ2] A1c E1d (Å) (ns) A2 E2 (Å) 
                      
0 31 4.026 3.861 0.78 0.04 52.43 0.928 0.22 0.77 25.36 
    [1.118] [1.025]               
                      
0.0156  4.032 3.873 0.82 0.04 52.78 0.993 0.18 0.75 25.73 
    [1.066] [0.956]              
                      
0.0331  4.028 3.894 0.79 0.03 54.36 0.974 0.21 0.76 25.62 
    [1.050] [1.080]               
                      
0.0569  4.036 3.859 0.81 0.04 51.81 0.900 0.19 0.78 25.18 
    [1.046] [1.067]               
                      
0.0878  4.114 3.903 0.75 0.05 50.41 0.949 0.25 0.77 25.36 
    [1.103] [1.047]               
                      
0.1353  4.099 3.915 0.76 0.04 51.60 0.967 0.24 0.76 25.49 
    [0.986] [1.078]               
                      
0.1952  4.077 3.896 0.59 0.04 51.70 1.017 0.41 0.75 25.80 
    [1.067] [1.103]               
                      
0.2913  4.076 3.876 0.52 0.05 50.81 0.974 0.48 0.76 25.56 
    [1.119] [1.114]               
                      
0.433  4.029 3.809 0.61 0.05 49.86 0.672 0.39 0.83 23.71 
    [1.071] [1.026]               
                      
0.7801  4.061 3.789 0.67 0.07 48.09 0.765 0.33 0.81 24.30 
    [1.105] [1.078]               
                      
1.9138  4.046 3.844 0.69 0.05 50.65 0.894 0.31 0.78 25.13 
    [1.16] [1.083]               
                      
a Förster distance (RO) is the distance where resonance energy transfer is 50% efficient.  This value was 
determined using the methodology described in section 6.3.2.8. 
b τD, τ1(DA) and τ2(DA) represent fluorescent lifetimes for donor alone (CaM-T34C-Alexa) and the primary and 
secondary lifetimes for donor-acceptor (Alexa/DAB labeled CaM), respectively.  2 exponential fits were carried 
out to minimize χ2 values using PicoQuant FluoFit software.    
c RET values were calculated using E = 1 – (τDA/τD), where E represents energy transfer efficiency. 
d A1 and A2 represent fractional contribution of fluorescence lifetime decay measurements. 
e Distance values (da1 and da2) were calculated using R = RO[(1-E)/E]1/6, where R represents the calculated 
distance between the donor and acceptor (D-A) in Å. 
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It is apparent from the determined FRET distances that CaM alone is in a predominantly extended 
conformation (~80%) with a smaller population of CaM being in a compact form (~20%).  This 
extended conformation would be expected to be similar to previously solved NMR structure of apo-
CaM where the distance between T34 and T110 is greater than 40 Å (Kuboniwa et al., 1995).  
Interestingly, as the free Ca2+ concentration increased, the relative distances between the Alexa Fluor 
546 and DABMI dyes remained the same; however, the fractional contribution of the predominant 
fluorescent lifetime decreased from 80 – ~60% while the amplitude of the secondary fluorescent 
decay increased from 20 – ~40% (Table 6.4).  This demonstrates that holo-CaM is predominantly in 
an extended conformation, as previously shown in Figure 6.1A (Chattopadhyaya et al., 1992); 
however, holo-CaM can also be in a closed and compact form, as previously shown in Figure 1.3D 
(Fallon and Quiocho, 2003).  This ability of holo-CaM to adopt a variety of conformations has been 
attributed to the flexible central linker region which can unwind readily bringing the N- and C-
domains of CaM in close proximity to one another.  These results correlate well with a previous 
FRET study that showed two lifetimes fit the fluorescence decay of a T34C/T110C donor/acceptor 
labeled CaM, with the predominant species having an amplitude of 75% corresponding to a distance 
of ~40 Å and the secondary species having an amplitude of 25% and a distance of ~25 Å (Torok et 
al., 2001).  Another study demonstrated at a Ca2+ concentration of 150 nM a similar ratio of extended 
to compact forms (Slaughter et al., 2005a).  
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FRET distance determination: Dually-labeled CaM with cNOS peptides 
Table 6.5 and Table 6.6 provide summaries of the fluorescent lifetimes and determined FRET 
distances for CaM T34C/T110C Alexa/DABMI in the presence of eNOS and nNOS CaM-binding 
domain peptides with increasing free Ca2+ concentrations.   
Table 6.5 – Determined FRET distances for Alexa 546/DAB-T34C-T110C CaM in the presence 
of eNOS peptide with increasing free Ca2+ concentrations. 
[Ca2+]free RO
a τDb τ1(DA)     
distance 
(da1)e τ2(DA)     
distance 
(da2) 
(μM) (Å) (ns) [χ2] (ns) [χ2] A1c E1d (Å) (ns) A2 E2 (Å) 
                      
0 31 4.020 3.891 0.78 0.03 54.69 0.969 0.22 0.76 25.61 
    [1.095] [1.078]               
                      
0.0156  4.034 3.862 0.82 0.04 52.07 1.007 0.18 0.75 25.80 
    [1.096] [1.075]              
                      
0.0331  4.028 3.839 0.79 0.05 51.21 0.774 0.21 0.81 24.40 
    [1.050] [0.987]               
                      
0.0569  4.018 3.855 0.81 0.04 52.52 0.836 0.19 0.79 24.81 
    [1.114] [1.101]               
                      
0.0878  4.100 3.863 0.75 0.06 49.36 0.737 0.25 0.82 24.07 
    [1.082] [1.101]               
                      
0.1353  4.017 3.846 0.76 0.04 52.08 1.418 0.24 0.65 28.02 
    [1.155] [1.004]               
                      
0.1952  4.046 3.770 0.59 0.07 47.93 0.754 0.41 0.81 24.25 
    [1.051] [1.078]               
                      
0.2913  4.077 0.633 0.52 0.84 23.38 3.619 0.48 0.11 43.75 
    [1.012] [1.124]               
                      
0.433  4.083 0.638 0.61 0.84 23.40 3.356 0.33 0.18 40.00 
    [1.065] [1.049]               
                      
0.7801  4.059 0.581 0.67 0.86 23.01 3.078 0.33 0.24 37.51 
    [1.121] [1.107]               
                      
1.9138  4.053 0.600 0.69 0.85 23.16 3.112 0.31 0.23 37.84 
    [1.086] [1.091]               
                      
a - e
 As previously described in Table 6.4. 
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Similar to the results observed for CaM alone, there are two lifetimes observed for dually-labeled 
CaM in the presence of eNOS peptide consisting of an extended species and a compact form.  At 
lower Ca2+ concentrations the predominant species in the sample was in an extended conformation 
greater than 45 Å (~80%) and the compact secondary species of ~25 Å (~20%).  As the free Ca2+ 
concentration increased to ~200 nM, a transition was observed with the compact CaM species 
becoming predominant with the secondary species representing a more extended CaM conformation.  
Above ~400 nM free Ca2+ concentration, measurements demonstrated no significant change in the 
lifetimes or amplitudes with the predominant species has a distance of ~23 Å (~65%) and the 
secondary species having a FRET distance of ~38 Å (~35%).  These results demonstrate that the 
association of dually-labeled CaM to the eNOS peptide is Ca2+-dependent and has a FRET distance of 
23 Å representing a tightly wrapped conformation, similar to the previously shown in x-ray structure 
of CaM-bound to the eNOS peptide (Figure 6.1B &C) (Aoyagi et al., 2003). 
 Similar to the FRET results observed for CaM associating with the eNOS peptide, dually-
labeled CaM in the presence of nNOS peptide also showed a similar transition from the extended to 
wrapped conformation with increasing free Ca2+ concentrations.  The predominant species had a 
FRET distance of ~23 Å (~62%) and a secondary species of ~38 Å (~38%), almost identical to the 
results with the eNOS peptide (Table 6.5).  This agrees with the tightly wrapped conformation 
observed in the recently released CaM-nNOS peptide crystal structure (Figure 6.1D & E) (Ng et al. – 
unpublished, co-ordinates released 2007-12-25).   
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Table 6.6 – Determined FRET distances for Alexa 546/DAB-T34C-T110C CaM in the presence 
of nNOS peptide with increasing free Ca2+ concentrations. 
[Ca2+]free RO
a τD b τ1(DA)     
distance 
(da1)e τ2(DA)     
distance 
(da2) 
(μM) (Å) (ns) [χ2] (ns) [χ2] A1c E1d (Å) (ns) A2 E2 (Å) 
                      
0 31 4.027 3.891 0.87 0.03 54.21 1.160 0.13 0.71 26.66 
    [1.036] [1.017]               
                      
0.0156  4.012 3.888 0.81 0.03 55.05 0.976 0.19 0.76 25.66 
    [1.130] [1.013]              
                      
0.0331  4.033 3.902 0.80 0.03 54.58 1.006 0.20 0.75 25.80 
    [1.091] [1.072]               
                      
0.0569  4.038 3.874 0.80 0.04 52.51 0.876 0.20 0.78 25.03 
    [1.120] [1.099]               
                      
0.0878  4.044 3.822 0.75 0.05 49.81 0.812 0.25 0.80 24.62 
    [1.046] [1.040]               
                      
0.1353  4.048 3.759 0.65 0.07 47.54 0.739 0.35 0.82 24.15 
    [1.101] [1.059]               
                      
0.1952  4.047 3.628 0.52 0.10 44.42 0.685 0.48 0.83 23.78 
    [1.151] [1.148]               
                      
0.2913  4.078 0.662 0.55 0.84 23.58 3.437 0.45 0.16 41.01 
    [1.155] [1.076]               
                      
0.433  4.070 0.581 0.62 0.86 22.99 3.253 0.38 0.20 39.03 
    [1.064] [1.069]               
                      
0.7801  4.074 0.592 0.65 0.85 23.07 3.130 0.35 0.23 37.86 
    [1.068] [1.19]               
                      
1.9138  4.073 0.623 0.61 0.85 23.31 3.036 0.39 0.25 37.08 
    [1.063] [1.103]               
                      
a - e
 As previously described in Table 6.4. 
 
6.3.3.3.2 FRET distance determination: Dually-labeled CaM with iNOS peptide 
Fluorescence decays and FRET distances determined with increasing free Ca2+ concentrations for 
CaM T34C/T110C Alexa/DABMI in the presence of iNOS CaM-binding domain peptide are 
summarized in Table 6.7.   
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Table 6.7 – Determined FRET distances for Alexa 546/DAB-T34C-T110C CaM in the presence 
of iNOS peptide with increasing free Ca2+ concentrations. 
[Ca2+]free RO
a τD b τ1(DA)     
distance 
(da1)e τ2(DA)     
distance 
(da2) 
(μM) (Å) (ns) [χ2] (ns) [χ2] A1c E1d (Å) (ns) A2 E2 (Å) 
                      
0 31 4.008 0.598 0.60 0.85 23.19 3.488 0.40 0.13 42.57 
    [1.057] [1.052]              
                     
0.0156  4.072 0.635 0.57 0.84 23.40 3.310 0.43 0.19 39.60 
    [1.072] [1.070]             
                     
0.0331  4.087 0.626 0.63 0.85 23.31 3.069 0.37 0.25 37.26 
    [1.050] [1.118]              
                     
0.0569  4.019 0.646 0.63 0.84 23.54 2.949 0.37 0.27 36.71 
    [1.031] [1.076]              
                     
0.0878  4.070 0.653 0.67 0.84 23.53 2.983 0.33 0.27 36.68 
    [1.069] [1.001]              
                     
0.1353  4.045 0.696 0.62 0.83 23.86 2.855 0.38 0.29 35.87 
    [1.114] [1.080]              
                     
0.1952  4.041 0.711 0.70 0.82 23.97 2.840 0.30 0.30 35.78 
    [1.085] [1.014]              
                     
0.2913  4.088 0.706 0.67 0.83 23.88 2.839 0.33 0.31 35.55 
    [1.059] [1.145]              
                     
0.433  4.124 0.729 0.65 0.82 23.99 2.830 0.35 0.31 35.32 
    [1.116] [1.206]              
                     
0.7801  4.099 0.766 0.67 0.81 24.26 2.949 0.33 0.28 36.27 
    [1.082] [1.108]              
                     
1.9138  4.140 0.755 0.64 0.82 24.14 2.769 0.36 0.33 34.85 
    [1.081] [1.101]              
                      
a - e
 As previously described in Table 6.4. 
 
In contrast to the results observed for the cNOS peptides, there was no transition from an extended to 
compact conformation as the free Ca2+ concentration increased.  Instead, the predominant species in 
the sample had a FRET distance of ~24 Å in each measurement and an amplitude of ~65%, consistent 
with CaM associating to the iNOS peptide in a Ca2+-independent manner.  Since the observed FRET 
distance for CaM bound the iNOS peptide is very similar to that observed with the cNOS peptides at 
higher Ca2+ concentrations (23 Å), it appears to support our previous assumption that CaM binds to 
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iNOS in a tightly wrapped conformation (section 6.3.3.2).  The secondary species in the sample 
demonstrated a slight decrease in FRET distance as the free Ca2+ concentration increased changing 
from ~40 to ~35 Å at a Ca2+ concentration of approximately 50 nM.  This slight change in the FRET 
distance of the secondary species may be related to the Ca2+-dependent conformational change in the 
C-terminal domain of CaM that we have previously observed using the Ca2+-deficient CaM mutants 
(Chapter 4).  Although the association of this domain is Ca2+-independent (Chapter 4 and Chapter 5), 
we have also shown that the C-terminal domain appears to have a Ca2+-dependent conformational 
change that refines the interactions between CaM and the iNOS peptide.  Clearly, CaM associates to 
the iNOS peptide in a Ca2+-independent manner and has a tightly wrapped conformation similar to the 
Ca2+-dependent cNOS peptides. 
6.3.3.3.3 FRET distance determination: Dually-labeled CaM with heme-free cNOS enzymes 
Table 6.8 and Table 6.9 summarize the experimentally determined lifetimes and FRET distances for 
CaM T34C/T110C Alexa/DABMI in the presence of heme-free cNOS enzymes (nNOS C415A and 
eNOS C186A) with increasing free Ca2+ concentrations.   
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Table 6.8 – Determined FRET distances for Alexa 546/DAB-T34C-T110C CaM in the presence 
of eNOS C186A with increasing free Ca2+ concentrations. 
[Ca2+]free RO
a τD b τ1(DA)     
distance 
(da1)e τ2(DA)     
distance 
(da2) 
(μM) (Å) (ns) [χ2] (ns) [χ2] A1c E1d (Å) (ns) A2 E2 (Å) 
                      
0 31 3.952 3.696 0.60 0.06 48.37 0.803 0.40 0.80 24.69 
    [1.007] [1.125]               
                      
0.0156  4.007 3.707 0.57 0.07 47.14 0.903 0.43 0.77 25.23 
    [1.193] [1.045]              
                      
0.0331  3.970 3.721 0.55 0.06 48.65 0.988 0.45 0.75 25.79 
    [1.121] [1.031]               
                      
0.0569  4.036 3.646 0.53 0.10 44.99 0.927 0.47 0.77 25.34 
    [1.123] [1.106]               
                      
0.0878  3.987 3.633 0.52 0.09 45.70 0.931 0.48 0.77 25.43 
    [1.098] [1.035]               
                      
0.1353  3.999 0.818 0.51 0.80 24.72 3.540 0.49 0.11 43.57 
    [1.039] [1.047]               
                      
0.1952  3.957 0.899 0.53 0.77 25.28 3.597 0.47 0.09 45.50 
    [1.165] [1.074]               
                      
0.2913  3.959 0.759 0.50 0.81 24.39 3.466 0.50 0.12 42.91 
    [1.130] [1.060]               
                      
0.433  3.996 0.851 0.52 0.79 24.93 3.424 0.48 0.14 41.77 
    [1.011] [1.061]               
                      
0.7801  3.969 0.781 0.55 0.80 24.52 3.306 0.45 0.17 40.52 
    [1.121] [1.117]               
                      
1.9138  3.969 0.778 0.58 0.80 24.50 3.242 0.42 0.18 39.77 
    [1.159] [1.128]               
                      
a - e
 As previously described in Table 6.4. 
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Table 6.9 – Determined FRET distances for Alexa 546/DAB-T34C-T110C CaM in the presence 
of nNOS C415A with increasing free Ca2+ concentrations. 
[Ca2+]free RO
a τD b τ1(DA)     
distance 
(da1)e τ2(DA)     
distance 
(da2) 
(μM) (Å) (ns) [χ2] (ns) [χ2] A1c E1d (Å) (ns) A2 E2 (Å) 
                      
0 31 3.998 3.813 0.63 0.05 50.91 0.995 0.37 0.75 25.79 
    [1.123] [1.163]              
                     
0.0156 31 4.047 3.734 0.64 0.08 46.86 0.940 0.36 0.77 25.40 
    [1.036] [1.114]             
                     
0.0331 31 4.019 3.744 0.61 0.07 47.90 0.960 0.39 0.76 25.56 
    [0.979] [1.105]              
                     
0.0569 31 4.039 3.681 0.56 0.09 45.71 0.938 0.44 0.77 25.40 
    [1.084] [1.101]              
                     
0.0878 31 4.012 0.933 0.53 0.77 25.41 3.543 0.47 0.12 43.42 
    [1.030] [1.177]              
                     
0.1353 31 4.007 0.900 0.59 0.78 25.22 3.364 0.41 0.16 40.84 
    [1.127] [1.100]              
                     
0.1952 31 3.914 0.795 0.60 0.80 24.68 3.117 0.40 0.20 38.91 
    [1.054] [1.104]              
                     
0.2913 31 3.938 0.784 0.63 0.80 24.58 2.962 0.37 0.25 37.30 
    [1.067] [1.120]              
                     
0.433 31 3.978 0.721 0.64 0.82 24.11 2.941 0.36 0.26 36.88 
    [1.068] [1.149]              
                     
0.7801 31 3.914 0.679 0.61 0.83 23.90 2.717 0.39 0.31 35.54 
    [1.124] [1.077]              
                     
1.9138 31 3.840 0.746 0.64 0.81 24.46 2.795 0.36 0.27 36.52 
    [1.085] [1.186]               
                      
a - e
 As previously described in Table 6.4. 
 
 
The FRET distances determined for dually-labeled CaM in the presence of the heme-free cNOS 
enzymes (~25 Å) are almost identical to the distances observed for CaM with the cNOS peptides (~23 
Å) (Tables 6.4, 6.5, 6.8 and 6.9).  However, the transition of CaM’s conformation from the extended 
to wrapped conformation with increasing free Ca2+ concentrations occurred at a lower Ca2+ 
concentration when compared to the cNOS peptides.  Instead, the transition/association of CaM to the 
eNOS C186A enzyme occurred at ~100 nM free Ca2+ concentration (Table 6.8), which is in good 
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agreement with previous Ca2+ titration activation profiles for CaM holo-eNOS (Nishida and Ortiz de 
Montellano, 1999).  Likewise, the transition/association of CaM to nNOS C415A occurred at a lower 
Ca2+ concentration of ~100 nM (Table 6.9), which is lower than the previously reported Ca2+ 
activation concentration for holo-nNOS of 200 nM (Ruan et al., 1996; Nishida and Ortiz de 
Montellano, 1999). 
6.3.3.3.4 FRET distance determination: CaM T34C-Alexa and CaM T110C-Alexa with 
dabsyl-labeled iNOS peptide 
In Chapter 5, we demonstrated that CaM binds to iNOS is in an antiparallel orientation (section 
5.3.4.1), similar to that observed in the cNOS enzymes.  To further study the subtle Ca2+-dependent 
conformational change that we previously suggested to occur in the C-terminal domain of CaM when 
associated to iNOS, FRET measurements were taken using CaM-T34C-Alexa and CaM-T110C-
Alexa with N-terminally dabsyl-labeled iNOS peptide (previously described in section 5.2.4) with 
increasing free Ca2+ concentrations. 
Tables 6.10 and 6.11 summarize the experimentally determined lifetimes and FRET distances 
for CaM-T34C-Alexa and CaM-T110C-Alexa in the presence of dabsyl-labeled iNOS peptide with 
increasing free Ca2+ concentrations.  The determined FRET distances of ~27 Å for CaM-T34C-Alexa 
and ~24 Å for CaM-T110C-Alexa showed no fluctuation over the Ca2+ titration range.  These results 
show that the N-terminal domain of CaM is further away from the N-terminus of the iNOS peptide 
than the C-terminal domain of CaM, signifying that CaM does bind to the iNOS peptide in an 
antiparallel orientation, further supporting our previous finding in Chapter 5.  Unfortunately, since the 
RO distance is 29 Å, the sensitivity to any subtle conformational changes in the C-terminal domain 
CaM is limited.  If the RO distance were smaller (eg. ~20 Å), there would be much greater sensitivity 
since FRET distance determination is the most responsive around its RO (as previously discussed in 
section 6.3.2.9).   
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Table 6.10 – Determined FRET distances for CaM-T34C-Alexa 546 in the presence of N-
terminally labeled DAB-iNOS peptide with increasing free Ca2+ concentrations. 
[Ca2+]free RO
a τD b τ1(DA)     
distance 
(da1)e τ2(DA)     
distance 
(da2) 
(μM) (Å) (ns) [χ2] (ns) [χ2] A1c E1d (Å) (ns) A2 E2 (Å) 
                      
0 31 3.574 1.079 0.61 0.70 26.96 2.775 0.39 0.22 38.15 
    [1.192] [1.087]              
                     
0.0156  3.346 1.006 0.59 0.70 26.93 2.579 0.41 0.23 37.94 
    [1.186] [1.130]             
                     
0.0331  3.243 1.043 0.60 0.68 27.37 2.598 0.40 0.20 39.10 
    [1.194] [1.084]              
                     
0.0569  3.269 0.968 0.61 0.70 26.83 2.601 0.39 0.20 38.88 
    [1.191] [1.026]              
                     
0.0878  3.169 0.812 0.62 0.74 25.96 2.441 0.38 0.23 37.93 
    [1.175] [1.111]              
                     
0.1353  3.274 0.892 0.66 0.73 26.32 2.665 0.34 0.19 39.65 
    [1.264] [1.025]              
                     
0.1952  3.275 0.968 0.67 0.70 26.82 2.691 0.33 0.18 39.99 
    [1.283] [1.218]              
                     
0.2913  3.099 0.892 0.66 0.71 26.66 2.616 0.34 0.16 41.08 
    [1.220] [1.154]              
                     
0.433  3.189 0.925 0.65 0.71 26.70 2.654 0.35 0.17 40.48 
    [1.182] [1.118]              
                     
0.7801  3.301 1.006 0.66 0.70 27.02 2.970 0.34 0.10 44.69 
    [1.139] [1.103]              
                     
1.9138  3.519 1.017 0.57 0.71 26.68 3.274 0.43 0.07 47.75 
    [1.157] [1.035]               
                      
a - e
 As previously described in Table 6.4. 
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Table 6.11 – Determined FRET distances for CaM-T110C-Alexa 546 in the presence of N-
terminally labeled DAB-iNOS peptide with increasing free Ca2+ concentrations. 
[Ca2+]free RO
a τD b τ1(DA)     
distance 
(da1)e τ2(DA)     
distance 
(da2) 
(μM) (Å) (ns) [χ2] (ns) [χ2] A1c E1d (Å) (ns) A2 E2 (Å) 
                      
0 31 2.911 0.551 0.64 0.81 24.33 2.265 0.36 0.22 38.21 
    [1.230] [1.124]               
                      
0.0156  3.124 0.527 0.67 0.83 23.76 2.237 0.33 0.28 36.17 
    [1.259] [1.201]              
                      
0.0331  3.234 0.490 0.66 0.85 23.26 2.212 0.34 0.32 35.26 
    [1.212] [1.170]               
                      
0.0569  3.079 0.571 0.66 0.81 24.22 2.288 0.34 0.26 37.00 
    [1.208] [1.154]               
                      
0.0878  3.116 0.575 0.67 0.82 24.20 2.279 0.33 0.27 36.63 
    [1.231] [1.161]               
                      
0.1353  3.005 0.526 0.67 0.82 23.94 2.144 0.33 0.29 36.09 
    [1.342] [1.142]               
                      
0.1952  2.939 0.530 0.69 0.82 24.09 2.147 0.31 0.27 36.61 
    [1.280] [1.082]               
                      
0.2913  3.015 0.548 0.70 0.82 24.12 2.187 0.30 0.27 36.45 
    [1.170] [1.182]               
                      
0.433  2.993 0.501 0.70 0.83 23.73 2.127 0.30 0.29 36.01 
    [1.181] [1.144]               
                      
0.7801  3.102 0.583 0.71 0.81 24.29 2.304 0.29 0.26 36.99 
    [1.237] [1.195]               
                      
1.9138  3.130 0.650 0.71 0.79 24.80 2.603 0.29 0.17 40.46 
    [1.185] [1.248]               
                      
a - e
 As previously described in Table 6.4. 
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6.3.3.3.5 FRET distance determination: CaM-T34C-Alexa and CaM-T110C-Alexa with iNOS 
coexpressed with nCaM 
FRET measurements were performed to test our hypothesis that two nCaM molecules can bind to 
iNOS and that the second nCaM associated to the C-type site of iNOS CaM-binding domain can be 
displaced by another CaM molecule at lower Ca2+ concentrations (previously described in Chapter 3 
and Chapter 5).  This experiment involved the use of iNOS coexpressed with unlabeled nCaM 
followed by the addition of labeled CaM; the displacement of the second nCaM by the labeled CaM 
would result in greater fluorescence quenching and a shorter lifetime.  Our previous study 
demonstrated that the heme is a potent quencher of Alexa Fluor 546 fluorescence (Chapter 5); 
therefore, the association of CaM-T34C-Alexa and CaM-T110C-Alexa to the iNOS enzyme could be 
monitored by the extent of fluorescence quenching.  It is anticipated that as Ca2+ concentrations 
increase, the second nCaM on the C-type site will not be displaced by the Alexa-labeled CaM protein 
resulting in a slight increase in fluorescence lifetimes.   
 A summary of determined fluorescent lifetimes and FRET distances for CaM-T34C-Alexa 
and CaM-T110C-Alexa in the presence of iNOS coexpressed with nCaM and increasing free Ca2+ 
concentrations is shown in Tables 6.12 and 6.13.   
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Table 6.12 – Determined FRET distances for CaM-T34C-Alexa 546 in the presence of iNOS 
coexpressed with nCaM with increasing free Ca2+ concentrations. 
[Ca2+]free RO
a τD b τ1(DA)     
distance 
(da1)e τ2(DA)     
distance 
(da2) 
(μM) (Å) (ns) [χ2] (ns) [χ2] A1c E1d (Å) (ns) A2 E2 (Å) 
                      
0 31 3.856 0.835 0.67 0.78 25.02 3.255 0.33 0.16 41.08 
    [1.100] [1.184]              
                     
0.0156  3.892 0.787 0.67 0.80 24.66 2.713 0.33 0.30 35.62 
    [1.131] [1.187]             
                     
0.0331  3.842 0.763 0.66 0.80 24.57 2.629 0.34 0.32 35.27 
    [1.085] [1.149]              
                     
0.0569  3.783 0.698 0.64 0.82 24.20 2.531 0.36 0.33 34.86 
    [1.130] [1.165]              
                     
0.0878  3.842 0.779 0.66 0.80 24.68 2.701 0.34 0.30 35.79 
    [1.120] [1.165]              
                     
0.1353  3.792 0.756 0.66 0.80 24.59 2.664 0.34 0.30 35.77 
    [1.087] [1.092]              
                     
0.1952  3.826 0.751 0.66 0.80 24.51 2.811 0.34 0.27 36.74 
    [1.180] [1.142]              
                     
0.2913  3.806 0.765 0.64 0.80 24.63 3.096 0.36 0.19 39.62 
    [1.180] [1.200]              
                     
0.433  3.796 0.810 0.60 0.79 24.94 3.619 0.40 0.05 51.26 
    [1.114] [1.157]              
                     
0.7801  3.802 0.799 0.55 0.79 24.86 3.630 0.45 0.05 51.53 
    [1.075] [1.158]              
                     
1.9138  3.781 0.829 0.61 0.78 25.09 3.594 0.39 0.05 50.74 
    [1.123] [1.106]               
                      
a - e
 As previously described in Table 6.4. 
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Table 6.13 – Determined FRET distances for CaM-T110C-Alexa 546 in the presence of iNOS 
coexpressed with nCaM with increasing free Ca2+ concentrations. 
[Ca2+]free RO
a τD b τ1(DA)     
distance 
(da1)e τ2(DA)     
distance 
(da2) 
(μM) (Å) (ns) [χ2] (ns) [χ2] A1c E1d (Å) (ns) A2 E2 (Å) 
                      
0 31 3.775 0.776 0.69 0.79 24.75 3.131 0.31 0.17 40.35 
    [1.121] [1.139]              
                     
0.0156  3.721 0.724 0.69 0.81 24.46 2.926 0.31 0.21 38.52 
    [1.114] [1.087]             
                     
0.0331  3.727 0.737 0.69 0.80 24.55 2.713 0.31 0.27 36.53 
    [1.111] [1.110]              
                     
0.0569  3.717 0.682 0.67 0.82 24.17 2.610 0.33 0.30 35.76 
    [1.100] [1.087]              
                     
0.0878  3.753 0.677 0.68 0.82 24.09 2.668 0.32 0.29 36.02 
    [0.962] [1.204]              
                     
0.1353  3.744 0.758 0.70 0.80 24.67 2.766 0.30 0.26 36.86 
    [1.113] [1.112]              
                     
0.1952  3.759 0.705 0.68 0.81 24.28 2.731 0.32 0.27 36.48 
    [1.162] [1.083]              
                     
0.2913  3.688 0.738 0.70 0.80 24.61 2.810 0.30 0.24 37.63 
    [1.076] [1.116]              
                     
0.433  3.686 0.752 0.66 0.80 24.71 3.101 0.34 0.16 40.93 
    [1.096] [1.190]              
                     
0.7801  3.586 0.788 0.58 0.78 25.10 3.474 0.42 0.03 54.95 
    [1.158] [1.177]              
                     
1.9138  3.570 0.814 0.63 0.77 25.30 3.471 0.37 0.03 56.08 
    [1.038] [1.057]              
                      
a - e
 As previously described in Table 6.4. 
 
For both CaM-T34C-Alexa and CaM-T110C-Alexa, the fluorescence of Alexa Fluor 546 was 
markedly quenched in the presence of iNOS coexpressed with nCaM at all free Ca2+ concentrations.  
The calculated FRET distance was ~24 Å for each, and as previously described in section 6.3.3.3.4, 
this appears to be at the limit of sensitivity for these FRET dyes.  Interestingly, the lifetime of the 
secondary species for each CaM protein demonstrated a marked increase in amplitude and FRET 
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distance at free Ca2+ concentrations above 400 nM (Figure 6.18).  The amplitude increased from ~30 
to ~40% for both CaM-T34C-Alexa and CaM-T110C-Alexa representing that this secondary species 
becomes more pronounced as the free Ca2+ concentration increased.  Likewise, the FRET distances 
for CaM-T34C-Alexa and CaM-T110C-Alexa demonstrated a decrease in quenching, indicative of 
Alexa-labeled CaM not binding to the iNOS enzyme (Tables 6.13 and 6.14).  This is significant 
because it suggests that at a certain Ca2+ concentration threshold, the Alexa Fluor dye is no longer 
quenched as strongly as it was at lower Ca2+ levels.  Although speculative, this large increase in 
FRET distance represents a marked change in the distance between the heme and Alexa Fluor 546 
dye in the sample which may be the result of the Alexa-labeled CaMs being blocked by the second 
nCaM at the C-type site of the iNOS CaM-binding domain.   
As a control experiment, the heme-free iNOS (iNOS C200A) coexpressed with nCaM was 
examined to prove that the observed quenching of Alexa Fluor 546 with holo-iNOS coexpressed with 
nCaM was related solely to the heme (Table 6.14).  These results demonstrate that there is no 
quenching of Alexa Fluor 546 by the heme-free iNOS enzyme coexpressed with nCaM. 
 
Table 6.14 – Control time-resolved fluorescence measurements of Alexa 546 labeled CaM 
proteins with iNOS C200A coexpressed with nCaM. 
 [Ca2+]free RO
a τD b τ1(DA)     
distance 




CaM (μM) (Å) (ns) [χ2] (ns) [χ2] A1c E1d (Å) (ns) A2 E2 (Å) 
                        
T34C 0 31 3.969 3.982 0.68 0.00 CND f 0.705 0.32 0.82 24.01 
      [1.136] [1.091]               
                        
  10  3.991 4.013 0.66 0.00 CND 0.850 0.34 0.79 24.93 
      [1.060] [1.055]              
                        
T110C 0 31 3.919 3.894 0.67 0.01 71.91 0.702 0.33 0.82 24.05 
      [1.079] [1.123]               
                        
  10  3.768 3.845 0.67 0.00 CND 0.976 0.33 0.74 26.02 
      [1.070] [1.076]               
 
                       
a - e
 As previously described in Table 6.4. 
f CND – Could not be determined. 
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6.3.4 Discussion 
Although crystal structures of CaM bound to cNOS-target peptides have been solved (Figure 
6.1), there have been no reported structures for CaM in complex with an iNOS peptide or any regions 
outside of the CaM-binding domain for all three NOS enzymes.  This has been attributed to a high 
amount of mobility in various regions of the protein, particularly in the reductase domain making it 
difficult to form crystals for its structural determination.   
The conformational variability of CaM alone and in complex with the target peptides and 
proteins has been studied extensively by x-ray crystallography and NMR spectroscopy.  For instance, 
the crystal structure of holo-CaM has shown an extended conformation with an intact central linker α-
helix (Chattopadhyaya et al., 1992); however, a more recent holo-CaM structure demonstrated a 
closed, compact conformation with the central linker bent bringing the N- and C-terminal domains 
into close proximity with each other (Fallon and Quiocho, 2003).  The distance between the T34 and 
T110 hydroxyl groups is ~54 Å in the extended holo-CaM structure and ~17 Å in the compact holo-
CaM structure.  Such a large conformation change should be detectable by FRET measurements.  As 
mentioned previously, CaM T34C/T110C has been used extensively to monitor conformational 
changes in CaM alone or in the presence of CaM target peptides and proteins (Drum et al., 2000; 
Torok et al., 2001; Slaughter et al., 2005a; Slaughter et al., 2005b; Xiong et al., 2005; Maximciuc et 
al., 2006).   
After reviewing all of the released NMR and x-ray crystal structures of CaM alone and CaM-
target peptide complexes, two common CaM conformations were found – a wrapped/compact 
conformation and an extended structure.  This is evident from a summary of the distances between 
CaM residues 34 and 110 (Table 6.15).  Most of the distances observed between T34 and T110 
demonstrate that CaM is in a compact form, as previously demonstrated in Figure 1.5 and Figure 1.6, 
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but there are also some examples of extended conformations, as previously shown in Figure 1.3 and 
Figure 1.7.   
In order to determine the conformation of CaM bound to the holo-NOS enzymes, we have 
used dually-labeled CaM T34C/T110C with the FRET donor-acceptor dyes Alexa Fluor 546 C5-
maleimide and DABMI to determine the conformation of CaM bound to the NOS peptides and holo-
NOS enzymes. 
Table 6.15 – Measured distances between T34 and T110 in the solved CaM NMR and x-ray 
crystal structures. 
a File downloaded from the Protein Data Bank (PDB). 
b Measured distance between CaM T34 and T110 hydroxyl groups using ViewerLite 5.0 (Accelrys). 
c The two values shown for the apo-CaM with myosin V complex represent the two CaM molecules found in 
the x-ray crystal structure (Houdusse et al., 2006). 
d The two values shown for the calcineurin structure represent the two CaM-CaN peptide fusion proteins found 
in the x-ray crystal structure (Ye et al., 2006). 
 PDB a Compact Conformation 
Distance 





       
       
CaM 1PRW compact holo-CaM 17.0 1CFD apo-CaM 40.3 
    1CLL holo-CaM 54.0 
    1Y6W 
trapped intermediate 
of holo-CaM 49.7 
       
       
CaM- 2O60 Neuronal NOS 15.5 1CFF Ca2+-pump 33.9 
target 1NIW Endothelial NOS 15.3 1G4Y SK K+ channel 32.5 
complex 2BBN Myosin light chain kinase 17.8 1K93 Anthrax edema factor 43.4 
 1CDM CaM-dep protein kinase II 17.8 1NWD Glutamate decarboxylase 37.6 
 1CKK CaM-dep kinase kinase (NMR) 16.3 2F2O Calcineurin (fusion) d 51.9 
 1IQ5 CaM-dep kinase kinase (X-ray) 17.4   52.8 
 1IWQ MARCKS 16.8    
 1L7Z Myristolated CAP-NAP 15.1    
 1MXE CaM-dep protein kinase I 14.6    
 1SY9 Olfactory CNG channel 16.1    
 1WRZ Death associated protein kinase 2 15.7    
 1YR5 Death-associated protein kinase I 16.6    
 1ZUZ DAPk-related protein kinase I 16.2    
 2BE6 CaV1.2 IQ domain  15.0    
 2FOT Alpha-II spectrin 13.5    
 2HQW Glutamate NMDA receptor 16.8    
 2BCX Ryanodine receptor 24.1    
 2IX7 Apo-CaM with myosin V c 20.6    
   19.9    
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The dually-labeled CaM protein bound to the cNOS peptides and enzymes had almost identical FRET 
distances demonstrating that CaM assumes a tightly wrapped conformation (Tables 6.5, 6.6, 6.8 and 
6.9).  Although the FRET distances are not equivalent to the measured distance between T34 and 
T110 hydroxyl groups in the CaM-eNOS and -nNOS crystal structures, they are still similar.   
To clarify the data shown in Tables 6.5, 6.6, 6.8 and 6.9, a summary figure was complied so 
that the Ca2+-dependence for the association of CaM to the cNOS peptides and enzymes could be 
compared (Figure 6.17).  There is a definite trend in the Ca2+-dependent conformation change of CaM 
in the presence of the cNOS peptides as free Ca2+ concentrations increased (Figure 6.17A and B).  
This transition at 100-200 nM free Ca2+ concentration is in good agreement with the previous reports 
on the Ca2+-dependent activation of holo-eNOS and holo-nNOS (Nishida and Ortiz de Montellano, 
1999; Montgomery et al., 2000).  
 
 
Chapter 6:FRET Studies of CaM Bound to NOS 
250 
 
Figure 6.17 – Determined FRET distances for dually-labeled CaM to cNOS peptides and 
enzymes at varying free Ca2+ concentrations. 
Averages FRET distances at each Ca2+ concentration were determined by using the following formula 
(A1*D1)+(A2*D2).  This value was then divided into two generalized FRET distance ranges – 20-35 Å 
(black) and 35 to 50 Å (grey).  These average FRET distance values were multiplied by their 
fractional contribution to the fluorescence decay (A1 or A2) and ploted to observe any trends in the 
FRET distances determined.  Data shown is derived from Tables 6.5, 6.6, 6.8 and 6.9.  Average FRET 
distances for dually-labeled CaM with (A) eNOS peptide, (B) nNOS peptide, (C) eNOS C186A 
(heme-free eNOS), and (D) nNOS C415A (heme-free nNOS).  The Ca2+-dependent activation of 
holo-eNOS and holo-nNOS is shown to compare the binding events we observe with the dually-
labeled CaM with the known free Ca2+ concentrations required for cNOS activation.  Ca2+-dependent 
activation of (E) holo-eNOS, and (F) holo-nNOS.  Panels E and F are derived from a previously 
published study (Nishida and Ortiz de Montellano, 1999).  Inset figures are of the identical cNOS 
Ca2+-activation data ploted in panels E and F with the free Ca2+ concentration plotted on a logarithmic 
scale. 
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In contrast, the Ca2+-dependent association of the CaM occurred at a lower free Ca2+ 
concentration for the cNOS enzymes than the cNOS peptides (Figure 6.17).  The average FRET 
distance observed with dually-labeled CaM in the presence of the heme-free cNOS enzymes was ~10 
Å shorter than the average FRET distance observed with the cNOS peptides.  This may be related to 
the environment of the Alexa Fluor 546 dye which may be in close proximity to the flavins.  This 
would increase the extent of quenching observed and give the appearance of a shorter FRET distance.  
The increase in CaM’s affinity for the cNOS enzymes at lower Ca2+ concentrations may also be 
related to the various residues found outside of the CaM-binding domain such as the FMN domain 
itself and possibly the oxygenase domain that have previously been suggested to form contacts with 
CaM (Ghosh and Salerno, 2003; Newman et al., 2004).  Although CaM’s conformation may be 
wrapped at a lower concentration of Ca2+ than previously reported (Ruan et al., 1996; Nishida and 
Ortiz de Montellano, 1999; Montgomery et al., 2000), it is also important to note that these previous 
studies were determining the Ca2+ concentration required for NOS activity.  It is possible that CaM 
has a compact conformation when the Ca2+-replete C-terminal domain of CaM initially binds to the 
cNOS enzymes; however, as the Ca2+ concentration increases, the N-terminal domain of CaM can 
become Ca2+-replete and fully activate the enzyme.  This is in good agreement with a previous model 
for the activation of the cNOS enzymes by the sequential binding of CaM’s C- and N-terminal 
domains (Lane and Gross, 2000) (previously described in Figure 1.20).  Furthermore, since these 
FRET distances for CaM bound to the cNOS peptides and enzymes are equal, it is fair to say that the 
solved crystal structures of CaM bound to cNOS CaM-binding domain peptides are a strong working 
model of CaM’s true conformation when bound to the holo-cNOS enzymes.   Future structural studies 
of CaM in complex with the CaM-binding domain and flanking regions in the reductase domain 
would clarify the true structure of CaM in complex with nNOS and eNOS (discussed further in 
section 8.2.2). 
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 Interestingly, CaM’s conformation when bound to the iNOS peptide appears to be very 
similar to the cNOS peptides, which is not surprising since the CaM-binding domains for the three 
mammalian NOS enzymes show a high degree of sequence similarity (Figure 6.14A).  As previously 
mentioned in Chapter 5, the orientation of CaM when bound to the iNOS CaM-binding domain was 
suggested to be in a parallel fashion (Gribovskaja et al., 2005).  In order to test this theory, we used 
singly labeled N- and C-terminal domains of CaM with an N-terminal dabsyl-labeled iNOS peptide 
and measured the amount of quenching.  Using this method, we were able to deduce that CaM binds 
to the iNOS CaM-binding domain in an antiparallel orientation similar to the cNOS enzymes (Spratt 
et al., 2007b).  In the same study, we have previously suggested that there is a subtle Ca2+-dependent 
conformational change in the C-terminal domain of CaM when bound to iNOS while the N-terminal 
domain was Ca2+-insensitive.  In order to further test this slight Ca2+-dependent conformational 
change in the C-terminal domain of CaM, the same FRET methodology using the N-terminally 
dabsyl-labeled iNOS peptide with CaM-T34C-Alexa and CaM-T110C-Alexa was used in the 
presence of increasing free Ca2+ concentrations.  Unfortunately, we were unable to observe any Ca2+-
dependent changes in CaM and we attributed this to the RO of the FRET donor-acceptor dyes (section 
6.3.3.3.4).  If another set of FRET donor-acceptor dyes with a shorter RO were to be used (ie. ~20 Å 
instead of 31 Å), these FRET measurements would be more sensitive to monitor the subtle Ca2+-
dependent conformational changes occurring in the C-terminal domain of CaM when bound to the 
iNOS CaM-binding domain.   
We also tested the displacement of a secondary nCaM from the C-type site of the iNOS CaM-
binding domain with fluorescently labeled CaM proteins.  Figure 6.18 is another summary figure 
created to clarify our observations for displacement of the secondary nCaM from iNOS at varying 
free Ca2+ concentrations (Tables 6.13 and 6.14). 
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Figure 6.18 – Determined FRET distances for iNOS coexpressed with nCaM with (A) CaM-
T34-Alexa CaM and (B) CaM-T110C-Alexa at varying free Ca2+ concentrations. 
Averages FRET distances at each Ca2+ concentration were determined as described in Figure 6.17. 
Data shown is derived from Tables 6.12 and 6.13. 
 
 
We found that at free Ca2+ concentrations lower than 400 nM, the secondary nCaM could be 
displaced by Alexa-labeled CaM proteins; however, above this free Ca2+ concentration threshold of 
400 nM, the nCaM no longer appeared to be displaced.    
 
6.3.5 Conclusions 
We have observed the dynamic conformational changes of CaM alone in solution and in 
association with NOS peptides and enzymes by determining the change in FRET distances between 
CaM’s N- and C-terminal lobes.  CaM wraps around all three NOS CaM-binding domain peptides in 
a compact structure, in agreement with the x-ray structures of CaM-eNOS (Aoyagi et al., 2003) and 
CaM-nNOS peptide (Ng et al. – unpublished).  These results test previous models for CaM’s 
association to the cNOS enzymes and clarify the conformation CaM when bound to the holo-
enzymes.  Past investigations have shown that regions flanking the NOS CaM-binding domain can 
interact with CaM, such as the autoinhibitory domain and FMN domain itself (Ruan et al., 1996; 
Venema et al., 1996; Newman et al., 2004; Ishida and Vogel, 2006).  For this reason, FRET 
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measurements were performed with peptides and holo-NOS enzymes to determine if there were any 
significant differences in CaM’s conformation due to these regions outside of the CaM-binding 
domain.  There appears to be no significant difference in the conformation of CaM when bound to the 
cNOS peptides and holo-cNOS enzymes; however, there does appear to be a variance in the free Ca2+ 
concentration required for CaM to bind to the cNOS enzymes.  By determining the conformation and 
the effect of free Ca2+ concentrations on the association of CaM to the three NOS enzymes, we have 
expanded upon the present understanding of the mechanism CaM uses to bind, and subsequently 
activate, the NOS enzymes.  Future structural studies suggested in Chapter 8 will hopefully expand 














NOTE: Please see Appendix B for an updated and simplified FRET analysis of Alexa 546/DAB-




Preliminary NMR Structural Analysis of Calmodulin Bound 
to the CaM-binding Domain of Inducible Nitric Oxide 
Synthase 
7.1 Introduction 
Protein-protein interactions and the dynamic conformational changes that result from the 
association of two or more proteins play an important role in enzyme catalysis and protein function.  
In order to gain a better understanding of how proteins change their conformation due to interactions 
with other proteins, many of the methods previously described, such as circular dichroism (Chapter 4 
and 6), fluorescence (Chapter 5) and FRET (Chapter 6), can be used.  However, these methods 
typically give lower structural resolution than the information that can be obtained from nuclear 
magnetic resonance (NMR) spectroscopy.   
NMR spectroscopy is a powerful biophysical technique that can be used to determine the 
solution three-dimensional structure of proteins in solution at high resolution and to monitor protein-
ligand interactions (which include protein-protein, protein-DNA, protein-small molecule complexes) 
and protein dynamics at the atomic level (Wüthrich, 1986; Jahnke and Widmer, 2004; Carlomagno, 
2005).  Unlike x-ray crystallography which gives a static representation of a protein structure, NMR 
spectroscopy is able to monitor the inherent dynamic flexibility in some proteins that would not be 
amenable to x-ray crystallography (Brunger, 1997; Van Holde et al., 1998).  In order to determine the 
3D NMR structure of a protein, the sequence specific resonance assignments must first be 
determined.  These are determined using through-bond spin-spin triple resonance heteronuclear NMR 
experiments (Bax et al., 1994; Kay, 1997) (Figure 7.1).   
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Figure 7.1 – Heteronuclear multidimensional NMR experiments typically used for the 
resonance assignment of proteins. 
These NMR experiments, which send magnetization through bonds in a protein, are used to determine 
the resonance assignments for each 1H, 13C, and 15N in a protein.  Asterisks represent the initial atom 
that is magnetized for each experiment.  (A) 15N-heteronuclear single quantum correlation (15N-
HSQC – shown in red) – 2D experiment which shows a single cross-peak for amide groups (15N—1H) 
in a protein. (B) HNCA (shown in green) – 3D experiment with magnetization starting at an amide 
proton (15N—1H), which is then transferred through the 15N to the 13Cα, and finally transferred back to 
the originating 15N—1H. (C) HN(CO)CA (shown in pink) - 3D experiment with magnetization 
starting at an amide proton, which is then transferred through the 15N and 13C=O to the 13Cα, and 
finally transferred back to the originating amide proton. (D) CBCANH (shown in blue) - 3D 
experiment with magnetization starting at protons attached to a 13Cβ, which is then transferred through 
the 13Cα to the 15N—1H.  (E) CBCA(CO)NH (shown in purple) - 3D experiment with magnetization 
starting at protons attached to a 13Cβ, which is then transferred through 13Cα and 13C=O to the 15N—
1H.  (F) 3D-TOtal Correlation SpectroscopY (TOCSY – shown in cyan) – 3D experiment with 
magnetization starting at protons attached to 13C found in the sidechains of the protein.  HNCA, 
HN(CO)CA, CBCANH and CBCA(CO)NH are useful NMR experiments to assign the resonance 
peaks for nuclei in the peptide backbone, while TOCSY is used to assign sidechain resonance peaks 
for each residue in the protein (Van Holde et al., 1998; Cavanagh et al., 2007). 
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Following the determination of the resonance assignments of all the 1H, 13C, and 15N atoms in the 
protein, distance constraints can then be determined using through-space nuclear Overhauser effect 
spectroscopy (NOESY) (Cavanagh et al., 2007).  NOSEY experiments give NOE cross-peaks that 
arise from dipole-dipole spin interactions of nuclei that are distant in a protein’s primary sequence but 
are in close proximity (~5 Å) in the protein’s folded structure (Van Holde et al., 1998).  NOE 
experiments also give information on the local secondary structure in a protein – for instance, an α-
helix has strong sequential CαH/NH cross-peaks between residues i and i + 3, whereas β-sheets have 
strong CαH/NH cross-peaks between residues i and i + 1 (Van Holde et al., 1998).  These local 
secondary structures and NOE distances determined from the NOESY experiments are then used as 
conformational constraints when solving the 3D structure of a protein using computational molecular 
dynamics (Cavanagh et al., 2007).  
Most of the published structures of CaM alone and bound to target peptides have been 
determined using x-ray crystallography.  However, there are also numerous NMR structural studies 
on holo-CaM (Ikura et al., 1990), apo-CaM (Kuboniwa et al., 1995), and truncated CaM mutants, 
such as Ca2+-replete and -deplete nCaM and cCaM (Finn et al., 1995; Ishida et al., 2000; Chou et al., 
2001) and the recently published structure of a CaM mutant consisting of only EF hands II and III 
(Lakowski et al., 2007).  There is also precedent for using NMR to study CaM’s 3D structure when 
associated to CaM-target peptides.  These structures include holo-CaM bound to CaM-binding 
domain peptides derived from CaM-dependent kinase kinase (Osawa et al., 1999), olfactory CNG 
channel (Contessa et al., 2005), glutamate decarboylase (Yap et al., 2003), plasma membrane Ca2+ 
pump (Elshorst et al., 1999), and myosin light chain kinase (Ikura et al., 1992).  To date, there is no 
reported NMR structure of CaM when bound to any of the NOS CaM-binding domains.  The 
conformational dynamics of CaM alone and in complex with target peptides have also been studied 
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by NMR (Barbato et al., 1992; Torok et al., 1992; Tjandra et al., 1995; Lee et al., 2002; Chang et al., 
2003; Prabhu et al., 2003).  
Although numerous x-ray structures of the oxygenase and reductase domains of the NOS 
enzymes have been solved (Figure 6.2), the structure of the holo-NOS enzymes in complex with CaM 
has not been determined.  This is due in large part to the inherent flexibility and dynamic nature of the 
NOS CaM-binding domains.  The x-ray structures of holo-CaM bound to peptides corresponding to 
the CaM-binding domains of eNOS (Aoyagi et al., 2003) and nNOS (Ng et al. – co-ordinates released 
12-25-2007) have also been determined (Figure 1.5 C & D), however, the high resolution 3D 
structure of CaM bound to the CaM-binding domain of iNOS has not yet been determined.  The 
solved structure of a CaM-iNOS peptide complex would be of great interest due to the important role 
iNOS-derived •NO has in various physiological processes within the cell. 
This chapter describes the development of expression systems for 15N and 13C isotopic 
labeling of CaM and an iNOS peptide for the resonance assignments and NOESY experiments which 
will be used to solve the 3D structure a CaM-iNOS peptide complex.  The NMR analysis of holo-
CaM bound to an iNOS CaM-binding domain peptide is well underway in collaboration with Dr. 
Thorsten Dieckmann (Associate Professor, U of Waterloo) and Dr. Dara Gilbert (U of Waterloo).  
Conventional through-bond spin-spin and through-space NOESY triple resonance NMR experiments 
(Figure 7.1) are presently being used to make resonance assignments (Sattler et al., 1999) and to 
assign NOE interactions in the CaM-iNOS peptide complex.  It is important to note that the solved 
CaM-iNOS peptide structure will only be a working model for CaM binding to iNOS, since regions 
flanking the CaM-binding domain have been implicated in the Ca2+-independent association of CaM 
to iNOS (Ruan et al., 1996).  These studies will determine and clarify the underlying structural 
differences in the binding, and ultimately the activation, of the Ca2+-dependent cNOS and the Ca2+-
independent iNOS enzymes by CaM.   
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7.2 Experimental Procedures 
7.2.1 13C and 15N Isotope Incorporation into Wild-type CaM and CaM1234 
E. coli BL21 (DE3) were transfected with pET9dCaM (section 2.2.2) or pCaM1234Kan (section 4.2.1) 
and grown in 50 mL LB medium with 30 mg/mL of kanamycin at 225 rpm, 37°C to an OD600 of 0.8-
1.0.  Once the cells reached the optimal density, 4 mL of the starter culture was harvested by 
centrifugation at 6000 x g for 7 minutes in a sterile 50 mL Oakridge tube.  The cells were then 
resuspended in 5 mL of sterile complete NMR minimal medium.  Complete NMR minimal medium 
was prepared as previously described (Markley and Kainosho, 1993) by autoclaving 1 L of 
Na2HPO4•7H2O (12.8 g/L), KH2PO4 (3.0 g/L), and NaCl (0.5 g/L) and allowing it to cool to room 
temperature, followed by the addition of media additives, which included: NH4Cl or 15NH4Cl (1.0 
g/L), glucose or U-13C6-glucose (2.0 g/L), MgSO4 (2 mM), CaCl2 (100 μM), thiamine (0.05 mg/L) 
and kanamycin (30 mg/L).  Depending upon which isotope was to be incorporated, glucose and/or 
NH4Cl was substituted with U-13C6-glucose or 15NH4Cl.  This liter of complete NMR minimal 
medium was then inoculated with the resuspended cells and the cells were grown to an OD600 of 0.8-
1.0 at 200 rpm, 37oC (approximately 10-12 hours).  Protein expression was then induced with the 
addition of IPTG (500 μM final concentration), and induction continued for 5 hours with shaking at 
200 rpm, 37 °C.  The cells were then harvested by centrifugation, flash frozen on dry ice, and stored 
at –80°C.   
7.2.2 Purification of 13C and 15N isotope labeled wild-type CaM and CaM1234 
13C-15N wild-type CaM and 15N wild-type CaM were purified as previously described by hydrophobic 
interaction chromatography on phenyl–Sepharose CL-4B (section 2.2.3).  15N CaM1234 was purified as 
previous described (section 4.2.2).  The sample was subsequently concentrated to ~ 2 mL using a 
Vivaspin 15 ultrafiltration spin column (Sartorius AG Biotechnology, Goettingen, Germany) and 
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filtered through a 0.45 μm filter to remove any particulate material.  The sample was then subjected to 
gel filtration using a HiLoad 16/60 Superdex 75 prep grade column (GE Healthcare Bio-Sciences, 
Baie d’Urfe, PQ) equilibrated with 50 mM Tris-HCl, pH 7.5, and 150 mM NaCl, and 1 mM DTT.    
The flow rate was maintained at 1.0 mL/min using an AKTApurifier System for Chromatography 
(GE Healthcare Bio-Sciences) and eluted protein was monitored at 278 and 254 nm.  A gel filtration 
standard kit (Sigma, Oakville, ON) containing multiple molecular mass markers was used to calibrate 
the column.  The purified 13C-15N wild-type CaM, 15N wild-type CaM and 15N CaM1234 were finally 
dialyzed overnight into 50 mM Tris-HCl, 1 mM CaCl2, pH 7.5 with 0.5 mM DTT (to prevent any 
unwanted oxidation of methionine residues found in CaM).  The proteins were then aliquoted, flash 
frozen on dry ice, and stored at –80oC.  The purified CaM proteins were analyzed by ESI-MS using a 
Micromass Q-Tof Ultima GLOBAL mass spectrometer (Manchester, U.K.) with an internal standard 
as previously described in section 2.2.5. 
7.2.3 Molecular Cloning of NOS CaM-binding domain peptides 
7.2.3.1 piNOSpep 
The cloning of the CaM-binding domain of human iNOS (residues 507-531; RPKRR EIPLK 
VLVKA VLFAC MLMRK) involved the use of three pairs of single-stranded complementary 
oligonucleotides using a similar methodology to a previously published study (Bisaglia et al., 2005).  
These primers were designed to have complementary sticky ends for the facile ligation of the 5’ and 
3’ ends of the open-reading frame (eg. for NcoI which recognizes and cuts C/CATGG, the 5’ end of 
the first primer was 5’ CATGG).  The primers used to construct the CaM-binding domain of iNOS 
are summarized in Table 7.1 and a schematic depiction of this cloning methodology is shown in 
Figure 7.2.  This construction also involved the incorporation of a 10-histidine tag followed by a 
thrombin cleavage site (LVPR/GS) upstream from the open-reading frame for the future cleavage and 
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removal of the poly-histidine-tag.  The primers were synthesized by Sigma-Genosys (Mississauga, 
ON) and were 5’ phosphorylated to aid in the efficiency of the ligation reaction.   
 
Table 7.1 – Primers used to construct phiNOSCBDKan, prnNOSCBDKan, and 
peNOSCBDKan  
 
In preparation for the ligation of these primers, the six primers (iCBDp1fr, iCBDp2fr, iCBDp3fr, 
iCBDp1rv, iCBDp2rv, and iCBDp3rv) were mixed in equal portions, heated to 95oC for 10 minutes 
and allowed to cool slowly to room temperature to facilitate annealing of the overlapping sequences.  
The annealed DNA was then cloned into the kanamycin resistant pET28a (Novagen) plasmid using 
the unique flanking NcoI and HindIII restriction sites.  The resulting vector, piNOSpep, was verified 
by DNA sequencing (UW Molecular Biology Core Facility). 
 
Primer Sequences 
iCBDp1fr 5’ CATGGGCAGCAGCCATCATCATCATCACCATCATCATCATCACAGCAGCGGCCTGGTACCGCGGGGCAGCCA 3’ 
iCBDp2fr 5’ TATGCGCCCCAAGCGCCGCGAGATCCCCCTTAAGGTTCTTGTTAAGGCC 3’ 
iCBDp3fr 5’ GTTCTTTTCGCCTGCATGCTTATGCGCAAGTAATAGGGATCCGAATTCA 3’ 
iCBDp1rv  5’ CCGCGGTACCAGGCCGCTGCTGTGATGATGATGATGGTGATGATGATGATGGCTGCTGCC 3' 
iCBDp2rv 5’ CAAGAACCTTAAGGGGGATCTCGCGGCGCTTGGGGCGCATATGGCTGCC 3’ 





    GTAATAGGGATCCGAATTCA 3' 
nCBDrv 
5’ AGCTTGAATTCGGATCCCTATTACTGCCCCATCAACTTGGCGGAAAATTTAACGGCCTCGGCTAGCTTTTTAAA 
      CCCAATGGCGCGCCGTTTCA 3' 
eCBDfr 
5’ TATGACGCGTAAGAAAACTTTTAAAGAGGTGGCCAACGCCGTGAAGATATCGGCTAGCCTTATGTAATAGGGA 
     TCCGAATTCA 3' 
eCBDrv 
5’ AGCTTGAATTCGGATCCCTATTACATAAGGCTAGCCGATATCTTCACGGCGTTGGCCACCTCTTTAAAAG 
      TTTTCTTACGCGTCA 3' 
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Figure 7.2 – Characteristics of the human iNOS CaM-binding domain expression vector 
phiNOSCBDKan 
Arrows indicate the transcriptional orientation of the corresponding genes and promoters. The human 
iNOS CaM-binding domain sequence was cloned between the unique NcoI and HindIII sites found in 
the multiple cloning site of pET28a (Novagen).  Abreviations used are: KanR, kanamycin-resistance 
determinant; lac o, lac operator sequence; lacI, gene coding for the lac repressor; T7p, T7 promoter; 
T7t, T7 terminator; RBS, ribosomal binding site. 
 
7.2.3.2 peNOSpep and pnNOSpep 
Using piNOSpep as the parent vector, the CaM-binding domains of bovine eNOS (residues 493-512; 
TRKKT FKEVA NAVKI SASLM) and rat nNOS (residues 725-747; KRRAI GFKKL AEAVK 
FSAKL MGQ) were cloned using a similar methodology as described above (section 7.2.3.1) but 
using a single pair of primers corresponding to the eNOS and nNOS CaM-binding domains, were 
used with complementary sticky ends for the 5’ NdeI and 3’ HindIII restriction sites (eg. for NdeI 
CA/TATG, 5’ end of the primer was 5’ TATG).  The primers used to construct the eNOS and nNOS 
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CaM-binding domain expression vectors are shown in Table 7.1.  The resulting vectors, peNOSpep 
and pnNOSpep, were verified by DNA sequencing.   
7.2.3.3 piNOSCBD-intein, peNOSCBD-intein, and pnNOSCBD-intein 
Difficulties were experienced when expressing the iNOS CaM-binding domain peptide using the 
expression vector piNOSpep in E. coli BL21 (DE3).  These difficulties included dramatic cell density 
decreases upon induction and the grey to black cell dicolouration, most likely due to the aggregation 
of the over-expressed hydrophobic iNOS peptide (see section 3.4 for further discussion).  
Furthermore, since only one aromatic residue (Phe) is found in these peptides, it was difficult to 
monitor all three NOS peptides by absorbance during their purification.  In order to circumvent these 
problems, the coding regions for iNOS, eNOS and nNOS CaM-binding domains were subcloned into 
pTYB12 (New England Biolabs, Markham, ON), an ampicillin resistant vector coding for a chitin-
binding domain-intein fusion protein with a multiple cloning site downstream at its 3’ end.  The 
coding regions for the three NOS CaM-binding domains were amplified by PCR, introducing unique 
flanking NdeI and HindIII restriction sites for subcloning into pTYB12.  The primers used were 
iCBDp1fr (Table 7.1) and NOSCBDrv 5’ ATAACTGCAGCCCGGGAAAACAGCATTCCAGG 3’.  
The coding regions of each CaM protein were then subcloned into the pTYB12 vector using the 
unique NdeI and PstI restriction sites.  The resulting vectors, piNOSCBD-intein, peNOSCBD-intein, 
and pnNOSCBD-intein, were verified by DNA sequencing to ensure that no spontaneous mutations 
had occurred.  Although the peNOSCBD-intein and pnNOSCBD-intein vectors will not be mentioned 
again in this chapter, they will be discussed in Chapter 8 where future experiments and conclusions 
are discussed. 
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7.2.4 Expression of intein-iNOS CaM-binding domain fusion protein 
An overnight culture of E. coli ER2566 (DE3) transfected with piNOSCBD-intein (section 7.2.3.3) 
was used to inoculate 2 x 1 L of LB media in 4 L flasks supplemented with 100 µg/ml of ampicillin.  
These 1 L cultures were grown at 37ºC, 200 rpm to an O.D600 of 0.6 – 0.8, induced with 500 µM 
IPTG and harvested after 6 hours of expression.  Cells were harvested by centrifugation at 6000 x g at 
4oC for 5 minutes, flash frozen on dry ice, and subsequently stored at –80ºC.   
 In preparation for future 15N isotope incorporation, a minimal medium expression test of the 
intein-iNOS CaM-binding domain fusion protein was performed in complete NMR minimal medium 
as previously described for wild-type CaM and CaM1234 (section 7.2.1) with the following 
modifications: (1) Cells were grown in the presence of 100 mg/L of ampicillin, (2) the incubator 
temperature was lowered to 22oC immediately after induction with 500 µM IPTG which has 
previously been shown to be the optimal temperature for intein-fusion protein expression (New 
England Biolabs, Pickering, ON), and (3) the cells were harvested 6 hours after induction.     
7.2.5 Purification of iNOS CaM-binding domain peptide from the intein fusion 
protein 
The following purification was performed by the candidate with the assistance of Yay Duangkham 
(MSc. student, U of Waterloo).  Cells were thawed on ice, resuspended in 4 volumes of Lysis Buffer 
(20 mM HEPES, 500 mM NaCl, 1 mM EDTA, 0.1% Tween 20, pH 7.0) and lysed by 
homogenization using an Avestin EmulsiFlex-C5 homogenizer (Ottawa, ON).  The lysate was then 
clarified by centrifugation at 48,000 x g for 30 minutes at 4oC.  All of the following steps were carried 
out at 4oC in a refrigerator or on ice.  10 mL of chitin beads (New England Biolabs) in a 1 cm x 30 cm 
Econo-column (Bio-Rad Laboratories, Mississauga, ON) was equilibrated with High Salt Wash 
Buffer (20 mM HEPES, 500 mM NaCl, 1 mM CaCl2, pH 7.0) prior to loading the clarified 
supernatent.  The clarified supernatant was then loaded onto the column at a flow rate of 0.5 mL/min 
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to allow for the chitin-binding domain of the fusion protein to associate to the resin.  After the sample 
was loaded, the resin was washed with 80 mL of High Salt Wash Buffer (8 column volumes) at a rate 
of 2 mL/min.  The resin was subsequently washed with 40 mL of Low Salt Wash Buffer (4 column 
volumes of 20 mM HEPES, 150 mM NaCl, 1 mM CaCl2, pH 7.0), which removes any proteins that 
interact weakly with the resin.  15 mg of wild-type CaM in 5 mL (3 mg/mL) was then loaded onto the 
resin at 0.5 mL/min to bind and protect the iNOS CaM-binding domain from aggregation.  The 
addition of wild-type CaM yields a stable complex with the iNOS CaM-binding domain and makes it 
easier to monitor the elution of this CaM-NOS peptide complex by absorbance later in the 
purification.  Furthermore, this method allows for the addition of unlabeled wild-type CaM with 15N-
iNOS CaM-binding domain peptide for future NMR studies exclusively on the iNOS peptide.  The 
resin was finally washed with 140 mL of Low Salt Wash Buffer (14 column volumes) at 2 mL/min to 
finish removing any non-specific interactions with the resin and excess CaM that did not associate to 
the intein-iNOS peptide fusion protein.  Finally, the column was quickly flushed with 35 mL of 
Cleavage Buffer (3.5 column volumes of 20 mM HEPES, 500 mM NaCl, 1 mM CaCl2, 50 mM DTT, 
pH 8.5) and incubated for 40 hours at room temperature to induce the intein thiol-dependent cleavage 
and release the CaM-iNOS peptide complex.  DTT, the higher pH and temperature were used to 
increase the efficiency of intein cleavage to mimic the conditions routinely used by the manufacturer 
(New England Biolabs).  After the 40 hour incubation, the CaM-iNOS peptide complex was then 
eluted from the column with cleavage buffer without DTT.   
The sample was then concentrated to ~1 mL using a Vivaspin 15 ultrafiltration spin column 
and filtered through a 0.45 μm filter to remove any particulate material prior to loading the sample 
onto a HiLoad 16/60 Superdex 75 prep grade gel filtration column, as previously described for 15N 
wild-type CaM (section 7.2.2).  Fractions containing CaM-iNOS peptide were pooled, aliquoted, flash 
frozen on dry ice, and stored at –80oC.  The CaM-iNOS peptide complex was then sent for ESI-MS 
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analysis as previously described (section 2.2.5) to confirm purification of wild-type CaM and the 
presence of the iNOS CaM-binding domain peptide.  The purified CaM was also run on a gel shift 
mobility assay as previously described (section 3.2.8) to confirm that the CaM-iNOS peptide complex 
was formed.   
7.2.6 Sample preparation for NMR experiments 
15N-13C-labeled, 15N-labeled and unlabeled wild-type CaM samples were prepared for NMR 
measurements by transferring the proteins into an NMR buffer consisting of 100 KCl, 10 mM CaCl2, 
0.2 mM NaN3 and 91%/9% 2H2O at pH 6.0 using a Ym10 centrifugal filter device (Millipore, 
Billerica, MA, USA).  This NMR buffer has previously used in another CaM-target peptide complex 
NMR study (Yap et al., 2003).  Two wild-type CaM-iNOS peptide samples with different 
combinations of isotope labeling were used during the NMR experiments.  Sample A consisted of 
15N-labeled wild-type CaM in complex with unlabeled iNOS peptide, while Sample B consisted of 
15N-13C-labeled wild-type CaM in complex with unlabeled iNOS peptide.  All NMR samples 
contained at least 1.0 mM wild-type CaM and 1.2 mM human iNOS peptide (to ensure complex 
saturation) in a total volume of 500 μL.  Lyophilized iNOS peptide (synthesized by Sigma-Genosys) 
was added to the CaM solution in small titrating increments until complex saturation was observed by 
complete peak changes observed in the 15N-HSQC spectrum.  
 
7.2.7 NMR spectroscopy and data analysis 
All NMR data were acquired at 25oC on Bruker 600 and 700 MHz spectrometers equipped with 
1H/13C/15N triple-resonance probes with XYZ-gradients (Bruker, Billerica, MA, USA).  In order to 
determine resonance assignments for isotopically labeled wild-type CaM in complex with unlabeled 
iNOS peptide, the following set of experiments were conducted.  The amide cross-peaks were 
obtained from an 15N-HSQC experiment (Muhandiram and Kay, 1994).  Using the previously 
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published resonance assignments of holo-CaM alone as a reference (accession code bmr547 in the 
Biological Magnetic Resonance Data Bank, Ikura et al., 1990), the initial assignment of the amide 
protons in the CaM-iNOS complex in the 15N-HSQC spectrum was performed.  To assign the amide 
protons that could not initially be resolved in the 15N-HSQC spectum, the peptide backbone 
resonances were assigned using standard 3D NMR measurements, which included HNCA, 
HN(CO)CA, CBCANH, and CBCA(CO)NH experiments using sample B (Grzesiek and Bax, 1992; 
Muhandiram and Kay, 1994).  Side-chain resonance assignments were obtained from a HCCH-
TOCSY spectrum of sample B (Bax et al., 1990).  Data were analyzed using Computer Aided 
Resonance Assignment (CARA), a free downloadable program from www.nmr.ch (Keller, 2004).   
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7.3 Results 
7.3.1 CaM Protein Expression and Purification 
Each of the expressed and purified 15N-labeled wild-type CaM, 15N-13C wild-type CaM, and 15N 
CaM1234 proteins produced high yields of 40.1, 37.9, and 22.7 mg/L, respectively.  These purified 
CaM proteins were judged to be over 95% homogeneous by SDS-PAGE (results not shown).  
Likewise, ESI-MS was used to further assess the homogeneity and proved that the expression and 
purification protocol used (sections 7.2.1 and 7.2.2) resulted in virtually complete isotope 
incorporation for 13C-15N wild-type CaM, 15N wild-type CaM and 15N CaM1234 (Table 7.2). 
Table 7.2 – Masses of isotope-labeled wild-type CaM and CaM1234 
      
                      Mass (Da) a 
     
     
  Observed Theoretical b 
 CaM proteins     
   
Wild-type CaM c 16706.0 16706 
15N wild-type CaM d 16891.5 16894 
15N-13C wild-type CaM e 17592.0 17608 
CaM1234 f 16530.0 16530 
15N CaM1234 g 16713.5 16718 
   
a Masses of deconvoluted ESI-MS spectra were determined with an accuracy of ± 5 Da. 
b Calculated masses based upon amino acid sequence. 
c Mass of wild-type CaM as previously determined in Table 2.1. 
d Expected mass difference with 15N isotope labeled wild-type CaM is 188 Da. 
e Expected mass difference with 15N-13C isotope labeled CaM is 902 Da.  The large discrepancy in the mass is due to the use 
of 99% 13C6-glucose. 
f Mass of CaM1234 as previously determined, see Table 4.1. 
g Expected mass difference with 15N isotope labeled CaM1234 is 188 Da. 
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7.3.2 CaM-iNOS CaM-binding domain peptide purification 
The iNOS CaM-binding domain peptide alone was difficult to purify due to its propensity to 
aggregate.  This aggregation was overcome by the binding of wild-type CaM to the intein-iNOS 
peptide fusion protein on the column.  Since CaM is highly hydrophilic with a pI of ~4, it not only is 
able to protect the peptide from aggregation during purification, but it also ensured that the CaM-
peptide complex will remain in solution throughout purification.  Furthermore, this method allows for 
the copurification of the isotopically labeled iNOS peptide in complex with unlabeled wild-type CaM.  
This complex can then be used in future NMR experiments to determine the resonance assignments 
and NOE interactions of the iNOS peptide when bound to CaM.   
The expressed and copurified CaM-iNOS peptide complex produced a yield of 0.5 mg/L. 
ESI-MS was used to assess the homogeneity and confirm that the copurification with wild-type CaM 
was successful (Table 7.3).  Subsequent to the ESI-MS result, the copurified CaM-iNOS peptide 
complex was tested using a gel shift mobility assay (section 3.2.8) to ensure that the purified complex 
was pure, saturated and demonstrated the expected mobility shift when compared to wild-type CaM 
alone (Figure 7.3). 
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Table 7.3 – Masses of unlabeled iNOS peptide copurified with wild-type CaM. 
      
 Mass (Da) a 
     
     
  Observed Theoretical b 
 Proteins/Peptides     
   
iNOS peptide (from intein-fusion protein) c 3391.9 3393 
Wild-type CaM (copurified) 16704.5 16706 
   
iNOS peptide (synthesized by Synpep) d 2995.5 2997 
iNOS peptide (synthesized by Sigma Genosys) e 2995.5 2997 
   
a Masses of deconvoluted ESI-MS spectra were determined with an accuracy of ± 4 Da. 
b Calculated masses based upon amino acid sequence. 
c Expected mass of intein-fusion protein derived iNOS peptide with addition N-terminal residues AGHM. 
d & e  Synthesized iNOS peptides used to saturate 15N wild-type CaM and 15N-13C wild-type CaM for NMR experiments, 
respectively.   These measurements were taken to ensure the identity of the peptides after a report that an investigation of 
Synpep for illegally falsifying their peptide analyses was published.  The correct mass was observed signifying that the 




Figure 7.3 – Gel Mobility Shift Assay of wild-type CaM with synthetic and recombinantly 
expressed iNOS peptides. 
Wild-type CaM (20 μM) was incubated with synthetic iNOS peptide in the presence 0.2 mM CaCl2. 
CaM-iNOS peptide derived from intein-iNOS peptide fusion protein was loaded without any 
additional peptide added.  The samples were then analyzed by PAGE (15% acrylamide) containing 
0.375 M Tris, pH 8.8, 4 M urea, and 0.2 mM CaCl2 and visualized with Coomassie Blue R-250. 
Lanes 1 & 5 – wild-type CaM alone; Lane 2 – wild-type CaM with 0.5 molar equivalents of synthetic 
iNOS peptide; Lane 3 – wild-type CaM with 2 molar equivalents of synthetic iNOS peptide; Lane 4 – 
wild-CaM copurified with iNOS peptide derived from intein-iNOS peptide fusion protein.  
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The iNOS-peptide from the intein-fusion protein demonstrates a greater mobility shift which can be 
attributed to the extra histidine residue derived from the cleaved intein fusion protein at the N-
terminus of the peptide (additional N-terminal of AGHM; Figure 7.3).  Clearly, a pure, saturated 
CaM-iNOS peptide complex is purified using the purification methodology described in section 7.2.5.   
 Furthermore, expression tests using the intein-iNOS peptide in NMR minimal medium 
demonstrate that the fusion protein expresses well after 6 hours of induction (Figure 7.4). 
  
Figure 7.4 – 12% SDS-PAGE of intein alone and intein-iNOS peptide time-course expression 
test in minimal medium. 
Protein was loaded in a standard SDS-loading buffer.  Samples consisted of ER 2566 (DE3) E. coli 
transformed with pTYB12 (intein alone) or piNOSpep-intein (intein-iNOS peptide) before and after 6 
hours induction with 500 μM IPTG. Lane 1, low molecular mass protein standard (GE Healthcare 
Bio-sciences); Lane 2, intein alone at t = 0; Lane 3, intein alone at t = 6 hours; Lane 4, intein-iNOS 
peptide at t = 0; Lane 5, intein-iNOS peptide at t = 6 hours.  Expected size of intein alone and intein-
iNOS peptide fusion protein are 60.4 and 61.8 kDa, respectively. 
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These results for the purification of unlabeled CaM-iNOS peptide complex and expression tests for 
iNOS-peptide in complete NMR minimal medium demonstrate that the future purification of 15N-
labeled iNOS peptide from the intein-fusion protein for NMR experiments should be feasible. 
7.3.3  Preliminary NMR Spectral Analysis 
15N wild-type CaM was titrated with lyophilized synthetic iNOS peptide until the CaM-iNOS sample 
was saturated with iNOS peptide.  The disappearance and corresponding appearance of resonance 
peaks during iNOS peptide titration demonstrated the formation of the CaM-iNOS peptide complex.  
Analysis of the 15N-HSQC of 15N wild-type CaM complexed with iNOS peptide demonstrated 
marked chemical shift perturbations in the NMR spectra when compared to 15N wild-type CaM.  As 
described in section 7.2.7, the initial assignment of the amide protons in the CaM-iNOS complex in 
the 15N-HSQC spectrum was performed and compared to the previously published resonance 
assignments of holo-CaM alone as a reference spectrum (Ikura et al., 1990).   
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Figure 7.5 – 1H,15N-HSQC spectra of CaM alone and in complex with iNOS peptide. 
(A) Spectra from CaM alone and in complex with iNOS peptide are shown in blue and red, respectively.  Residues are labeled with preliminary 
resonance assignments for the CaM-iNOS peptide complex.  These assignments are only preliminary and need to be further refined using other 
types of 3D NMR experiments.  (B) Magnification of highlighted region panel A (green) is shown to demonstrate the chemical shift perturbations 
observed for wild-type CaM residues G25, G61, G98, and G134 when alone (blue) and bound to iNOS peptide (red).  
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The 3D-HNCA, 3D-HN(CO)CA, 3D-CBCANH, and 3D-CBCA(CO)NH experiments have 
been acquired and appear to be of good quality with many cross-peaks.  This will enable the next 
stage of peptide backbone resonance assignments for CaM in complex with iNOS peptide.  A future 
3D-HCCH-TOCSY is planned to complete the resonance assignments for sidechains in CaM.  3D-
NOESY experiments will then be performed to obtain through-space distance constraints for pairs of 
protons and localized secondary structure in CaM from chemical shifts and peptide backbone NOE 
interactions.  Finally, 13C-12C half filter experiments are also planned to determine interactions 
between 13C-labeled side chains of CaM in close proximity to unlabeled sidechains of the iNOS 
peptide.  The tertiary structure calculation of CaM in complex with the iNOS peptide will involve 
using distance restraints obtained from 13C and 15N-NOESY experiments and standard computational 
molecular dynamic algorithms (Cavanagh et al., 2007).  
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7.4 Future Studies 
The experiments described in this chapter provide the ground work and establish the feasibility of the 
structural determination of a holo-CaM-iNOS peptide complex.  As mentioned in section 7.3.3, 
numerous 3D NMR experiments have been performed or are planned to complete the resonance 
assignments of CaM in complex with an iNOS peptide.  The purification of 15N-labeled iNOS peptide 
with unlabeled wild-type is also planned (see section 7.3.2) in order to obtain more detailed 3D 
structural information on the peptide when bound to CaM.  The detailed 3D NMR solution structure 
of CaM bound to iNOS that will be solved in the future from this study will be compared with the 
known crystal structures of CaM bound to eNOS (Aoyagi et al., 2003) and the recently released 
structure of CaM bound to nNOS (Ng et al., co-ordinates released 12-15-2007).  It is anticipated that 
the inherent structural differences in the association of CaM to Ca2+-dependent cNOS enzymes and 
Ca2+-independent iNOS will be determined. 
Furthermore, the Ca2+-independent association of CaM with the CaM-binding domain of 
iNOS is of great interest due to the diverse and manifold physiological roles iNOS-derived •NO plays 
in the cell.  In order to discern if any major structural differences are present in holo- and apo-CaM 
when bound to the iNOS peptide, future NMR experiments using CaM1234 to mimic apo-CaM 
(Chapter 4) are planned.  To date, only 15N-labeled CaM1234 has been expressed and purified; 
however, the expression and purification of 13C-15N CaM1234 is also planned.  In addition, the 
copurification of 15N-isotopically labeled iNOS peptide from the intein-iNOS peptide fusion protein 
with unlabeled CaM1234 is also planned for the detailed 3D solution structure of the iNOS peptide in 
complex with apo-CaM. 
These NMR structural studies of holo- and apo-CaM in complex with an iNOS CaM-binding 
domain peptide will provide a better understanding of the Ca2+-independent binding and mechanistic 




Original Contributions and Recommendations for Future 
Studies 
8.1 Original Contributions 
Differential activation of NOS isozymes by CaM-TnC chimeras (Chapter 2). 
Using CaM-TnC chimeric proteins, we determined that EF hand I was critical for cNOS activation. 
The iNOS enzyme was coexpressed with each CaM-TnC to test their effect on iNOS activity.  In 
contrast to the results observed for the cNOS enzymes, EF hands II and III were found to contain 
important elements required for the Ca2+-independence of the enzyme.  This study was novel in that 
we were the first to ever report on specific elements in CaM required for the activation of iNOS.  
Prior to this study, iNOS could only be produced in the presence of wild-type CaM (Cho et al., 1992); 
The development of this coexpression methodology to produce iNOS bound to mutant forms of CaM 
was a significant milestone in studying CaM-iNOS interactions. 
 
 
Binding and activation of NOS isozymes by CaM EF hand pairs (Chapter 3). 
In this study, four different mutant CaM proteins were used to investigate the role of the two CaM EF 
hand pairs in the binding and activation of the mammalian NOS enzymes.  Our results show that the 
N-terminal EF hand pair in conjunction with the central linker region is required for cNOS enzyme 
binding and activation, whereas the N-terminal EF hand pair of CaM (nCaM) contains important 
binding and activating elements for iNOS.  This is novel since prior to this study, iNOS could only be 
produced with CaM or CaM mutants having all four EF hands present.  In our gel filtration studies, 
we demonstrated under Ca2+-deplete conditions that the addition of excess CaM is able to protect 
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iNOS against aggregation.  We also found that two nCaMs could associate to the iNOS CaM-binding 
domain simultaneously using gel mobility shift assays.  From these data, we proposed a model 
explaining why the iNOS enzyme must be coexpressed with wild-type CaM in vitro due its 
propensity to aggregate when residues of the highly hydrophobic CaM-binding domain are exposed to 
an aqueous environment.  
 
 
Ca2+-deficient CaM binding and activation of neuronal and inducible NOS (Chapter 4). 
We used CaM mutants deficient in Ca2+-binding with mutations in the N-lobe (CaM12), the C-lobe 
(CaM34), or both lobes of CaM (CaM1234) to determine their effect on the binding and activation of the 
Ca2+-dependent nNOS and Ca2+-independent iNOS isoforms. Four different kinetic assays were 
employed to monitor the effect of these CaM mutants on electron transfer rates in NOS.  The CaM 
mutants were unable to activate nNOS, however, our CD results demonstrated that the Ca2+-replete C-
terminal lobe of CaM is capable of binding to the nNOS peptide.  A future experiment is 
recommended to expand upon this particular finding of the C-terminal binding to nNOS without 
activation (described in section 8.2.1).  The results from this study also proved for the first time 
without the use of chelators that apo-CaM is capable of binding to iNOS peptides and holoenzymes.  
We also found that the activation of iNOS by the N-terminal domain of CaM was Ca2+-independent, 
whereas activation by the C-terminal domain of CaM was Ca2+-dependent. 
 
Differential binding of CaM domains to constituitive and inducible NOS (Chapter 5). 
In order to investigate the binding of specific regions in CaM to NOS peptides and enzymes, we 
developed a methodology to selectively label specific residues in the N-terminal lobe, C-terminal 
lobe, or linker region of the protein with fluorescent dyes.  We used an N-terminally labeled an iNOS 
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CaM-binding domain peptide with dabsyl chloride in order to perform FRET studies between Alexa-
labeled residues in the N- and C-terminal domains of CaM and determined that CaM binds to iNOS in 
an antiparallel orientation.  Steady-state fluorescence and circular dichroism studies show that both 
the N- and C-terminal EF hand pairs of CaM bind to the CaM-binding domain peptide of iNOS in a 
Ca2+-independent manner; however, only the C-terminal domain showed large Ca2+-dependent 
conformational changes when associated with the target sequence.  Steady-state fluorescence showed 
that Alexa-labeled CaM proteins are capable of binding to holo-iNOS coexpressed with nCaM.  The 
nCaM protein binds to both the N- and C-type sites of the iNOS CaM-binding domain with nCaM 
bound at the C-type site being able to be displaced with the addition of excess CaM.  Noteably, the 
nCaM bound to the N-type site demonstrated that its association is Ca2+-independent and is markedly 
more stable than its association to the C-type site.  These results were novel since no one had 
previously shown that the association of CaM to iNOS is not permanent.  It is likely that the N-
terminal lobe of CaM binding to the iNOS CaM-binding domain is Ca2+-independent whereas the C-
terminal lobe of CaM demonstrated a Ca2+-dependent conformational change when bound to iNOS.  
This variation of the Ca2+-dependent/independent association of the N- and C-terminal domains of 
CaM contrasts to the previously proposed model of CaM’s sequential association to the nNOS 
enzyme (Weissman et al., 2002).  This investigation provided further insight into why iNOS remains 
active even under basal levels of Ca2+ in the cell. 
 
 
FRET conformational studies of CaM bound to NOS enzymes (Chapter 6). 
This study was first to use FRET in monitoring the dynamic conformational changes in CaM when 
associated to NOS peptide and enzymes in the presence of increasing free Ca2+ concentrations.  We 
found that CaM has a wrapped conformation when bound to the iNOS and cNOS peptides similar to 
the previously solved x-ray crystal structures of the CaM-eNOS and CaM-nNOS peptide complexes.  
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Furthermore, the conformation of CaM bound to the both full-length eNOS and nNOS is identical to 
its conformation bound to the NOS peptides signifying that the crystal structures of CaM bound to the 
cNOS peptides are a good working model.  Future recommended experiments to further the findings 
of CaM’s conformation bound to the holo-NOS enzymes are described in section 8.2.2.  
 
 
Preliminary NMR structural determination of CaM bound to the CaM-binding domain of 
iNOS (Chapter 7). 
The 3D structure of a CaM-iNOS peptide complex is currently being studied and will hopefully be 
completed in the coming year.  A method to isotopically label the iNOS peptide bound to unlabeled 
CaM was developed which has never been reported before.   This novel methodology allowed us to 
overcome the difficulty with the aggregation properties of the iNOS CaM-binding domain.  The NMR 
structural determination of holo- and apo-CaM in complex with an iNOS CaM-binding domain 
peptide will be of great interest to the NOS research community and provide a better understanding of 
the Ca2+-independent binding and mechanistic control of iNOS by CaM.  This study will also serve as 
a foundation for future NMR CaM-NOS interaction studies that are recommended in sections 8.2.1 
and 8.2.2. 
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8.1.1 Working Model of the CaM-dependent regulation of iNOS 
By combining the cumulative results in this thesis, a working model for the CaM-dependent 
regulation of iNOS is proposed (Figure 8.1).  This model builds on the previous model proposed by 
Garcin and coworkers for the Ca2+-dependent activation of the cNOS enzymes (Figure 1.15) (Garcin 
et al., 2004).  Since previous studies have shown that electron transfer in the reductase domain of 
iNOS is CaM-independent (Newton et al., 1998), the only point of electron transfer that appears to be 
affected directly by CaM is the FMN to heme electron transfer step.  
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Figure 8.1 – Working model for CaM-dependent regulation of •NO by iNOS. 
This model is based upon a previous study (Garcin et al., 2004) with the exception that the reductase 
domain is not shown as a dimer (for explanation, please see section 1.2.2).  Each monomer of NOS is 
shown in white and grey, respectively.  The structural zinc at the dimer interface of the oxygenase 
domain is shown in yellow.  The N- and C-terminal domains of CaM are shown in red and blue 
respectively.  Ca2+-deplete and Ca2+-replete EF hands of CaM are shown as white and green circles.  
Based upon our previous study, CaM binds in an antiparallel fashion (Chapter 5).  The N-terminal 
domain of CaM binds closer the reductase domain and interacts directly with the FMN domain.  The 
C-terminal domain of CaM binds closer to the oxygenase domain.  Our studies have shown that the 
N-terminal domain of CaM contains important binding and activating elements for iNOS (Chapter 3).  
At basal Ca2+ concentrations, this CaM domain is Ca2+-deplete and binds very tightly to the N-type 
site of the iNOS CaM-binding domain.  The N-terminal domain of CaM does not appear to have any 
Ca2+-dependent affect on electron transfer rates within iNOS, as previously shown in Chapters 4 and 
5.  (A) Apo-CaM is able to bind to the iNOS enzyme.  The reductase domain of iNOS is CaM-
independent and is able to transfer electrons efficiently from NADPH through the reductase domain 
to the FMN (Newton et al., 1998).  After electrons are transferred to the FMN, a CaM-dependent 
conformational change in the FMN domain occurs, where the FMN domain moves from an electron 
accepting position to an electron donating position.  The electrons from FMNH2 are able to 
transferred to the catalytic heme of the other NOS monomer; however, this structural change in the 
reductase domain is not perfect (~70% when compared to Ca2+-replete CaM) and electrons are able to 
be uncoupled from •NO production to produce •O2-.  •O2- production has previously been linked to 
electron uncoupling from the flavins in the reductase domain of iNOS (Xia et al., 1998).  This 
uncoupling, which results in an NADPH oxidized to •NO produced ratio greater than 2:1, and lower 
•NO production rates by iNOS has been attributed to the Ca2+-deplete C-terminal lobe of CaM, as 
previously described in Chapters 4 and 5.  (B) An increase in free Ca2+ concentration causes the C-
terminal domain of CaM to become Ca2+-replete.  This directly affects the CaM-dependent 
conformational change in the FMN domain to dock perfectly with the oxygenase domain so that it 
can pass its electons efficiently to the catalytic heme.  This results in the reductase domain derived 
electrons being tightly coupled to •NO production with an NADPH oxidation to •NO produced ratio 
of 1.5:1.  Although it is still unclear if the N-terminal domain of CaM is Ca2+-deplete or Ca2+-replete 
in the fully active form iNOS, it is clear that Ca2+ binding to CaM is required for electrons to be fully 
coupled to •NO synthesis. 
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Although this model is simplistic in describing the effect of the various domains of CaM on electron 
transfer with iNOS, it does demonstrate the importance of Ca2+ binding to the C-terminal domain of 
CaM to promote efficient electron transfer from the FMN domain to the heme for •NO synthesis.  The 
completion of the NMR structural study of Ca2+-replete and Ca2+-deplete CaM bound to an iNOS 
CaM-binding domain peptide (Chapter 7) will determine the specific interactions that are occurring 
between CaM and the iNOS CaM-binding domain.  Since nCaM alone is able to bind and activate 
iNOS, and the N-terminal domain of CaM binds closest to the FMN domain of iNOS, an experiment 
is suggested.  This experiment would involve the structural determination of CaM in complex with an 
extended iNOS CaM-binding domain-FMN domain construct (section 8.2.2).  This investigation 
would help refine the working CaM-iNOS model since important contacts between CaM and regions 
flanking the CaM-binding domain have been implicated in the Ca2+-independence of iNOS (Ruan et 
al., 1996).  This study may also provide information on the dynamic properties of the FMN domain 
with varying free Ca2+ concentrations, as previously described in Chapter 6.  Clearly, a better 
understanding of how CaM binds and activates the iNOS enzyme continues to be of great interest due 
to the diverse physiological roles performed by •NO and this working model is a progressive step in 
clarifying this enzyme’s mechanism. 
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8.2 Recommendations for Future Studies 
The following is a summary of recommended experiments to expand upon the findings presented in 
this thesis.  These suggested experiments would test current models and clarify the mechanism of 
CaM binding and activation of the NOS enzymes. 
8.2.1 NMR structural determination of CaM mutants with NOS peptides 
As previously described in Chapter 7, intein-fusion protein expression systems for all three NOS 
CaM-binding domains have been created.  These vectors can be used to produce 15N and 13C isotope 
labeled peptides for future NMR studies with various CaM mutants that have been described 
throughout this thesis.  There are several combinations of CaM mutant proteins bound to NOS CaM-
binding domain peptides that can possibly be investigated by NMR spectroscopy.  Once the NMR 
structure of CaM bound to the iNOS peptide has been determined, the assigned resonance peaks for 
the CaM-iNOS peptide complex can act as a reference spectrum for these future studies. 
A CaM mutant of particular interest would be CaM12, which is incapable of binding Ca2+ in 
its N-terminal domain (Chapter 4).  Using circular dichroism, it was demonstrated that this mutant 
could bind to the nNOS CaM-binding domain peptide (section 4.3.4.2).  In a previous model, it was 
proposed that the Ca2+-replete C-terminal domain of CaM can bind to the cNOS enzymes first, and 
following a subsequent increase in cytosolic Ca2+ concentrations, the N-terminal domain of CaM is 
then able to bind and activate the enzyme (Weissman et al., 2002).  In order to test this model as well 
as observe a possible intermediate species in the binding and activation of the cNOS enzymes, the 3D 
structural determination of CaM12 in complex with the CaM-binding domains of nNOS and/or eNOS 
is suggested.  The elucidation of this intermediate structure would also be of general interest to the 
CaM research community since this sequential mode of CaM binding and activation has been 
suggested to occur in other Ca2+-dependent CaM-target proteins such as the plasma Ca2+-ATPase 
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(Sun and Squier, 2000), CaM-dependent protein kinase II (Torok et al., 2001), and MLCK 
(Persechini et al., 1994; Bayley et al., 1996). 
8.2.2 NMR structural determination of the FMN domains for nNOS and iNOS 
The FMN domain of the NOS reductase domain plays a pivotal role in electron transfer within the 
NOS enzymes; however, the detailed 3D structure of the FMN domain in complex with CaM has yet 
to be determined.  It has been suggested that the FMN domain of the NOS enzymes are highly 
dynamic and undergo a large conformational change when bound to CaM (section 1.2.3; Figure 8.1).  
The cNOS enzymes also contain a putative autoinhibitory element in their FMN domains that have 
also been suggested to undergo a conformational change upon CaM binding to the enzyme (section 
1.2.5.1.1).  Although the crystal structure of nNOS’s reductase domain has previously been solved 
(Garcin et al., 2004), this crystal structure did not contain the CaM-binding domain or show the 
autoinhibitory element, important regulatory regions that control electron transfer within the NOS 
enzyme.  These regulatory regions have been suggested to be highly dynamic making their structural 
determination difficult using x-ray crystallography.  As mentioned previously, NMR spectroscopy is 
able to observe the intrinsic flexibility in some proteins and would be able to monitor the movement 
of these regulatory elements in nNOS.  This would be a ground-breaking study and of great interest to 
the NOS research community if the underlying structural and mechanistic basis for the autoinhibitory 
element in regulating electron transfer within the cNOS enzymes was determined.  Furthermore, this 
structure would expand upon the solved crystal structures of CaM bound to the CaM-binding domain 
peptides of eNOS (Aoyagi et al., 2003) and nNOS  (Ng et al. – unpublished) by determining other 
contacts between CaM and the cNOS enzymes that have previously been suggested to occur with the 
reductase domain or possibly the autoinhibitory domain itself (Newman et al., 2004; Spratt et al., 
2006). 
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In order to determine the structure of the nNOS FMN domain in the presence and absence of 
CaM, constructs have previously been created that include the CaM-binding domain and autohibitory 
domain of nNOS based upon a previous study (Garnaud et al., 2004).  This nNOS construct 
(nNOSFMNCaM) has been demonstrated to produce stable soluble protein that is FMN replete; 
however, sufficient yields when expressed in minimal media from NMR measurements may become 
an obstacle.  Optimization of expression in minimal medium will have to be performed to maximize 
15N and 13C isotope incorporation and may require subcloning of this construct into a more suitable 
expression vector containing a T7-promoter.  Once stable protein has been produced, the 3D NMR 
structure could be determined in the presence and absence of CaM.  Particular focus should be given 
to the conformational changes that occur in the FMN domain upon CaM binding in the CaM-binding 
domain and the autoinhibitory domain.  The effect of free Ca2+ concentration could also be studied 
using Ca2+/EGTA buffers (Chapter 6) to determine the effect of Ca2+ on the nNOSFMNCaM protein.    
Unlike the cNOS enzymes, iNOS does not contain an autohibitory element.  Since regions in 
iNOS’s FMN domain flanking the CaM-binding domain have also been implicated in the Ca2+-
independent association of CaM to iNOS (Ruan et al., 1996), it would be advantageous to determine 
the structure of iNOS’s FMN domain.  A construct coding for the FMN domain of iNOS in 
conjunction with its CaM-binding domain has been cloned by the candidate.  This construct is based 
upon the sequence alignment of the aforementioned nNOSFMNCaM construct that produces soluble 
protein (Garnaud et al., 2004).  Using the soon-to-be solved 3D NMR structure of CaM bound to the 
iNOS CaM-binding domain peptide as a starting point (Chapter 7), the iNOSFMNCaM construct 
could be solved using standard triple resonance NMR spectroscopic techniques.  By solving the 
structure of both the nNOS and iNOS FMN domains in complex with CaM, a detailed comparison of 
the differences between their FMN domains can be performed that will help to further clarify the 
regulatory differences between the Ca2+-dependent and Ca2+-independent NOS enzymes. 
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8.2.3 Characterization of CaM binding and activation of other CaM-dependent 
target proteins 
Numerous CaM mutant proteins have been created to elucidate the specific elements or regions in 
CaM required for the binding and activation of the NOS enzymes.  These various mutant CaM 
proteins, which include CaM-troponin C chimera (Chapter 2), CaM EF hand pair mutants (Chapter 
3), Ca2+-deficient CaM mutants (Chapter 4), and numerous other CaM with point mutations, have 
been instrumental in expanding our knowledge on the interactions that occur between CaM and NOS.  
Clearly, with this large repertoire of CaM mutants and experience studying protein-protein 
interactions involving CaM, it is conceivable that studying another CaM-dependent target protein of 
physiological interest would be a logical progression.  For example, the x-ray crystal structures of 
CaM associated to the CaM-binding domains of death-associated protein kinases have recently been 
solved (Kursula et al. - unpublished).  These kinases are linked to a variety of cell death-related 
signaling pathways (Bialik and Kimchi, 2006); however the detailed affect of CaM and its various 
regions on the activation of these important kinases has not yet been determined.  With over 300 
proteins and enzymes in the cell suggested to be CaM-dependent (Ikura and Ames, 2006), there is a 





Appendix A – CaM and NOS DNA Sequences 
Sequences of CaM and NOS Vectors used in this thesis 
(in order of appearance in this Appendix): 
 
pCaMChlor - Wild-type CaM in pACMIP 
pET9dCaM - Wild-type CaM in pET9d 
pCaM-1TnCKan – CaM-1TnC in pET28a 
pCaM-2TnCKan – CaM-2TnC in pET28a 
pCaM-3TnCKan - CaM-3TnC in pET28a 
pCaM-4TnCKan – CaM-4TnC in pET28a 
pCaM-3,4TnCKan – CaM-3,4TnC in pET28a 
pnCaMChlor – nCaM in pCaMChlor 
pcCaMKan – cCaM in pET28a 
pCaMNNKan – CaMNN cloned in pET9dCaM 
pCaMCCKan – CaMCC cloned in pET9dCaM 
pCaM-L9 – CaM-L9 in pET15b 
pT34MCaM-L9 – T34M CaM-L9 in pCaM-L9 
pT110CCaM-L9 – T110C CaM-L9 in pCaM-L9 
pT34M-T110CCaM-L9 – T34M/T110C CaM-L9 in pT34MCaM-L9 
pCaM-T34C – CaM-T34C in pET9dCaM 
pCaM-T110C – CaM-T110C in pET9dCaM 
pCaM-T34C/T110C - CaM T34C/T110C in pCaM-T110C 
pCaM1234Kan – CaM1234 in pET28a 
pCaM12Kan – CaM12 in pET28a 
pCaM34Kan – CaM34 in pET28a 
piNOSpep – iNOS CaM-binding domain with N-terminal polyhistidine tag in pET28a 
pnNOSpep – nNOS CaM-binding domain with N-terminal polyhistidine tag in pET28a 
peNOSpep – eNOS CaM-binding domain with N-terminal polyhistidine tag in pET28a 
piNOSCBD-intein – iNOS CaM-binding domain-intein fusion protein in pTYB12 
pnNOSCBD-intein – nNOS CaM-binding domain-intein fusion protein in pTYB12 
peNOSCBD-intein – eNOS CaM-binding domain-intein fusion protein in pTYB12 
pΔ70iNOShisAmp – Human Δ70iNOS with N-terminal polyhistidine tag in pCWOri 
pnNOShisAmp – Rat nNOS with N-terminal polyhistidine tag in pCWOri  
peNOShisAmp – Bovine NOS with N-terminal polyhistidine tag in pCWOri 
pCWOri-iNOSC200A – Human Δ70iNOS C200A with N-terminal polyhistidine tag in  
pCWOri 
pCWOri-nNOSC415A – Rat nNOS C415A with N-terminal polyhistidine tag in pCWOri 
pCWOri-eNOSC186A – Bovine eNOS C186A with N-terminal polyhistidine tag in pCWOri 
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pCaMChlor - Wild-type CaM in pACMIP – cloned between NcoI and PstI 
 
 
pET9dCaM - Wild-type CaM in pET9d – cloned between NcoI and BamHI 
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pCaM-1TnCKan – CaM-1TnC in pET28a – cloned between NcoI and NdeI 
             Note: NNN represents ~800 extra bp that were required for cloning of this construct 
 
 
pCaM-2TnCKan – CaM-2TnC in pET28a – cloned between NcoI and NdeI 
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pCaM-3TnCKan - CaM-3TnC in pET28a – cloned between NcoI and NdeI 
             Note: NNN represents ~800 extra bp that were required for cloning of this construct 
 
 
pCaM-4TnCKan – CaM-4TnC in pET28a – cloned between NcoI and NdeI 
             Note: NNN represents ~400 extra bp that were required for cloning of this construct 
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pCaM-3,4TnCKan – CaM-3,4TnC in pET28a – cloned between NcoI and NdeI 
             Note: NNN represents ~400 extra bp that were required for cloning of this construct 
 
 
pnCaMChlor – nCaM in pCaMChlor – produced by incorporating stop codon at 76 by  
      mutagenesis (XbaI reporter site)  
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pcCaMKan – cCaM in pET28a – cloned between NcoI and EcoRI 
 
 
pCaMNNKan – CaMNN cloned in pCaMKan – cloned between NcoI and PstI 
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pCaMCCKan – CaMCC cloned in pCaMKan – cloned between NcoI and PstI 
 
 
pCaM-L9 – CaM-L9 in pET15b (Ampr) – cloned between NcoI and BamHI 
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pT34MCaM-L9 – T34M CaM-L9 in pCaM-L9 – produced by incorporating Met at  
         codon 34 by mutagenesis (removal of SacI reporter site)  
 
 
pT110CCaM-L9 – T110C CaM-L9 in pCaM-L9 – produced by incorporating Cys at  
               codon 110 by mutagenesis (PmlI reporter site) 
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pT34M-T110CCaM-L9 – T34M/T110C CaM-L9 in pT34MCaM-L9 – produced by  
         incorporating Cys at codon 110 by mutagenesis (PmlI reporter site) 
 
 
pCaM-T34C – CaM-T34C in pET9dCaM – produced by incorporating Cys at codon 34  
      by mutagenesis (SacI reporter site) 
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pCaM-T110C – CaM-T110C in pET9dCaM – produced by incorporating Cys at codon 110  
      by mutagenesis (removal of PmlI reporter site) 
 
 
pCaM-T34C/T110C - CaM T34C/T110C in pCaM-T110C – produced by incorporating  
 Cys at codon 34 by mutagenesis (SacI reporter site) 
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pCaM1234Kan – CaM1234 in pET28a – cloned between NcoI and SacI 
 
 
pCaM12Kan – CaM12 in pET28a – cloned between NcoI and SacI 
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pCaM34Kan – CaM34 in pET28a – cloned between NcoI and SacI 
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piNOSpep – iNOS CaM-binding domain with N-terminal polyhistidine tag in pET28a (Kanr)  
– cloned between NcoI and BamHI 
 
 
pnNOSpep – nNOS CaM-binding domain with N-terminal polyhistidine tag in pET28a (Kanr)  
– cloned between NcoI and BamHI 
 
 
peNOSpep – eNOS CaM-binding domain with N-terminal polyhistidine tag in pET28a (Kanr) 
– cloned between NcoI and BamHI 
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piNOSCBD-intein – iNOS CaM-binding domain-intein fusion protein in pTYB12 (Ampr)  
             –  cloned between NdeI and PstI 
Note: NNN represents ~1200 extra bp that were required for cloning of this construct 
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piNOSCBD-intein (con’t - 2) 
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pnNOSCBD-intein – nNOS CaM-binding domain-intein fusion protein in pTYB12 (Ampr)  
             –  cloned between NdeI and PstI 
Note: NNN represents ~1200 extra bp that were required for cloning of this construct 
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pnNOSCBD-intein (con’t - 2) 
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peNOSCBD-intein – eNOS CaM-binding domain-intein fusion protein in pTYB12 (Ampr)  
             –  cloned between NdeI and PstI 
Note: NNN represents ~1200 extra bp that were required for cloning of this construct 
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peNOSCBD-intein (con’t - 2) 
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Primers used for NOS Sequencing: 
The following primers were used to sequence the entire open reading frames of the NOS enzymes in 
pCWOri before and after mutagenesis at intervals of ~500 bp (Section 6.3.2.3).   
For Human iNOS: 
pCWOri-fr  5' TCGGCTCGTATAATGTGTGG 3' 
505iNOSfr  5' TTCACCATAAGGCCAAAGGG 3' 
1000iNOSfr  5' TCCGCTATGCTGGCTACCAG 3' 
1550iNOSfr  5' GAATGAATACCGGTCCCGTG 3' 
2002iNOSfr  5' CTGGCAATGGAGAGAAACTG 3' 
2501iNOSfr  5' GAACTACCTGCCGGGGGAGC 3' 
3069iNOSfr  5' GACCCAGTGCCCTGCTTTGTGC 3' 
3496iNOSfr  5' AGCTGGTGGCTGCCAAGCTG 3' 
 
For Rat nNOS: 
pCWOri-fr 5’ TCGGCTCGTATAATGTGTGG 3’ 
432nNOSrv 5’ CCATTACCCAGACCTGTGAC 3’ 
303nNOSfr  5’ GGGCTTCACTACACATCTGG 3’ 
778nNOSfr 5’ ATGACCTGTGGGGGAAGGAC 3’ 
1334nNOSfr 5’ ATGTCAAGTATGCCACCAAC 3’ 
1820nNOSfr 5’ TGGAGGAAGTAGCCAAGAAG 3’ 
2422nNOSfr 5’ ACCTTTGGCAATGGAGACCC 3’ 
2945nNOSfr 5’ AAGGTCTTTCCAATGTTCAC 3’ 
3411nNOSfr 5’ GTGGAAGTGGGGCAAGAACC 3’ 
3903nNOSfr 5’ CAAGGGCGTCTTCAGAGAGC 3’ 
4200nNOSfr 5’ AACGTATGAAGTGACCAACC 3’ 
 
For Bovine eNOS: 
pCWOri-fr 5’ TCGGCTCGTATAATGTGTGG 3’ 
93eNOSrv 5’ CCGAACACCAGCTCACTCTC 3’ 
292eNOSfr  5’ GACCTCCACCCGCTGAGCAG 3’  
777eNOSfr  5’ AACATGCTGCTGGAAATCGG 3’ 
1295eNOSfr  5’ GAGAATGGAGAGAGTTTTGC 3’ 
1762eNOSfr 5’ GGGACCACATAGGCATCTGC 3’ 
2263eNOSfr 5’ GATTTTGGCAGGAGAGGCTG 3’ 
2364eNOSfr 5’ TGCCCGCCCCGCTGCTCCTC 3’ 
2690eNOSfr 5’ GAGAGGGGCTGTCATTCCAC 3’ 
 
NOTE: For clarify purposes, the sites where these primers anneal are shown in the following NOS 
sequences. 
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pΔ70iNOShisAmp – Human Δ70iNOS with N-terminal polyhistidine tag in pCWOri  
 – cloned between NdeI and HindIII 
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pΔ70iNOShisAmp (con’t - 2) 
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pΔ70iNOShisAmp (con’t - 3) 
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pnNOShisAmp – Rat nNOS with N-terminal polyhistidine tag in pCWOri  
      – cloned between NdeI and BamHI 
Note: Mutations relative to Pubmed sequence: I269V and P959A (found in human nNOS) and F1014S 
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pnNOShisAmp (con’t - 2) 
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pnNOShisAmp (con’t - 3) 
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pnNOShisAmp (con’t - 4) 
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peNOShisAmp – Bovine NOS with N-terminal polyhistidine tag in pCWOri 
       – cloned between NdeI and EcoRI with upstream polyhistidine tag 
         Note: Mutations relative to Pubmed sequence: C109R and T750A 
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peNOShisAmp (con’t - 2) 
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peNOShisAmp (con’t - 3) 
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peNOShisAmp (con’t - 4) 
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pCWOri-iNOSC200A – Human Δ70iNOS C200A with N-terminal polyhistidine tag in  
          pΔ70iNOShisAmp – produced by incorporating Ala at codon  
      200 by mutagenesis (XhoI reporter site) 
     Note: Only showing region of iNOS with mutation – rest of sequence shown in pΔ70iNOShisAmp 
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pCWOri-nNOSC415A – Rat nNOS C415A with N-terminal polyhistidine tag in  
       pnNOShisAmp – produced by incorporating Ala at codon  
    415 by mutagenesis (XhoI reporter site) 
            Note: Only showing region of nNOS with mutation – rest of sequence shown in pnNOShisAmp 
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pCWOri-eNOSC186A – Bovine eNOS C186A with N-terminal polyhistidine tag in  
          peNOShisAmp – produced by incorporating Ala at codon  
      186 by mutagenesis (XhoI reporter site) 






Appendix B – Further FRET Analysis of CaM Binding to NOS 
Peptides and Enzymes 
Upon further analysis of the FRET data tables in Chapter 6 (Tables 6.4-14), it became 
apparent that two general fluorescence species were observed – a longer lifetime, corresponding to an 
extended CaM conformation (~4 ns), and a shorter lifetime, representing a compact structure of CaM 
in complex with the NOS peptides and enzymes (~0.8 ns).  In collaboration with Dr. Michael Palmer, 
all of the collected time-resolved fluorescence raw data was re-fitted using these two lifetimes and the 
fractional contribution of the longer (~4 ns) and shorter (~0.8 ns) lifetime components were 
determined.  Since the longer lifetime was at the limit of FRET distance analysis, we focused 
specifically on the shorter lifetime component and plotted the change in its contribution to the 
fluorescent decay in relation to the free Ca2+ concentration (Figure B-1). 
 
Figure B-1 – Assocition of Alexa 546/DAB-T34C-T110C CaM to NOS peptides and enzymes 
with increasing free Ca2+ concentrations.  The short lifetime contribution increase represents CaM 
associating to the peptides and enzymes in a wrapped conformation.  
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Although Figure B-1 is quite different than Figure 6.17, the new figure clearly demonstrates 
that there is a Ca2+-dependence on the fractional contribution of the shorter lifetime in all of the FRET 
measurements with NOS peptides and enzymes.  It is apparent that the eNOS and nNOS peptides 
require a higher free Ca2+ concentration for their association with CaM (KCa ~ 250 nM), whereas 
eNOS C186A and nNOS C415A require lower free Ca2+ concentrations (KCa ~ 100 nM).  As 
discussed in Chapter 6, this can be attributed to the regions flanking the CaM-binding domain of 
eNOS and nNOS that are involved in the recruitment of CaM such as the FMN domain.  Interestingly, 
the iNOS peptide appears to have some Ca2+-dependence in its binding, however, this occurs at very 
low free Ca2+ concentrations (< 30 nM).  This is good agreement with the activation and fluorescence 
studies presented throughout this thesis. 
 
Future measurements to further clarify the findings presented here would include: 
 
1. Perform more measurements using Alexa 546/DAB-T34C-T110C CaM with eNOS C186A at 
free Ca2+ extremes (< 100 nM and > 2 uM) to have more data points to better fit the data (see 
Figure B-1). 
2. Perform more FRET measurements using Alexa 546/DAB-T34C-T110C CaM with iNOS 
peptide at very low free Ca2+ concentrations to further confirm the observed Ca2+-dependence 
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